<SEC-DOCUMENT>0001104659-21-100800.txt : 20210805
<SEC-HEADER>0001104659-21-100800.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805163634
ACCESSION NUMBER:		0001104659-21-100800
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		53
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211148960

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>syn-20210630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/5/2021 7:37:04 PM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: 19a589a9-7306-49b2-9d1e-21f82f2b038b -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:syn="http://www.syntheticbiologics.com/20210630" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" xs:nil="true" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_9dXNRMZPnkq5ly83tC4RTA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" xs:nil="true" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_Vt6DMeS51kOxMfvORNJaVg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_WncZ9lUjfE-MTJQXil_NHA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_xduacBc4F0Gmcu7XseHoeA">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityCentralIndexKey" id="Tc_OZxyHpTX6k2qtd_txg-ggg_2_1">0000894158</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:CurrentFiscalYearEndDate" id="Tc_RcErDEPLZkW2ovJJjlvUKQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentFiscalYearFocus" id="Tc_AYLGqKGDB0aCpBl-k_AhjA_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentFiscalPeriodFocus" id="Tc_1WTU2zuANkKGAWAtMcLb9A_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityRegistrantName" id="Hidden_nBJ8GuZ62UGLYSMG0yfutw">Synthetic Biologics, Inc.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:AmendmentFlag" id="Narr_dt9BJfnIRUeSP5kFZHL2xw">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityShellCompany" id="Hidden_Qp3dlV33Gkug0H3pW_avuQ">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" name="us-gaap:PreferredStockSharesIssued" id="Hidden_eaHBVV3jI0G3SJsyY6yxlw">3973</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q" decimals="INF" name="syn:AdditionalNumberOfCommonStockToBeIssued" id="Hidden_LwEQCHh2xU-yhl4vl9nF_A">2420000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" id="Hidden_uVawnFnrhUC47_sVB7xw5A">0.17</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_N8SN6UjVJEax0ioF-Lc0bA">120000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="syn-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_11_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember__J-NQrr_RUyU2Fj9hkVnmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_Q4U6TfXbjUGV399zEsrnGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_slSCc3YOzk2ByscUunSdgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dvzYRfZpzUCe7pw2pnnTzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_bdhxK7hqDECM_T4Lq_vhjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ML7WRtDK4EuEsagAjFhinw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-11</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_CuZd8Dnu20mqdbWiRYxlvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-11</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_10_2018_To_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_7OFHeCdRt0-vhR2n4qUlMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-10</xbrli:startDate><xbrli:endDate>2018-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_p9VkK2Ce20-b03B7rUyXiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_nSmA-ONebUWYUQwXwaT0Gw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aTsVxcHS_kyEMZppZUpQLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_X7y6Hk8vxEOjkWQto03hMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_19HxwprrtEmkvH9Lq7SqzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R1-WdN0260eTxfcWqIiCSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KLY6iI306EmWk0dZhmpc3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_VF5eg1rhD0m77f4_pFE9cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yO2RP4h8dkysRRaDK9-uEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_vFY0pex4Okuv5Sk4DegLEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZxMhHz9iRUiCA6Tf_pX0rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_5ldZMfCabU28j_zFOz5BcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0twBlUhqq06j7sVl2-oL5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UrUccS3ylEaTH5G8z_ou6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_0Bxf9tnUNU2MTTKPvvGusg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5tZWGDYmrUaKJjhAjOyXfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fp5r6nH_SUy0VUUzbxxn2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_GRpJOcy1vUmpHvwH4bofIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LjtrdEDbDkeCwbuDZRK4Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_P3gsqp5SGkCisHeuk5iOZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iref35WiQk68aCukJLQswQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_I1SZ6FMPUEiPzXXIzzj76g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kyVeOBFLm0uK15XMpvVbZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zlQvdoOjn0eIo5zMpiXNXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_LcbLiBbyFECO_hZVyJHpuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_RJbNJpRBXUSt0ueloEGWTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_81VpuqIrTUGMs7nm1_pSJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_mDQnCUaukkitwCFkDu49Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_aNYaq92HaUaThT1YEHFknQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_9p8BUi9xpESM0XFssipxEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VBR-eClC6UGC07S2WEllbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zJO5Vy7y90-lmBQP2GMq9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_20_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_wLkfa3YyAUWs_EVe-EPt2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-03-20</xbrli:startDate><xbrli:endDate>2007-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MlNR2bKVWUa5Wq8G6pRRRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_QlvAWBKoYkCi7DFbZ1TTXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_81t85iLAZkue0k_haly1qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_VjVpgqccckeC1Ovt7HdvKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-05</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_t4jWqATDt0GII2ExNce1_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_qSjb2MQlSkOywB4mpExYgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_6GJQIqP4z0u-0VYhtn0pwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_w5NkU2_sOU2NkvPwvNTs-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_V3AVcyTze0yXKy6SgCQQOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_GfHbuB9ZRUGhg2eteRKuJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2018_To_10_15_2018_9YpmMUjlgU6Rx_oNzkSWFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-11</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-11</xbrli:startDate><xbrli:endDate>2017-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HMJmPJ9JF06CqnhSeF83-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_yr0zg1OZHUiIwiJG12_IyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HJ0Vognp00iLodsId7AO5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_SQNPifEGMk-kiOEU3qgr6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-27</xbrli:startDate><xbrli:endDate>2021-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWKm6b2HsEu3yxsVRW_tpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__gb_XUJNFEe-pMBsJgUlhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__Tyt_vo2eUyKoSKTspRpcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_adtzoVUoL0KulWbPEZXKug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_83AqlMwHVEuP9zHFSSM5Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_D6zkksit4UCwIionHXMP8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_u4kbim5KiEyW-zB1-W8-HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-11</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_WSxxQJt6wkSqtxqIte9ptg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_njvvYCOrE0G7--zGCHARcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_15_2020_FnMilutR6Uaa49a8AX4Ozg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_6_2020_3pJ_Ridqok6114OiGur1oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_5_2020_iKgSvuSwK0Katgd-IjQ9Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2018_V2vD4wi4-UCmh8saJ-KESA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_cKJV1gyygk-EpbEXDFtKXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_93GgZzd5OUWNIi3WddVejA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_mdSu6IH6FkWLzuUBCfIegQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FyVHAd_teEGuTL1oBAt_OQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_5hLd6ZKkzkCO5-jO7JCpEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_RVKQ0qDznE-qz2ggQLkq-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OwL8Ke43jku7YbqZh3ch4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_RVsezu3jr0CBpCVpvdx8lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CseERA5zh0ynTz1Zu6va3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8Voeje09P0KdHrvytlGF5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_Zk4qTUzc2EeG7AwMKOnF_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_PFI4t1qvYUeUPVPhulwM0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_GjoOepJsFkG33JO-DraytA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_IC8EXhUAzkGZ5rMnpHL2gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_eIcfeMgtzUC9ndcccKwg3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_f5pVsHeOF0esc-wKzvKXnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_7LiVHRy2BUaPnoZoXiYlag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_gAS70YQ3kEWbAigVthvfbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_a9LDsj3uzkuOTiqR1RdjjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aqlwFNKohE-KfzX_Eclrdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5AoLC7KQ1Uawve2qPbgbzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aPnGd6B3pESapmPXpuMoYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_YSUSLqISakeFFs0u8z32iQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_dAV91tPf8kmgXysC3CKWIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-11</xbrli:startDate><xbrli:endDate>2017-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_JR9Vjj4m3kihR7DJRSC05w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:OctoberTwoThousandEighteenWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice5248Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice138Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice5248Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice138Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_zr1590HAfU6H-r0oJu1zEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_onT3wd_AR0CjAZdM083VMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_CDRBLE4qQkaDOCYG-eI5Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_5_2018_To_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_DphhO0tkBE28K8KwCLVQRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-05</xbrli:startDate><xbrli:endDate>2018-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_S0B-4Run_kKbm47QoMWZuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Xxe3gAXhZU-l1BDNtcdQBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_BusinessAcquisitionAxis_syn_CedarssinaiMedicalCenterMember_z73xOnQ6cEihGg2og9Jxtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_7Uo71EUX6UCZ6ImKlbActA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2021_fvNYIeFxxEu--oykbEn2Hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA"><xbrli:measure>syn:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg"><xbrli:measure>syn:D</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;min-height:5.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_054b91e3_0bdb_47ad_94b1_5a30d021e1d8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentType" id="Narr_czUcULnlb0-z2sR11qMqSA"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">(Mark One)</p><a id="_bf0479c4_7d2b_4d09_9a62_d0dbc40db70f"></a><a id="Tc_ZJxOBcJ7tU6f_W2VRPMhBQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentQuarterlyReport" id="Tc_GP1nloTea06rKLyGTtuSpQ_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 50.4pt;"><b style="font-size:9pt;font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentPeriodEndDate" id="Narr_9rA_yzUtsECW9RVD5Z94BQ"><b style="font-size:9pt;font-weight:bold;">June 30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db256ec5_dac2_40bd_8470_b58125f09dfb"></a><a id="Tc_GGThocJZPEmfFfbZa-jR3w_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:DocumentTransitionReport" id="Tc_ha1eEY68eEauZKukNXfVFQ_1_0"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 8pt 50.4pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160; ____________ to&#160;&#160;____________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityFileNumber" id="Narr_0O7lRNj8MUyuMtnMU_aylg"><b style="font-size:9pt;font-weight:bold;">001-12584</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_nBJ8GuZ62UGLYSMG0yfutw;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-align:center;">SYNTHETIC BIOLOGICS,&#160;INC.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Exact name of Registrant as Specified in Its Charter)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2ec54721_3dba_42f7_a407_f281e1a8388f"></a><a id="Tc_J4uQ2liH-ECc2SR6Pmhk2w_1_0"></a><a id="Tc_Yu-E--UBrkqTeA9y3nf4EA_1_1"></a><a id="Tc_8GS_dWxDQkKPWlHA25SY2g_4_0"></a><a id="Tc_fxhYy_PgQEWwHexoKraVnw_5_0"></a><a id="Tc_eRbKvzld50ef220KIBUqUA_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityIncorporationStateCountryCode" id="Tc_xtjHZZ0HS0mD318brdxQyw_0_0"><b style="font-size:9pt;font-weight:bold;">Nevada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityTaxIdentificationNumber" id="Tc_FWTyqL5zREyQmXoWu-3G2w_0_1"><b style="font-size:9pt;font-weight:bold;">13-3808303</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(State or Other Jurisdiction of Incorporation or Organization)</i></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(I.R.S. Employer Identification No.)</i></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityAddressAddressLine1" id="Tc_Y9rvTnEEpUKBIZW5UYjyLQ_3_0"><b style="font-size:9pt;font-weight:bold;">9605 Medical Center Drive, Suite 270</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityAddressCityOrTown" id="Narr_ruZmPz71TEmi2LfopwkxMg"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityAddressCountry" id="Narr_QbTrDhUosECM7gg0Ihp0SQ"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityAddressPostalZipCode" id="Tc_aSmXutrBbUWVKpeTmlpftg_4_1"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:53.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of Principal Executive Offices)</i></p></td><td style="vertical-align:bottom;width:46.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Zip Code)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:CityAreaCode" id="Narr_sgP0zBYoFUSOkDeqiVx9yA"><b style="font-size:9pt;font-weight:bold;">301</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:LocalPhoneNumber" id="Narr_5YxjaDyjtEmPMK7kDeEMqQ"><b style="font-size:9pt;font-weight:bold;">417-4364</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(<i style="font-style:italic;">Registrant&#8217;s Telephone Number, Including Area Code</i>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 7pt 0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_9200a66c_9dd8_497f_8616_bc3999c8052c"></a><a id="Tc_NlMmdpNKAEmlg46zlJ88mA_0_0"></a><a id="Tc_NTROe5VWNEWrGd7HwoxaoQ_0_1"></a><a id="Tc_LtLKwioXuEG5cXIefqNEYg_0_2"></a><a id="Tc_m1df5T-He0G6PnZV2ZMQQw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:95.91%;"><tr><td style="vertical-align:bottom;width:33.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:bottom;width:33.32%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:Security12bTitle" id="Tc_4SUq-421CkeZQHAD1JEObQ_1_0"><span style="font-size:9pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:TradingSymbol" id="Tc_Xb8ZxTJAUUmPAMBfMBjwcg_1_1"><span style="font-size:9pt;">SYN</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:SecurityExchangeName" id="Narr_1cKUxlNsfE-P9gac_FpyQQ"><span style="font-size:9pt;">NYSE</span></ix:nonNumeric><span style="font-size:9pt;"> American</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:7pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityCurrentReportingStatus" id="Narr_zlkv6Fz3MEuuJVk4lqw1Nw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="font-family:'Wingdings';">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityInteractiveDataCurrent" id="Narr_xWOTHtlakEuNK8ToA_Xazg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Times New Roman';font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Wingdings';">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><a id="_73253c25_e2a9_40e7_91a5_976b36bcf372"></a><a id="Tc_2AdlIRevmkCACPy-_sDUUg_0_0"></a><a id="Tc_-96y6RAY8U-2bGXnS-NVgg_0_1"></a><a id="Tc_jwtvqqb9KkWy9gW1Y2bGSQ_0_3"></a><a id="Tc_U8aBq2e7mEe38yIiEzTZEQ_0_4"></a><a id="Tc_kCBNmz70LEy6yEgtxZ1g3w_2_1"></a><a id="Tc_oZAt0jLXBkqavHvzI2TOKQ_2_3"></a><a id="Tc_wy1kzHyaMECC2WsYvPeiYw_4_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:27.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large Accelerated Filer</p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Accelerated Filer</p></td><td style="vertical-align:bottom;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityFilerCategory" id="Tc_AcNhnTA64ECvGu-HxdYBOw_2_0"><span style="font-size:9pt;">Non-accelerated Filer</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Smaller Reporting Company</p></td><td style="vertical-align:bottom;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntitySmallBusiness" id="Tc_jusZxN6VqU6-H7adQzTZEA_2_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:27.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:40.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:bottom;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="dei:EntityEmergingGrowthCompany" id="Tc_QufRMH65sUagvSyZjti0WA_4_4"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 8pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Wingdings';font-size:10pt;">&#168;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="font-size:9pt;">Yes </span><span style="font-family:'Wingdings';">&#168;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="-sec-ix-hidden:Hidden_Qp3dlV33Gkug0H3pW_avuQ;"><span style="font-family:'Times New Roman';font-size:9pt;font-style:normal;font-weight:normal;text-align:center;">&#8999;</span></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 7pt 0pt;">As of&#160;August 3, 2021,&#160;the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_3_2021_fvNYIeFxxEu--oykbEn2Hw" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_KyBTNlSWzUmPDMG9NqQG_w">132,042,538</ix:nonFraction> shares of common stock, $0.001 par value per share, outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a6891444_00a8_486c_ae57_a19c83e2ff00"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SYNTHETIC BIOLOGICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Quarterly Report on Form&#160;10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). In particular, statements contained in this Quarterly Report on Form&#160;10-Q, including but not limited to, statements regarding the timing of our clinical trials, the development and commercialization of our pipeline products, the sufficiency of our cash, our ability to finance our operations and business initiatives and obtain funding for such activities and the timing of any such financing, our future results of operations and financial position, business strategy and plan prospects, or costs and objectives of management for future research, development or operations, are forward-looking statements. These forward-looking statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;goals,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and &#8220;continue&#8221; or similar words. Readers are cautioned that these forward-looking statements are based on our current beliefs, expectations and assumptions and are subject to risks, uncertainties, and assumptions that are difficult to predict, including those identified below, under Part&#160;II, Item&#160;1A. &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form&#160;10-Q, and those identified under Part&#160;I, Item&#160;1A of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2020 (the &#8220;2020 Form&#160;10-K&#8221;) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;4, 2021. Therefore, actual results may differ materially and adversely from those expressed, projected or implied in any forward-looking statements. We undertake no obligation to revise or update any forward-looking statements for any reason.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTE&#160;REGARDING COMPANY REFERENCES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Throughout this Quarterly Report on Form&#160;10-Q, &#8220;Synthetic Biologics,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Synthetic Biologics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTE&#160;REGARDING TRADEMARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All trademarks, trade names and service marks appearing in this Quarterly Report on Form&#160;10-Q are the property of their respective owners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8fccea7c_fe60_4eb2_b990_912fb812330c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SYNTHETIC BIOLOGICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">FORM&#160;10-Q</p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:8.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_38997"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;I. FINANCIAL INFORMATION</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1FINANCIALSTATEMENTSUNAUDITED_821372"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1FINANCIALSTATEMENTSUNAUDITED_821372"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements (Unaudited)</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedBalanceSheets_13010"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets as of June&#160;30, 2021 and December&#160;31, 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofOperati"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations for the Three&#160;and Six Months ended June&#160;30, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofStockho"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Six&#160;Months ended June&#160;30, 2021 and 2020</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CondensedConsolidatedStatementsofCashFlo"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows for the Six &#160;Months ended June&#160;30, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#OrganizationNatureofOperationsandBasisof"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes&#160;to Condensed Consolidated Financial Statements</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial&#160;Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_532997"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4CONTROLSANDPROCEDURES_532997"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_625995"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_182785"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1LEGALPROCEEDINGS_182785"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_227197"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM1ARISKFACTORS_227197"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_373292"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM3DEFAULTSUPONSENIORSECURITIES_373292"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_919457"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM4MINESAFETYDISCLOSURES_919457"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_597535"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM5OTHERINFORMATION_597535"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ITEM6EXHIBITS_463066"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ITEM6EXHIBITS_463066"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">40</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:8.56%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:top;width:86.01%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#SIGNATURES_21868"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">SIGNATURES</span></a></p></td><td style="vertical-align:bottom;width:5.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">41</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_40d7cdd1_087c_479e_96b5_5237ab301692"></a><a id="PARTIFINANCIALINFORMATION_38997"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I&#8211;FINANCIAL INFORMATION</b></p><a id="ITEM1FINANCIALSTATEMENTSUNAUDITED_821372"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 8pt 0pt;">ITEM&#160;1. FINANCIAL STATEMENTS (UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="CondensedConsolidatedBalanceSheets_13010"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands except share and par value amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ea1ff00d_a289_4469_b305_561e1c48a9c2"></a><a id="Tc_dd_kca2FuEmUVEb0se-BKA_1_2"></a><a id="Tc_VClytZId8kGTygxuikX6nw_1_5"></a><a id="Tc_t3D7KSPUf0S0kdhZ7eX8MQ_2_0"></a><a id="Tc_mgg3R5XYBEOX6DNN-37-4g_4_0"></a><a id="Tc_jbMAZwrsME25o7GEUjitKA_5_0"></a><a id="Tc_VOYo-lNIj0iBVHxKXrkYoA_5_2"></a><a id="Tc_mM8YchSDrUKLGgpH0DZR8A_5_5"></a><a id="Tc_0-jvXDgnrU2iewQ1xqgDaw_6_0"></a><a id="Tc_vCeiUc-fSEWgTQvMa_lFmw_7_0"></a><a id="Tc_12R5LzHaZUS06IJXR_T2jQ_9_0"></a><a id="Tc_-M52SFSMhUuIv7EgWohjPw_11_0"></a><a id="Tc_olUVAptMf06fPbtUKZfKkA_13_0"></a><a id="Tc_qMKYNMOegUK_oJIijfD6jg_15_0"></a><a id="Tc_HRNm1VDWkEGyjtIUmy8cGA_15_2"></a><a id="Tc_G2wh-DIq80iE7jvcG8XTAA_15_5"></a><a id="Tc_0ROLYq4KVUGOUps1aKGaDQ_17_0"></a><a id="Tc_2U9Squav1k6iFYPJ8ojBhA_19_0"></a><a id="Tc_pGPVIZj8BEa8fe166tg5KQ_20_0"></a><a id="Tc_6tL6lK5zjk-tU9bguAuyTQ_20_2"></a><a id="Tc_Srtl8hHzLEW_XH50ojywJQ_20_5"></a><a id="Tc_Wb912j_kSEWvc7QheXgY0Q_21_0"></a><a id="Tc_zcSVmDGC_Um4DwpACskTmw_22_0"></a><a id="Tc_gWZAjevd0UirwuD5yPGeIA_23_0"></a><a id="Tc_XcELB0SSM028Yzgbk4MfUg_24_0"></a><a id="Tc_tD1L7tB8g02HWKGlNWLnSQ_26_0"></a><a id="Tc_XIp77jaF-k6ItHdTuPDwMw_28_0"></a><a id="Tc_R6_Gb7Nry0W7W2nIELVzvg_29_0"></a><a id="Tc_mhAU1kNC2Ei4W5iJyVYRlA_30_0"></a><a id="Tc_ZfRilISS3kmRpUjHsO_lbA_31_0"></a><a id="Tc_h-Vhw87hHEGGLoAXufkB1A_32_0"></a><a id="Tc_jTnzISGzSEaofu2Fv2gJKw_33_0"></a><a id="Tc_9Z72V8QzKESIL_u20dOn_Q_34_0"></a><a id="Tc_ySa0dVGiTkCDyzZeB8530Q_35_0"></a><a id="Tc_FRb4GG0Hrka5faYp4S0iZA_36_0"></a><a id="Tc_lgme9ahM2U2craFk18J5-g_37_0"></a><a id="Tc_qrfgenzBk0aAMQf-nDhs_Q_38_0"></a><a id="Tc_sRosoetiv0u34WbHN64k2A_40_0"></a><a id="Tc_Ik-pCA24x0WgKUJguYqJLA_40_2"></a><a id="Tc_Pe2sRpdKU0KCIvkJsTLhIA_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current Assets</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_sKC04oFjbUSI-vY7HYzQsg_5_3">74,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_JB6GmKsCAUSXwXACTT9lCQ_5_6">6,227</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_euHrSgu1y0-Htu2P_YUgiQ_6_3">1,341</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_xKMH9qMpRky4dRHDevNKiQ_6_6">1,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Current Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_JADzu0hME0qz82h7NT_tSA_7_3">75,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Ss0zuAjmnESzLTtyWw8UlQ_7_6">7,934</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_-PnUNe1nyEGxheyOwRXAJQ_9_3">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_KKRMqZCWvEq2mwiFl-XiQA_9_6">174</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right of use asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_slc-bShfQUia1wXV96rA_A_11_3">1,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_9cBWuUxuCEmaaS5nTPkznw_11_6">279</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deposits and other assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:DepositsAndOtherAssetsNoncurrent" scale="3" id="Tc_YPS8sq6Hn06YcqN6XkcSSQ_13_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:DepositsAndOtherAssetsNoncurrent" scale="3" id="Tc_FOC0uyx0Vk2ohEJd_64wdQ_13_6">23</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_tvgzJWlQW0a7yqhhUqMDMA_15_3">77,255</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_4H2YU--bZESDc6TCAd5t9g_15_6">8,410</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#39; Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_x5cf_uV2NUG-vQeyYYnGuw_20_3">568</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_G0AUGQd_sEemVkDMk36Ldw_20_6">886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_dLLaO4FBgku75l9-8HDREQ_21_3">794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_7R-xx2p6rkqQHnVEj5HngQ_21_6">925</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued employee benefits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_tShtDcg8mk-XaNldJ-HC3Q_22_3">540</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_mVxLBqR7sUCKjq-cCwfd_A_22_6">868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_R-rdMCD1z0G0IwieeiQHIw_23_3">196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_JGE2wEkAe0yEmcJx2qA6yA_23_6">287</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Current Liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_WBUowp9VTUq44IVAFAwVYA_24_3">2,098</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_nxyTPTU62E6l4kuotG8V3Q_24_6">2,966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liability - Long term</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_AIShUfX9m0ytXgY7M5E1wQ_26_3">1,426</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_oYOoFSgmeE-Y0y5FmV7DyQ_26_6">186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_X1JVvi9jHU-_w7yQa2Wkjg_28_3">3,524</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_bFfRLJZxvkKAkuWn5h2qmQ_28_6">3,152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and Contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Series A convertible preferred stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_Z07XhIWUuk2s9l5oogiJjw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_ZIBoS8h2CE6P0DjVZMkQdw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_5y1ayAcXI0yP8IXz4vHPCw"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_bTyZpPbYxESMyHXCJiq0YQ">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_855fRIHnCEKusbrXnN0WeA">0</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="Narr__KDT9eMVAkK2Hf0jYKlbkA">120,000</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_WncZ9lUjfE-MTJQXil_NHA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_N8SN6UjVJEax0ioF-Lc0bA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span><span style="font-size:8pt;"> as of June 30, 2021 and December 31, 2020, respectively</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_Hzp0HwsMm0uwoDGiLnanSQ_30_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_ZaIIK2A1DEC4MUIB1rpjcQ_30_6">12,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#39; Equity (Deficit):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;">Series B convertible preferred stock, </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Ow5IlD46A0e0ylbyXa2tWA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_UaOiXCBxp0K3hzi1VriELA">1,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_4JKYoHTpPEa5CtqBrSEJRw"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_-QHJpakDhU2agXpswqq8jA">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_Izff0jspwkKGrAsyVhywWw">0</ix:nonFraction></span><span style="font-size:8pt;"> issued and </span><span style="-sec-ix-hidden:Hidden_xduacBc4F0Gmcu7XseHoeA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">outstanding</span></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_1ycE-XuiO0qvOsMvlLn98g">3,973</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_eaHBVV3jI0G3SJsyY6yxlw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;text-align:left;">issued</span></span><span style="font-size:8pt;"> and outstanding as of June 30, 2021 and December 31, 2020, respectively</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_y2laZxn2xU6fpfRMyVFTDQ_32_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_JjNjrO0u4Eu29830edu7uQ_32_6">2,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_b1bxrdxh7UGH1yqqrxxnuA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_FaJ6S8zhikiBYqsuP8_3Ng">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Eg7TRe4NdUO34wr_G3JtBQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_eDmMhVVKeUS4DlRrO5tFfQ">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_z4bgKIVTjEKHCph4gojWvg">132,044,866</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_fB_omQlvL02qvMxKnm_ZaA">132,042,538</ix:nonFraction> outstanding at June 30, 2021 and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_MNE-GbiDd06ZYn6bfmErQA">29,252,253</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_tquafKYK4Uyw9EF7-lHn-g">29,249,925</ix:nonFraction> outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_26FNOuVI80OrXZjEwiv5uw_33_3">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_6eIqH7zDGkW_udyKchSx8Q_33_6">29</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_aZP83Z8lxU2tp2KfvEnDsw_34_3">339,121</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_1Wpn3S8Wb0iBLEDWRFtxNA_34_6">240,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_y6D9svsWBEe4YifhctDqLw_35_3">262,748</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_oYMvqO1rbUeOcZHxDotp4A_35_6">248,094</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wzN48scP4E65lUQgBrp8yw_36_3">76,505</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_gyvezuFsAEO6mzzBRcBk2g_36_6">4,767</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" sign="-" scale="3" id="Tc_oFkeREj3ekGNag0WSgm1vw_37_3">2,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" sign="-" scale="3" id="Tc_UtzJV8eNvUaeFUB2SsA4mQ_37_6">2,773</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Stockholders&#39; Equity (Deficit)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_WQjRlUL8YU-K_CxlT3piRg_38_3">73,731</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_CY738T_UZUmtjYpv3Gz8yg_38_6">7,540</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities and Stockholders&#39; Equity (Deficit)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_UlZjpBv8S0ecNLeRluU-4Q_40_3">77,255</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_B7fROcwaF0eGvVVsHL-r7w_40_6">8,410</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_109397a3_6fe7_4b6f_8aed_080f9e4a221d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="CondensedConsolidatedStatementsofOperati"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6883cf9b_eb3a_468c_b36d_64a761e24c20"></a><a id="Tc_3zMQAxHbIUKjCEO1baexfA_1_2"></a><a id="Tc_CZ_V8FRBnESrRk7JSXYxwA_1_8"></a><a id="Tc_cWgxW_7ubEKSZs4whvMBoQ_2_2"></a><a id="Tc_X3A8ZBnaykiLbxjoIOGu-Q_2_5"></a><a id="Tc_5NIX2lB0EE2dbMc1VrZ87Q_2_8"></a><a id="Tc_XRw86FTyVEGFPOQ2foIe7Q_2_11"></a><a id="Tc_jxSClgmg1kCYkqsQm1hraA_3_0"></a><a id="Tc_uTrtJRQrhUCQTCDFWUYMrQ_4_0"></a><a id="Tc_Hf_IPXthikqc0ALfU1D6XQ_4_2"></a><a id="Tc_PZ1VyMQpukCNpDW0deRLmg_4_5"></a><a id="Tc_3JQahso1O06LzicrDhC1-Q_4_8"></a><a id="Tc_Tb_oEZbkn0-lEXMhM1HP5w_4_11"></a><a id="Tc_JkRsb9QuPkWqrzrfVtjNiw_5_0"></a><a id="Tc_PUTw_2eeP06rX55_MJ0_jQ_6_0"></a><a id="Tc_mj0pJHC8vESjg-SdsE6veQ_8_0"></a><a id="Tc_pTw384oNgUaBXD2XIIfEoQ_10_0"></a><a id="Tc_sa280n0V80W8-XtNelldGg_11_0"></a><a id="Tc_mWhdH50JC0W9HJ81I9Y40g_12_0"></a><a id="Tc_qdh9V3ORGEOGbvPIWbFstg_14_0"></a><a id="Tc_FLYzh8QkzUi8szf43W3Qhw_16_0"></a><a id="Tc_TOzAaqrRsUKSIhcpav2XRQ_18_0"></a><a id="Tc_n9jPRxWjOkG3m3bWAxl34Q_18_2"></a><a id="Tc_sUOp3HSR8UqPCS6NqCkMxQ_18_5"></a><a id="Tc_YYcb_xwOXkWBcqfnKjiTFQ_18_8"></a><a id="Tc_EkJgT2s4YUyDjbl4KMBQrw_18_11"></a><a id="Tc_awiWEK5uOkqYp4CbkRIPOQ_19_0"></a><a id="Tc_PyeiXK4wYk-v90smmRHTvA_20_0"></a><a id="Tc_iWRhaYKm1kq5CB27TSjdGQ_21_0"></a><a id="Tc_9m6eaR_5LEGhqCF1zyunXw_23_0"></a><a id="Tc_JiU49xrMfkWGNLGKOmGWEg_23_2"></a><a id="Tc_GTqVMMqQvkGp8nvfZHvrHg_23_5"></a><a id="Tc_0-iVlR0bn0ewyd5m99d2Fw_23_8"></a><a id="Tc_R9VRrAgasEGjm23yaOsBDg_23_11"></a><a id="Tc_ztvHDSYDdUyJ153RHqkvVw_25_0"></a><a id="Tc_5NxqoKwzTkSaFsVAaZbAPw_25_2"></a><a id="Tc_zgk7hozbV0CMUYPJ7WemYg_25_5"></a><a id="Tc_GZKroeHNpEWq4H_Y2tjUfA_25_8"></a><a id="Tc_sv5sIwDioEefjf5YA5rfXA_25_11"></a><a id="Tc_eovIZLF-TkuzwbJe0Y5BiA_27_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the three months ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the six months ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating Costs and Expenses:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_jazdgiKzt0mOYYyLDijLDQ_4_3">1,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_aBwDsgM4pEiyNhryYwj-OA_4_6">1,286</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_H6erlwLasEKk5LbimUdKPw_4_9">2,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ZofbW4I4H0GxD0g63dMLSw_4_12">2,679</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_hegWj3zcnkaELDvd7OOzPw_5_3">1,932</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_RiNm9GOvy0GxkZzr6VrH0w_5_6">1,603</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_PWyclazM-U65Lg1hYiUB9Q_5_9">3,049</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_anV9CcewVEaNAwSydXOx0A_5_12">3,238</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Operating Costs and Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_tBWxLeNn-kC5HLcRpwchPw_6_3">3,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_d0z_4ojEck-DyI6FGRoZdg_6_6">2,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_O1I22x1IE06LfKgAZVG-_A_6_9">5,734</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_cIbRmH24okamEDk7rW1MJA_6_12">5,917</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from Operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_CedGHy8CXkarUBHcGnQ5Wg_8_3">3,197</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_b3OZMY4CdkOFri9Z8hkBBA_8_6">2,889</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_odLVJPGcNky_7wHKbUgCNg_8_9">5,734</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_OqxMe-29ekOIeTLlGoKnJg_8_12">5,917</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_gd1US6kMNE6zZbprkNSx4w_11_3">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_8UUl-McUYUKWzeObDWZJ2w_11_6">6</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_47sld0LX3EqvDfDtUE55kQ_11_9">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_FWVEQqUaTEOKVD4DHW0PKw_11_12">44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Other Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_bNlfoKcAa0eVMQFGGmwM3w_12_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_c7PTUPtn40uwk2dDuJ84BA_12_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_6lTcMM2geECsK0l-nU1d-Q_12_9">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_iov7EPmzcUq7GPOCA4dHBQ_12_12">44</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_N3k35iJd1EG0zseqCtDrGA_14_3">3,195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_5bpCNLHP8U2gSfQiPQsNuw_14_6">2,883</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Be50bor6Q06zSgRUhLNdrg_14_9">5,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_FeUDO1FixEGIdAnW3qxGSg_14_12">5,873</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss Attributable to Non-controlling Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_c4IDxQz4zkSyuEcPv0-EuQ_16_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_od74mq2-2EmPR0BNz0wMJQ_16_6">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_xSKyxaQ47E6WVv_UGWNeTQ_16_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_cYmTsQzSJU2mlbe3yW2ssw_16_12">42</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ajDhGFoIxkS6CCah6oT08A_18_3">3,195</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_niFUhUTgl02S2cuBuuqYdw_18_6">2,867</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_fF0y6yBAOEKjnOJZmCSJjg_18_9">5,731</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_22rXGwCgeUCtWTN2oIplnQ_18_12">5,831</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Series A Preferred Stock Dividends</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_8qrVNeCK7Eao6d-MkVKNKQ_19_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_MbsC1b-g70mdyKYeQ1I_Sg_19_6">63</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_BdZw-vHaeUKP1Oy35_r1hA_19_9">24</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_aYsHsJcVjUmQpy6acXEYng_19_12">125</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_4YAUheQ0u0iwQwqnldbvMw_20_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_tjKp1PDyOUOsA0iLBsQbeQ_20_6">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-3" format="ixt:numdotdecimal" name="syn:PreferredStockPriceAdjustment" sign="-" scale="3" id="Tc_Ug8V0Ap-5kCGJTKOB2Cn3A_20_9">7,402</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_hRBtoOsHFEWC8g26VsIDgw_20_12">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Series B Preferred Stock Dividends</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_a-vRSm6yfUSUgCH9N8QbQw_21_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_AWOBdXNqbEeTrkTgsme9HA_21_6">392</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_xNh4EcwpcU2RSWS5WPYTRg_21_9">1,497</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_8YT3-H8EME6WdwH1sgP_kA_21_12">796</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss Attributable to Common Stockholders</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_1sSleBRepki7I9Bk-ffSvw_23_3">3,195</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_21k9y-6DGkS6prwYl9hEOA_23_6">3,322</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_xh3e1LZTuUGh-SJ_DYPGzA_23_9">14,654</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_DteRh46xeUmxCIfdazOqkA_23_12">6,752</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Loss Per Share - Basic and Dilutive</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_U24HSo-KpEq7Xe_ipI78ew_25_3">0.02</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_CTlA574bMUyjSdEn_22JWA_25_6">0.18</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_McCpmcLjzkmyJvY4_fqhlw_25_9">0.13</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_m5Pe_NAT1Ue7G8cV_D0TPw_25_12">0.38</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:44.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of shares outstanding during the period - Basic and Dilutive</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_W2qkItu0ZUKc4u8SWlZwAg_27_3">132,042,538</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_ylGZnMtt60K2cdba1ek0HA_27_6">18,405,884</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_wOfxS1SrmE-ISCFNx137wA_27_9">111,539,024</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_j1Y-EX_Ua0KN3OLXO4potw_27_12">17,748,688</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5cd5f841_0638_4c96_9f9d_fd757c90c3a7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="CondensedConsolidatedStatementsofStockho"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Stockholders Equity (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and par value amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_d6c30a0c_6ad5_46be_b6e8_de5367aa5271"></a><a id="Tc_lenzb7xeKkaivn3AKLrceA_1_2"></a><a id="Tc_TD8RYHABUUS31ZpWzzZigA_1_7"></a><a id="Tc_s3cvzbxf2Uq9bqg63SFdVw_1_15"></a><a id="Tc_js0-7QUvVUO0PEnYWhia2w_1_18"></a><a id="Tc_ulduLfGYVEiQNV0J9viNPQ_1_21"></a><a id="Tc_akSYNsE0v0ScCWve16z7Wg_2_2"></a><a id="Tc_3UJHK9IDYUel4-MqBFpGIw_2_4"></a><a id="Tc_3MGOvMY61UqSeBp_nQw57w_2_7"></a><a id="Tc_LnA6ArimpU2l8fZdbzr3pQ_2_9"></a><a id="Tc_49kJFWuhR0qbYZQuMtR3WA_2_12"></a><a id="Tc_3LnCgExH8kyaj2oMP0L2ag_2_15"></a><a id="Tc_jni4fudIW0iRBesM54p9aQ_2_18"></a><a id="Tc_OBEK5XZvSUC3SUdEZXGFGg_2_21"></a><a id="Tc_6VoHyMSgrEmyjWI-SacJkA_4_0"></a><a id="Tc_g3Xitom9yUK7u96QpbqHRA_4_4"></a><a id="Tc_uzOJfP6tXEKk4LHzMwrssw_4_9"></a><a id="Tc_8c9hC_cUgEuYWmMHjUZV-g_4_12"></a><a id="Tc_VqpAPD8TYEm9wCII5CTKaQ_4_15"></a><a id="Tc_7gByp0Bj70Oj3svBswF85g_4_18"></a><a id="Tc_Vspv059IV0ugBZuUN_GrxA_4_21"></a><a id="Tc_1Prt3Hz0Pk-b6FbpKGKumA_6_0"></a><a id="Tc_0RT4L0p5VkO-JL4Ut_IFtw_7_0"></a><a id="Tc_b_TehPxqaEa5Sg7WuIsVdQ_8_0"></a><a id="Tc_Ark-nNoUjE-mJ1xsA-E64A_9_0"></a><a id="Tc_9PXf_pODKkq_xnrb5F22NQ_9_2"></a><a id="Tc_QMEIPTCM0EinieIWmgsAJg_9_7"></a><a id="Tc_FgY1gA_2pU-p0-IFzpc6zQ_9_19"></a><a id="Tc_84mE58JZOkGI9oxr_THfpQ_10_0"></a><a id="Tc_voAIY2kcakWXWWpU-xzWRg_11_0"></a><a id="Tc_b45KYkdsdEO_P8lQN6t0bw_12_0"></a><a id="Tc_BCA1iSaZWEmr65EWYOEdDQ_13_0"></a><a id="Tc_zUpr7Ipu4UqgH_VbMU0zFQ_13_2"></a><a id="Tc_hYcpBut2v0mqSv4AS483Tw_13_7"></a><a id="Tc_il6YxbKZbUuA5R6zJxW2JA_13_19"></a><a id="Tc_VkKXRyd6c0accQIHKNTkuQ_14_0"></a><a id="Tc_GBYkA2j0HEirWdgr5n-Yhw_14_2"></a><a id="Tc_n9cuoVD-gE-DvlGelP6e1A_14_7"></a><a id="Tc_d5tdytY_ekWnyIokRqIQHg_14_16"></a><a id="Tc_qTDlZh_-UEKZUv7aVMemFQ_16_0"></a><a id="Tc_fa3ayMauA0u1lw9kQ8W4GA_16_4"></a><a id="Tc_qJCS3ppVAkKGqfLPnijK8w_16_7"></a><a id="Tc_MG_4-_5FFEWk4o-x91J6yg_16_9"></a><a id="Tc_Ar5UbU5k9UauqM85OaPd2w_16_12"></a><a id="Tc_LL07STpvd0WtQWzVvjKX6g_16_15"></a><a id="Tc_FNGStEgf-EqbAsovdjv2YQ_16_18"></a><a id="Tc_SsJPClkE8Eq8zP6gtMvM0g_16_21"></a><a id="Tc_OMcFuXi_6E-PcKDN0ObpMg_18_0"></a><a id="Tc_BgT0a1sBwk2HGX3lp51SPA_18_2"></a><a id="Tc_65oY3A0Se0-hbEcfbKDbWw_18_7"></a><a id="Tc_I8c5-_w31USQLfT99Wyk7w_18_16"></a><a id="Tc_eMitKCqXtUCPsG128gL5Zg_18_19"></a><a id="Tc_L53oLJrJ10-S1RAYpNjr8A_19_0"></a><a id="Tc_BcNOCKJST0ydoEU5Lr2pRA_19_2"></a><a id="Tc_CoqG-7VhPUqjnLA8SRkYxw_19_7"></a><a id="Tc_mWrQbpzsXUuLUIfx1YA4Mw_19_19"></a><a id="Tc_mKMSL2XVRU6zH2tb0K1Gwg_21_0"></a><a id="Tc_l27nPjiQCUyx0tPZ9V1QQw_21_4"></a><a id="Tc_bY0gK95ktkKPP35h5WSKNw_21_7"></a><a id="Tc_92dt7j1vBUKXEfH46A7W7g_21_9"></a><a id="Tc_V2ah9aRGlUm1qR0w3jgBiA_21_12"></a><a id="Tc_notjgBRa10KTLvCnn1l2Kg_21_15"></a><a id="Tc_JIEK5Fs_BUqKBU9DJIZaDg_21_18"></a><a id="Tc_1YuCmmR0wE2kRCeNZh_N6w_21_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock $0.001</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Par Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Controlling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">APIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0nlaUMXEQ0O-Yy0Iw5PC-A_4_2">29,249,925</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_se3wARcrJ0WxjQDLj0OR5g_4_5">29</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_uO2zHK_Xmk2kkMUULRSoNw_4_7">3,973</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_HBNufuI5l0WWgcu0HtEf8Q_4_10">2,477</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0twBlUhqq06j7sVl2-oL5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_ePUY_qh_OEOb3_We4RH8EQ_4_13">240,821</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZxMhHz9iRUiCA6Tf_pX0rQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_oQhXh2up0kWE-_dF6QxJ9g_4_16">248,094</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_5ldZMfCabU28j_zFOz5BcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_EJ162lhm5U2gDveOQ_ei1Q_4_19">2,773</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_PWeEqtcsh0WWhnkuwixI5w_4_22">7,540</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_PoEGNnebcUC05gddbWx_ig_6_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_Xxk43ckcBkq2az_A6i3gUQ_6_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_hQdW43sFS0GQUtBo7IObLA_6_7">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_LOwFIcpS2ECHqZ1xnBL9iQ_6_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_QdQyXACy2UW-7s1oXWAVRw_6_13">101</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_hl-Nf19eL02fNELrWcfdrw_6_16">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_zPi9n7VMqEi6FhGpCVWcaA_6_19">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_p2ZkD1ygyUWBdaswMAEz_Q_6_22">101</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock issued under &quot;at-the-market&quot; offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingShare" scale="0" id="Tc_6s8-XuoM20qomIdPI7CiyA_7_2">78,685,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_nfy1J2K86EuN-kvBbtXc_w_7_5">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="0" id="Tc_52VuOZS5Vk-LFgg8NTw9Ow_7_7">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_q3eziVWWwkSF518jxM30hg_7_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_NWNNoiKBmUmSkHifl4gfuA_7_13">65,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_b8RPWL5FE02Mug_mjzW7Sg_7_16">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_e7_mRxCQxEKa7N0wVnLy1w_7_19">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_uVN-Mzji8EKSgCzn41z6oA_7_22">65,960</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Warrants Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_KctEZyR3w0On0aglilArlw_8_2">11,655,747</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_lnQTnQc4dku-p9MSWDOMdw_8_5">12</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_3g6ZVm4zQU2v_4CusjF6PA_8_7">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_k3k9Je0qu02VsosnvEY-AA_8_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_yxbOWu2mqkuvWXPFGGd-og_8_13">8,030</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_AZOOWhesp06UV8D8BeIKZQ_8_16">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_3CHnkFECUEqSreVNAxcUhQ_8_19">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_rYUORqvCjEm4mW_9ds5NNQ_8_22">8,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock Dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_WCFxZvN0KUmsVIzSFSQOPQ_9_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_c87BvsgBkECnTgipChKYww_9_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_pks3ITJNJEWV88FWEtHnTQ_9_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_R5UnesqNmUetL-iqaomY_w_9_16">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_-2SPZEVU00W8u06Qy01_5w_9_22">24</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="0" id="Tc_73K638knAUCpUUkCyMqikQ_10_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_2PdDnzJhCki9KWQp7yx5Yg_10_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="0" id="Tc_AbbRYLXEaku4HBXr6A37-A_10_7">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_ei3DneJ4gEmlIq-oLuz77A_10_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_gg7YvNBz8E2mltn6btjiUQ_10_13">7,402</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfPreferredStockPrice" sign="-" scale="3" id="Tc_FCqY7LMJKUyQ_jq2N7r-Ww_10_16">7,402</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_ZWU92p4mwUel65k6KH-JoQ_10_19">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_Sa7jbWWIcEmssWKrLNZDpw_10_22">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series A Preferred Stock to Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:numdotdecimal" name="syn:Conversionofseriesapreferredstocktocommonstockshares" scale="0" id="Tc_JNJ3bW5TsE-qSyks0LcjYA_11_2">8,996,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_31eZ2GBpgEG3Sbx63gqlhw_11_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="0" id="Tc_fgV5grEWVUO5YsxFtCnVAQ_11_7">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_BTmYRjEbC0-p33YVL8xtxQ_11_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_mmoVGh4DxUWt0v-TXaPdEg_11_13">12,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_PryCQLAgmUy2MKK7yDtPtw_11_16">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_Wqec-QGsDkWc5iqoZHVDzA_11_19">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_YFzeKW1KxkKE8ZHNVNjk3g_11_22">12,822</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series B Preferred Stock to Common</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" scale="0" id="Tc_JDHyBsauRkWOlLoac2S8Bw_12_2">3,454,783</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_JJq3g4sa3kiiWAFy7dOebg_12_5">3</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" sign="-" scale="0" id="Tc_8RTCQfNjZEq38UQCmkpuLg_12_7">3,973</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_61zfXtBgWEOcz007cLaWag_12_10">2,477</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_NMyAWhlEGUyi7WpgBO2QJA_12_13">3,971</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_c9lOhJ82i0aBw3caoid1yw_12_16">1,497</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_-XUDwouw_UC_3oCEDCiZKw_12_19">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_SFMfIZn0MUWXhNt-nqB7Ow_12_22">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_D_55ASoV9UqC4iMSBdTmdQ_13_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_2vMxZwv3yU2Elmw3bv5M_g_13_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_gFVdA1tcUUWxzsJqD7mnGw_13_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_b262EtANvE-7_iKYHDUndA_13_16">2,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_GzKJ2-j13UamXtWVFou30Q_13_22">2,536</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Non-controlling interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_tjAp8M-rRUKzBUX4zIagDg_14_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_XYOo48JQY0SYWHQ5GEIlDA_14_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_eq0hp46DDEGede0wopYrCA_14_13">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_zIJhOyiO0E-QgKt1jwDa2w_14_19">1</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_ELboQVvBd0ytPsjhJYEEmQ_14_22">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March 31, 2021</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2ple3jL5BUWNx9hgvENg_A_16_2">132,042,538</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_L8xX_MUcD0-zPJ8m3Lq3wg_16_5">132</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> -</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R1-WdN0260eTxfcWqIiCSw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc__yZ5dsWBA0qmkT60JAO1-Q_16_10">-</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yO2RP4h8dkysRRaDK9-uEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_xVSVO8HLdEqs2HIzi688ug_16_13">339,019</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KLY6iI306EmWk0dZhmpc3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_dhDqeji3PUWWKGBR14MZhg_16_16">259,553</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_VF5eg1rhD0m77f4_pFE9cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc__vMhrzF6dU-m2PMqS9CBaw_16_19">2,774</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2021_vFY0pex4Okuv5Sk4DegLEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_DSR0Mi9NNk2kaUrhXN4lJw_16_22">76,824</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_A2Xh_COGZUGqi-ImIbp6vQ_18_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_6p2mTtSAUUC_pk9f8inYxw_18_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_olbGoJTy_0erYJ7IiNBAOA_18_13">102</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_GrsFoQHNyECk94CoHuT75A_18_22">102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_bzRX2GW-IkybxA9WrfqkmQ_19_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_45L6B-HFaEe3VVO1An43Gg_19_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_XJf6JOkXyE2Dz80EEsCBCA_19_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWKm6b2HsEu3yxsVRW_tpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_s-C5ZXefjE-SZUK73thy_g_19_16">3,195</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HQthhHFKZUuoCwuMRAsrpA_19_22">3,195</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_gWlQbSbv70uki_XhHs6XyQ_21_2">132,042,538</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_7ro9J49lu0-h10zzxHlgZw_21_5">132</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> -</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_nSmA-ONebUWYUQwXwaT0Gw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_nSCi2qfY4E60pCtyulROUw_21_10">-</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_19HxwprrtEmkvH9Lq7SqzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_1dDbvfXDQE-E-PYtG9ngYg_21_13">339,121</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aTsVxcHS_kyEMZppZUpQLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_BuUROQ248kWpV0SO--tv_A_21_16">262,748</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_X7y6Hk8vxEOjkWQto03hMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_LzLf5DCWf0CObTojqo68kQ_21_19">2,774</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_-Hr_gu7J30ymh37zfUYL0Q_21_22">73,731</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9fecfe1c_72c0_4c67_80b9_6c1d419a2db9"></a><a id="Tc_AhUMot-Q60uMfivVP3HJpw_1_2"></a><a id="Tc_zmpPnnaq6EStjsTZX7jKCQ_1_7"></a><a id="Tc_Jgy2z-iDWk6y7KQJwCM0cQ_1_15"></a><a id="Tc_1FW4BHezek2s0lYrJpsglw_1_18"></a><a id="Tc_v9y-NxadrUGO35qTNL4B6g_1_21"></a><a id="Tc_VnJ3t9BRB025Ad33xoRosw_2_2"></a><a id="Tc_IPyLa9B2BUm85tovSdtURg_2_4"></a><a id="Tc_ncDTSend8k6zJPTvwx4WZA_2_7"></a><a id="Tc_iiH7DHer8U-3sZgVOAboJg_2_9"></a><a id="Tc_NbRM9u4xcE-Sgag-w8dKhA_2_12"></a><a id="Tc_Qf38Gu0G8UKttfVylIwrvw_2_15"></a><a id="Tc_juSKC6GD40m1ne9PH40ckw_2_18"></a><a id="Tc_1JiHk9jDL0K_mAAzWAhuxg_2_21"></a><a id="Tc_1MVQn_v72UOLDLnn0VN4TA_4_0"></a><a id="Tc_W1qAU_2DbEyc03MPhfwUrQ_4_4"></a><a id="Tc_yI6KU8eSZUGIOKKNjM6tBg_4_9"></a><a id="Tc_K-N_YvcqFkq-19fE7cvDRg_4_12"></a><a id="Tc_x6aRLG2Hdk-l4VEQ7jlhrw_4_15"></a><a id="Tc_716xKwgNukqwboSosrkzSQ_4_18"></a><a id="Tc_R2fHmh2gZ06dXBaBrFB0Ug_4_21"></a><a id="Tc_ccWLGWppWECbgXT3V3isiw_6_0"></a><a id="Tc_9QbVue7utkCAdF0XyPWFzw_7_0"></a><a id="Tc_LcjeNNaVFkSJ9762k5k_wA_8_0"></a><a id="Tc_w1i7IA0cQE-_a2Xw7WNyFQ_9_0"></a><a id="Tc_THaj7r8FI0SY1gpz3xfBjA_10_0"></a><a id="Tc_uVK_GO2RmEW6KOhqnu0Ubg_10_2"></a><a id="Tc_jQj2_n90vUGhbLpR3VWMQw_10_7"></a><a id="Tc_FDrIf3PZcEmVSiRV8yJCYQ_10_19"></a><a id="Tc_TN-Sl3EOUUKosgwmio3z9Q_11_0"></a><a id="Tc_dbSXqC1w7EStdJVkO4P83g_11_2"></a><a id="Tc_tGmeVzfipUOJyggzPM9GFw_11_7"></a><a id="Tc_Da2AWZ21hUOxYERZh2oJyQ_11_16"></a><a id="Tc_CfRY1hkpaEiZEu2wW-NZkw_13_0"></a><a id="Tc_NILqKggxWEeC1XsWfiWsLA_13_4"></a><a id="Tc_hVEHrZwTkE6ZsP5xbjTVeg_13_9"></a><a id="Tc_Ki76EHQizEe6UHdrWdtItw_13_12"></a><a id="Tc_U7rjYUA4cUec6VhzazVjAw_13_15"></a><a id="Tc_4i1BJxTnAEGtOvWJrR8hfQ_13_18"></a><a id="Tc_pbyVHeqY60uvb6_qL1BlZw_13_21"></a><a id="Tc_xxr9ybG4LU-eVhyvI2xVJg_15_0"></a><a id="Tc_lfVl-jeEN0i_RqkrlSv_4g_15_2"></a><a id="Tc_oSNg8gFuu0eemcI-ka7QDg_15_7"></a><a id="Tc_yXP-XiI9u0e6VRWs7fbZYw_15_16"></a><a id="Tc_c4StvUJHm0m44fb7vQoG4g_15_19"></a><a id="Tc__YwNzqaJKE2uGsC_uRyxhA_16_0"></a><a id="Tc_CD34u8Kc0EaDq8Q7fb2PlQ_16_2"></a><a id="Tc_OfG_ehRaJEahHFGJ98q1DQ_16_7"></a><a id="Tc_XY0sfY0lV0SsKntUawZGFw_16_19"></a><a id="Tc_OHUsT_mg50Kai_v3cjezJw_17_0"></a><a id="Tc_jlvl5j9MXUuQY1j9yoXXzw_17_2"></a><a id="Tc_IGwpYUD2N0iWY1nEtjv83Q_17_7"></a><a id="Tc_yqoMnx4Rp0y-aP4INa7Dxg_17_16"></a><a id="Tc_DxhfV1Im2kejFL-ACGVzmA_18_0"></a><a id="Tc_FrHBvfvrg0mYFDV3q-VD2g_18_19"></a><a id="Tc_JJowZ8T130eObWuwmT6eww_19_0"></a><a id="Tc_1vMWQ0H8AkKnMxl5SOnh3Q_19_2"></a><a id="Tc_dV5NcfOSP02XL_2lnf90IA_19_7"></a><a id="Tc_CKo6ItLajESuzFxZBYxOFQ_19_19"></a><a id="Tc_SXX2xnCRpEuj7_mzZs67aw_20_0"></a><a id="Tc_Rm01hJpZqUyO8d0XJdy8Sw_20_2"></a><a id="Tc_a2Qj3uVqPkmziJu5pfBfkw_20_7"></a><a id="Tc_NGne3ahF0E2jA-xwkiTu5g_20_10"></a><a id="Tc_5jQLYv4DLUGBHC6FaI5Ljw_20_16"></a><a id="Tc_SRZuohfcZ0GO9ImwkxP6Iw_22_0"></a><a id="Tc_ORFpDc4vSUGsEiG5Vz5Lag_22_4"></a><a id="Tc_iwQl_GabwkOFV2goFrJzKQ_22_9"></a><a id="Tc_tsKtZv8YUUWuozEOJ6TJ5g_22_12"></a><a id="Tc_D80LbfrTwE2VdRcwEAEzQg_22_15"></a><a id="Tc_JkS7cZoFUUqZImFrKDgLgQ_22_18"></a><a id="Tc_bdHLVlpbnEm7wHVYQAZTaQ_22_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock $0.001</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">Par Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Controlling</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">APIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2019</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_4kDW2X_NQEuyhIuKoEO_sw_4_2">16,806,430</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_QU2EcEE5zUmsF3I1jyr3sQ_4_5">17</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_PzeOcKa-4U2tVNQrki72sA_4_7">7,638</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_J97h0RadV0u8cxefUooXuA_4_10">4,761</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kyVeOBFLm0uK15XMpvVbZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_KXbKo5xOOke6UCq2qvgBRg_4_13">232,580</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iref35WiQk68aCukJLQswQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_peAra28Wd0uAwpb0u2u9vQ_4_16">235,537</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_I1SZ6FMPUEiPzXXIzzj76g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_gV9Lsdpd20--cSmHEgNXWg_4_19">2,878</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_y1QhOB5xa0KOuhB9hj3rzQ_4_22">1,057</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_uuak98WitEK2EWT_7XO95Q_6_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_9rE55sRp0kCtoKhrK_ctCQ_6_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="0" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_4byig69qUE2Kri3F8U7sXA_6_7">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_HsPFw7dh9EONj0K3p_yZog_6_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_Zur2kSHKukOzAMNyEawH8w_6_13">83</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_jBHa65fzzUOWZ-rSaHQbFg_6_16">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_OMJge_AjEkuYZnsAgfffEg_6_19">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_sQuszGC48E22zKuHbRwlUQ_6_22">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock Dividends ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__Tyt_vo2eUyKoSKTspRpcA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="Narr_XEER9xi970eM8U4UJ8mm0w">0.01</ix:nonFraction> per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="0" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="0" id="Tc_sflpKcrrhkORtQjIfVo6Og_7_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_7ES5CNpCj0abgR9U24BS-Q_7_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="0" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="0" id="Tc_yVWkMoafF0m71qtftcjdCw_7_7">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_8txmoTOvk02J0Nrm36KG4w_7_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc__RqEasvhn0SHSpuJjEMXAw_7_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc__23ny_xspkGo61cDz-U7-g_7_16">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_IzDs0RcLgEK6jlZuhZ9Hmg_7_19">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_o6V0bbcSrEOKUC6yPMLAvg_7_22">62</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of SYN Biomics Stock</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="0" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="0" id="Tc_gPl8GmMjtUumMyT9VxKx6g_8_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_izH6KWnrW0Smw1qApfZwEA_8_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="0" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="0" id="Tc_h2VECml3g0i6DxIiCQNwTQ_8_7">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_ep9rW-zO0kmNpIFI0bESNA_8_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_RVNlW2HmxkG0MZgRRDukag_8_13">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_UnPhorVYzk--axq5VS_t9g_8_16">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_0d7cNN7WmkSfsPMki2FBBw_8_19">26</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_mwKOxyTj80KHPTc8lYc0Wg_8_22">26</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series B Preferred Stock to Common ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="Narr__fP3-pKKR0a65U3Aul_6xA">0.03</ix:nonFraction> per share)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" scale="0" id="Tc_3MoNe7vAoES1fDxqDqh0zw_9_2">933,045</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_9FPXfcWLckGK1mv_nG8t1g_9_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" sign="-" scale="0" id="Tc_tra6e-xhzUG2BYp0zusg8g_9_7">1,073</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_UIwPONtkuU65pq56IRtT7Q_9_10">669</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_RsqOwK5CJk6PPLc_EiocIQ_9_13">1,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_h79f1hvseEmQaqtoMm1NdA_9_16">404</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_E1L0f79nXk22ETb8zah8mw_9_19">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_EHYWjXndkEiq9OTkdWHpRQ_9_22">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_efKXfwpJAE6PSF-CMH4aDw_10_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_zavg1olvQUCatmumM76ixQ_10_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_UwDpYKy4Xkiz8PyYcpXrOg_10_13">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_X3ARkBkYf0iiuDffPE1pcw_10_16">2,964</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_i-BmypNM0kqL6vWhDQVjOQ_10_22">2,964</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_Wk9sABFG7UqimZfn0cNgpw_11_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_R05cBJGHlkK8MHFDHzHeLQ_11_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_sxlPKgJ-ykeTTCk2cYgMxQ_11_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_atL-5I-2D0C-UwfzaFHCHQ_11_19">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_n-_peT2iA0-_KGLOdwBV3Q_11_22">26</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_xM75bPqmQUSH0hhtwVB0Sg_13_2">17,739,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Rgm5BrfDLEqNDvcMhfpgbg_13_5">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_qqvQ6ejv-kWrR5bUe6fAmQ_13_7">6,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_2VVJDRhsDEak59uQ-r1aKw_13_10">4,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LjtrdEDbDkeCwbuDZRK4Eg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_kl0B7hAjh0O7Kfk9qxqg9w_13_13">233,735</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fp5r6nH_SUy0VUUzbxxn2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_4_i47LUC50C48ygMhz7GDg_13_16">238,967</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_GRpJOcy1vUmpHvwH4bofIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_zWZ5d-tGf0KsO7WMDbFU2A_13_19">2,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_3_31_2020_P3gsqp5SGkCisHeuk5iOZg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_1E4zXz7160av7c2zYuvAtg_13_22">4,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_K2uLct-Mak6PkVBBiG5sQg_15_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_LIc6j7MgCUWFRM34Y0dWCQ_15_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_XRIBE_FXJU27XGeQrySs9Q_15_13">86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_oNvnMSBYF0SsKziMopDJng_15_22">86</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock Dividends ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__gb_XUJNFEe-pMBsJgUlhA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="Narr_7EmsoQU-aU-38c6OqrkwXA">0.01</ix:nonFraction> per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_AXci-R79YkaXFd3VVQtytA_16_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_WCnvwwvDzUi_KDVeIhxlJA_16_10">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_w9rb9zCzXEe7WRMI193kqw_16_13">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_fnmidggcyEehl_CGUm7pww_16_16">63</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_uz2yNSguyESyAt1WmVAd-g_16_22">63</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of SYN Biomics Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_tKarb0H_t0iweIIRBRTKsQ_17_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_zLAT5KC600W_kSPir_J0_A_17_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_cZPk_eORRkuTCHIGFd3WbA_17_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_DW_kaqLDQkSPfWgPozUuTQ_17_19">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_qYal5pQOi020JU1d0P4new_17_22">10</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series B Preferred Stock to Common ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="Narr_Iy4wswLSmEaGUYEvwLtX7A">0.03</ix:nonFraction> per share)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="INF" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" scale="0" id="Tc_avwWQDRUtUuqgABRWeCX7Q_18_2">904,349</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_RoYPslTWckSc95Y9QAwZOQ_18_5">1</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="INF" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" sign="-" scale="0" id="Tc_R7QHd47NF0CR0wy3JhjSQA_18_7">1,040</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_Uoj_T4IckkuEoOGmKOc-5Q_18_10">648</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_xFnM3nwDgUeoqwZgqoTuXA_18_13">1,039</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_fFhjbPyN2kGr2X7Zhq8DTQ_18_16">392</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_MZUV0fjAMEOW8cGBd6q6Aw_18_22">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_NtmSOe8zJ0COEDm5Hv5dow_19_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_VU1XkhBxyUqljDMfZIJ_Aw_19_10">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_maldTnm4tk--CvnA7vG2dQ_19_13">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_EqHx6nyDGUG-39U76RuQgw_19_16">2,867</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ABzmhJZM_EmBj0efS6u71g_19_22">2,867</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Non-controlling interest</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_AsdajAxafEqbwjc0hbNT1g_20_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA" decimals="-3" format="ixt:zerodash" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="Tc_k505g8z5rkmMzGhYOOhj-A_20_13">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_UqQzwMolAUW6rnBPewByvw_20_19">16</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_RENMTXacM0iW-huSc-Gl6A_20_22">16</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:20.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_N6jWB6WX8Ee2Wl5Ff-4mpw_22_2">18,643,824</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_jweiNu2j2EGPK_Y6xL2Vgg_22_5">19</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_fBTR99q6ykyVa58mbDeVGQ_22_7">5,525</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_CDiQkIMNM0O-WtTJAlAGGQ_22_10">3,444</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5tZWGDYmrUaKJjhAjOyXfg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Ss8dv9X7yU211ISX5P88zQ_22_13">234,860</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UrUccS3ylEaTH5G8z_ou6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_RM48WvlrG0uhYZaggryw-g_22_16">242,289</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_0Bxf9tnUNU2MTTKPvvGusg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_by0bI14YO0OKnaWNdlsl8g_22_19">2,884</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_S85InnGkhEGUbHe6-TKNNg_22_22">6,850</ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8f37f275_a7f2_4e3c_88f3_d4d32518b00d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="CondensedConsolidatedStatementsofCashFlo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Unaudited)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_389b153e_ee3a_45a0_a92a_40929261acbd"></a><a id="Tc_NkLSkfRuVECNjFAjhg59qA_1_2"></a><a id="Tc_uXfzX70ILUiBiUTmHpUHqA_2_2"></a><a id="Tc_Mm3vzDCi9k22hJXglDs4GQ_2_5"></a><a id="Tc_zuxsZp3tL0eKeDYJC6geLg_3_0"></a><a id="Tc_skiacgVdkUu0D6l0kE6Wtw_4_0"></a><a id="Tc_pife3KC9vkaJrPBCJgNVPQ_4_2"></a><a id="Tc_Y36jD5G4UE6jonkZx9_B6A_4_5"></a><a id="Tc_pWlVqlilEkCSvSppIlbhIw_5_0"></a><a id="Tc_kQWaXOXQyUyXHYf-H1a8NA_6_0"></a><a id="Tc_4id3o88-CEmJ_K-3rxmG-Q_7_0"></a><a id="Tc_7fC1BFTzjUmXNayNRSEaFw_8_0"></a><a id="Tc_QWNsBInRoUyr27f75tdIUQ_9_0"></a><a id="Tc_nH4obaqniEyiLiSRH3faGA_10_0"></a><a id="Tc_gkqCqzVmi0WHxR7xTQft2g_11_0"></a><a id="Tc_HqiOg8MEbEKyMK6vKA7sBQ_12_0"></a><a id="Tc_1llSjJCBgEiseEQzAB_79Q_13_0"></a><a id="Tc_9xPJW3ZQ20C7rmYk-NlmYQ_14_0"></a><a id="Tc_TJYb3A8sp06tKScWyAbNpw_15_0"></a><a id="Tc__xqE28DXAUynbS4HO3kjOw_16_0"></a><a id="Tc_gCh-6A-JWEeugEO6lzYSAw_18_0"></a><a id="Tc_M4pSDF0BDUer45W1clTUsw_19_0"></a><a id="Tc_3obZC4XxhU2Dw9oJuha6mg_20_0"></a><a id="Tc_uHLutwK6t0OBs6Ejx7e62g_22_0"></a><a id="Tc_hLLH1UT0QEW2PZ2XR0GLGw_23_0"></a><a id="Tc_GhMlh51VXUicdctDaRIP9w_24_0"></a><a id="Tc_4UpPZbYzdECtmG8ldC-9_Q_25_0"></a><a id="Tc_Gm9vXusl4Uir4aq6vJtxJg_27_0"></a><a id="Tc_D7fwLK3UpEmMspVEnxFvyA_29_0"></a><a id="Tc_a9y72XY8FkOGpr9C2v2n4w_31_0"></a><a id="Tc_ZBvpcV5IQ0yT-RPvCn-dxw_31_2"></a><a id="Tc_UF-CUYry9UuYrCkWHbXd8w_31_5"></a><a id="Tc_J103RqPW1EKsa9FH6KZf0w_33_0"></a><a id="Tc_7P73eTfBvU2QDo76LvcabQ_34_0"></a><a id="Tc_V9jZZmmueESVPu5tatm1bA_34_2"></a><a id="Tc_7HrlRNVl_0qDfINrsdZUvQ_34_5"></a><a id="Tc_g3TD7cMCj0Sw_cciHHpTDQ_35_0"></a><a id="Tc_mtfrIU7lOkWDpWu0Z8QmFg_35_2"></a><a id="Tc_RqJ19eZ7KEKAYiZ-3D2PNA_35_5"></a><a id="Tc_mWgX5G5BdEmyeVzkelRkUA_36_0"></a><a id="Tc_MsDjaDFBQkizIgZ5_hU7UA_36_2"></a><a id="Tc_T0MxuHoJREuVAKYTRvErhw_36_5"></a><a id="Tc_ujz1kXzLcU6VS3Gk6M5u8Q_37_0"></a><a id="Tc_L0iem7gXdESQQtdaJhfjzg_37_2"></a><a id="Tc_xe7reM6Z6EmGfo1Y2BCqrQ_37_5"></a><a id="Tc_5BsuazyCHUC7uRbT8jPu6Q_38_0"></a><a id="Tc_tvpIsYPXDEib0LsBFWJdbQ_38_2"></a><a id="Tc_ltir6UW97USBx4zdAYJsMA_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows From Operating Activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_h-qTEbrWIU2_cg1AXXb7ug_4_3">5,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_ZlECbgFBvUufMYw-_-zuuw_4_6">5,873</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_-a245v6lHUyVAPx9arczKA_6_3">203</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_EJnTstUx8UaAPN5T0t12EA_6_6">169</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Subsidiary stock issued to vendor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:zerodash" name="syn:SubsidiaryStockIssuesToVendor" scale="3" id="Tc_kR6v9OzNIkWU73RxQsgRZQ_7_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="syn:SubsidiaryStockIssuesToVendor" scale="3" id="Tc_97aJJvIPt0qDICP4MysrAA_7_6">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_YcLNQTkXa0Obouzp7UMIRA_8_3">56</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_SO2juw5GEEG9FDUaRDTGVw_8_6">116</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_Un5Lu9yYaUOGGIjWjYMuhg_10_3">366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_7Scjg1Md_UOBhK_-UToEgA_10_6">484</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right of use asset</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_bJTLvf-1P0KIaInemJY30Q_11_3">81</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_Y3hnoRrtZ0OUqZFLTp_enw_11_6">67</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_MPNUjzO4aEuUhR-hfWnYAA_12_3">318</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_jp4GD_dC4UepjJI3dvi3Rw_12_6">1,290</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_zbTUZNM-uEyjisck6GidvA_13_3">131</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_RgIANicgnECHn0AhYsqU9g_13_6">567</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_u2Cv-yHtWEGE8NDZeMNj8A_14_3">328</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_LLRz-PZNyEOHp04O2TB3Yw_14_6">8</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating Lease liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_FNhNDxFOtEqywB_Sdv-KhQ_15_3">121</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_9wAiqhMoU0ipMwhOj7AXcQ_15_6">120</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Cash Used in Operating Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_n5qCFOqItUmDhHjzXIXzqw_16_3">5,924</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_-5K7B6A8CUOBzQgyxgo_OQ_16_6">6,986</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_p0fpbjzIDUSAJ6he7QuPEg_19_3">14</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_USa17cbuhkCA7GHkQ-caTQ_19_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Cash Used in Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_cqaNzULcFk2E2BNGS8aOGA_20_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_NLq0r2yEbkWgZw7li4KpZw_20_6">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash Flows from Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from &quot;at the market&quot; stock issuance</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Sxw3zy6lUEyTMaY0gD23aA_23_3">65,960</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_TX7zO15Wr0eN5FzOAYezrw_23_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock for warrant exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_X4wO23A9R0WzhOXKbCA20g_24_3">8,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_gW0MB6fVoE-g0wV9A5rMcw_24_6">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Cash Provided by Financing Activities</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_MiQV0b7lW0q9G3dqcwZnUw_25_3">74,002</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_s2AISWt0VEqv0JodqKJ1BQ_25_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_lQy9SRgXhUG61GphtJaaig_27_3">68,064</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_WRIdgm4C2UKa-jObVfuvqQ_27_6">6,986</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents at the beginning of this period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_cAjoDKOgY06g6ivK8P7Yfg_29_3">6,227</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_4f1h5RyEzkGK-_3OcjprBQ_29_6">15,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of this period</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_T6bxUea8806JKup1HXimfg_31_3">74,291</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Hgr-SXgtnEWFAIWtdPAEjg_31_6">8,059</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Noncash Financing Activities:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_K2_h2mx_tE6K6x4BdQ_GPA_34_3">7,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_rip6yxPhpEK32apcLYd-Zg_34_6">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right of use asset from operating lease</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_bKPnXd9rz02nD4D9xMXvvQ_35_3">1,270</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_5uVmYkpawU67A7kfZ24N3Q_35_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Conversion of Series B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_FWa4an93_0KMAxTpJgFUeQ_36_3">2,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_7W_XWjJwjkK_EgvJDfdRlQ_36_6">1,317</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deemed dividends for accretion of Series B Preferred Stock discount</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="syn:DeemedDividendsWithBeneficialConversionFeature" scale="3" id="Tc_Wd0c2icsBk2-GZ_59wRhKQ_37_3">1,497</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="syn:DeemedDividendsWithBeneficialConversionFeature" scale="3" id="Tc_8DP30rRsgUalyREIN6GjOg_37_6">796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In-kind dividends paid in preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockPaidinkind" scale="3" id="Tc_RnSJgppipUaYy85uxCuYzA_38_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockPaidinkind" scale="3" id="Tc_NOgdB06yx0eQeTp-4KJ_Ow_38_6">125</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="OrganizationNatureofOperationsandBasisof"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_O5T9le_idEGw5nTPfcUV_w" continuedAt="Tb_O5T9le_idEGw5nTPfcUV_w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization, Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a diversified clinical-stage company developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#8217;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company&#8217;s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full&#160;year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&#8217;s 2020 Form&#160;10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements and Developments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update &#160;(&#8220;ASU&#8221;)2020-06, <i style="font-style:italic;">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (subtopic 815-40)</i>: <i style="font-style:italic;">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O5T9le_idEGw5nTPfcUV_w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization, Nature of Operations and Basis of Presentation</b><b style="font-weight:bold;">&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Long-lived assets include property, equipment and right-of-use assets. In accordance with ASC 360, <i style="font-style:italic;">Property, Plant and Equipment</i> (&#8220;ASC 360&#8221;), management reviews the Company&#8217;s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset&#8217;s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. During the three months ended March&#160;31, 2020, the Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_xCICwmPnfEy7yS7c-d2wXw"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_Hw5E6X9ghU2l61_eoKfgbA"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_N6r5u8937U-QOX2khxsUBQ"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="0" id="Narr_9xitxy2sy02lqbxmK4JoRg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges were recorded during the three and six months ended June 30, 2021 and 2020.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_UXiGgTrylUys1FCijJ53SQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 1 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 2 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 3 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ab86ef36_ce94_4a73_aebd_d6dac1d05cfc"></a><a id="Tc_DiWN42zEXkKhD9NfzqCI1A_1_2"></a><a id="Tc_tgT2v777DkCAnU-eeFy9vQ_1_5"></a><a id="Tc_CmWpdui1PEyWntl5Z1I5sg_2_2"></a><a id="Tc_9e_fHUBC3E-AXHDEyd_ssQ_2_5"></a><a id="Tc_Ck9nNolLO0mM_NEbolFLEA_3_0"></a><a id="Tc_F8wyVGIeMEaBDzG4qa7_OQ_3_2"></a><a id="Tc_302sG0YSY0WOS-mC3xuRJQ_3_5"></a><a id="Tc_TEu8E_dkyEm-GzgbwQGAFQ_4_0"></a><a id="Tc_tqCZKC4q7UiIJyqX7dG6tw_5_0"></a><a id="Tc_yo5AGpnopUC4PILHaQkOGw_6_0"></a><a id="Tc_uD_2XHAmzEWtTzK0V7_wWw_7_0"></a><a id="Tc_rgeHnxnfgUiZYpRw0Mlq7w_9_0"></a><a id="Tc_lNHMksCa3kiDZeJU8yJcGg_9_2"></a><a id="Tc_JuxyjbJaXkO8lbyeGwZx7g_9_5"></a><a id="_da70a795_c3aa_4999_b6fb_231cc10811bd"></a><a id="Tc_F98NnoANk0-ktuN2TBSNtQ_1_2"></a><a id="Tc_G8e0udjT_kymTNMXgM_AHw_1_5"></a><a id="Tc_VK3U5_nmyUSysWf7qDshEA_2_2"></a><a id="Tc_KKPNet0PTkepm1aj9yuwZQ_2_5"></a><a id="Tc_FnshC0BGqkmDtFcW8nmR1Q_3_0"></a><a id="Tc_UXUrUzVQIk-PHqB-RorkdQ_3_2"></a><a id="Tc_mhSart_-XU21wOw-48szSw_3_5"></a><a id="Tc_1HgpGodC6kKv6wgX_HueqA_4_0"></a><a id="Tc_zU2uYAs6_kifx7rjSf0kqA_5_0"></a><a id="Tc_YFKyhZj2b0-UKYfZwvCRQA_7_0"></a><a id="Tc_JpD5HrJr0EChg60B6wIoqA_9_0"></a><a id="Tc_gr1S3VaJ2Uu0fHAHZ91ZLQ_9_2"></a><a id="Tc_NjukMGzvbUikulY1JqbBRg_9_5"></a><a id="_21d3f10a_d57d_41c8_ab72_544f5a26e92b"></a><a id="Tc_7QhwbqTcG0mAMo66d5apVA_1_2"></a><a id="Tc_vNH5Q3IhmkeKUyVMB6I6-g_1_5"></a><a id="Tc_VVmEtDjNNkqsaCBEm0ZfVA_2_2"></a><a id="Tc_Qncc-eDpMUONrGf4kxsQeg_2_5"></a><a id="Tc_KfgpVJMZ7Eu_NgiglG3dww_3_0"></a><a id="Tc_GurP6q-IdkqglckMlxVz-Q_3_2"></a><a id="Tc_VcIosx_boEWv8EtcNzZuVw_3_5"></a><a id="Tc_0JAFYr9Kw0mHcmblgiXTXQ_4_0"></a><a id="Tc_OTTXcBRh7UywSArR2OfWDA_5_0"></a><a id="Tc_7YVl8v09xE2sylRFltI1Ig_7_0"></a><a id="Tc_bW7-obVDPkO7ZM4_4T9RnQ_7_2"></a><a id="Tc_lcb-7wjmbEK0yx-k0y8-PA_7_5"></a><a id="_33e5a711_80d5_4eb4_b5d2_cd30e10b683d"></a><a id="Tc_dUqvi2X5ikGHBQOVDtPTWQ_1_2"></a><a id="Tc_uVgdTG_ZGkix6Q6mB9QYKw_1_5"></a><a id="Tc_DxftP_VQAEKwf96k7w_bUg_2_2"></a><a id="Tc_EWLWt2qBbkmKAteETRM_cw_2_5"></a><a id="Tc_wP_o03B3-0WOlVDjH-XCWg_3_0"></a><a id="Tc_T5ElzWUtdk2N1tNKCGUKmg_3_2"></a><a id="Tc_sUndOnkfTkeqKY3u_l5XyA_3_5"></a><a id="Tc_QoANQnfyYE-g8a6F8tDcCQ_4_0"></a><a id="Tc_8r72VM7aqUaEHm-yQXA4Lg_6_0"></a><a id="Tc_CJeqDJldXkOhXGnoSwRNcA_6_2"></a><a id="Tc_ZJ_h7cwKWUqOA3UqaSv0vw_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_r-DzZIj9Pkiz-7tadzuVhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Selected Balance Sheet Information</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="Tb_E4X17OGjwEK5q3EHRC4kwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Prepaid expenses and other current assets (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidClinicalResearchOrganizationsExpenseCurrent" scale="3" id="Tc_t9CUecMDXUi69qEBpguT7g_3_3">880</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidClinicalResearchOrganizationsExpenseCurrent" scale="3" id="Tc_nuWp4yjwrUuQlwwJuXokiA_3_6">470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_THK7nCPL2EGMcnp48-oufw_4_3">280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_ZS0AUKfrBUSXhKrhbUoXyg_4_6">639</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidConsultingSubscriptionsAndOtherExpenses" scale="3" id="Tc_cJIawalzjEaSQeKSFApfYQ_5_3">181</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidConsultingSubscriptionsAndOtherExpenses" scale="3" id="Tc_VF66cUzSc0GxCtcSZCC-fQ_5_6">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_UcEX6sKKy0iNKlAExmkNDw_6_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_t_VLEE_kU0GHabwO3F8gEA_6_6">469</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:zerodash" name="syn:PrepaidManufacturingExpense" scale="3" id="Tc_-E3UX4Yw40WSbO7B9fc0Xg_7_3">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidManufacturingExpense" scale="3" id="Tc_BNpCLNOWPkK_EOUGSSHZHQ_7_6">39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_Ol5NU27tC0eDve2icl3J-g_9_3">1,341</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_NCXca-5Na0CnBIMoIuKxGw_9_6">1,707</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prepaid clinical research organizations (CROs) expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_Rul3vnK7dEmjjJgq83LjyQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Property and equipment, net (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_6GJQIqP4z0u-0VYhtn0pwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YuzGsLfOWkK83tAU1j4z-g_3_3">827</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_GfHbuB9ZRUGhg2eteRKuJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_87zdNBCSzUq9o_JNRVqvfQ_3_6">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_t4jWqATDt0GII2ExNce1_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_cl499vMDFUCk-EqZWfaxlQ_4_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_w5NkU2_sOU2NkvPwvNTs-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_sdOCeLWmdE2EvZOXXiVvfQ_4_6">439</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_qSjb2MQlSkOywB4mpExYgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_EVAPWewJj0OfNThlWbiVRw_5_3">11</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_V3AVcyTze0yXKy6SgCQQOg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_jr5gF9F7n06_mm2Z2sRdJg_5_6">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_VZElBLZW40eY-GrpBqCHyA_6_3">932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_QM7ys6SENUysRRLemIanCQ_6_6">1,263</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_-LDHi5WRqUGlSTa9LKlPQw_7_3">800</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_wjm5amvVvUOS2XYwJps0bA_7_6">1,089</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_vK0wdnMxbkOQH-XvmZD5-Q_9_3">132</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_X-siDkhnnkGU6j_w4BQgww_9_6">174</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="syn:AccruedExpensesTableTextBlock" id="Tb_J3-gPAw5f0qZxZa8rWjQuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;">Accrued expenses (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedClinicalConsultingServices" scale="3" id="Tc_Ldqxl6AioEGqqGKXMI0pUQ_3_3">700</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedClinicalConsultingServices" scale="3" id="Tc_-a-x-d639EaimpacoMwldw_3_6">700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedVendorPayments" scale="3" id="Tc_oAaS4sJY_0WSk5DmU21t9Q_4_3">92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedVendorPayments" scale="3" id="Tc_jAEvbufOLU6ZrAi5CzicFQ_4_6">225</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_shcIpdnkoEq-kn2rCz-S1w_5_3">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_8LDvsICCik2PL5sQ0Tx6_g_5_6">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Xd4OYb5ioUqM4OQGSDJ-kQ_7_3">794</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_FWbYI9tbGUmuB5SIlNMlRg_7_6">925</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="syn:AccruedEmployeeBenefitsTableTextBlock" id="Tb_OzvDxPdcoUCBQ-eBKxoKVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Accrued employee benefits (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_dVMmHg5ZJU-7ZNZHBM-8EQ_3_3">361</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_DwIYWw0O_0SPW4CBeWRBaQ_3_6">724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_1Mrhjwr200-c0QN0ptva4Q_4_3">179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_JAbIxaBp0Ei0yyDo94NAmQ_4_6">144</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_NkZXIwgYCUG-IV3LjbiENA_6_3">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_16BkV9Pk8EWbnEjl-g7FFA_6_6">868</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_aw-3DQByvE-0bM8TL3qtIg" continuedAt="Tb_aw-3DQByvE-0bM8TL3qtIg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_9p8BUi9xpESM0XFssipxEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_x-gcC2BYIki8KsrBHHK5IQ">71,429</ix:nonFraction> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and could be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 stock plan shall not exceed <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_3_20_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_wLkfa3YyAUWs_EVe-EPt2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_BBAPhcnqAUCb_5fvb6vKzQ">7,143</ix:nonFraction>. Options become exercisable over various periods from the date of grant and generally expire ten years after the grant date. As of June 30, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_81VpuqIrTUGMs7nm1_pSJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_SJaXoTtJmkqVjbvUycnuEw">5,145</ix:nonFraction> options issued and outstanding under the 2007 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_aNYaq92HaUaThT1YEHFknQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_CVWx6bf2aUq4Q8eJmO1cMQ">85,714</ix:nonFraction> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten years after the grant date. As of June 30, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_LcbLiBbyFECO_hZVyJHpuQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_7OS_1xIBnUGbGurKERS85w">2,452,273</ix:nonFraction> options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan (&#8220;2020 Stock Plan&#8221;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_mDQnCUaukkitwCFkDu49Aw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_L5Vw_XTg2UqPYQTjuDYkPg">4,000,000</ix:nonFraction> shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of June 30, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_RJbNJpRBXUSt0ueloEGWTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_0BNKk8PR3Ey_aJdkOKswiQ">1,540,000</ix:nonFraction> options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee&#8217;s options. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has applied fair value accounting for all stock-based payment awards at grant date. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. There were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zJO5Vy7y90-lmBQP2GMq9w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_WddvdXnK-UWSho3H3qTAeQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VBR-eClC6UGC07S2WEllbg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ohl7IJM3a0aPvx6V_ZTGiQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_nxcbCHk90UKWsKac8p3Wzw"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_u9ws48CLOUekneGx1DkoNA">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> options granted during the three and six months ended June 30, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividends</i> <i style="font-style:italic;">&#8212;</i>The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#8212;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#8217;s common stock over a period approximately equal to the expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#8212;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_aw-3DQByvE-0bM8TL3qtIg_cont1" continuedAt="Tb_aw-3DQByvE-0bM8TL3qtIg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected life of the option</i>&#8212;The period of time that the options granted are expected to remain unexercised. Options granted during the year have a maximum term of seven years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">immediate vesting,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">in full on the one-year anniversary date of the grant date,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">half vesting immediately and the remaining over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">quarterly over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">annually over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-third immediate vesting and the remaining annually over two years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-half immediate vesting and the remaining over nine months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-quarter immediate vesting and the remaining over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-quarter immediate vesting and the remaining over 33 months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">monthly over one year, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">monthly over three years.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4ce84f4d_a1a9_49c4_ae0e_f013cff06035"></a><a id="Tc_n12lgyxIhk6UJxF4cEWZQQ_1_4"></a><a id="Tc_YUAsUyhy8Um3Dx6vLGprRw_1_7"></a><a id="Tc_nuC_FWOac0mBkVJUEirB_A_1_9"></a><a id="Tc_7s1owx0PfEyHTAt8VvYk1Q_2_4"></a><a id="Tc_jJg8GW6Oc0q7HPGFOfPd-Q_2_7"></a><a id="Tc_xrF4ItvHKUyF2epVDX4ZVQ_2_9"></a><a id="Tc_UduiZQJbCk2UFDGLGHPJNA_3_2"></a><a id="Tc_3IEJ4LdAXEqtnzxF2qQtXQ_3_4"></a><a id="Tc_PPrxmIK780q68kfAzhG7Iw_3_7"></a><a id="Tc_hTiyeRqGtkSW5iYOjiH6Ug_3_9"></a><a id="Tc_qFv9z4VoKUatgfByE1ArGw_5_0"></a><a id="Tc_TXGygHzUkUuWyIMIIdjUtA_5_4"></a><a id="Tc_jCCPwofqGUeEulFSi90kIw_5_7"></a><a id="Tc_vfZ381nTeUuVJbk7gCrJoA_5_9"></a><a id="Tc_ytFFGx_iMkq8Xe3mT-H7Ww_7_0"></a><a id="Tc_Tidi38Ag90uTdKqqYYhWAw_8_0"></a><a id="Tc_TChpt2Sqk06q4E8tda1i8w_9_0"></a><a id="Tc_YMmL08sTGEmsAiHEKfgtCQ_10_0"></a><a id="Tc_vJDBU-zk60mloGTepp0U0A_11_0"></a><a id="Tc_KwvUx5Dy4U6C2Vvexn70dw_11_7"></a><a id="Tc_kK11GbBdEECyN6RLaNiEmA_13_0"></a><a id="Tc_EkNzUJbCFk2yvUL1awBzkw_14_0"></a><a id="Tc_IZh_KFoF8ECwEPRwR2kSYA_15_0"></a><a id="Tc_S95InPk2fUOF1kYFEIrSYg_16_0"></a><a id="Tc_Z4DFaWot80yXnoOp9mu3MA_18_0"></a><a id="Tc_EeqhMiseykihiOs2JEqDBQ_18_4"></a><a id="Tc_P7KA9JUc7UCdahHfGQbjLA_18_7"></a><a id="Tc_tgXpCZ4_t0SIqypHezz_Jg_18_9"></a><a id="Tc_3wmnjG2piEeMqMEe9hO71g_20_0"></a><a id="Tc_ilpoccjmBkixAOTAkluwsA_20_4"></a><a id="Tc_anUIpt3LT0CCG0ePeopeug_20_7"></a><a id="Tc_f7zsWOfk0k28dGQ2nK0y1g_20_9"></a><a id="Tc_69IQNNX6IEqDr3jKHvWJiA_22_0"></a><a id="Tc_szPeqI79dke-LdxTrWdTmw_22_4"></a><a id="Tc_P9GxN4o8w0GgElgCR7xbUQ_24_0"></a><a id="Tc_MRNKQNPITECi5fhjT7RcAg_24_4"></a><a id="Tc_S5n8KHch-EiKZUaoyJLoWg_26_0"></a><a id="Tc_vqURmA-4WEqdwZrv9EYI2Q_26_4"></a><a id="Tc_FLOPmRLgoUmY1sJcEF85sQ_28_0"></a><a id="Tc_t6Fa9hwFRkSp_zPUdTYckg_28_4"></a><ix:continuation id="Tb_aw-3DQByvE-0bM8TL3qtIg_cont2" continuedAt="Tb_aw-3DQByvE-0bM8TL3qtIg_cont3"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_obukUe9YmEK0F_7Jx1coHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_hktsnjR0zEee6qPkTT9Pgw_5_2">2,502,012</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_DDdguYKFu06THcUIsNwhVw_5_5">3.62</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zlQvdoOjn0eIo5zMpiXNXQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_8A48e067bU--kl7n5A4HbQ">6.51</ix:nonNumeric> years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_QCLZkHG0UECDBkKe-P8UMw_5_10">153,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_uxJxJrb4F0uSm1wAIXVatg_7_2">1,540,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_8lBnUtuX-UyJM9Q10tzlgg_7_5">0.42</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_Ng7eOXaQp0awKhFl67-jrA_8_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_1ubrPifx3kSOB-scO77WBQ_8_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_QiCT_1D620qLHR0Icdhflw_9_2">14,944</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__-FHhrLSKUe-llXgqWfL5g_9_5">17.57</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_3l-HPB_lTEu-_hH1iTD58g_10_2">29,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__OeTUY1l4068P4gLoVhhwg_10_5">0.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_72-7nQf0_kWoX9Qf5e3ifA_11_2">3,997,418</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_wBXsh1cObk6bX9NKNlSdaw_11_5">2.35</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_gpcMJIYARUKMSCM_bLoj3w">6.09</ix:nonNumeric> years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_1EJieLkoZ0uYoBsyPQo4aw_11_10">-</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_RDk768TZP06SZEISL59p_g_13_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_A3TvGRpdLEWSKgNmXUqbcg_13_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="0" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc__UcOrnI4k0iZlVHozMeDoQ_14_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_uixQ3Tz5Yk-NT_UDHaKWPg_14_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_m4JaG4J1xECEoRV6bcr1QQ_15_2">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_k3AgJ4KHQUSGTlja4VI_mQ_15_5">-</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_nfa95Q9_U0mtQBu6sHv92w_16_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_E8zjIv36u0-k-YzcfY1pxQ_16_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_mn9qEc6j8E6b7vKz-d5e-Q_18_2">3,997,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_o8CK-kp3LU2p3DXntutmMg_18_5">2.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_LwL3i2PAxEO55ba4MVABmQ">5.28</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_30ActVx93kmNwXMdPuunhg_18_10">598,074</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_0-glJ3ytmUiwIcU7kRkblg_20_2">1,970,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_L6AbNyctdUS6cUjc1Prrsg_20_5">4.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_2k7TzQbfSUSBv-uIE4Et7Q">4.55</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_6BtdOt17i0u0b-YL-vQpYA_20_10">239,357</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg" decimals="0" format="ixt:zerodash" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" scale="0" id="Tc_QhW1NEYCAUmu1TR8Z4UllQ_22_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_G3qSFmjtw02bra2VwyZjTg_24_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" scale="0" id="Tc_jPUzqvCZB0SKIMobb3sw7g_26_5">412,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_yDQDvp6AZECDAwR-iuq9LA_28_5">0.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_D5zQtc11wUOnLMnkObcf0g"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_5PGqrqKAJ0eLs7JEJ6V0Eg">34,000</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_eIcfeMgtzUC9ndcccKwg3g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_UHU3qMiROky60n9GwFOgAg">67,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_a9LDsj3uzkuOTiqR1RdjjQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_9qBpmumvl0GUmKHkqPSIXQ">40,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_YSUSLqISakeFFs0u8z32iQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_8oUEIyhPLUK3vnCcFU3kGg">79,000</ix:nonFraction> for the three and six months ended June 30, 2020, respectively. Stock-based compensation expense included in research and &#160;development expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8Voeje09P0KdHrvytlGF5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_nXKjAbVsskmAoi_xahqJmw">16,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_GjoOepJsFkG33JO-DraytA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_HYmTeNkFYESHRj_6Wp-aMA">31,000</ix:nonFraction>,respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_7LiVHRy2BUaPnoZoXiYlag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_ie_UsdBf8EeV9szGRHx4eA">15,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5AoLC7KQ1Uawve2qPbgbzg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_5UwktT8g40-hJoiHzIROLQ">31,000</ix:nonFraction> for the three and six months ended June 30, 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_PFI4t1qvYUeUPVPhulwM0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_snqbLlz6v0KuhXKbKgyBaA">49,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_f5pVsHeOF0esc-wKzvKXnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_V67RxBah8U-HzOsTupFWaA">98,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aqlwFNKohE-KfzX_Eclrdg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_bS4H2OCH-kWl3Rqz7mJzRw">27,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_dAV91tPf8kmgXysC3CKWIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_a2cQDhxOjUqtyP344o2Umw">53,000</ix:nonFraction> for the three and six months ended June 30, 2020, respectively.&#160;Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_Zk4qTUzc2EeG7AwMKOnF_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_rC8AwrKYeEu4fVhL0vJ_bg">3,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_IC8EXhUAzkGZ5rMnpHL2gg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_qmd-EU04bkewu-tJ-eMLCA">7,000</ix:nonFraction>, respectively, and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_gAS70YQ3kEWbAigVthvfbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_5FssuGRVzEuEyq7IB54Erw">4,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aPnGd6B3pESapmPXpuMoYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Narr_1oy7YQc-50u0_E7xJGQ8PA">6,000</ix:nonFraction> for the three and six months ended June 30, 2020.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_aw-3DQByvE-0bM8TL3qtIg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2021, total unrecognized stock-based compensation expense related to stock options was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_ti5CO7cffUqO135yayXcxg">483,000</ix:nonFraction>, which is expected to be expensed through April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FASB&#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June&#160;30, 2021 and 2020.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="syn:StockPurchaseWarrantsTextBlock" id="Tb_apvHBk6fukydPDZ0DSqjqQ" continuedAt="Tb_apvHBk6fukydPDZ0DSqjqQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_WAOIaebx8E24nOYIBnwUSA">18.6</ix:nonFraction> million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_bdhxK7hqDECM_T4Lq_vhjQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_oKjxhP9tEk6CZKsml01qJw">2,520,000</ix:nonFraction> Class A Units (the &#8220;Class A Units&#8221;), with each Class A Unit consisting of one share of the Common Stock, and one <ix:nonNumeric contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_JR9Vjj4m3kihR7DJRSC05w" format="ixt-sec:durwordsen" name="syn:WarrantTerm" id="Narr_HWetZYs3rEGCNpL0p1O1LQ">five-year</ix:nonNumeric> warrant to purchase one share of Common Stock at an initial exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_kLYbSCxQNU-mZmUxNjtqEw">1.38</ix:nonFraction> per share, which subsequently was reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_J_3IY1NzsUSQCK8IVUzs-w">0.69</ix:nonFraction> per share (each a &#8220;Warrant&#8221; and collectively, the &#8220;Warrants&#8221;), with each Class A Unit to be offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_3gTs8oyOF0aB6OtGcYRXyA">1.15</ix:nonFraction>, and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dvzYRfZpzUCe7pw2pnnTzA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_s7-vEgSdmk2Y0HrHaCkGAA">15,723</ix:nonFraction> Class B Units (the &#8220;Class B Units&#8221;, and together with the Class A Units, the &#8220;Units&#8221;), with each Class B Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_9Rurn2JU6kCY8TJx-JJxBQ">1,000</ix:nonFraction> per Class B Unit and consisting of one share of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Series B Preferred Stock&#8221;), with a stated value of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Narr_Ai2407qLBUWEFBaut32TWg">1,000</ix:nonFraction> and convertible into shares of Common Stock at the stated value divided by a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_bVT6B8UxQ0GBuF7OioYUCQ">1.15</ix:nonFraction> per share, with all shares of Series B Preferred Stock convertible into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_dvdguscxeU-VR3CHbkrGTA">13,672,173</ix:nonFraction> shares of Common Stock, and issued with an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_u4kbim5KiEyW-zB1-W8-HQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_FUHx6ihDpUO1Eay2kk10EQ">13,672,173</ix:nonFraction> Warrants. On November 16, 2020, the exercise price of the Warrants was reduced from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_15_2020_FnMilutR6Uaa49a8AX4Ozg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_vh71-6RqTECrQfQg6NwS6w">1.38</ix:nonFraction> per Warrant per full share of the Company&#8217;s common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_thl0hRrJMU20WWIJ_jpHTA">0.001</ix:nonFraction> par value per share (the &#8220;Common Stock&#8221;), to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_1ZW4AgestUid_aQT2R1b2g">0.69</ix:nonFraction> per Warrant per full share of Common Stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg" decimals="0" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="0" id="Narr_RqQnKbsYDEm7WCPycmVHUQ">880,000</ix:nonFraction> during the year ended December&#160;31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#8220;Underwriters&#8221;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_slSCc3YOzk2ByscUunSdgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Jsujyl53g0KdtsmKJ5gLpA">2,428,825</ix:nonFraction> shares of Common Stock and/or additional Warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_njvvYCOrE0G7--zGCHARcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_kxvHf2qj1kO9TkyKNpVL1g">2,428,825</ix:nonFraction> shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg" decimals="0" format="ixt:numdotdecimal" name="syn:IssueOfWarrantsToPurchaseCommonStock" scale="0" id="Narr_zRjDkVdPeEi-TpF_cZcfwg">1,807,826</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_11_16_2020_To_11_16_2020_Q4U6TfXbjUGV399zEsrnGQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_QuhFm4VPEUOnYuAK0sAciA">No</ix:nonFraction> fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the six months ended June 30, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_WSxxQJt6wkSqtxqIte9ptg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_4vFbrYWC50qUemIKfEILKw">11,655,747</ix:nonFraction> warrants were exercised for cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_eLHHnAPaY0ijrW_gAodjMA">8.0</ix:nonFraction> million. There were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="0" format="ixt-sec:numwordsen" name="syn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_CIrp6LehQkG1JrXbEsHgyg">no</ix:nonFraction> warrants exercised during the 3 months ended June 30, 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_073318d3_fed2_422b_bca1_06b48b76d939"></a><a id="Tc_zW7tsvnmIk2RYYTTZT2s0A_1_2"></a><a id="Tc_5bXCpNCsOkup1rhq1bM3qw_1_4"></a><a id="Tc_sxyJIMjh7Uygb0aw61tWEQ_2_2"></a><a id="Tc_u7BbBUsk10qRauvkPdtCgg_2_4"></a><a id="Tc_STh5wnUtA06zSy_Z95cqjg_4_0"></a><a id="Tc_xqhEYtBNUUGouOLoHlPgBw_4_4"></a><a id="Tc_bH4AyB24tE-3TUeBrP7pHA_5_0"></a><a id="Tc_i0LuNdy39k-64JBmgqJuPw_5_2"></a><a id="Tc_72x3pugYXU2_Kf7m2nxWYg_5_5"></a><a id="Tc_24NibSehfEmioJ6zbvSYEQ_6_0"></a><a id="Tc_zh5Pnm5eUk6QJxt4xKWxPw_6_2"></a><a id="Tc_esY-Xlp2NEG1TzQs8wfTgg_6_5"></a><a id="Tc_8tQ-U-MXZES5kiA9PNm2gg_7_0"></a><a id="Tc_bA8UNiq7-U-eYF3Y74q63Q_8_0"></a><a id="Tc_Trhl_gzNQ0euSnteiebCAw_8_4"></a><a id="Tc_XmhOcPh1gEuDH-5t6r2ZTQ_9_0"></a><a id="Tc_A_3KT3O9pkSLv4SeW8ftbw_10_0"></a><a id="Tc_-Ob2Wa8FGEKrh2Iaei7jhw_11_0"></a><a id="Tc_4ySjhlhhAkm6WcEi_aIjnQ_12_0"></a><a id="Tc_rTXUEWn1WU6NUaGcnOKunw_12_4"></a><a id="_e9a6186d_d1c1_419c_8a7e_b25bd3de508f"></a><a id="Tc_5FesUHYTzEW1PeW64Nlc1Q_1_7"></a><a id="Tc_dWwqm5MkX0m8QYBCDX685g_2_0"></a><a id="Tc_4H3iWDGxLEOpI8sKnQfBJg_2_3"></a><a id="Tc_JosbenrTKECJlZBTD-W9KQ_2_5"></a><a id="Tc_naDLSkrzJkO75QwplV6n1A_2_7"></a><a id="Tc__LBnBRk3lECUuqcx24fD1w_3_0"></a><a id="Tc_5Nf2AELKN0CPGzNHRGi1NQ_3_3"></a><a id="Tc_wR4fK-za20G-3vOZHVKOTQ_3_5"></a><a id="Tc_WNS7LVrzsEK3dpHbjgU8Ng_3_7"></a><a id="Tc_o0nD7bOccEagj7YWriHVug_4_0"></a><a id="Tc_P3362es9OkKDtTu-F41cGA_4_7"></a><a id="Tc_6Xv7kWB_u0OPK7hksBlrJg_5_7"></a><a id="Tc_OxQioBlYck-GJBso3SBeoA_6_0"></a><a id="Tc_vmrWd4yEEk2qTZ3nGQeBdA_6_7"></a><ix:continuation id="Tb_apvHBk6fukydPDZ0DSqjqQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Stock Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 18, 2016, the Company completed a public offering of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_p9VkK2Ce20-b03B7rUyXiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_vsf615aV9kqDqS3VPf1BEw">714,286</ix:nonFraction> shares of common stock in combination with accompanying warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_HpVqWybDaUGuM797NB-s8Q">1,428,571</ix:nonFraction> shares of the common stock. The stock and warrants were sold in combination, with <ix:nonFraction unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_CDRBLE4qQkaDOCYG-eI5Zg" decimals="INF" format="ixt-sec:numwordsen" name="syn:NumberOfShareSold" scale="0" id="Narr_2pzui7iKL0W00URp2ueuOw">two</ix:nonFraction> warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase <ix:nonFraction unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_onT3wd_AR0CjAZdM083VMg" decimals="INF" format="ixt-sec:numwordsen" name="syn:NumberOfSharesPurchase" scale="0" id="Narr_nEmsDRdvBEmQ62C9pb3Xsg">one</ix:nonFraction> share of common stock. The purchase price for each share of common stock and accompanying warrants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_GY0ranx6xEycwGoED8rfWA">35.00</ix:nonFraction>. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_93GgZzd5OUWNIi3WddVejA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_sK7-JcHFck2cYj-gf9r32w">50.05</ix:nonFraction> and the per share exercise price of the Series B warrants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_mdSu6IH6FkWLzuUBCfIegQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_uBV9pfmB7E2DYZ3zGDHfHw">60.20</ix:nonFraction>, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The Series A warrants expired November 18, 2020 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_P0C1FZF1VUenjOMOZHMVbw">15.7</ix:nonFraction> million and changes in estimated fair value will be recorded as non-cash income or expense in the Company&#8217;s Statement of Operations at each subsequent period. At November 18, 2020, the fair value of the warrant liability was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_11_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember__J-NQrr_RUyU2Fj9hkVnmA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_0xv_1--mfEqIaJoHSLA-uA">100</ix:nonFraction>. The warrants were valued on the date of grant and on each remeasurement period.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="syn:ScheduleOfWarrantActivityTableTextBlock" id="Tb_eqmfrA9HKECAha9UBmg5rQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_HQvjTFQDrkyxS8mrFWQpvw_4_2">18,714,999</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_llD__M-BAEmmOjpA3bE6JQ_4_5">3.24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_iKRj-U9zmUWO56HdcWBaeQ_7_2">714,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_32E9SiwkVUCs5A1mOoRq0Q_7_5">50.05</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_9W7AwPjr-kiSMQBs2aC5Jw_8_2">18,000,713</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_7__S-bHTQkW9InGcuyIGIA_8_5">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_wuKsYiKmXkW_6SsAi0IgEw_9_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_gfrIpoNCLkSdYyxiGkKEfQ_9_5">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" sign="-" scale="0" id="Tc_6gbGgBaYZUS7DXFN4oxxgA_10_2">11,655,747</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="2" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_xo59arK9R0CAlCPaNucINQ_10_5">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_OCnty1KrdkuL94fXGUtDRw_11_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_Lo0KNTevREy1OmUVnWhYig_11_5">-</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_MyIWbFztv0OWbgBiFyo-rQ_12_2">6,344,966</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_7LViJ6VxY0GfvCUyo0TLsQ_12_5">0.69</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" id="Tb_jUYiVHDVNEOzKQFgDAazMw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all outstanding and exercisable common stock warrants as of June&#160;30, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_7KfqlU57IkicVgVMVfCeWw_4_1">0.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_bHLXoKqswEu7EW5wfu64Eg_4_3">6,344,252</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_KyoADx6oBE2UVe8LhoeyHg_4_5">6,344,252</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_BFoeVzlEtkKU7bl58_NOFQ">2.28</ix:nonNumeric> years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_Hs9mZtaM-ESCzIv6nt_RCw_5_1">18.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_oaIKGhvhe0W7jj9YfuiX3g_5_3">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_4Tu_GX-8VEq9gUqdvN5I6g_5_5">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_wJWPaNjQX0OyqM6yj4Ptjw">1.49</ix:nonNumeric> years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_gERrM0yTVEicCbMhEDSmbg_6_1">0.69</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_vS2ymYJKl0qHXhRWoVoxxQ_6_3">6,344,966</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_6boirPqCAkKV4iVETrsKeg_6_5">6,344,966</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_rh-PyW7gN0ayESa5hVl1vw">2.28</ix:nonNumeric> years</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:EarningsPerShareTextBlock" id="Tb_PP4JjW9p9EeK0A1ZkRGXwg" continuedAt="Tb_PP4JjW9p9EeK0A1ZkRGXwg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_PP4JjW9p9EeK0A1ZkRGXwg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">stockholders for the six months ended June 30, 2021 excludes net loss attributable to non-controlling interest of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_TqSvM-jVEECZeJl_oqra2Q">0.1</ix:nonFraction> million and includes the accretion of the Series B preferred discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="6" id="Narr_gVmPKuKEWkmn_e48-X5WoA">1.5</ix:nonFraction> million as a result of converted shares and Series A preferred stock accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="6" id="Narr_0lnDzSCzGE2X0drZJ3VCaw">0.1</ix:nonFraction> million and the deemed dividend of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-5" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="6" id="Narr_FzOmmrAISk--HCrc2-jq2g">7.4</ix:nonFraction> million resulting from the effect of the Series A preferred stock price adjustment during the first quarter of 2021. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_fScPcCssHkSS3zCzWQj3aQ"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_dBqgHYEsFEG-PEqSFiRoDw">0.1</ix:nonFraction></ix:nonFraction> million and includes the accretion of Series B preferred discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="6" id="Narr_5tDurpZKKkiQV63n5OeK4g"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="6" id="Narr_6nzIFjKcRUmDNJC6gjzEag">0.4</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockAccretionOfRedemptionDiscount" scale="6" id="Narr_mSuomuwpxUWFoO1VztZgBQ">0.8</ix:nonFraction> million, respectively, on converted shares and Series A preferred stock accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="Narr_iXpC6E1nS0ulWfkc7PFrJg"><ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="6" id="Narr_usqNJwxkgkm3iCmeFM01AQ">0.1</ix:nonFraction></ix:nonFraction> million. There were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="0" format="ixt-sec:numwordsen" name="syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" scale="0" id="Narr_F2OqQCyeGE-vda9Kx3iHXA"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A" decimals="0" format="ixt-sec:numwordsen" name="syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" scale="0" id="Narr_sOB4BfGUEUi0mBvKcuKkVQ">no</ix:nonFraction></ix:nonFraction> shares of common stock underlying Series B preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2021 since all remaining Series B preferred stock were converted to common stock. A total of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw" decimals="0" format="ixt:numdotdecimal" name="syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" scale="0" id="Narr_huc9lGrkck6GCflQbmBlcQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="0" format="ixt:numdotdecimal" name="syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" scale="0" id="Narr_jrtQv_EOKkqs7JbI5ihyAw">4,804,348</ix:nonFraction></ix:nonFraction> shares of common stock underlying Series B preferred shares convertible to common stock were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020. The number of options and warrants for the purchase of common stock were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2021 were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FyVHAd_teEGuTL1oBAt_OQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_1-LX3MOOok6T7A2hSyYWzQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_RVKQ0qDznE-qz2ggQLkq-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_gNKLmJsGx02QZ5Pe0BEPyg">3,997,418</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_5hLd6ZKkzkCO5-jO7JCpEg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_AotgLGDvtUmKabeU9lSqDw">6,344,966</ix:nonFraction>, respectively, and for the six months ended June 30, 2020 were <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OwL8Ke43jku7YbqZh3ch4w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr__pXAjX74j0umK-X_tHL_oQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CseERA5zh0ynTz1Zu6va3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_A9L4UEkCZE-zfm18N1cxzQ">2,472,362</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_RVsezu3jr0CBpCVpvdx8lg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_tF9jxh3-AEmrLrIHLgccYQ">18,714,999</ix:nonFraction>, respectively, because their effect is anti-dilutive.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_EjPck93_MU2iUDRtO_ph2w" continuedAt="Tb_EjPck93_MU2iUDRtO_ph2w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest is accounted for under ASC 810, <i style="font-style:italic;">Consolidation</i> (&#8220;ASC 810&#8221;), and represents the minority shareholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, Synthetic Biomics, Inc. (&#8220;SYN Biomics&#8221;). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company&#8217;s equity interest in SYN Biomics is <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_oDzf2-zkl0-8UnFBVXq7NQ">83</ix:nonFraction>% and the non-controlling stockholder&#8217;s interest is <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_5w-HRzOROUyk_ATlgriJ7A">17</ix:nonFraction>%. As of June 30, 2021 and 2020, the accumulated net loss attributable to the non-controlling interest is $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ" decimals="-5" format="ixt:numdotdecimal" name="syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest" scale="6" id="Narr_Y4vL_9je3kGDFunxH__x5w">2.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_7Uo71EUX6UCZ6ImKlbActA" decimals="-5" format="ixt:numdotdecimal" name="syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest" scale="6" id="Narr_QSNuSt_PGUOzY8sX3GG9Ng">2.9</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In consideration of the support provided by CSMC for the Study, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_Y-87kg_AbEC4UNo2GvJVuQ">328,000</ix:nonFraction> to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA" decimals="0" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeIssued" scale="0" id="Narr_zvcWC-6MzECBi7oLyNlsdQ">50,000</ix:nonFraction>) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ" decimals="INF" format="ixt:numdotdecimal" name="syn:AdditionalNumberOfCommonStockToBeIssued" scale="0" id="Narr_lFL27LSJK0icDFUEDea9UQ">2,420,000</ix:nonFraction>) shares of common stock of its subsidiary SYN Biomics, Inc. (&#8220;Synbiomics&#8221;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ" decimals="INF" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeHeldByRelatedParty" scale="0" id="Narr_CqYGwRYF5UOtkJ2u_1sf_A">7,480,000</ix:nonFraction>) shares of common stock of SYN Biomics, representing seventeen percent (<ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_4l1pA3laJU6FCSzmQBG6UQ">17</ix:nonFraction>%) of the issued and outstanding shares of SYN Biomics&#8217; common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_9_5_2018_To_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_DphhO0tkBE28K8KwCLVQRA" decimals="0" format="ixt:numdotdecimal" name="syn:FairValueOfSharesIssued" scale="0" id="Narr_MmzEFMz3xkms4luGHGyyIw">285,000</ix:nonFraction>) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_QlvAWBKoYkCi7DFbZ1TTXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_zlYBCRmYhECwV4CgZgNv8w">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_81t85iLAZkue0k_haly1qg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_3cWXoxTMPUiI0ZHDNjIlrA">92,000</ix:nonFraction>, respectively. There was <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_VjVpgqccckeC1Ovt7HdvKw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_1tnCEKBD0ESF_MuljxRtnw">no</ix:nonFraction> expense recorded related to this transaction during the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Non-controlling Interest &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#8217;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_EjPck93_MU2iUDRtO_ph2w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_LTQD6t4xS02GzuCQLOCyDg" continuedAt="Tb_LTQD6t4xS02GzuCQLOCyDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Common and Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Series&#160;B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_10_11_2018_To_10_15_2018_9YpmMUjlgU6Rx_oNzkSWFQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_iroMYSWJYUSRTQzTARdOwA">18.6</ix:nonFraction> million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_CuZd8Dnu20mqdbWiRYxlvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_aZp6_fszH06nq8QCOdkrtg">2,520,000</ix:nonFraction> Class&#160;A Units , with each Class&#160;A Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_qqY6Tz--Xk2pwmZ0FVvMqQ">1.15</ix:nonFraction>, and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ML7WRtDK4EuEsagAjFhinw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Adde7K9B0UyIO2toeeQqiw">15,723</ix:nonFraction> Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Narr_4Mi9-3vKwUWxQyGCMjBZsQ">1,000</ix:nonFraction> per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Preferred Stock, with a stated value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_odmDaA-9mUGKXUT_jU6jzg">1,000</ix:nonFraction> and convertible into shares of Common Stock at the stated value divided by a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_zb6kHYb640GtXxDx-aLG_g">1.15</ix:nonFraction> per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_7i_tydJERk2EP1uh6EHKyg">13,672,173</ix:nonFraction> shares of Common Stock, and issued with an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_2EeKPmaG5k2pyph-kPcKPg">13,672,173</ix:nonFraction> October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_10_10_2018_To_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_7OFHeCdRt0-vhR2n4qUlMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SeycJOQmXUmnodjzq71KKg">2,428,825</ix:nonFraction> shares of Common Stock and/or additional warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_JVfFKzSUd02N29gfjg3Ykg">2,428,825</ix:nonFraction> shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg" decimals="0" format="ixt:numdotdecimal" name="syn:IssueOfWarrantsToPurchaseCommonStock" scale="0" id="Narr_XXqWlvViEEOvN_3y18tAQQ">1,807,826</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Units were offered by the Company pursuant to a registration statement on Form&#160;S-1 (File No.&#160;333-227400), as amended, filed with the SEC, which was declared effective by the SEC on October&#160;10, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_LTQD6t4xS02GzuCQLOCyDg_cont1" continuedAt="Tb_LTQD6t4xS02GzuCQLOCyDg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_5_2020_iKgSvuSwK0Katgd-IjQ9Wg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_2cifPy8a9EWE-0QNR-mqng">1.38</ix:nonFraction> per Warrant per full share of common stock to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_6_2020_3pJ_Ridqok6114OiGur1oQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_8IKGy_-J60OVB2ov4Iwl9A">0.69</ix:nonFraction> per Warrant per full share of common stock. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg" decimals="0" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="0" id="Narr_dIDIZ68bZ0mvDxwzpCguiA">880,000</ix:nonFraction>, which reduces the income available to common stockholders for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The October&#160;2018 Warrants are immediately exercisable at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_15_2018_cKJV1gyygk-EpbEXDFtKXQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_yXp2ctAbM0-taAzRecIrdw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_10_31_2018_V2vD4wi4-UCmh8saJ-KESA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_xYUZ5q-MHk-AUazxPfASxQ">1.38</ix:nonFraction></ix:nonFraction> ($<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_23G3GcW3IkSSWMFE16Xmpw">0.69</ix:nonFraction> effective November 16, 2020) per share of common stock (which was <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="Duration_10_1_2018_To_10_31_2018_zr1590HAfU6H-r0oJu1zEw" decimals="2" format="ixt:numdotdecimal" name="syn:PercentageOfIssueOfThePublicOffering" scale="-2" id="Narr_jnLmxB23uU6BQ-6bZaqpOg">120</ix:nonFraction>% of the public offering price of the Class&#160;A Units) and will expire on October&#160;15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the six months ended June 30, 2021 and 2020, <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_W5yi2FFMZkmRNRwahjLVQg">3,973</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_n9rfjJj0mESL-Iu40IjEcg">2,113</ix:nonFraction> shares, respectively, were converted resulting in the recognition of a deemed dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw" decimals="-5" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="6" id="Narr_J-1co-0VfE2pNIcLQfqXMA">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw" decimals="0" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="0" id="Narr_VF0qd1kBK0ulyV9m4TWP5w">795,000</ix:nonFraction>, respectively, for the amortization of the Series B Preferred Stock discount upon conversion. There we <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_zqbZwaYPLECdFz-jA03Uug">no</ix:nonFraction> shares converted during the three months ended June 30, 2021. During the three months ended June 30, 2020, <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_aZ9ttxGpHUGJPkZkqO71fw">1,040</ix:nonFraction> shares were converted resulting in the recognition of a deemed dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ" decimals="0" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="0" id="Narr_YkTvtY9kT0GONtlsu63BZg">392,000</ix:nonFraction> for the amortization of the Series B Preferred Stock discount upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Series&#160;A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;Investor&#8221;), pursuant to which the Company offered and sold in a private placement <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_aTw5WWrc0ECZygCFzI6_gg">120,000</ix:nonFraction> shares of its Series&#160;A Convertible Preferred Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HJ0Vognp00iLodsId7AO5Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_PQNkTxFf8kOZTrF7ZXmlQA">0.001</ix:nonFraction> per share (the &#8220;Series&#160;A Preferred Stock&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_hrKt5-IpwUKyuVdqdTYwwA">12</ix:nonFraction> million, or $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="0" id="Narr_Tmg1yLpvBUKOVEhUutUkbg">100</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock ranks senior to the shares of the Company&#39;s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights to the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_SPtkVVy7-EKLoEacDxeDuQ">2.0</ix:nonFraction>%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_T8LyOaatL0ijdSra_QsWLw">0.54</ix:nonFraction> per share which was increased to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceIncrease" scale="0" id="Narr_c6xPyggBeUmDKtrW5egRgg">18.90</ix:nonFraction> after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" id="Narr_b-1OYgwqskW_20WVEF5F2w">1.50</ix:nonFraction> on January 27, 2021, see below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holder&#8217;s ability to convert the Series A Preferred Stock into common stock was subject to <ix:nonNumeric contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="Narr_UkEy70eBkEmZ5DX0jTm65Q">(i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that would prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii) applicable regulatory restrictions.</ix:nonNumeric></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_LTQD6t4xS02GzuCQLOCyDg_cont2" continuedAt="Tb_LTQD6t4xS02GzuCQLOCyDg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series A Preferred Stock were entitled to a preference on liquidation equal to the greater of (i) an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series A Preferred Stock (the &#8220;Accreted Value&#8221;), and (ii) the amount such holders would have received in such liquidation if they converted their shares of Series A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i) and (ii), is referred to as the &#8220;Liquidation Value&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by law, the holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of <i style="font-style:italic;">pari passu</i> or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of (i) the Accreted Value and (ii) the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock were converted into common stock immediately prior to the change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or at any time after&#160;(i) the VWAP (as defined in the Certificate of Designation) for at least <ix:nonFraction unitRef="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="Narr_aow35V-mKUSrJ4CHA-0RPw">20</ix:nonFraction> trading&#160;days in any <ix:nonFraction unitRef="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="Narr_z3FGOfC5Mkmur6aU5-L42g">30</ix:nonFraction> trading day period is greater than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="Narr_a-V7hvuAaku_JKjnadc0fg">70.00</ix:nonFraction>, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit" scale="0" id="Narr_D3PTngFEBUOYB7Ox5yq8Cw">7,875.00</ix:nonFraction>, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#8217;s control. Since the effective conversion price of the Series A Preferred Stock was less than the fair value of the underlying common stock at the date of issuance, there was a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_SQNPifEGMk-kiOEU3qgr6w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_GJXHaU9vZEyOYHCFCecS3Q">6.9</ix:nonFraction> million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="2" format="ixt:numdotdecimal" name="syn:PercentageOfStatedDividendRate" scale="-2" id="Narr_OGG5DlecwkKrLQjRLCAxtA">2</ix:nonFraction>% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three months ended June 30, 2021, the Company did not record any Series A Preferred Stock dividends since all shares were converted to shares of common stock during the three months ended March 31, 2021. During the six months ended June 30, 2021, the Company accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="Narr_fudsOdB0eUyPDICGCfQtHQ">24,000</ix:nonFraction>. During the three and six months ended June 30, 2020, the Company accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="Narr_VGf8NOFWjEamI40hl8zIyw">63,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="Narr_3XiAmaWnpkSFLARCVZKpLg">125,000</ix:nonFraction>, respectively.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_LTQD6t4xS02GzuCQLOCyDg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put, as an inducement for the holder to fully convert its Series A Preferred Stock. The Amendment to the Certificate of Designation for its Series A Convertible Preferred Stock (the &#8220;Certificate of Amendment&#8221;) with the Secretary of State of the State of Nevada adjusted the conversion price from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_1uZwVK7Xb0OWhu98AgvN5Q">18.90</ix:nonFraction> per share to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ" contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" id="Narr_gE6GUiLHI02DDtyw9v1PeA">1.50</ix:nonFraction> per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#8220;Certificate of Designation&#8221; from <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Xxe3gAXhZU-l1BDNtcdQBw" decimals="4" format="ixt:numdotdecimal" name="syn:BeneficialOwnershipPercentage" scale="-2" id="Narr_A_4Csr5ovkaQAkX0B1DoAg">4.99</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg" decimals="4" format="ixt:numdotdecimal" name="syn:BeneficialOwnershipPercentage" scale="-2" id="Narr_hdFdZgvb70OuYHylrn6L5A">9.99</ix:nonFraction>%, such increase to be effective 61 days from the date hereof. During the three months ended March 31, 2021, all outstanding shares of Series A Convertible Preferred Stock were converted to approximately <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_adtzoVUoL0KulWbPEZXKug" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="6" id="Narr_wJopobILoUavmpzc5ock7w">9.0</ix:nonFraction> million shares of the Company&#8217;s common stock. There are no remaining shares of the Series A Convertible Preferred stock outstanding after these conversions. During January and February 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_1_31_2021_D6zkksit4UCwIionHXMP8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_PA_b28PL20yuyJeexFAjOQ"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_2_28_2021_83AqlMwHVEuP9zHFSSM5Bw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_L84020NmgEmaV-E7kJjQiA">8,996,768</ix:nonFraction></ix:nonFraction> shares of its common stock upon the conversion effected on such date by the holder of <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_yr0zg1OZHUiIwiJG12_IyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_AQ4w3qfpLkeBGhzPy0UvOA"><ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HMJmPJ9JF06CqnhSeF83-w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_kgkCicx460ue18Pp5b5AbA">120,000</ix:nonFraction></ix:nonFraction> shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion is accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated fair value of the inducement consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-5" format="ixt:numdotdecimal" name="syn:EstimatedFairValueOfInducementConsideration" scale="6" id="Narr_dlcBttopP0aOhI3N43bgvg">7.4</ix:nonFraction> million and as a result has recorded a corresponding deemed dividend of $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw" decimals="-5" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="6" id="Narr_VaUJ5ib2FUiy2_0fTPku0A">7.4</ix:nonFraction> million during the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">B. Riley Securities Sales Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of common stock from time to time through B. Riley Securities, Inc. as the Company&#8217;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#8220;at-the-market&#8221; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_S0B-4Run_kKbm47QoMWZuw" decimals="3" format="ixt:numdotdecimal" name="syn:BrokerageCommissionPercentage" scale="-2" id="Narr_uFaI-wb86UuNP9erpoRWCg">3.0</ix:nonFraction>% of gross sales in connection with the sale of the Common Stock sold on the Company&#8217;s behalf. The Company did not sell any shares of common stock during the three and six months ended June 30, 2020 through the Riley Securities Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#8220;B. Riley&#8221;) and A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) in order to include AGP as an additional sales agent for the Company&#8217;s &#8220;at the market offering&#8221; program (the &#8220;Amended and Restated Sales Agreement&#8221;). The Sales Agreement amended and restated the At Market Issuance Sales Agreement, dated August 5, 2016, with B. Riley Securities, Inc. (formerly known as B. Riley FBR, Inc.), as amended by amendment no. 1, dated May 7, 2018, to the At Market Issuance Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the six months ended June 30, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately <ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_-RHgwdA7SU6bLWAbPCiXVA">78.7</ix:nonFraction> million shares of the Company&#8217;s common stock and received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_vU3EUgVuwki7LR-tMehVHQ">66.0</ix:nonFraction> million. The Company did not sell any shares of common stock during the three months ended June 30, 2021 through the Riley Securities Sales Agreement.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_sADAAKvGPE-qlNmB0NSA1A" continuedAt="Tb_sADAAKvGPE-qlNmB0NSA1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company: (i)&#160;issued to CSMC fifty thousand (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA" decimals="0" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeIssued" scale="0" id="Narr_k2gnfDEIikmcWyF3RWuk7w">50,000</ix:nonFraction>) shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional <span style="-sec-ix-hidden:Hidden_LwEQCHh2xU-yhl4vl9nF_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">two million four hundred twenty thousand</span></span> (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_BusinessAcquisitionAxis_syn_CedarssinaiMedicalCenterMember_z73xOnQ6cEihGg2og9Jxtw" decimals="0" format="ixt:numdotdecimal" name="syn:AdditionalNumberOfCommonStockToBeIssued" scale="0" id="Narr_bDYNAppCb0WwjT8guTKThQ">2,420,000</ix:nonFraction>) shares of common stock of its subsidiary Synthetic Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (<ix:nonFraction unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g" decimals="0" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeHeldByRelatedParty" scale="0" id="Narr_hkOWBmi4okCsCcBekfn7Pg">7,480,000</ix:nonFraction>) shares of common stock of SYN Biomics, representing <span style="-sec-ix-hidden:Hidden_uVawnFnrhUC47_sVB7xw5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seventeen&#160;percent</span></span> (<ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_BPOS5r2GkkmEzYnjZj3xSw">17</ix:nonFraction>%) of the issued and outstanding shares of SYN Biomics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#8217;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment was completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2013, through SYN Biomics, the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2021 and 2020, the Company did not owe and did not pay CSMC for milestone payments related to this license agreement.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_sADAAKvGPE-qlNmB0NSA1A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="Tc_Vd4XRzNK4UKAimPH2XBHhw_1_0"></a><a id="Tc_zKJF4uI5RkCqgsWThKvjiA_2_0"></a><a id="Tc_e7udykncKUWdL-Dl0gmJfQ_2_2"></a><a id="Tc_PQNIU-bovEqPfttjk1dHIQ_3_0"></a><a id="Tc_cGmLPzwE9keO5OWLl_p2Vg_4_0"></a><a id="Tc_81DkOAHbRU-78G-czmJpIw_5_0"></a><a id="Tc_D34juM7ODkagFfln2o68RQ_6_0"></a><a id="Tc_thVpuz_O9EeSRlEpIUXlmg_7_0"></a><a id="Tc_Ijs75KVMpUuQ6zuwKB7zKQ_8_0"></a><a id="Tc_SrlGIn7lhEu4RHuPkCg5vA_9_0"></a><a id="Tc_iMvNrKKe8ECbDbOFmHi0IQ_11_0"></a><a id="Tc_A3FQG7Gg8UCuOHSl39mQag_12_0"></a><a id="Tc_vb30e4YRCkmU7jMrK6PYgw_13_0"></a><a id="Tc_Fwr9AGt9rU--uUuOav8dRg_14_0"></a><a id="Tc_TaxDQe0Wb0Kd9W6mvqTd7Q_14_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_O0vkba6bL0mmsR4_-5p5KQ" continuedAt="Tb_O0vkba6bL0mmsR4_-5p5KQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of the Company&#8217;s existing leases as of June 30, 2021 are classified as operating leases. As of June 30, 2021, the Company has <ix:nonFraction unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="INF" format="ixt-sec:numwordsen" name="syn:NumberOfOperatingLeaseForFacilities" scale="0" id="Narr_5te6rDFM1UuDZYP6wjtXMw">one</ix:nonFraction> operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for <ix:nonNumeric contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_wZ4gsqgzXEC8jlWVWB1-QA">63 months</ix:nonNumeric> beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a <ix:nonNumeric contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" format="ixt-sec:durwordsen" name="syn:LeaseRentAbatementPeriod1" id="Narr_PTOxFFWtmEOdj7qnmAHI3g">3 month</ix:nonNumeric> rent abatement. &#160;The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. &#160;The Second Amendment also gives the Company the Right to Expand their space by giving notice to the landlord before December 31, 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an <ix:nonFraction unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="1" format="ixt:numdotdecimal" name="syn:PercentageOfFundsToBeBorrowedByCompany" scale="0" id="Narr_ZdkEDGiQOkWIDBKpLwBXgg">8.5</ix:nonFraction>% interest rate, which is the discount rate used in this modification analysis. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the three and six months ended June 30, 2021 approximated $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_7spLu6nDlEeC466hPQdGog">68,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_9tZuYKGvSU6qNydZWmWS_w">118,000</ix:nonFraction>, respectively and for the three and six months ended June 30, 2020 approximated $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_LdeJ-bru1EqmFml8xjc8FQ">50,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_en5CqSYL9EONld9Hx_zncg">101,000</ix:nonFraction>, respectively. For the three and six months ended June 30, 2021, operating cash flows used for operating leases approximated $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_HP8fWfxtYkiPBbPnBCjEBg">80,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_E7qRmD5gaUevDH-nht8dPA">160,000</ix:nonFraction>, respectively, and for three and six months ended June 30, 2020 approximated $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_ugHo29gjKUqGivkxA2KR-g">77,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_ekpA8pgtTECiY9YuAoZpVQ">154,000</ix:nonFraction>, respectively, and right of use assets exchanged for operating lease obligations was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="Narr_6u-XznWmFE6B7mth-D8tzw">1.3</ix:nonFraction> million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MlNR2bKVWUa5Wq8G6pRRRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="0" id="Narr_FgCQKgYCe0SCRUJ_dZwmnA">538,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A maturity analysis of our operating leases as of June 30, 2021 is as follows <i style="font-style:italic;">(amounts in thousands of dollars)</i>:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_xpCFUDCTWEed2aDqBUBTGA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending June 30:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_8mkRMXZ3yEGh-PxVRcmdAg_2_3">163</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_BfVGt-tQs0-gIJmAtwY3Rw_3_3">247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_8t6QpiNdzUmB6tY8HCYPDw_4_3">327</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_-KbzJw9kjU-CXL9D12RQHA_5_3">337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_MjIy0cb3c0WJZx8jU4KDMg_6_3">347</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_RlRSLWOCOESBjhIipllH2w_7_3">357</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="syn:LesseeOperatingLeaseLiabilityToBePaidYearSix" scale="3" id="Tc_D4-sLlW4pEuyJ3ulw_fhOQ_8_3">368</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_QfrKbtS6mEiVwR4_LYAQIw_9_3">2,146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_BX2ADRhuXUqsV6LE_JvnKQ_11_3">524</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_Req-EpZ7aU2TXtp1EEhHhg_12_3">1,622</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_49ftlJ8WYUGKVcPuCz-Qcw_13_3">196</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg" contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_uHi6TAAeGkqFgqgcF52GHw_14_3">1,426</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Synthetic Biologics, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Condensed Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_O0vkba6bL0mmsR4_-5p5KQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;"><b style="font-style:normal;font-weight:bold;">10. Commitments and Contingencies &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;">Risks and Uncertainties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19&#8221; outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including halting the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#8217;s suppliers and other commercial partners, the Company&#8217;s corporate development objectives and the value of and market for the Company&#8217;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#39;s business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c5855043_b6d9_4564_abb2_1fcd4952ca7b"></a><a id="ITEM2MANAGEMENTSDISCUSSIONANDANALYSISOFF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form&#160;10-Q, and our audited consolidated financial statements and notes thereto for the&#160;year ended December&#160;31, 2020 included in our 2020 Form&#160;10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See &#8220;Note&#160;Regarding Forward-Looking Statements&#8221; for a discussion of the uncertainties, risks and assumptions associated with these statements. Our actual results and the timing of events could differ materially from those expressed or implied by the forward-looking statements due to important factors and risks including, but not limited to, those set forth below under &#8220;Risk Factors&#8221; and elsewhere herein, and those identified under Part&#160;I, Item&#160;1A of our 2020 Form&#160;10-K.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a diversified clinical-stage company developing therapeutics designed to treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical development candidates are: (1)&#160;SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)&#160;beta-lactam antibiotics within the GI tract to prevent microbiome damage, <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2)&#160;SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to explore and evaluate a range of strategic options, which may include: in-licensing opportunities; evaluation of potential acquisitions; or other potential strategic transactions. In the meantime, we remain focused on working with our clinical development partners to advance the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT patients, and advancing the clinical development program for SYN-020 intestinal alkaline phosphatase (IAP) in multiple potential indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are continuing to assess the potential impact of the COVID-19 pandemic. We are in close contact with our clinical development partners in order to assess the impact of COVID-19 on our studies and current timelines and costs. While we currently do not anticipate any interruptions in our operations due to COVID-19, it is possible that if the COVID-19 pandemic were to increase in severity for an extended period of time, we could once again experience delays in our clinical trials which could result in significant disruptions to our clinical development timelines due to the COVID-19 pandemic, which would adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In response to the spread of COVID-19 as well as public health directives and orders, we have implemented a number of measures designed to ensure employee safety and business continuity. We have limited access to our offices and are allowing our administrative employees to continue their work outside of our offices in order to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state and local government and health authorities. The full extent to which the COVID-19 outbreak will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted. The effects of the governmental orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.7pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Our Product Pipeline:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="syn-20210630x10q001.jpg" alt="Graphic" style="display:inline-block;height:207.7pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;">*Based on management&#8217;s current beliefs and expectations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">aGVHD</b> acute graft-vs-host disease; <b style="font-weight:bold;">allo-HCT</b> allogeneic hematopoietic cell transplant patients; <b style="font-weight:bold;">AMR</b> antimicrobial resistance; <b style="font-weight:bold;">CDI </b><i style="font-style:italic;">Clostridioides difficile</i> infection. <b style="font-weight:bold;">SAD</b> single ascending dose</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#185;Additional products with preclinical proof-of-concept include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterococci and SYN-007 (ribaxamase) DR to prevent antibiotic associated diarrhea with oral &#946;-lactam antibiotics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#178;Dependent on funding/partnership.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#179;Announced option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation and gut barrier dysfunction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional pipeline products with preclinical proof-of-concept include SYN-006 (carbapenemase) being designed to prevent aGVHD, microbiome damage and infection due to treatment with carbapenem antibiotics, and SYN-007 (ribaxamase) delayed release (&#8220;DR&#8221;) being designed to prevent antibiotic associated diarrhea with oral &#946;-lactam antibiotics.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt;"><b style="font-style:normal;font-weight:bold;">Summary of Clinical and Preclinical Programs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:33.78%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Therapeutic Area</b></p></td><td style="vertical-align:bottom;width:2.12%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:16.87%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product</b><br /><b style="font-weight:bold;">Candidate</b></p></td><td style="vertical-align:bottom;width:2.1%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:45.11%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Current Status</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prevention of microbiome damage, CDI, overgrowth of pathogenic organisms, AMR, and aGVHD in allogeneic HCT recipients (Degrade IV beta-lactam antibiotics)</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SYN-004</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(ribaxamase)<br />(oral enzyme)</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;white-space:pre-wrap;">&#8239;</span><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Announced outcomes from End of Phase 2 meeting, including Food and Drug Administration (FDA)-proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval on the basis of a single Phase 3 clinical trial (Q4 2018)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Clarified market/potential partner needs and identified potential additional indications in specialty patient populations such as allogeneic hematopoietic cell transplant (HCT) patients</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Announced clinical trial agreement (CTA) with Washington University School of Medicine to conduct a Phase 1b/2a clinical trial to evaluate safety, tolerability and pharmacokinetics in up to 36 evaluable adult allogeneic HCT recipients (Q3 2019)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Received official meeting minutes from FDA Type-C meeting held on December&#160;2, 2019 to discuss development in allogeneic HCT recipients who are administered IV beta-lactam antibiotics in response to fever (Q1 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Received written notification from the FDA informing the Company that the FDA determined the Phase 1b/2a clinical program in adult allogeneic hematopoietic cell transplant (HCT) recipients may proceed per the submitted clinical program protocol (Q3 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Washington University began enrollment and the first patient was dosed in the first of three antibiotic cohorts for the Phase 1b/2a clinical trial of SYN-004 in adult HCT recipients (Q2 2021)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.2pt;text-align:justify;text-indent:-16.2pt;margin:0pt 0pt 0pt 2.34pt;"><span style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Preserve gut barrier, treat local GI inflammation, and &#160;&#160;restore gut microbiome</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SYN-020<br />(oral IAP enzyme)</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Generated high expressing manufacturing cell lines for intestinal alkaline phosphatase (IAP) (1H 2017)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Identified basic Drug Supply manufacturing process and potential tablet formulation (2H 2017)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Identified potential clinical indications with unmet medical need including enterocolitis associated with radiation therapy for cancer (Q1 2019)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Completed pre-IND (Investigational New Drug) meeting with the FDA to clarify requirements for IND-enabling toxicology studies and manufacturing requirements (Q2 2019)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Entered into an agreement with Massachusetts General Hospital (&#8220;MGH&#8221;) granting the Company an option for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases (Q2 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Submitted IND application with U.S. FDA supporting an initial indication for the treatment of radiation enteropathy secondary to pelvic cancer therapy (Q2 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Received study-may-proceed letter from U.S. FDA to conduct a Phase 1 single ascending dose (&#8220;SAD&#8221;) study in healthy volunteers, designed to evaluate SYN-020 for safety, tolerability, and pharmacokinetic parameters (Q3 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Announced enrollment commenced and three out of a total of four cohorts have been dosed in a Phase 1SAD study of SYN-020 (Q2 2021)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Announced that patient enrollment, dosing and observation has been completed in the Phase 1, open label, SAD clinical trial. Analyses of preliminary data demonstrated SYN-020 maintained a favorable safety profile and was well tolerated at all dose levels (Q2 2021)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prevention of CDI, overgrowth of pathogenic &#160;organisms and AMR (Degrade IV carbapenem &#160;antibiotics)</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SYN-006</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(oral enzyme)</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Identified P2A as a potent carbapenemase that is stable in the GI tract</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Manufactured a formulated research lot for oral delivery (2017)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Demonstrated microbiome protection in a pig model of ertapenem administration (Q1 2018)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Reported supporting data demonstrating SYN-006 attenuated emergence of antibiotic resistance in a pig model, including encoded beta-lactamases and genes conferring resistance to a broad range of antibiotics such as aminoglycosides and macrolides (Q1 2019)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.55pt;text-indent:-16.55pt;margin:0pt 0.7pt 0pt 2.15pt;"><span style="font-size:12pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Prevention of antibiotic-associated diarrhea (AAD), overgrowth of pathogenic organisms and AMR (Degrade oral beta-lactam&#160;antibiotics)&#160;</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SYN-007<br />(oral enzyme)</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Preclinical work ongoing to expand the utility of SYN-004 (ribaxamase) for use with oral beta-lactam antibiotics</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Reported supportive data from a second canine animal model demonstrating that when co-administered with oral Amoxicillin and oral Augmentin (combination amoxicillin/clavulanate), oral SYN-007 did not interfere with systemic absorption of antibiotics but did diminish microbiome damage associated with these antibiotics (Q2 2018)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="margin-top:12pt;"></div></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:6.5pt;text-indent:-6.5pt;margin:0pt 0pt 0pt -0.05pt;">&#160;</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Reported supportive data demonstrating SYN-007 mitigated antibiotic-mediated gut microbiome alterations and maintained gut microbiome integrity when co-administered with oral amoxicillin in a dose-response canine study (Q2 2019)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Reported supportive data demonstrating SYN-007 protected the gut microbiome of dogs from amoxicillin and the beta-lactam/beta-lactamase&#8239;inhibitor Augmentin&#8239;and also reduced the emergence of antibiotic resistance in a canine study (Q1 2020)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:6.5pt;text-indent:-6.5pt;margin:0pt 0pt 0pt -0.05pt;">&#160;</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:6.5pt;text-indent:-6.5pt;margin:0pt 0pt 0pt -0.05pt;">Prevention and treatment of pertussis</p></td><td style="vertical-align:top;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">SYN-005<br />(monoclonal antibody<br />therapies)</p></td><td style="vertical-align:top;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.11%;margin:0pt;padding:0pt;"><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Reported supportive preclinical data demonstrating that an extended half-life version of hu1B7, a component of SYN-005, provided protection from pertussis for five weeks in a neonatal non-human primate study (Q4 2017)</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div><div style="border-collapse:collapse;display:table;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><div style="display:table-row;"><div style="width:2.15pt;display:table-cell;"></div><div style="display:table-cell;font-family:'Times New Roman';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:16.55pt;padding:0pt;">&#9679;</div><div style="display:table-cell;padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;text-align:justify;">Collaboration with UT Austin</span></div><div style="width:0.7pt;display:table-cell;"></div></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Recent Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Our Gastrointestinal (GI) and Microbiome-Focused Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our SYN-004 (ribaxamase) and SYN-020 clinical programs are focused on the gastrointestinal tract (GI) and the gut microbiome, which is home to billions of microbial species and composed of a natural balance of both &#8220;good&#8221; beneficial species and potentially &#8220;bad&#8221; pathogenic species. When the natural balance or normal function of these microbial species is disrupted, a person&#8217;s health can be compromised. All of our programs are supported by our growing intellectual property portfolio. We are maintaining and building our patent portfolio through: filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent applications.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Clinical and Pre-Clinical Update</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">SYN-004 (ribaxamase)&#160;&#8212;&#160;Prevention of antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Phase 1b/2a Clinical Study in Allogeneic HCT Recipients</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2019, we entered into a Clinical Trial Agreement (CTA) with the Washington University School of Medicine (Washington University) to conduct a Phase 1b/2a clinical trial of SYN-004 (ribaxamase) for treatment of allogeneic HCT recipients who are administered IV beta-lactam antibiotics in response to fever. Under the terms of this agreement, we serve as the sponsor of the study and supply SYN-004 (ribaxamase). Dr. Erik R. Dubberke, Professor of Medicine and Clinical Director, Transplant Infectious Diseases at Washington University and a member of the SYN-004 (ribaxamase) steering committee serves as the principal investigator of the clinical trial in collaboration with his Washington University colleague Dr. Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation and Leukemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Phase 1b/2a clinical trial is a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients. The goal of this study is to evaluate the safety, tolerability and potential absorption into the systemic circulation (if any) of 150 mg oral SYN-004 (ribaxamase) administered to allogeneic HCT recipients four times per day who receive an IV beta-lactam antibiotic to treat fever. Study participants are being enrolled into three sequential cohorts administered a different study-assigned IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN-004 (ribaxamase) and four will receive placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring Committee, which will make a recommendation on whether to proceed to the next IV beta-lactam antibiotic. The clinical trial will also evaluate potential protective effects of SYN-004 (ribaxamase) on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 (ribaxamase) in allogeneic HCT recipients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 14, 2021, we announced that enrollment has commenced and the first patient of the first antibiotic cohort of this study had been dosed. If enrollment proceeds as planned, a data readout for the first cohort is anticipated in Q4 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the unique challenges posed by the global COVID-19 pandemic, Washington University continues to evaluate non-essential activities which may have a direct impact on planned and ongoing clinical trials. Continuation of the Phase 1b/2a clinical trial including, but not limited to, the enrollment of new patients remains largely at the discretion of Washington University and is contingent upon their ability to conduct this clinical program free from the impact of COVID-19. We remain in close contact with Washington University and are actively monitoring the crisis caused by the spread of COVID-19 and its impact to the clinical development plans for our SYN-004 (ribaxamase) program.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">SYN-020&#160;&#8212;&#160;Oral Intestinal Alkaline Phosphatase</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SYN-020 is a quality-controlled, recombinant version of bovine Intestinal Alkaline Phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery. The published literature indicates that IAP functions to diminish GI and systemic inflammation, tighten the gut barrier to diminish &#8220;leaky gut,&#8221; and promote a healthy microbiome. Despite its broad therapeutic potential, a key hurdle to commercialization has been the high cost of IAP manufacture which is commercially available for as much as $10,000 per gram. We believe we have developed technologies to traverse this hurdle and now have the ability to produce more than 3 grams per liter of SYN-020 for roughly a few hundred dollars per gram at commercial scale. Based on the known mechanisms as well as our own supporting animal model data, we intended to initially develop SYN-020 to mitigate the intestinal damage caused by radiation therapy that is routinely used to treat pelvic cancers. And, while we believe SYN-020 may play a pivotal role in addressing acute and long-term complications associated with radiation exposure to the GI tract, we have also begun planning to develop SYN-020 in indications that may offer a more accelerated or streamlined pathway to registration while also addressing significant unmet medical needs. Such indications include celiac disease, non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), and indications to treat and prevent metabolic and inflammatory disorders associated with aging which are supported by our collaboration with Massachusetts General Hospital (&#8220;MGH&#8221;). Across the six major markets, the total prevalent cases of celiac disease are expected to increase from 5.8 million cases in 2013 to an expected 8.1 million cases in 2023, representing an annual growth rate of approximately 4%. During the same period, prevalent cases in the U.S. are expected to increase from 2.8 million in 2013 to an expected 4.3 million in 2023, representing a significant market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 30, 2020, we submitted an IND application to the FDA in support of an initial indication for the treatment of radiation enteropathy secondary to pelvic cancer therapy. On July 30, 2020, we announced that we received a study-may-proceed letter from the FDA to conduct a Phase 1a single-ascending-dose (&#8220;SAD&#8221;) study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. On April 1, 2021, we announced that enrollment had commenced in the Phase 1 SAD clinical trial of SYN-020. On June 29, 2021, we announced that enrollment, patient dosing and observation had been completed in its Phase 1, open-label, SAD study of SYN-020. The SAD study enrolled 6 healthy adult volunteers into each of four cohorts with SYN-020 given orally as single doses ranging from 5 mg to 150 mg. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well tolerated at all dose levels, and no adverse events were attributed to study drug. No serious adverse events were reported. Additional data from this clinical trial is expected during the third quarter of 2021. Planning for a second Phase 1 study evaluating multiple-ascending doses (&#8220;MAD&#8221;) of SYN-020 is also underway and participant screening is anticipated to commence during the third quarter of 2021. A topline data readout of the Phase 1 MAD clinical study is anticipated during the second quarter of 2022, pandemic conditions permitting. Following the completion of Phase 1 safety studies, we may consider conducting a placebo-controlled Phase 1b/2a gluten challenge study in as many as 40 celiac patients who present with predominantly GI symptoms followed by a Phase 2b proof-of-concept clinical trial in a similar patient population. We may also seek to initiate clinical trials of SYN-020 evaluating its potential therapeutic benefit in NAFLD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of 2020, we announced that we entered into an agreement with Massachusetts General Hospital granting us an option for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. During the second quarter of 2021, we announced an amendment to our option for an exclusive license agreement with MGH to include intellectual property and technology related to the use of SYN-020 to inhibit liver fibrosis in select diseases, including NAFLD. Research published by a team of investigators led by Richard Hodin, MD, Chief of the Massachusetts General Hospital Division of General and Gastrointestinal Surgery and Professor of Surgery, Harvard Medical School, evaluated long-term oral supplementation of IAP, including SYN-020, in mice. Dr.&#160;Hodin&#8217;s research demonstrated that IAP administration, starting at 10&#160;months of age, slowed the microbiome changes, gut-barrier dysfunction, and gastrointestinal and systemic inflammation that normally accompany aging. Additionally, the IAP administration resulted in improved metabolic profiles in the aged mice, diminished frailty, and extended lifespan. Under the terms of the agreement, we are granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging. If executed, we plan to use this license in the advancement of an expanded clinical development program for SYN-020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our programs are supported by growing patent estates. In total, we have over 80 U.S. and foreign patents and over 65 U.S. and foreign patents pending. The SYN-004 (ribaxamase) program is supported by IP that is assigned to Synthetic Biologics, namely U.S. patents and foreign patents (in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others) and U.S. and foreign patents pending in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others). For instance, U.S. Patent Nos. 8,894,994 and 9,587,234, which include claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004 (ribaxamase), have patent terms to at least 2031. Further, U.S. Patent 9,301,995 and 9,301,996, both of which will expire in 2031, cover various uses of beta-lactamases, including SYN-004 (ribaxamase), in protecting the microbiome, and U.S. Patent Nos. 9,290,754, 9,376,673, 9,404,103, 9,464,280, and 9,695,409 which will expire in at least 2035, covers further beta-lactamase compositions of matter related to SYN-004 (ribaxamase).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SYN-020 (oral intestinal alkaline phosphatase (IAP)) program is supported by IP that is assigned to Synthetic Biologics, namely U.S. and foreign patent applications (in many major markets, e.g. Europe, Canada, and Australia). These patent applications, which cover various formulations, medical uses and manufacture of SYN-020, are expected to expire in 2038-2040, if granted, and without taking potential patent term extensions or patent term adjustment into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our goal is to (i)&#160;obtain, maintain, and enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, (ii)&#160;preserve our trade secrets, and (iii)&#160;operate without infringing on the proprietary rights of other parties worldwide. We seek, where appropriate, the broadest intellectual property protection for product candidates, proprietary information, and proprietary technology through a combination of contractual arrangements and patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenues and expenses in the periods presented. We believe that the accounting estimates employed are appropriate and resulting balances are reasonable; however, due to inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods. The critical accounting estimates that affect the condensed consolidated financial statements and the judgments and assumptions used are consistent with those described under Part&#160;II, Item&#160;7 of our 2020 Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Three Months Ended June 30, 2021 and 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by 2% to approximately $1.26 million for the three months ended June 30, 2021, from approximately $1.29 million for the three months ended June 30, 2020. This decrease is primarily due to lower legal costs and vacation expense offset by higher insurance costs, audit fees and registration fees. The charge related to stock-based compensation expense was $83,000 for the three months ended June 30, 2021, compared to $67,000 for the three months ended June 30, 2020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased by 21% to approximately $1.9 million for the three months ended June 30, 2021, from approximately $1.6 million for the three months ended June 30, 2020. This increase is primarily the result of increased clinical trial expenses as we began dosing patients in the Phase 1b/2a clinical trial of SYN-004 and Phase 1 SAD clinical trial of SYN-020 during the three months ended June 30, 2021, offset by lower indirect program costs for the three months ended June 30, 2021, including salary and related expense reductions, a decrease in manufacturing costs for SYN-020 and market research. In addition, as a result of the global COVID-19 pandemic, our clinical development partner (Washington University) reduced their operating capacity during 2020 to include only essential activities as part of their pandemic response, which delayed the start of our clinical trial until 2021. We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients. &#160;The charge related to stock-based compensation expense was $19,000 for the three months ended June 30, 2021, compared to $19,000 related to stock-based compensation expense for the three months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth our research and development expenses directly related to our therapeutic areas for the three months ended June 30, 2021 and 2020. These direct expenses were external costs associated with preclinical studies and clinical trials. Indirect research and development expenses related to employee costs, facilities, stock-based compensation and research and development support services that are not directly allocated to specific drug candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Therapeutic Areas</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SYN-020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 697</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ribaxamase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 332</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SYN-010</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 94</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">SYN-005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,029</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 138</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total indirect costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 903</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,465</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Research and Development</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,932</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,603</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Other Income/Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income was $2,000 for the three months ended June 30, 2021, compared to other income of $6,000 for the three months ended June 30, 2020. Other income for the three months ended June 30, 2021 and 2020 is primarily comprised of interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net Loss Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our net loss attributable to common stockholders was approximately $3.2 million, or $0.02 per basic and dilutive common share for the three months ended June 30, 2021, compared to a net loss of approximately $3.3 million, or $0.18 per basic common share and dilutive common share for the three months ended June 30, 2020. Net loss attributable to common stockholders for the three months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $16,000 and includes the accretion of Series B preferred discount of $392,000 on converted shares and Series A Preferred Stock accrued dividends of $63,000.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Six Months Ended June 30, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the six months ended June 30, 2021 of $2.69 million were relatively unchanged from six months ended June 30, 2020. The movement for the period primarily consisted of decreased legal costs related to business development, patent execution and employee contract matters, vacation expense and travel, offset by insurance costs, audit fees and registration fees. The charge related to stock-based compensation expense was $165,000 for the six months ended June 30, 2021, compared to $132,000 for the six months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses decreased by 6% to $3.0 million for the six months ended June 30, 2021, from $3.2 million for the six months ended June 30, 2020. This decrease is primarily the result of lower indirect program costs for the six months ended June 30, 2021, including salary and related expense reductions, a decrease in manufacturing costs for SYN-020 and market research offset by increased clinical trial expenses as we began dosing patients in the Phase 1b/2a clinical trial of SYN-004 and Phase 1 SAD clinical trial of SYN-020. In addition, as a result of the global COVID-19 pandemic, our clinical development partner (Washington University) reduced their operating capacity during 2020 to include only essential activities as part of their pandemic response, which delayed the start of our clinical trial until 2021. We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients. Research and development expenses also include a charge relating to stock-based compensation expense of $38,000 for the six months ended June 30, 2021, compared to $37,000 for the six months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth our research and development expenses directly related to our therapeutic areas for the six months ended June 30, 2021 and 2020. These direct expenses were external costs associated with preclinical studies and clinical trials. Indirect research and development expenses related to employee costs, facilities, stock-based compensation and research and development support services that are not directly allocated to specific drug candidates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Therapeutic Areas</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SYN-020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 869</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Ribaxamase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 480</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 105</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SYN-010</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 248</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">SYN-005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,352</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 381</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total indirect costs</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,697</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,857</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:75.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total Research and Development Expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,049</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,238</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><i style="font-weight:normal;">Other Income/Expense</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income was $2,000 for the six months ended June 30, 2021, compared to other income of $44,000 for the six months ended June 30, 2020. Other income for the six months ended June 30, 2021 and 2020 is primarily comprised of interest income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Attributable to Common Stockholders</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our net loss attributable to common stockholders was approximately $5.7 million, or $0.13 per basic and dilutive common share for the six months ended June 30, 2021, compared to a net loss of approximately $5.8 million, or $0.38 per basic common share and dilutive common share for the six months ended June 30, 2020. Net loss attributable to common stockholders for the six months ended June 30, 2021 excludes net loss attributable to non-controlling interest of $1,000 and includes the accretion of the Series B preferred discount of $1.5 million on converted shares, Series A Preferred Stock accrued dividends of $24,000 and the deemed dividend for the effect of the Series A preferred shares price adjustment of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">$7.4 million. Net loss attributable to common stockholders for the six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $42,000 and includes the accretion of Series B preferred discount of $796,000 on converted shares and Series A Preferred Stock accrued dividends of $125,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With the exception of the three months ended June 30, 2010 and the three months ended December 31, 2017, we have experienced significant losses since inception, incurred negative cash flows from operations, and have a significant accumulated deficit. We have incurred an accumulated deficit of $262.7 million as of June 30, 2021 and expect to continue to incur losses in the foreseeable future. During the six months ended June 30, 2021, our operating activities used net cash of approximately $5.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents totaled $74.3 million as of June 30, 2021, an increase of $68.1 million from December 31, 2020. During the three and six months ended June 30, 2021, the primary use of cash was for working capital requirements and operating activities which resulted in a net loss of $3.2 million and 5.7 million for the three and six months ended June 30, 2021, respectively. During the six months ended June 30, 2021, we raised approximately $74.0 million from cash received via the exercise of approximately 65% of the 2018 Warrants and sales of our common stock in &#8220;at the market&#8221; offerings pursuant to the Sales Agreement that we had entered into in 2016 with FBR Capital Markets &amp; Co. (now known as B. Riley Securities) (the &#8220;Original ATM Sales Agreement&#8221;) and the Amended and Restated ATM Sales Agreement. During the three months ended June 30, 2021 we did not sell any of our common stock through the Original ATM Sales Agreement and the Amended and Restated ATM Sales Agreement. We believe that our cash and cash equivalents at June 30, 2021 will be sufficient to fund our operations through at least the end of the first quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of the global COVID-19 pandemic, our clinical development partner (Washington University) reduced their operating capacity during 2020 and the first quarter of 2021 to include only essential activities as part of their pandemic response. These delays impacted the timelines for our clinical programs, which included delaying commencement of the Phase 1b/2a clinical trial of SYN-004 until the second quarter of 2021. These delays also resulted in a decrease in anticipated expenses as no clinical trials had yet commenced during that period. If enrollment in our ongoing Phase 1b/2a clinical trial being conducted by Washington University is halted due to COVID-19 developments, we may experience reduced expenses until such time as enrollment resumes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we are experiencing limited, if any, adverse impact to our financial stability stemming from the global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with the COVID-19 pandemic, including uncertainty regarding our clinical timelines, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Historically, we have financed our operations primarily through public and private sales of our securities, and we expect to continue to seek and obtain additional capital in a similar manner. During the year ended December 31, 2020, our only source of financing was from sales of 9.2 million shares of our common stock utilizing our at-the-market offering program through the Original ATM Sales Agreement pursuant to which we received net proceeds of approximately $3.4 million. During the six months ended June 30, 2021, we received proceeds of approximately $8.0 million from the cash exercise of approximately 11.6 million of our 2018 warrants and sold approximately 78.7 million shares of our common stock for net proceeds of approximately $66.0 million pursuant to the Original ATM Sales Agreement and the Amended and Restated ATM Sales Agreement, all of which were received during the three months ended March 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Amended and Restated ATM Sales Agreement enables us to offer and sell shares of our common stock from time to time through B Riley and AGP as our sales agents. Sales of common stock under the Amended and Restated ATM Sales Agreement are made in sales deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 promulgated under the Securities Act. B Riley and AGP are entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of our common stock sold on our behalf. There can be no assurance that we will be able to continue to raise funds through the sale of shares of common stock through the Amended and Restated ATM Sales Agreement. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain funding for future clinical trials when needed, we </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">will be unable to carry out our business plan and we will be forced to delay the initiation of future clinical trials until such time as we obtain adequate financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have committed, and expect to continue to commit, substantial capital in order to implement our business strategy, including our planned product development efforts, preparation for our planned clinical trials, and performance of clinical trials and our research and discovery efforts. We believe our cash position of $74.3 million as of June 30, 2021 is sufficient to fund our operations through at least the end of the first quarter of 2023, including continuation of our ongoing Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients for the prevention of aGVHD, as well as our ongoing Phase 1 SAD study and planned Phase 1 MAD study and Phase 2 clinical programs for SYN-020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the anticipated completion of our ongoing Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients, the ongoing Phase 1 SAD and planned MAD studies and planned Phase 2a clinical trial of SYN-020, we may need to obtain additional funds for future clinical trials, the amount of which will depend upon the trial size and number of clinical sites. We anticipate that our future clinical trials will be much larger in size and require larger cash expenditures than the aforementioned clinical programs. We do not have any committed sources of financing for future clinical trials at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the COVID-19 coronavirus continues to spread around the globe, we have experienced disruptions that impacted our business and clinical trials, including postponement of commencement of the now ongoing Phase 1b/2a clinical trial of SYN-004. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. We are actively monitoring the global situation and its potential impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the future effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three and six months ended June 30, 2021, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Contractual Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;text-decoration:underline;text-decoration-color:#000000;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the inception of a contract we determine if the arrangement is, or contains, a lease. Right-of-use (&#8220;ROU&#8221;) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We have made certain accounting policy elections whereby we (i) do not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12-months or less) and (ii) combine lease and non-lease elements of our operating leases. ROU assets are included in other noncurrent assets and lease liabilities are included in other current and non-current liabilities in our condensed consolidated balance sheets. As of June 30, 2021, we did not have any material finance leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e5fe486c_5bc1_4a66_b8c2_8061d1f1e5db"></a><a id="ITEM3QUANTITATIVEANDQUALITATIVEDISCLOSUR"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The primary objective of our investment activities is to preserve our capital to fund operations. We also seek to maximize income from our investments without assuming significant risk. Our exposure to market risk is confined to our cash and cash equivalents. As of June&#160;30, 2021, our cash and cash equivalents consisted primarily of investments in treasury securities. We do not engage in any hedging activities against changes in interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we would not expect our operating results or cash </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">flows to be affected to any significant degree by the effect of a sudden change in market interest rates or credit conditions on our securities portfolio. We may, however, require additional financing to fund future obligations and no assurance can be given that the terms of future sources of financing will not expose us to material market risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_590f22eb_f8a0_4f6b_a7b4_4f5809c9c6ef"></a><a id="ITEM4CONTROLSANDPROCEDURES_532997"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;CONTROLS AND PROCEDURES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">(a)&#160;Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted and maintains disclosure controls and procedures (as defined Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is collected, recorded, processed, summarized and reported within the time periods specified in the rules&#160;of the SEC. The Company&#8217;s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule&#160;13a-15, the Company&#8217;s management, including the Chief Executive Officer, who also serves as the Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures as of June&#160;30, 2021, the end of the period covered by this Quarterly Report on Form&#160;10-Q, has concluded that based on such evaluation, the Company&#8217;s disclosure controls and procedures are effective as of June&#160;30, 2021 to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">(b)&#160;Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There have not been any changes in our internal controls over financial reporting during the three&#160;months ended June&#160;30, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f30cc066_b645_42d9_ad8a_7fe509bf29a1"></a><a id="PARTIIOTHERINFORMATION_625995"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II&#8211;OTHER INFORMATION</p><a id="ITEM1LEGALPROCEEDINGS_182785"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1.&#160;LEGAL PROCEEDINGS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b85f8fff_61b5_4f4a_b2b1_5d92a5b06814"></a><a id="ITEM1ARISKFACTORS_227197"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;1A. RISK FACTORS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following information updates, and should be read in conjunction with, the information disclosed in Part&#160;I,&#160;Item&#160;1A, &#8220;Risk Factors,&#8221; contained in our 2020 Form&#160;10-K. Except as disclosed below, there have been no material changes from the risk factors disclosed in our 2020 Form&#160;10-K.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">RISKS RELATING TO OUR BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to raise additional capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate our development programs or commercialization efforts. In addition, potential capital raises and strategic opportunities may require the issuance of additional securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2021, our operating activities used net cash of approximately $5.9 million and our cash and cash equivalents were approximately $74.3 million as of June 30, 2021. With the exception of the three months ended June 30, 2010 and the three months ended December 31, 2017, we have experienced significant losses since inception and have a significant accumulated deficit. As of June 30, 2021, our accumulated deficit totaled approximately $262.7 million on a consolidated basis. We expect to incur additional operating losses in the future and therefore expect our cumulative losses to increase. With the exception of the quarter ended September&#160;30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March&#160;2012, we have generated very minimal revenues. We do not expect to derive revenue from any source in the near future until we or our potential partners successfully commercialize our products, if ever. We expect our expenses to increase in connection with our anticipated activities, particularly as we continue research and development, initiate and conduct later stage clinical trials, and seek marketing approval for our product candidates. Until such time as we receive approval from the FDA and other regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing and collaboration fees and grants, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital to fund our operations and meet our current timelines and we cannot be certain that funding will be available on acceptable terms on a timely basis, or at all. Any failure to raise additional capital as and when needed, as a result of insufficient authorized shares or otherwise, could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. Based on our current plans, our cash and cash equivalents will be sufficient to complete our planned Phase 1a/2a clinical trial of SYN-004, our planned Phase 1 single-ascending and multiple-ascending dose clinical trials of SYN-020, and a potential Phase 2a clinical trial of SYN-020 but, may not be sufficient for post-Phase 2a future clinical programs for SYN-020 or additional trials of SYN-004, which are expected to require significant cash expenditures. In addition, based on the significant anticipated cost of a Phase 3 clinical program in a broad indication for SYN-004, we expect it will not be feasible for us to initiate and complete this trial at this time without a partner given the capital constraints tied to our current market cap and share price. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. We may also issue shares of our common stock in connection with strategic opportunities. However, our remaining authorized and unissued shares of common stock available may be insufficient to complete potential future equity financing transactions and/or strategic transactions we may seek to undertake. Accordingly, we anticipate taking steps, when appropriate, to increase our number of available shares which may have the effect of facilitating such transactions. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business and also have a dilutive effect on our stockholders. A failure otherwise to secure additional funds when needed in the future whether through an equity or debt financing or a sufficient amount of capital without a strategic partnership could result in us being unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. We also may be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock has been and may continue to be volatile and adversely affected by various factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. By way of example, on February&#160;8, 2021, the price of our common stock closed at $1.17 per share while on April&#160;19, 2021, our stock price closed at $0.52 per share with no discernable announcements or developments by the company or third parties. On February&#160;9, 2021, the intra-day sales price of our common stock fluctuated between a reported low sale price of $0.91 and a reported high sales price of $1.19. We may incur rapid and substantial decreases in our stock price in the foreseeable future that are unrelated to our operating performance or prospects. In addition, the recent outbreak of the novel strain of coronavirus (COVID-19) has caused broad stock market and industry fluctuations. The stock market in general and the market for biotechnology and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock could fluctuate significantly in response to various factors and events, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">investor reaction to our business strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our continued compliance with the listing standards of the NYSE American;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">results of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the success of our efforts to acquire or in-license additional products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developments concerning our collaborations or partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">developments or disputes concerning patents or other proprietary rights, including litigation matters and our ability to obtain patent protection for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">declines in the market prices of stocks generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">sales of our common stock by us or our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">general economic, industry and market conditions; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">other events or factors, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, public health issues including health epidemics or pandemics, such as the recent outbreak of the novel coronavirus (COVID-19), and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Further, recent increases are significantly inconsistent with any improvements in actual or expected operating performance, financial condition or other indicators of value. Since the stock price of our common stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.&#160;There can be no guarantee that our stock price will remain at current prices or that future sales of our common stock will not be at prices lower than those sold to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, recently, securities of certain companies have experienced significant and extreme&#160;volatility in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221; &#160;These short squeezes have caused extreme volatility in those companies and in the market and have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated price face the risk of losing a significant portion of their original investment as the price per share has declined steadily as interest in those stocks has abated. While we have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that we won&#8217;t be in the future, and you may lose a significant portion or all of your investment if you purchase our shares at a price that is significantly disconnected from our underlying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to seek to raise additional capital in the future, which may be dilutive to stockholders or impose operational restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expect to seek to raise additional capital in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity or of debt securities, the&#160;percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions, issue equity as consideration for acquisitions or part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity that may be dilutive. We are authorized to issue 200,000,000 shares of common stock, of which 132,042,548 shares of common stock were issued and outstanding as of August&#160;3, 2021. At August&#160;3, 2021, we had reserved 10,342,384 shares of common stock for issuance upon exercise of our outstanding options and warrants. In addition, at such date, we had 2,460,000 shares of our common stock reserved for future issuance under our equity incentive plans. If all of these securities were to be exercised, the total number of shares of our common stock that we would be required to issue is 12,802,384, which in addition to the 132,042,548 shares issued and outstanding, would leave 55,155,079 authorized but unissued shares of common stock. As a result of our limited number of authorized and unissued shares of common stock, we may have insufficient shares of common stock available to issue in connection with any future equity financing transactions or strategic transactions we may seek to undertake. Accordingly, we anticipate taking steps, when appropriate, to increase our number of available shares which may have the effect of facilitating such transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share paid by existing stockholders, thereby subjecting such stockholders to dilution. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by existing stockholders, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. In the event that we sell shares or other securities at prices below the exercise price of the warrants that we issued in our October&#160;2018 offering, the price protection anti-dilution provisions of the warrant provide that the exercise price of the warrants sold in our October&#160;2018 offering is to be reduced which may result in additional warrant exercises and additional dilution to stockholders as was the case in 2020 and during the first quarter of 2021 when we utilized our at-the-market facility and the warrant exercise price was reduced. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATING TO OUR SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We cannot assure you that our common stock will be liquid or that it will remain listed on the NYSE American.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is listed on the NYSE American. The NYSE American&#8217;s listing standards generally mandate that we meet certain requirements relating to stockholders&#8217; equity, stock price, market capitalization, aggregate market value of publicly held shares and distribution requirements. We cannot assure you that we will be able to maintain the continued listing standards of the NYSE American. The NYSE American requires companies to meet certain continued listing criteria including a minimum stockholders&#8217; equity of $6.0 million if an issuer has sustained losses from continuing operations and/or net losses in its five most recent years, as outlined in the NYSE American Company Guide. At December 31, 2020, we had a stockholders&#8217; deficit of $7.5 million. The NYSE American Company Guide also states that the NYSE normally will not consider removing from listing securities of an issuer if it is in compliance with all of the following: a total value of market capitalization of at least $50.0 million; 1,100,000 publicly-held shares; a market value of publicly held shares of at least $15.0 million; and 400 round lot shareholders. Although we have more than 1,100,000 shares publicly held and 400 round lot shareholders, our stock price is volatile and, during 2019 and 2020, the price of our common stock experienced a sustained decrease resulting in a period where our market capitalization fell below $50.0 million. Our market capitalization is currently above $50.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our common stock falls below $0.20 per share on a 30-trading-day average it will become subject to the continued listing evaluation and follow-up procedures set forth in Section 1009 of the NYSE American Company Guide which could, among other things, result in initiation of immediate delisting procedures. In the event that we were to fail to meet the requirements of NYSE American per share price requirement or stockholders&#8217; equity requirement and we could not timely cure such deficiency, our listing could become subject to NYSE American continued listing evaluation and follow-up procedures, which could result in delisting procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 25, 2021, we received notification from the NYSE American that the Company had regained compliance with all of the continued listing standards set forth in Part 10, Section 1003 of the NYSE American Company Guide (the &#8220;Company Guide&#8221;) relating to the Exchange&#8217;s continued listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We previously received notification from the NYSE American citing failure to comply with the minimum stockholders&#8217; equity continued listing standard as set forth in Part 10, Section 1003 of the Company Guide. As a result of management&#8217;s efforts to regain compliance, the Exchange has informed the Company that it has cured the previously cited deficiencies and is in full compliance with the continued listing standards set forth in Part 10, Sections 1003 (i), (ii), and (iii) of the Company Guide. We reported stockholders&#8217; equity of approximately $79.6 million in its most recent Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 5, 2021. Effective at the start of trading on May 26, 2021, the &#8220;.BC&#8221; designation, signifying non-compliance with NYSE American listing standards, was removed from the &#8220;SYN&#8221; trading symbol. &#160;However, there can be no assurance that we will continue to meet the NYSE American continued listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b36cad8a_6ba6_4b2a_b6c9_dc13e4ed77d6"></a><a id="ITEM2UNREGISTEREDSALESOFEQUITYSECURITIES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We did not sell any equity securities during the quarter ended June 30, 2021 in transactions that were not registered under the Securities Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_975ad1ad_8deb_4e50_9184_b5c33a036aa5"></a><a id="ITEM3DEFAULTSUPONSENIORSECURITIES_373292"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;3.&#160;DEFAULTS UPON SENIOR SECURITIES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4eabeadf_dd8b_4ef6_8d19_36519bd2f651"></a><a id="ITEM4MINESAFETYDISCLOSURES_919457"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;4.&#160;MINE SAFETY DISCLOSURES.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ade9ddec_c6cb_4820_bf3f_eb89bb2fca22"></a><a id="ITEM5OTHERINFORMATION_597535"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;5.&#160;OTHER INFORMATION.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3853fea2_a44f_4fad_84a8_8e80260bc6cf"></a><a id="ITEM6EXHIBITS_463066"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">ITEM&#160;6. EXHIBITS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The exhibits filed or furnished as part of this Quarterly Report on Form&#160;10-Q are set forth on the Exhibit&#160;Index, which Exhibit&#160;Index is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a697f2a4_e5dc_44d7_a7af_9a320126d046"></a><a id="SIGNATURES_21868"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:49.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">SYNTHETIC BIOLOGICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">/s/ Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Chief Executive Officer, Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:50.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:45.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Date: August&#160;5, 2021</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6e79d05c_ee2c_43bf_97be_ea31f267d8e4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;INDEX</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b> <br /><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Title</b></p></td></tr><tr><td style="vertical-align:top;width:9.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921016924/tm216028d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated At Market Issuance Sales Agreement dated February 9, 2021 by and among Synthetic Biologics, Inc. and B. Riley Securities, Inc. and A.G.P./Alliance Global Partners (Incorporated by reference to Exhibit 1.1 of the Registrant&#8217;s Current Report on Form 8-K filed February 10, 2021, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Certificate of Incorporation, as amended (Incorporated by reference to (i) <a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016308000665/s11-8824_ex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 16, 2008, File No. 001-12584</span></a>, (ii) <a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000095012401502861/c64437ex3-1.txt"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibit 3.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001 filed August 14, 2001, File No. 001-12584;</span></a> and (iii) <a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694-index.html"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits 3.1, 4.1 and 4.2 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 1998 filed August 14, 1998, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Articles of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Articles of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420411060729/v238878_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amended and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed November 2, 2011, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed February 16, 2012, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed May 18, 2015, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 8, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Designations for Series A Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 12, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418043710/tv500716_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Change Pursuant to NRS 78. 209 (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed August 13, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.11</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418050928/tv503400_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 26, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.12</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Designations for Series B Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 15, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.13</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to Certificate of Designations for Series B Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed October 15, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.14</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921009794/tm214840d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K/A filed on February 1, 2021 File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="syn-20210630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a)*</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;" href="syn-20210630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase*</p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;">*Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>syn-20210630xex31d1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/5/2021 07:36:52 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO RULE 13a-14(a)&#160;OR RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Steven A. Shallcross, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Synthetic Biologics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;">c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;">d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#39;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 72pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 5, 2021</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;</p></td><td style="vertical-align:top;width:48.43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#160;Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>3
<FILENAME>syn-20210630xex32d1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/5/2021 07:36:55 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION&#160;OF PRINCIPAL EXECUTIVE OFFCIER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:44pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics, Inc. (the &#8220;Registrant&#8221;) hereby certifies, to such officer&#8217;s knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the accompanying Quarterly Report on Form 10-Q of the Registrant for the quarter ended June 30, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 5, 2021</p></td><td colspan="2" style="vertical-align:top;width:51.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;</p></td><td style="vertical-align:top;width:48.43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#160;Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:48.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>syn-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 7:37:14 PM-->
<!--Modified on: 8/5/2021 7:37:14 PM-->
<schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.syntheticbiologics.com/20210630" elementFormDefault="qualified" xmlns:syn="http://www.syntheticbiologics.com/20210630" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails">
        <link:definition>40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails">
        <link:definition>40303 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails">
        <link:definition>40304 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" id="DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical">
        <link:definition>00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>40401 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" id="DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails">
        <link:definition>40402 - Disclosure - Stock-Based Compensation - Stock incentive plan and other information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails" id="DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails">
        <link:definition>40501 - Disclosure - Stock Warrants - Summary of all warrant activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" id="DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails">
        <link:definition>40502 - Disclosure - Stock Warrants - Summary of all outstanding and exercisable warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails" id="DisclosureStockWarrantsStockWarrantsDetails">
        <link:definition>40503 - Disclosure - Stock Warrants - Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" id="DisclosureNetLossPerShareAdditionalInformationDetails">
        <link:definition>40601 - Disclosure - Net Loss per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" id="DisclosureNonControllingInterestDetails">
        <link:definition>40701 - Disclosure - Non-controlling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails" id="DisclosureCommonAndPreferredStockDetails">
        <link:definition>40801 - Disclosure - Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>40901 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>41002 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" id="DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>10201 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" id="DisclosureSelectedBalanceSheetInformation">
        <link:definition>10301 - Disclosure - Selected Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>10401 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrants" id="DisclosureStockWarrants">
        <link:definition>10501 - Disclosure - Stock Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>10601 - Disclosure - Net Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" id="DisclosureNonControllingInterest">
        <link:definition>10701 - Disclosure - Non-controlling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock" id="DisclosureCommonAndPreferredStock">
        <link:definition>10801 - Disclosure - Common and Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>10901 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" id="DisclosureSelectedBalanceSheetInformationTables">
        <link:definition>30303 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>30403 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables" id="DisclosureStockWarrantsTables">
        <link:definition>30503 - Disclosure - Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31003 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" id="DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <element name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syn_DepositsAndOtherAssetsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="ConversionOfSeriesBPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ConversionOfSeriesBPreferredStockToCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="StockIssuedDuringPeriodValueOfSynBiomicsStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element name="ConversionOfSeriesBPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" substitutionGroup="xbrli:item" />
  <element id="syn_IncreaseDecreaseRightOfUseAssets" name="IncreaseDecreaseRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_DeemedDividendsWithBeneficialConversionFeature" name="DeemedDividendsWithBeneficialConversionFeature" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element name="StockWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockWarrantsAbstract" substitutionGroup="xbrli:item" />
  <element id="syn_StockPurchaseWarrantsTextBlock" name="StockPurchaseWarrantsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_AccruedExpensesTableTextBlock" name="AccruedExpensesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_AccruedEmployeeBenefitsTableTextBlock" name="AccruedEmployeeBenefitsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" name="PrepaidClinicalResearchOrganizationsExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" name="PrepaidConsultingSubscriptionsAndOtherExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="ComputersAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_ComputersAndOfficeEquipmentMember" substitutionGroup="xbrli:item" />
  <element id="syn_AccruedClinicalConsultingServices" name="AccruedClinicalConsultingServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="syn_AccruedVendorPayments" name="AccruedVendorPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="StockPlan2007Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockPlan2007Member" substitutionGroup="xbrli:item" />
  <element name="StockPlan2010Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockPlan2010Member" substitutionGroup="xbrli:item" />
  <element name="GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
  <element name="StockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" substitutionGroup="xbrli:item" />
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
  <element name="ExercisePrice1820Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_ExercisePrice1820Member" substitutionGroup="xbrli:item" />
  <element name="ExercisePrice138Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_ExercisePrice138Member" substitutionGroup="xbrli:item" />
  <element name="WarrantsExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_WarrantsExercisePrice" substitutionGroup="xbrli:item" />
  <element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element name="OctoberTwoThousandEighteenWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_OctoberTwoThousandEighteenWarrantsMember" substitutionGroup="xbrli:item" />
  <element name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_UnderwrittenPublicOfferingMember" substitutionGroup="xbrli:item" />
  <element id="syn_WarrantTerm" name="WarrantTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_NumberOfCommonStockToBeIssued" name="NumberOfCommonStockToBeIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_AdditionalNumberOfCommonStockToBeIssued" name="AdditionalNumberOfCommonStockToBeIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_NumberOfCommonStockToBeHeldByRelatedParty" name="NumberOfCommonStockToBeHeldByRelatedParty" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_FairValueOfSharesIssued" name="FairValueOfSharesIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="BrokerageCommissionPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syn_BrokerageCommissionPercentage" substitutionGroup="xbrli:item" />
  <element id="syn_IssueOfWarrantsToPurchaseCommonStock" name="IssueOfWarrantsToPurchaseCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element name="PercentageOfIssueOfThePublicOffering" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_PercentageOfIssueOfThePublicOffering" substitutionGroup="xbrli:item" />
  <element id="syn_StockIssuedDuringPeriodAtMarketOfferingValue" name="StockIssuedDuringPeriodAtMarketOfferingValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="syn_StockIssuedDuringPeriodAtMarketOfferingShare" name="StockIssuedDuringPeriodAtMarketOfferingShare" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_BalanceSheetInformationAbstract" name="BalanceSheetInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_PrepaidManufacturingExpense" name="PrepaidManufacturingExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="syn_SubsidiaryStockIssuesToVendor" name="SubsidiaryStockIssuesToVendor" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_SYNBiomicsMember" name="SYNBiomicsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_IntrexonMember" name="IntrexonMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_SyntheticBiomicsIncMember" name="SyntheticBiomicsIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_CedarssinaiMedicalCenterMember" name="CedarssinaiMedicalCenterMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_ExercisePrice5248Member" name="ExercisePrice5248Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_ConsultantMember" name="ConsultantMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_AccretionOfPreferredStockDeemedDividend" name="AccretionOfPreferredStockDeemedDividend" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_FbrCapitalMarketsCoMember" name="FbrCapitalMarketsCoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_StockPlan2020Member" name="StockPlan2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" name="AccumulatedNetGainLossAttributableToNoncontrollingInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="syn_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_WarrantExercisePriceAdjustment" name="WarrantExercisePriceAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_Conversionofseriesapreferredstocktocommonstockshares" name="Conversionofseriesapreferredstocktocommonstockshares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_Conversionofseriesbpreferredstocktocommonstock" name="Conversionofseriesbpreferredstocktocommonstock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="syn_PreferredStockPriceAdjustment" name="PreferredStockPriceAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="syn_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_AdjustmentsToEffectOfPreferredStockPrice" name="AdjustmentsToEffectOfPreferredStockPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" name="LesseeOperatingLeaseLiabilityToBePaidYearSix" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="syn_EstimatedFairValueOfInducementConsideration" name="EstimatedFairValueOfInducementConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_LeaseRentAbatementPeriod1" name="LeaseRentAbatementPeriod1" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_PercentageOfFundsToBeBorrowedByCompany" name="PercentageOfFundsToBeBorrowedByCompany" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="syn_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" name="PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_NumberOfSharesPurchase" name="NumberOfSharesPurchase" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_NumberOfShareSold" name="NumberOfShareSold" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_PercentageOfStatedDividendRate" name="PercentageOfStatedDividendRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="syn_NumberOfOperatingLeaseForFacilities" name="NumberOfOperatingLeaseForFacilities" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>syn-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 7:37:14 PM-->
<!--Modified on: 8/5/2021 7:37:14 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" />
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637637890330709429" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637637890330709429" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890330709429" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637637890330709429" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890330709429" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637637890330709429" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637637890330709429" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_637637890330709429" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_637637890330709429" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637637890330719159" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637637890330719159" xlink:to="us-gaap_LiabilitiesCurrent_637637890330719159" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637637890330719159" xlink:to="us-gaap_AccountsPayableCurrent_637637890330719159" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637637890330719159" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637637890330719159" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637637890330719159" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637637890330719159" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637637890330719159" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637637890330719159" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637637890330719159" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890330719159" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637637890330719159" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637637890330719159" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890330729507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890330729507" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637637890330729507" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890330729507" xlink:to="us-gaap_StockholdersEquity_637637890330729507" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637637890330739342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637637890330729507" xlink:to="us-gaap_PreferredStockValue_637637890330739342" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637637890330739342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637637890330729507" xlink:to="us-gaap_CommonStockValue_637637890330739342" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637637890330739342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637637890330729507" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637637890330739342" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637637890330739342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637637890330729507" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637637890330739342" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest_637637890330739342" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890330729507" xlink:to="us-gaap_MinorityInterest_637637890330739342" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637637890330749284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637637890330749284" xlink:to="us-gaap_ProfitLoss_637637890330749284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637637890330749284" xlink:to="us-gaap_OperatingIncomeLoss_637637890330749284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637637890330749284" xlink:to="us-gaap_OperatingExpenses_637637890330749284" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637637890330749284" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637637890330749284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637637890330749284" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637637890330749284" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637637890330749284" xlink:to="us-gaap_NonoperatingIncomeExpense_637637890330749284" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637637890330749284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637637890330749284" xlink:to="us-gaap_InvestmentIncomeInterest_637637890330749284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637637890330749284" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890330759164" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890330759164" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="syn_PreferredStockPriceAdjustment_637637890330759164" order="3" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_ProfitLoss_637637890330759164" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_ShareBasedCompensation_637637890330759164" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637637890330759164" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability_637637890330759164" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="syn_IncreaseDecreaseInOperatingLeaseLiability_637637890330759164" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="syn_SubsidiaryStockIssuesToVendor_637637890330769163" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637637890330769163" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_637637890330769163" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637637890330769163" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637637890330769163" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890330759164" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637637890330769163" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637637890330769163" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637637890330769163" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637637890330769163" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890330769163" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890330769163" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890330769163" xlink:to="us-gaap_ProceedsFromWarrantExercises_637637890330779175" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890330769163" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890330779175" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637637890330779175" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637637890330779175" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637637890330779175" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense_637637890330779175" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidManufacturingExpense_637637890330779175" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_637637890330788810" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637637890330788810" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637637890330788810" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="syn_AccruedClinicalConsultingServices_637637890330788810" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="syn_AccruedVendorPayments_637637890330788810" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637637890330788810" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637637890330788810" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637637890330788810" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_637637890330788810" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases payments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637637890330799144" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637637890330799144" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637637890330799144" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637637890330799144" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637637890330799144" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_637637890330799144" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637637890330799144" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637637890330799144" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>6
<FILENAME>syn-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 7:37:14 PM-->
<!--Modified on: 8/5/2021 7:37:14 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsStockWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNonControllingInterestDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommonAndPreferredStockDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890330809073" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_637637890330809073" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PreferredStockPriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637637890330829163" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637637890330829163" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890330879090" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890330879090" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="syn_ComputersAndOfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637637890330889057" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637637890330889057" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stock-Based Compensation - Stock incentive plan and other information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637637890330919076" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_637637890330919076" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2010Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637637890330929071" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_637637890330929071" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_ConsultantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637637890330929071" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637637890330929071" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637637890330939156" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637637890330939156" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637637890330949062" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637637890330949062" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637637890330949062" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637637890330949062" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Stock Warrants - Summary of all outstanding and exercisable warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890330969301" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890330969301" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice138Member" xlink:label="syn_ExercisePrice138Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice138Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice1820Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice5248Member" xlink:label="syn_ExercisePrice5248Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice5248Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_WarrantsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Stock Warrants - Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637637890331059055" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637637890331059055" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="syn_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_WarrantTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_PreferredStockConversionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_PercentageOfIssueOfThePublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_NumberOfShareSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_NumberOfSharesPurchase" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Net Loss per Share - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331129119" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331129119" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="syn_AccretionOfPreferredStockDeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PreferredStockDiscountOnShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Non-controlling Interest (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_CedarssinaiMedicalCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_MinorityInterestTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637637890331149058" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_637637890331149058" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="syn_SYNBiomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_NumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_FairValueOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common and Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637637890331178844" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637637890331178844" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="syn_FbrCapitalMarketsCoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PreferredStockConversionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PercentageOfIssueOfThePublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDiscountOnShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_BeneficialOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_EstimatedFairValueOfInducementConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_AccretionOfPreferredStockDeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_BrokerageCommissionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfStatedDividendRate" xlink:label="syn_PercentageOfStatedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PercentageOfStatedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637637890331269091" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637637890331269091" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IntrexonMember" xlink:label="syn_IntrexonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="syn_IntrexonMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="syn_IntrexonMember" xlink:to="syn_CedarssinaiMedicalCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_CedarssinaiMedicalCenterMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="syn_SyntheticBiomicsIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="syn_NumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637637890331289056" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_637637890331289056" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LeaseRentAbatementPeriod1" xlink:label="syn_LeaseRentAbatementPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_LeaseRentAbatementPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfFundsToBeBorrowedByCompany" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PercentageOfFundsToBeBorrowedByCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfOperatingLeaseForFacilities" xlink:label="syn_NumberOfOperatingLeaseForFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_NumberOfOperatingLeaseForFacilities" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>syn-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 7:37:14 PM-->
<!--Modified on: 8/5/2021 7:37:14 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at the end of this period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of this period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DepositsAndOtherAssetsNoncurrent" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability - long term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Deficit):</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at June 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Costs and Expenses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Costs and Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income :</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Loss Attributable to Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred stock accrued dividends</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredStockPriceAdjustment" xlink:to="syn_PreferredStockPriceAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">The amount represents the effect of preferred stock price adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Preferred Stock Price Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Effect of Series A Preferred Stock Price adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Effect of Series A Preferred Stock price adjustment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Loss Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Basic and Dilutive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the period - Basic and Dilutive</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Stockholders Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Stock Issued During Period At Market Offering Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Stock issued under "at-the-market" offering</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Number of new stock issued during the period at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Stock Issued During Period At Market Offering Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Stock issued under "at-the-market" offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Series A Preferred Stock Dividends</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">The amount of adjustment to effect of preferred stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">Adjustments To Effect Of Preferred Stock Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">Effect of Series A Preferred Stock price adjustment</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Represents the value of new stock of syn biomics stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Stock Issued During Period Value Of Syn Biomics Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Issuance of SYN Biomics Stock</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Number of conversion of series B preferred stock to common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common (in shares)</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Represents conversion of preferred stock to common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_Conversionofseriesbpreferredstocktocommonstock" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">Conversion Of Series B Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">ConversionOfSeriesBPreferredStockToCommonStock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock to Common</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">Conversion of preferred shares to common</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">ConversionOfSeriesAPreferredStockToCommonStockShares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock to Common (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividends Payable, Amount Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xml:lang="en-US">Dividend payable per preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SubsidiaryStockIssuesToVendor" xlink:to="syn_SubsidiaryStockIssuesToVendor_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Subsidiary Stock Issues To Vendor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Subsidiary stock issuances to vendor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncreaseDecreaseRightOfUseAssets" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">An amount of increase decrease in lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">Increase decrease Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="syn_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of operating lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase Decrease In Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from "at the market" stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Cash proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Financing Activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use asset from operating lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_DeemedDividendsWithBeneficialConversionFeature" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeemedDividendsWithBeneficialConversionFeature" xlink:to="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Amount of Deemed Dividends With Beneficial Conversion Feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Deemed dividends for beneficial conversion features</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Deemed dividends for accretion of Series B Preferred Stock discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockPaidinkind" xlink:to="us-gaap_DividendsPreferredStockPaidinkind_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_lbl" xml:lang="en-US">Dividends, Preferred Stock, Paid-in-kind</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_lbl" xml:lang="en-US">In-kind dividends paid in preferred stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_BalanceSheetInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BalanceSheetInformationAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BalanceSheetInformationAbstract_lbl" xml:lang="en-US">Selected Balance Sheet Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Selected Balance Sheet Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockWarrantsAbstract" xlink:to="syn_StockWarrantsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockWarrantsAbstract_lbl" xml:lang="en-US">Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="syn_StockPurchaseWarrantsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPurchaseWarrantsTextBlock" xlink:to="syn_StockPurchaseWarrantsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockPurchaseWarrantsTextBlock_lbl" xml:lang="en-US">The entire disclosure related to Stock Purchase Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPurchaseWarrantsTextBlock_lbl" xml:lang="en-US">Stock Purchase Warrants [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockPurchaseWarrantsTextBlock_lbl" xml:lang="en-US">Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="syn_AccruedExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedExpensesTableTextBlock" xlink:to="syn_AccruedExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Accrued Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedEmployeeBenefitsTableTextBlock" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedEmployeeBenefitsTableTextBlock" xlink:to="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of information related to accrued employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Accrued Employee Benefits [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of warrant activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Summary of all warrant activity</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure relates to warrant outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Summary of all outstanding and exercisable warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturity analysis of operating leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Sum of the amount paid in advance for clinical research organization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Prepaid Clinical Research Organizations Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Prepaid clinical research organizations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurances</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Sum of the amount paid in advance for consulting, subscriptions and other expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Prepaid Consulting Subscriptions And Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Prepaid consulting, subscriptions and other expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Stock sales receivable</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidManufacturingExpense" xlink:to="syn_PrepaidManufacturingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Amount of Prepaid Manufacturing Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Prepaid Manufacturing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Prepaid manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ComputersAndOfficeEquipmentMember" xlink:to="syn_ComputersAndOfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ComputersAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computers And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ComputersAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computers and office equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedClinicalConsultingServices" xlink:to="syn_AccruedClinicalConsultingServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">The carrying value of accrued clinical consulting services payable as on balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">Accrued Clinical Consulting Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">Accrued clinical consulting services</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedVendorPayments" xlink:to="syn_AccruedVendorPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Accrued Vendor Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Accrued vendor payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonus expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued vacation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options, Expired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2007Member" xlink:to="syn_StockPlan2007Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2007Member_lbl" xml:lang="en-US">Stock Plan2007 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockPlan2007Member_lbl" xml:lang="en-US">2007 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2010Member" xlink:to="syn_StockPlan2010Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2010Member_lbl" xml:lang="en-US">Stock Plan2010 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockPlan2010Member_lbl" xml:lang="en-US">2010 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2020Member" xlink:to="syn_StockPlan2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockPlan2020Member_lbl" xml:lang="en-US">Represents information pertaining to 2020 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2020Member_lbl" xml:lang="en-US">Stock Plan2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockPlan2020Member_lbl" xml:lang="en-US">2020 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">General And Administrative Expenses And Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">General and Administrative Expenses and Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Warrants, Granted</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Number of share warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice138Member" xlink:label="syn_ExercisePrice138Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice138Member" xlink:to="syn_ExercisePrice138Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice138Member_lbl" xml:lang="en-US">Exercise Price138 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ExercisePrice138Member_lbl" xml:lang="en-US">Exercise Price 0.69 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice1820Member" xlink:to="syn_ExercisePrice1820Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice1820Member_lbl" xml:lang="en-US">Exercise Price1820 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ExercisePrice1820Member_lbl" xml:lang="en-US">Exercise Price 18.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice5248Member" xlink:label="syn_ExercisePrice5248Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice5248Member" xlink:to="syn_ExercisePrice5248Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ExercisePrice5248Member_lbl" xml:lang="en-US">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice5248Member_lbl" xml:lang="en-US">Exercise Price5248 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ExercisePrice5248Member_lbl" xml:lang="en-US">Exercise Price 0.69 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantsExercisePrice" xlink:to="syn_WarrantsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Exercise price of the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Warrants Exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xml:lang="en-US">Class of Treasury Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockWarrantsMember" xlink:to="syn_StockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockWarrantsMember_lbl" xml:lang="en-US">Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_UnderwrittenPublicOfferingMember" xlink:to="syn_UnderwrittenPublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OctoberTwoThousandEighteenWarrantsMember" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember_lbl" xml:lang="en-US">October Two Thousand Eighteen Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember_lbl" xml:lang="en-US">October 2018 Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US">Equity, Class of Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from "at the market" stock issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantTerm" xlink:to="syn_WarrantTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Represents the warrant term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Warrant Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Warrant Term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredStockConversionPricePerShare" xlink:to="syn_PreferredStockConversionPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantExercisePriceAdjustment" xlink:to="syn_WarrantExercisePriceAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">The amount represents the effect of warrant exercise price adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">Warrant Exercise Price Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">Effect of Warrant exercise price adjustment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IssueOfWarrantsToPurchaseCommonStock" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">It represent additional of warrant to purchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Issue of warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PercentageOfIssueOfThePublicOffering" xlink:to="syn_PercentageOfIssueOfThePublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PercentageOfIssueOfThePublicOffering_lbl" xml:lang="en-US">Percentage of issue of public offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PercentageOfIssueOfThePublicOffering_lbl" xml:lang="en-US">Percentage of issue of the public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfShareSold" xlink:to="syn_NumberOfShareSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Represents the information pertaining to Number of Share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Number of Share sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Number of Share sold</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfSharesPurchase" xlink:to="syn_NumberOfSharesPurchase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Represents the shares purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Number of Shares purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Number of Shares purchase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccretionOfPreferredStockDeemedDividend" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_lbl" xml:lang="en-US">This element represents the amount of accretion of the Series B preferred stock deemed dividend.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_lbl" xml:lang="en-US">Accretion of Preferred Stock Deemed Dividend</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDiscountOnShares" xlink:to="us-gaap_PreferredStockDiscountOnShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDiscountOnShares_lbl" xml:lang="en-US">Preferred Stock, Discount on Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDiscountOnShares_lbl" xml:lang="en-US">Preferred Stock Redemption Discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_lbl" xml:lang="en-US">Accretion of preferred discount</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" xlink:to="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_lbl" xml:lang="en-US">Number of preferred shares convertible to common stock that were excluded from the computations of net loss per common share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_lbl" xml:lang="en-US">Preferred Shares Convertible To Common Stock Excluded From Net Loss Per Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_lbl" xml:lang="en-US">Convertible to common stock that were excluded from the computations of net loss per common share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US">Noncontrolling Interest [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Equity interest by parent</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfCommonStockToBeIssued" xlink:to="syn_NumberOfCommonStockToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">The number of common stock to be issued under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Number Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Number Of Common Stock To Be Issued</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdditionalNumberOfCommonStockToBeIssued" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">The additional number of common stock to be issued under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Additional Number Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Additional Number Of Common Stock To Be Issued</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">The additional number of common stock to be held by the related party under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">Number Of Common Stock To Be Held By Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">Number Of Common Stock To Be Held By Related Party</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_FairValueOfSharesIssued" xlink:to="syn_FairValueOfSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Amount represents the fair value of shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Fair Value Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Fair Value Of Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" xlink:to="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">The amount of accumulated net loss attributable to the non-controlling interest as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Accumulated Net Gain (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Accumulated net loss attributable to the non-controlling interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Increase</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Split</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BeneficialOwnershipPercentage" xlink:to="syn_BeneficialOwnershipPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Percentage of beneficial ownership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Beneficial Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Maximum percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Common stock issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EstimatedFairValueOfInducementConsideration" xlink:to="syn_EstimatedFairValueOfInducementConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Amount of Estimated Fair Value of Inducement Consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Estimated Fair Value of Inducement Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Estimated fair value of inducement consideration</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BrokerageCommissionPercentage" xlink:to="syn_BrokerageCommissionPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BrokerageCommissionPercentage_lbl" xml:lang="en-US">Represent that percentage of commission revenue from buying and selling securities on behalf of customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BrokerageCommissionPercentage_lbl" xml:lang="en-US">Brokerage Commission percentage</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfStatedDividendRate" xlink:label="syn_PercentageOfStatedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PercentageOfStatedDividendRate" xlink:to="syn_PercentageOfStatedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PercentageOfStatedDividendRate_lbl" xml:lang="en-US">Represents the percentage of stated dividend rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PercentageOfStatedDividendRate_lbl" xml:lang="en-US">percentage of stated dividend rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PercentageOfStatedDividendRate_lbl" xml:lang="en-US">percentage of stated dividend rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:to="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_lbl" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Discount factor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type Of Adoption [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Type of Adoption [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">Accounting Standards Update201602 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US">ASU 2016-02</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewed lease term</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LeaseRentAbatementPeriod1" xlink:label="syn_LeaseRentAbatementPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LeaseRentAbatementPeriod1" xlink:to="syn_LeaseRentAbatementPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LeaseRentAbatementPeriod1_lbl" xml:lang="en-US">Duration of lease rent abatement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LeaseRentAbatementPeriod1_lbl" xml:lang="en-US">Lease Rent Abatement Period 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LeaseRentAbatementPeriod1_lbl" xml:lang="en-US">Lease rent abatement period</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfFundsToBeBorrowedByCompany" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PercentageOfFundsToBeBorrowedByCompany" xlink:to="syn_PercentageOfFundsToBeBorrowedByCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany_lbl" xml:lang="en-US">Percentage at which funds can be borrowed by company for tenants improvements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany_lbl" xml:lang="en-US">Percentage Of Funds to be Borrowed By Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany_lbl" xml:lang="en-US">Rate of interest of funds borrowed by company</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfOperatingLeaseForFacilities" xlink:label="syn_NumberOfOperatingLeaseForFacilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfOperatingLeaseForFacilities" xlink:to="syn_NumberOfOperatingLeaseForFacilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfOperatingLeaseForFacilities_lbl" xml:lang="en-US">Represents the information pertaining to Number of operating lease for facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfOperatingLeaseForFacilities_lbl" xml:lang="en-US">Number of operating lease for facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfOperatingLeaseForFacilities_lbl" xml:lang="en-US">Number of operating lease for facilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConsultantMember" xlink:to="syn_ConsultantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConsultantMember_lbl" xml:lang="en-US">n/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employee Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title Of Individual With Relationship To Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SeriesWarrantsMember" xlink:to="syn_SeriesWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SeriesWarrantsMember_lbl" xml:lang="en-US">Series Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SeriesBWarrantsMember" xlink:to="syn_SeriesBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_CedarssinaiMedicalCenterMember" xlink:to="syn_CedarssinaiMedicalCenterMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_CedarssinaiMedicalCenterMember_lbl" xml:lang="en-US">This member stands for Cedarssinai Medical Center.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_CedarssinaiMedicalCenterMember_lbl" xml:lang="en-US">Cedarssinai Medical Center [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_CedarssinaiMedicalCenterMember_lbl" xml:lang="en-US">Cedarssinai Medical Center [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SYNBiomicsMember" xlink:to="syn_SYNBiomicsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SYNBiomicsMember_lbl" xml:lang="en-US">S Y N Biomics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SYNBiomicsMember_lbl" xml:lang="en-US">S Y N Biomics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_SYNBiomicsMember_lbl" xml:lang="en-US">SYN Biomics [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_FbrCapitalMarketsCoMember" xlink:to="syn_FbrCapitalMarketsCoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_FbrCapitalMarketsCoMember_lbl" xml:lang="en-US">FbrCapitalMarketsCoMember</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_FbrCapitalMarketsCoMember_lbl" xml:lang="en-US">Fbr Capital Markets Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_FbrCapitalMarketsCoMember_lbl" xml:lang="en-US">Fbr Capital Markets Co [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IntrexonMember" xlink:label="syn_IntrexonMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IntrexonMember" xlink:to="syn_IntrexonMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IntrexonMember_lbl" xml:lang="en-US">Intrexon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_IntrexonMember_lbl" xml:lang="en-US">Intrexon [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SyntheticBiomicsIncMember" xlink:to="syn_SyntheticBiomicsIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SyntheticBiomicsIncMember_lbl" xml:lang="en-US">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SyntheticBiomicsIncMember_lbl" xml:lang="en-US">Synthetic Biomics Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_SyntheticBiomicsIncMember_lbl" xml:lang="en-US">Synthetic Biomics Inc [Member]</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>syn-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 7:37:14 PM-->
<!--Modified on: 8/5/2021 7:37:14 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensation" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrants" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrants" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNetLossPerShare" roleURI="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNonControllingInterest" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommonAndPreferredStock" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureStockWarrantsStockWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNetLossPerShareAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureNonControllingInterestDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommonAndPreferredStockDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20210630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" />
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637637890331329098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637637890331329098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637637890331329098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637637890331329098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637637890331329098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637637890331329098" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637637890331339055" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637637890331339055" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637637890331339055" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637637890331339055" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637637890331339055" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637637890331339055" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637637890331339055" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637637890331339055" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637637890331339055" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637637890331339055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637637890331339055" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637637890331349067" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637637890331349067" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637637890331349067" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637637890331349067" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637637890331349067" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637637890331349067" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637637890331349067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637637890331349067" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637637890331359078" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637637890331359078" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637637890331359078" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637637890331359078" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637637890331359078" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637637890331359078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637637890331359078" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637637890331369083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637637890331369083" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637637890331369083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637637890331369083" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637637890331369083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637637890331369083" order="29" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_637637890331379091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637637890331379091" xlink:to="us-gaap_AssetsCurrentAbstract_637637890331379091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637637890331379091" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890331379091" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637637890331379091" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890331379091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637637890331379091" xlink:to="us-gaap_AssetsCurrent_637637890331379091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637637890331379091" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637637890331379091" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637637890331379091" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637637890331379091" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637637890331379091" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637637890331379091" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_637637890331389070" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637637890331379091" xlink:to="us-gaap_Assets_637637890331389070" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" xlink:to="us-gaap_AccountsPayableCurrent_637637890331389070" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637637890331389070" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637637890331389070" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637637890331389070" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637637890331399182" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637637890331389070" xlink:to="us-gaap_LiabilitiesCurrent_637637890331399182" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890331399182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_Liabilities_637637890331399182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_CommitmentsAndContingencies_637637890331399182" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637637890331399182" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_StockholdersEquityAbstract_637637890331399182" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637637890331399182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_PreferredStockValue_637637890331399182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_CommonStockValue_637637890331409316" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637637890331409316" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637637890331409316" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_StockholdersEquity_637637890331409316" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_MinorityInterest_637637890331409316" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331409316" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637637890331399182" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331409316" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637637890331419175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637637890331389070" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637637890331419175" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637637890331419175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637637890331419175" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637637890331419175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637637890331419175" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637637890331419175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued_637637890331419175" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637637890331419175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637637890331419175" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331429286" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637637890331429286" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637637890331429286" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637637890331429286" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637637890331429286" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637637890331429286" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637637890331429286" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637637890331429286" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_177" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637637890331429286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_177" xlink:to="us-gaap_StatementTable_637637890331429286" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331429286" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331439145" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331439145" xlink:to="us-gaap_ClassOfStockDomain_637637890331439145" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331439145" xlink:to="us-gaap_SeriesAPreferredStockMember_637637890331439145" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331439145" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331439145" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331429286" xlink:to="us-gaap_StatementLineItems_637637890331439145" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_OperatingExpensesAbstract_637637890331439145" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637637890331439145" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637637890331439145" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637637890331439145" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637637890331439145" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637637890331439145" xlink:to="us-gaap_OperatingExpenses_637637890331439145" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_OperatingIncomeLoss_637637890331439145" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637637890331439145" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637637890331439145" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637637890331439145" xlink:to="us-gaap_InvestmentIncomeInterest_637637890331449144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637637890331439145" xlink:to="us-gaap_NonoperatingIncomeExpense_637637890331449144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_ProfitLoss_637637890331449144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331449144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_NetIncomeLoss_637637890331449144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331449144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="syn_PreferredStockPriceAdjustment_637637890331449144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637637890331449144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637637890331449144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637637890331459197" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331439145" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637637890331459197" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_345" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_345" xlink:to="us-gaap_StatementTable_637637890331459197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331459197" xlink:to="us-gaap_StatementEquityComponentsAxis_637637890331459197" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331459197" xlink:to="us-gaap_CommonStockMember_637637890331459197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331459197" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637637890331459197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331459197" xlink:to="us-gaap_RetainedEarningsMember_637637890331459197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331459197" xlink:to="us-gaap_NoncontrollingInterestMember_637637890331459197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637637890331459197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331459197" xlink:to="us-gaap_EquityComponentDomain_637637890331459197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331459197" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331469044" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331469044" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331469044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331469044" xlink:to="us-gaap_ClassOfStockDomain_637637890331469044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331459197" xlink:to="us-gaap_StatementLineItems_637637890331469044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331469044" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_SharesOutstanding_637637890331469044" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637637890331469044" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue_637637890331469044" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare_637637890331469044" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_637637890331469044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised_637637890331469044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637637890331479260" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_DividendsPreferredStock_637637890331479260" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice_637637890331479260" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_637637890331479260" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_637637890331479260" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock_637637890331479260" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_637637890331479260" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock_637637890331479260" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_637637890331489122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares_637637890331489122" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637637890331489122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_NetIncomeLoss_637637890331489122" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331489122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331489122" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331489122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637637890331489122" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637637890331489122" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331469044" xlink:to="us-gaap_SharesOutstanding_637637890331489122" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637637890331498798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_637637890331498798" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331498798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331498798" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331498798" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331498798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331498798" xlink:to="us-gaap_ClassOfStockDomain_637637890331498798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637637890331498798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331498798" xlink:to="us-gaap_SeriesAPreferredStockMember_637637890331498798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331498798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331498798" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331498798" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637637890331509099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331498798" xlink:to="us-gaap_StatementLineItems_637637890331509099" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare_637637890331509099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331509099" xlink:to="us-gaap_DividendsPayableAmountPerShare_637637890331509099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_732" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637637890331509099" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637637890331509099" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637637890331509099" xlink:to="us-gaap_ProfitLoss_637637890331519074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637637890331509099" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" xlink:to="us-gaap_ShareBasedCompensation_637637890331519074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" xlink:to="syn_SubsidiaryStockIssuesToVendor_637637890331519074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637637890331519074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637637890331519074" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637637890331529270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637637890331529270" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_637637890331529270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_637637890331529270" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637637890331529270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637637890331529270" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637637890331529270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637637890331529270" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637637890331529270" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637637890331529270" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="syn_IncreaseDecreaseInOperatingLeaseLiability_637637890331539065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637637890331519074" xlink:to="syn_IncreaseDecreaseInOperatingLeaseLiability_637637890331539065" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890331539065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637637890331509099" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637637890331539065" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637637890331539065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637637890331539065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637637890331539065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637637890331539065" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637637890331539065" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637637890331539065" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637637890331539065" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637637890331539065" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637637890331549069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637637890331549069" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331549069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637637890331549069" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331549069" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637637890331549069" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637637890331549069" xlink:to="us-gaap_ProceedsFromWarrantExercises_637637890331549069" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890331559055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637637890331549069" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637637890331559055" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637637890331559055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637637890331559055" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890331559055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637637890331559055" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6376378903315590551" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6376378903315590551" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637637890331569084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" xlink:to="syn_PreferredStockPriceAdjustment_637637890331569084" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637637890331569084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637637890331569084" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_637637890331569084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" xlink:to="us-gaap_ConversionOfStockAmountConverted1_637637890331569084" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_DeemedDividendsWithBeneficialConversionFeature" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_637637890331569084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" xlink:to="syn_DeemedDividendsWithBeneficialConversionFeature_637637890331569084" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_637637890331569084" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637637890331559055" xlink:to="us-gaap_DividendsPreferredStockPaidinkind_637637890331569084" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_769" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637637890331579178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_769" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637637890331579178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="10201 - Disclosure - Fair Value of Financial Instruments">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637637890331579178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637637890331579178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" xlink:type="extended" xlink:title="10301 - Disclosure - Selected Balance Sheet Information">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637637890331579178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637637890331579178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="10401 - Disclosure - Stock-Based Compensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637637890331589133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637637890331589133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrants" xlink:type="extended" xlink:title="10501 - Disclosure - Stock Warrants">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="loc_syn_StockWarrantsAbstract_409748" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPurchaseWarrantsTextBlock" xlink:label="syn_StockPurchaseWarrantsTextBlock_637637890331589133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockWarrantsAbstract_409748" xlink:to="syn_StockPurchaseWarrantsTextBlock_637637890331589133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="10601 - Disclosure - Net Loss per Share">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_409879" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637637890331589133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_409879" xlink:to="us-gaap_EarningsPerShareTextBlock_637637890331589133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" xlink:type="extended" xlink:title="10701 - Disclosure - Non-controlling Interest">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_17" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_637637890331598746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_17" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_637637890331598746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock" xlink:type="extended" xlink:title="10801 - Disclosure - Common and Preferred Stock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637637890331598746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637637890331598746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="10901 - Disclosure - Related Party Transactions">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_26" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637637890331598746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_26" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637637890331598746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409456" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637637890331598746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409456" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637637890331598746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" xlink:type="extended" xlink:title="30303 - Disclosure - Selected Balance Sheet Information (Tables)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637637890331609117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637637890331609117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637637890331609117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637637890331609117" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="syn_AccruedExpensesTableTextBlock_637637890331609117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedExpensesTableTextBlock_637637890331609117" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedEmployeeBenefitsTableTextBlock" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_637637890331609117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedEmployeeBenefitsTableTextBlock_637637890331609117" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="30403 - Disclosure - Stock-Based Compensation (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637637890331609117" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637637890331609117" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Stock Warrants (Tables)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="loc_syn_StockWarrantsAbstract_409755" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_637637890331618731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockWarrantsAbstract_409755" xlink:to="syn_ScheduleOfWarrantActivityTableTextBlock_637637890331618731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_637637890331618731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockWarrantsAbstract_409755" xlink:to="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_637637890331618731" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31003 - Disclosure - Commitments and Contingencies (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409459" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637637890331618731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409459" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637637890331618731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation - (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_637637890331618731" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_AssetImpairmentCharges_637637890331618731" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637637890331719139" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PrepaidInsurance_637637890331719139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637637890331719139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637637890331719139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidManufacturingExpense_637637890331719139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890331719139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637637890331719139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637637890331729052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637637890331729052" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637637890331729052" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637637890331729052" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890331729052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890331729052" xlink:to="syn_ComputersAndOfficeEquipmentMember_637637890331729052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890331729052" xlink:to="us-gaap_LeaseholdImprovementsMember_637637890331729052" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637637890331729052" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_637637890331729052" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637637890331729052" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637637890331729052" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637637890331729052" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637637890331729052" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637637890331729052" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637637890331729052" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637637890331739051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637637890331729052" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637637890331739051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedClinicalConsultingServices_637637890331739051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedVendorPayments_637637890331739051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_637637890331739051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637637890331739051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedBonusesCurrent_637637890331739051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedVacationCurrent_637637890331739051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637637890331739051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637637890331739051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331749063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331749063" xlink:to="us-gaap_AwardTypeAxis_637637890331749063" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637637890331749063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637637890331749063" xlink:to="us-gaap_EmployeeStockOptionMember_637637890331749063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637637890331749063" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637637890331749063" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637637890331749063" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637637890331749063" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637637890331749063" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6376378903317490631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6376378903317490631" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637637890331749063" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637637890331749063" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637637890331749063" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637637890331749063" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637637890331759040" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637637890331759040" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637637890331759040" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637637890331759040" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637637890331759040" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637637890331759040" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637637890331759040" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637637890331759040" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637637890331759040" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_637637890331759040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_637637890331759040" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331749063" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637637890331769079" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stock-Based Compensation - Stock incentive plan and other information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="us-gaap_PlanNameAxis_637637890331769079" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637637890331769079" xlink:to="us-gaap_PlanNameDomain_637637890331769079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637637890331769079" xlink:to="syn_StockPlan2007Member_637637890331769079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637637890331769079" xlink:to="syn_StockPlan2010Member_637637890331769079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637637890331769079" xlink:to="syn_StockPlan2020Member_637637890331769079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331769079" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637637890331769079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331769079" xlink:to="us-gaap_RelatedPartyDomain_637637890331769079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637637890331769079" xlink:to="syn_ConsultantMember_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="us-gaap_IncomeStatementLocationAxis_637637890331779055" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637637890331779055" xlink:to="us-gaap_IncomeStatementLocationDomain_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637637890331779055" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637637890331779055" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637637890331779055" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="srt_RangeAxis_637637890331779055" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637637890331779055" xlink:to="srt_RangeMember_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637637890331779055" xlink:to="srt_MaximumMember_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637637890331779055" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637637890331779055" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331779055" xlink:to="us-gaap_EmployeeStockMember_637637890331779055" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637637890331779055" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="srt_TitleOfIndividualAxis_637637890331779055" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637637890331779055" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637637890331789040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637637890331789040" xlink:to="srt_DirectorMember_637637890331789040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331769079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637637890331789040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637637890331789040" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637637890331789040" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637637890331789040" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331789040" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637637890331789040" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Stock Warrants - Summary of all warrant activity (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637637890331809269" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_637637890331809269" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_637637890331809269" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637637890331809269" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376378903318092691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6376378903318092691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637637890331809269" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637637890331809269" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue_637637890331809269" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637637890331809269" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637637890331809269" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6376378903318092691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6376378903318092691" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Stock Warrants - Summary of all outstanding and exercisable warrants (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331819050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331819050" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637637890331819050" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637637890331819050" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890331819050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice138Member" xlink:label="syn_ExercisePrice138Member_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890331819050" xlink:to="syn_ExercisePrice138Member_637637890331819050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890331819050" xlink:to="syn_ExercisePrice1820Member_637637890331819050" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ExercisePrice5248Member" xlink:label="syn_ExercisePrice5248Member_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637637890331819050" xlink:to="syn_ExercisePrice5248Member_637637890331819050" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637637890331819050" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" xlink:to="syn_WarrantsExercisePrice_637637890331819050" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637637890331819050" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637637890331819050" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_637637890331819050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637637890331819050" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_637637890331819050" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Stock Warrants - Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsAbstract" xlink:label="loc_syn_StockWarrantsAbstract_410066" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockWarrantsAbstract_410066" xlink:to="us-gaap_ClassOfTreasuryStockTable_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_StatementEquityComponentsAxis_637637890331829116" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637637890331829116" xlink:to="us-gaap_EquityComponentDomain_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637637890331829116" xlink:to="us-gaap_WarrantMember_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_PlanNameAxis_637637890331829116" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637637890331829116" xlink:to="us-gaap_PlanNameDomain_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637637890331829116" xlink:to="syn_StockWarrantsMember_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637637890331829116" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637637890331829116" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331829116" xlink:to="us-gaap_IPOMember_637637890331829116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331829116" xlink:to="us-gaap_OverAllotmentOptionMember_637637890331829116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember_637637890331829116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331829116" xlink:to="syn_UnderwrittenPublicOfferingMember_637637890331829116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637637890331839067" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637637890331839067" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637637890331839067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637637890331839067" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember_637637890331839067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637637890331839067" xlink:to="syn_SeriesWarrantsMember_637637890331839067" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637637890331839067" xlink:to="syn_SeriesBWarrantsMember_637637890331839067" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331839067" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331839067" xlink:to="us-gaap_ClassOfStockDomain_637637890331839067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331839067" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331839067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637637890331829116" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637637890331839067" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637637890331839067" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637637890331839067" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_WarrantTerm_637637890331849188" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637637890331849188" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_SharesIssuedPricePerShare_637637890331849188" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331849188" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637637890331849188" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_PreferredStockConversionPricePerShare_637637890331849188" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637637890331849188" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637637890331849188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_WarrantExercisePriceAdjustment_637637890331849188" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637637890331859035" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_637637890331859035" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_PercentageOfIssueOfThePublicOffering_637637890331859035" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637637890331859035" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ProceedsFromWarrantExercises_637637890331859035" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637637890331859035" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637637890331859035" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637637890331859035" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331869060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331869060" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637637890331869060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637637890331869060" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold_637637890331869060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_NumberOfShareSold_637637890331869060" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase_637637890331869060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637637890331839067" xlink:to="syn_NumberOfSharesPurchase_637637890331869060" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Net Loss per Share - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_409912" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637637890331869060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_409912" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637637890331869060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637637890331869060" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637637890331879037" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637637890331879037" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331879037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331879037" xlink:to="us-gaap_StockOptionMember_637637890331879037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637637890331879037" xlink:to="us-gaap_WarrantMember_637637890331879037" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637637890331869060" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331879037" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331879037" xlink:to="us-gaap_ClassOfStockDomain_637637890331879037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331879037" xlink:to="us-gaap_SeriesAPreferredStockMember_637637890331879037" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331879037" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331879037" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637637890331869060" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_637637890331879037" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331879037" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="us-gaap_PreferredStockDiscountOnShares_637637890331879037" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="us-gaap_PreferredStockAccretionOfRedemptionDiscount_637637890331879037" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331879037" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares" xlink:label="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_637637890331879037" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares_637637890331879037" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637637890331879037" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637637890331889058" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Non-controlling Interest (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_637458043501911141" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_637458043501911141" xlink:to="us-gaap_MinorityInterestTable_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637637890331889058" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331889058" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331889058" xlink:to="us-gaap_RelatedPartyDomain_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637637890331889058" xlink:to="syn_CedarssinaiMedicalCenterMember_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637637890331889058" xlink:to="srt_OwnershipAxis_637637890331889058" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637637890331889058" xlink:to="srt_OwnershipDomain_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637637890331889058" xlink:to="syn_SYNBiomicsMember_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637637890331889058" xlink:to="us-gaap_MinorityInterestLineItems_637637890331889058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_637637890331889058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_637637890331889058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="syn_NumberOfCommonStockToBeIssued_637637890331898944" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_637637890331898944" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_637637890331898944" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637637890331898944" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637637890331898944" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="syn_FairValueOfSharesIssued_637637890331898944" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637637890331898944" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637637890331898944" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest" xlink:label="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest_637637890331898944" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637637890331898944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637637890331889058" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637637890331898944" order="11" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Common and Preferred Stock (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable_637637890331909148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331909148" xlink:to="us-gaap_StatementClassOfStockAxis_637637890331909148" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637637890331909148" xlink:to="us-gaap_ClassOfStockDomain_637637890331909148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331909148" xlink:to="us-gaap_SeriesAPreferredStockMember_637637890331909148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331909148" xlink:to="us-gaap_SeriesBPreferredStockMember_637637890331909148" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331909148" xlink:to="us-gaap_CommonClassAMember_637637890331909148" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637637890331909148" xlink:to="us-gaap_CommonClassBMember_637637890331909148" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331909148" xlink:to="dei_LegalEntityAxis_637637890331909148" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637637890331909148" xlink:to="dei_EntityDomain_637637890331909148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember_637637890331909148" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637637890331909148" xlink:to="syn_FbrCapitalMarketsCoMember_637637890331909148" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331909148" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637637890331919034" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637637890331919034" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331919034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331919034" xlink:to="us-gaap_OverAllotmentOptionMember_637637890331919034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637637890331919034" xlink:to="us-gaap_PrivatePlacementMember_637637890331919034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331909148" xlink:to="us-gaap_StatementLineItems_637637890331919034" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637637890331919034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637637890331919034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_SharesIssuedPricePerShare_637637890331919034" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637637890331919034" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637637890331919034" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_PreferredStockConversionPricePerShare_637637890331919034" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637637890331919034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637637890331919034" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637637890331929045" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_637637890331929045" order="9" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637637890331929045" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_WarrantExercisePriceAdjustment_637637890331929045" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_PercentageOfIssueOfThePublicOffering_637637890331929045" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockDiscountOnShares_637637890331929045" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637637890331929045" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637637890331929045" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637637890331929045" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637637890331939152" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease_637637890331939152" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_637637890331939152" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_637637890331939152" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdTradingDays_637637890331939152" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_637637890331939152" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare_637637890331939152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_DividendsPayableAmountPerShare_637637890331939152" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit_637637890331949050" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637637890331949050" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_BeneficialOwnershipPercentage_637637890331949050" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637637890331949050" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_PreferredStockSharesOutstanding_637637890331949050" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration_637637890331949050" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_EstimatedFairValueOfInducementConsideration_637637890331949050" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_637637890331959130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_637637890331959130" order="29" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage_637637890331959130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_BrokerageCommissionPercentage_637637890331959130" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331959130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637637890331959130" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfStatedDividendRate" xlink:label="syn_PercentageOfStatedDividendRate_637637890331959130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331919034" xlink:to="syn_PercentageOfStatedDividendRate_637637890331959130" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Related Party Transactions (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637054396826150177" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637054396826150177" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" xlink:to="us-gaap_BusinessAcquisitionAxis_637637890331969034" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637637890331969034" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_IntrexonMember" xlink:label="syn_IntrexonMember_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637637890331969034" xlink:to="syn_IntrexonMember_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IntrexonMember_637637890331969034" xlink:to="syn_CedarssinaiMedicalCenterMember_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331969034" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637637890331969034" xlink:to="us-gaap_RelatedPartyDomain_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember_6376378903319690341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637637890331969034" xlink:to="syn_CedarssinaiMedicalCenterMember_6376378903319690341" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" xlink:to="srt_OwnershipAxis_637637890331969034" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637637890331969034" xlink:to="srt_OwnershipDomain_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637637890331969034" xlink:to="syn_SyntheticBiomicsIncMember_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637637890331969034" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" xlink:to="syn_NumberOfCommonStockToBeIssued_637637890331969034" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_637637890331969034" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_637637890331969034" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_637637890331979046" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637637890331969034" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637637890331979046" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases payments (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_637637890331979046" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637637890331979046" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637637890331979046" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637637890331979046" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637637890331979046" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637637890331979046" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LesseeOperatingLeaseLiabilityToBePaidYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="syn_LesseeOperatingLeaseLiabilityToBePaidYearSix_637637890331979046" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637637890331979046" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637637890331979046" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637637890331979046" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_OperatingLeaseLiability_637637890331979046" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637637890331989038" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_416373" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637637890331989038" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="extended" xlink:title="41002 - Disclosure - Commitments and Contingencies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409480" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409480" xlink:to="us-gaap_StatementTable_637637890331989038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331989038" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637637890331989038" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_637637890331989038" xlink:to="us-gaap_TypeOfAdoptionMember_637637890331989038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_637637890331989038" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_637637890331989038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637637890331989038" xlink:to="us-gaap_StatementLineItems_637637890331989038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_637637890331989038" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_LeaseRentAbatementPeriod1" xlink:label="syn_LeaseRentAbatementPeriod1_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="syn_LeaseRentAbatementPeriod1_637637890331989038" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_PercentageOfFundsToBeBorrowedByCompany" xlink:label="syn_PercentageOfFundsToBeBorrowedByCompany_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="syn_PercentageOfFundsToBeBorrowedByCompany_637637890331989038" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="us-gaap_OperatingLeaseCost_637637890331989038" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637637890331989038" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="us-gaap_OperatingLeasePayments_637637890331989038" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637637890331999802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637637890331999802" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20210630.xsd#syn_NumberOfOperatingLeaseForFacilities" xlink:label="syn_NumberOfOperatingLeaseForFacilities_637637890331999802" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637637890331989038" xlink:to="syn_NumberOfOperatingLeaseForFacilities_637637890331999802" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>syn-20210630x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20210630x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )D!98# 2(  A$! Q$!_\0
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M(/\ \11_PD5U_P ^$/\ X$'_ .(K*S1FCVM3N'U:EV_,U?\ A(KK_GPA_P#
M@_\ Q%'_  D5U_SX0_\ @0?_ (BLK-&:/:U.X?5J7;\S5_X2*Z_Y\(?_  (/
M_P 11_PD5U_SX0_^!!_^(K*S1FCVM3N'U:EV_,U?^$BNO^?"'_P(/_Q%'_"1
M77_/A#_X$'_XBLK-&:/:U.X?5J7;\S5_X2*Z_P"?"'_P(/\ \11_PD5U_P ^
M$/\ X$'_ .(K*S1FCVM3N'U:EV_,U&\1W2J6^P0\#/\ Q\'_ .(I?^$BNO\
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MWS?[H_K0ZM3^8:PU+M^9L?\ "177_/A#_P"!!_\ B*/^$BNO^?"'_P "#_\
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M ,"#_P#$4?\ "177_/A#_P"!!_\ B*RLT9H]K4[A]6I=OS-7_A(KK_GPA_\
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M ($'_P"(K*S1FCVM3N+ZM2[?F:O_  D5U_SX0_\ @0?_ (BC_A(KK_GPA_\
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M1[6I_,/ZM2[?F=PIW*#CJ,T4D?\ JU^@HKT4>0<_KYQ=Q_[G]363FM7Q ?\
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M907&W;YL8?;G.,C.*EPDE=E1J0D[)EG-&:9FC-26/S1FF9HS2"P_-&:9FC-
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M<IP2CW)M,3Q&EX&U*:V>VVG(C'.>W:N8T>Q?Q??7L^H7<P$6TJL9X&[.,9Z
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M?2UF17B2-2Y'!VC%$:T(VL^OX#E0G*]UT7WF'K^KWB>%-+19F#W48\V0'YF
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MC6RAMKF9TG*%S(V2P9BI!QUZ5T5_H4MWXCM-46=%2$*"A')P2?ZTFIZ#+?\
MB&SU)9T5+<)E".3M8M_6M(UH))7TL92H3;<K:WT]#"U7S]?\9?V5+.T5M'P
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M<_FO_P 36[BC%'L*?8/K-;^8PO\ A%;;_GZN?S7_ .)H_P"$5MO^?JY_-?\
MXFMW%&*/84^P?6:W\QA?\(K;?\_5S^:__$T?\(K;?\_5S^:__$UNXHQ1["GV
M#ZS6_F,+_A%;;_GZN?S7_P")H_X16V_Y^KG\U_\ B:W<48H]A3[!]9K?S&%_
MPBMM_P _5S^:_P#Q-'_"*VW_ #]7/YK_ /$UNXHQ1["GV#ZS6_F,+_A%;;_G
MZN?S7_XFC_A%;;_GZN?S7_XFMW%&*/84^P?6:W\QA?\ "*VW_/U<_FO_ ,31
M_P (K;?\_5S^:_\ Q-;N*,4>PI]@^LUOYC"_X16V_P"?JY_-?_B:/^$5MO\
MGZN?S7_XFMW%&*/84^P?6:W\QA?\(K;?\_5S^:__ !-'_"*VW_/U<_FO_P 3
M6[BC%'L*?8/K-;^8PO\ A%;;_GZN?S7_ .)H_P"$5MO^?JY_-?\ XFMW%&*/
M84^P?6:W\Q@GPK;$$?:KGGW7_P")I?\ A%;;_GZN?S3_ .)K=HH]A3[!]9K?
MS&%_PBMM_P _5S^:_P#Q-'_"*VW_ #]7/YK_ /$UNXHQ1["GV#ZS6_F,+_A%
M;;_GZN?S7_XFC_A%;;_GZN?S7_XFMW%&*/84^P?6:W\QA?\ "*VW_/U<_FO_
M ,31_P (K;?\_5S^:_\ Q-;N*,4>PI]@^LUOYC"_X16V_P"?JY_-?_B:/^$5
MMO\ GZN?S7_XFMW%&*/84^P?6:W\QA?\(K;?\_5S^:__ !-'_"*VW_/U<_FO
M_P 36[BC%'L*?8/K-;^8PO\ A%;;_GZN?S7_ .)H_P"$5MO^?JY_-?\ XFMW
M%&*/84^P?6:W\QA?\(K;?\_5S^:__$T?\(K;?\_5S^:__$UNXHQ1["GV#ZS6
M_F,+_A%;;_GZN?S7_P")H_X16V_Y^KG\U_\ B:W<48H]A3[!]9K?S&%_PBMM
M_P _5S^:_P#Q-'_"*VW_ #]7/YK_ /$UNXHQ1["GV#ZS6_F,+_A%;;_GZN?S
M7_XFC_A%;;_GZN?S7_XFMW%&*/84^P?6:W\QA?\ "*VW_/U<_FG_ ,32#PI;
M 8^U7/YI_P#$UO44>PI]@^LUOYC"_P"$5MO^?JY_-?\ XFC_ (16V_Y^KG\U
M_P#B:W<48H]A3[!]9K?S&%_PBMM_S]7/YK_\31_PBMM_S]7/YK_\36[BC%'L
M*?8/K-;^8PO^$5MO^?JY_-?_ (FC_A%;;_GZN?S7_P")K=Q1BCV%/L'UFM_,
M87_"*VW_ #]7/YK_ /$T?\(K;?\ /U<_FO\ \36[BC%'L*?8/K-;^8PO^$5M
MO^?JY_-?_B:/^$5MO^?JY_-?_B:W<48H]A3[!]9K?S&%_P (K;?\_5S^:_\
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M_P (K;?\_5S^:_\ Q-;N*,4>PI]@^LUOYC"_X16V_P"?JY_-?_B:/^$5MO\
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M?\_5S^:__$UNXHQ1["GV#ZS6_F,+_A%;;_GZN?S7_P")H_X16V_Y^KG\U_\
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M78.9'J-%>7?\+ILO^@'>?]_4H_X739?] .\_[^I1R2[!S(]1HKR[_A=-E_T
M[S_OZE'_  NFR_Z =Y_W]2CDEV#F1ZC17EW_  NFR_Z =Y_W]2C_ (739?\
M0#O/^_J4<DNP<R/4:*\N_P"%TV7_ $ [S_OZE'_"Z;+_ * =Y_W]2CDEV#F1
MZC17EW_"Z;+_ * =Y_W]2C_A=-E_T [S_OZE')+L',CU&BO+O^%TV7_0#O/^
M_J4?\+ILO^@'>?\ ?U*.278.9'J-%>7?\+ILO^@'>?\ ?U*/^%TV7_0#O/\
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M"*YI1<3:,KEJBBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML'CC$8VHPZ$#L16%=>)9]/T5+JZ_L]I99Q!#-%<?Z.V1G>S'[H&#D=>/>IM
M\0MJ=_<6,L]A<21(LHFL)M\9!)&#Z$8_6BS#0W)K>&Y"">%) CAU#J#M8="/
M>IJS]5MDN+8-+/>1Q1$NZVC,KOQT^3YOP6LGPA<R7,-^3/</!'<%88[MB9XU
MP.'SSUR1GG&*+: :<?A_1X9O.BTJR27>'WK H.[USCK61JOA$:M=3/*VG+',
MWS.+ ?:-O=1)N[],[<U=U34]1AUNVTW3X;5FF@>4O<,P"[2!_#UZ]/UK-F\4
MZA#INXVEN;^+44L94WGRV)/WE/4 @CJ.*:N&AU"VL"SB<1)YP01^9M^;;G.,
M^F:KWNC:7J,JRWNG6MS(HP&FA5R!Z9(K)GU76HKRWTM8K!M0G5YMV7$4<:D#
MGNQ)/M2'Q/-%ITWFVJ?VE'=BR\I6/EM*>A!QG;@YI6871KW.CZ9>Q1PW6GVL
M\<0Q&DD*L$'H 1Q2OH^FR6*V+Z?:M:*<K 85V ^H7&.YK(36-6MK^YL[^*R+
M16)NE: MR<D8(/TIEGK&LW&@IJLPTJVBDMUD3SI7 !..6;L,9X^G-%F%T;MI
MIUEIX865I!;AL;A%&%S@8'2K=<AI?BZ2[GOK65K6>:"U-Q'+;*XC8#.0=W/7
M'3(YID7B/7C::5=/9:<8]1PD:"9U*L5W!B2,8X/'7W-%F%T=E17.VVJW$@U:
MRU=H;9[.,,]Q:NP 1E)R,\@C!JIX5O[:]U*\-CJ;3691?+@FO//D)&<R8+%D
M4\<'\A18+G6T444AA1110!P?BC_D<H_^P>O_ *,:J=7/%'_(Y1_]@]?_ $8U
M4ZWI_"9RW*&M6DM_HE[:0X\V:%D7)P,D5@>'O"*Q>&GTO6X(Y@;DS!4<X^Z
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M_P!!'6/^_P"G_P 11_PICP__ -!'6/\ O^G_ ,11[5!R,\8HKV?_ (4QX?\
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M_P!!'6/^_P"G_P 11_PICP__ -!'6/\ O^G_ ,11[5!R,\8HKV?_ (4QX?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *.L7QTO1;_4!'YAM;>2<(3C=M4MC/X5Y8OQJO&4
M,/#\.",_\?9_^)KTCQ;_ ,B;KG_8/N/_ $6U?-$/^IC_ -T5K3BI;D3DT>H?
M\+IO?^@!#_X%G_XFC_A=-[_T (?_  +/_P 37F5%:>SB9\[/3?\ A=-[_P!
M"'_P+/\ \31_PNF]_P"@!#_X%G_XFO,J*/9Q#G9Z;_PNF]_Z $/_ (%G_P")
MH_X73>_] "'_ ,"S_P#$UYE11[.(<[/3?^%TWO\ T (?_ L__$T?\+IO?^@!
M#_X%G_XFO,J*/9Q#G9Z;_P +IO?^@!#_ .!9_P#B:/\ A=-[_P! "'_P+/\
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ML/\ P8'_ .(K5HI<D2N9F5_PD/BW_H7;#_P8'_XBC_A(?%O_ $+MA_X,#_\
M$5JT4<D0YF97_"0>+/\ H7;#_P &!_\ B*/^$@\6?]"[8?\ @P/_ ,16K62W
MB725O6LS=$SK)Y141.<-G&,[<4<B#F8O_"0>+/\ H7;#_P &!_\ B*/^$@\6
M?]"[8?\ @P/_ ,126WB?1KNZ6VBOX_-9MJAU9-Q]%+  GZ5;N=2L[2\M;2>X
M6.>Z+"%#U?'6CD0<S*O_  D/BW_H7;#_ ,&!_P#B*/\ A(?%O_0NV'_@P/\
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MM3L8;RSF6:WE7<CJ>"*M5D6%%%% !1110 4444 %%%% !1110 4444 %%%%
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MBHIYH[>"2>9Q'%&I=W8X"@#))I+:YAN[:*YMY%EAE4/'(AR&4\@B@":BBB@
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M4KY63C!.3^IHL!@?#D_\4E'_ -=G_G7655L-/M-,M1;64(AA!+;%)ZGZU:H
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MJ7_7W_[(M)[#1Z!1114EA16/>^(H;+4);5K*]E$$2RSS0HK)&ISR?FW'[IZ
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M?-$/^IC_ -T5]+^+?^1-US_L'W'_ *+:OFB'_4Q_[HK:B95!]%%%;&84444
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M&Z3.MBJ*Y(YW3!_WG/.<?E70>+Y)?[%-O#:75S)+(A @B+XVNK'..G K?HH
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M .+H_P"%5^"_^@-_Y-3?_%UV-%',PLCCO^%5^"_^@-_Y-3?_ !='_"J_!?\
MT!O_ ":F_P#BZ[&BCF861QW_  JOP7_T!O\ R:F_^+H_X57X+_Z W_DU-_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 8&M>+++0KY+.XM[N61HA*#"BL,9([L/2L_P#X6)I?
M_/CJ7_?I?_BJQ/'?_(U0_P#7DO\ Z&U<]6T*:DKF<IV=CO/^%B:7_P ^.I?]
M^E_^*H_X6)I?_/CJ7_?I?_BJX.BJ]BB?:,[S_A8FE_\ /CJ7_?I?_BJ/^%B:
M7_SXZE_WZ7_XJN#HH]B@]HSO/^%B:7_SXZE_WZ7_ .*H_P"%B:7_ ,^.I?\
M?I?_ (JN#HH]B@]HSO/^%B:7_P ^.I?]^E_^*H_X6)I?_/CJ7_?I?_BJX.BC
MV*#VC.\_X6)I?_/CJ7_?I?\ XJC_ (6)I?\ SXZE_P!^E_\ BJX.BCV*#VC.
M\_X6)I?_ #XZE_WZ7_XJC_A8FE_\^.I?]^E_^*K@Z*/8H/:,[S_A8FE_\^.I
M?]^E_P#BJ/\ A8FE_P#/CJ7_ 'Z7_P"*K@Z*/8H/:,[S_A8FE_\ /CJ7_?I?
M_BJ/^%B:7_SXZE_WZ7_XJN#HH]B@]HSO/^%B:7_SXZE_WZ7_ .*H_P"%B:7_
M ,^.I?\ ?I?_ (JN#HH]B@]HSO/^%B:7_P ^.I?]^E_^*H_X6)I?_/CJ7_?I
M?_BJX.BCV*#VC/1M,\::?JNI0V,-K>1RS9VF5%"\ M_>]!72UY1X6_Y''3/^
MVO\ Z+:O5ZQG'E=C2+NKA1132P52S$ #DDU)0ZBN53QHMV99-,T74]0M8V*_
M:88U"/CKMW,"U3#QE8_V%+J[V5^D,$WD7$;PA9(3QRRD]/F'3/6G85T=)15:
M6]MH;%KYYT^RK'YIE!RNS&<\=>*YZ^\>:;8:18:G/:7ZPWNXQ*(U+@+W(W=,
M<_2A)L+G545GWNL6EGHDFKDM+:)%YP,6"67&015JWG6YMHIT!"2('4'K@C-(
M9-144\\5M;RSS.$BB4N['HH R37*KX^M?(BO9=*U*'3)'"+>O$-G)P&(SD+[
MXII-B;L=?165J^LKI4,+K97=Z\S;4CM(]Y/&<GG@>]4K'Q9%<:O'I=YIU[IU
MW,I:$7*C;)CJ 03S19A<Z*BL+5_$T&EZA#IT5I=7U_*ID%O;*"53^\22 !4F
MA^(;;7/M,:0SVUU:OLGMKA-KIGH?H:+,+FS1112&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1XGFE@\)ZS
M-#(\<L=C.R.C%65@C$$'L:^=X_$.OM&C'Q#J^2 ?^/V3_&OH;Q;_ ,B;KG_8
M/N/_ $6U?-$/^IC_ -T5M25S.9I_\)!K_P#T,.K_ /@;)_C1_P )!K__ $,.
MK_\ @;)_C6?16O*C.[-#_A(-?_Z&'5__  -D_P :/^$@U_\ Z&'5_P#P-D_Q
MK/HHY4%V:'_"0:__ -##J_\ X&R?XT?\)!K_ /T,.K_^!LG^-9]%'*@NS0_X
M2#7_ /H8=7_\#9/\:/\ A(-?_P"AAU?_ ,#9/\:SZ*.5!=FA_P )!K__ $,.
MK_\ @;)_C1_PD&O_ /0PZO\ ^!LG^-9]%'*@NS0_X2#7_P#H8=7_ / V3_&C
M_A(-?_Z&'5__  -D_P :SZ*.5!=EYO$.O@#'B#5_O ?\?LGK]:]C'A?(!_M_
MQ#_X,Y*\,?HO^\O\Q7TB/NCZ5+2*3,'_ (18?]!_Q#_X,Y*/^$6'_0?\0_\
M@SDK?HI60]3 _P"$6'_0?\0_^#.2C_A%A_T'_$/_ (,Y*WZ*+(-3 _X18?\
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MPF%3X@HHHK4S"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVFGQ!P L=G"5QUY+'K],5KTF-!1112&%%%% !1110 4444 8WBW_ )$W7/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.F?]M?\ T6U>KUR5?B.B'PA1114%A1110 4444 %%%% !1110 4444 %%%%
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MO_R/E]_UXP_^A/6I8:=::7;"WLH%ABR6VKGDGJ2>YJK?^'=+U.[^U7=NSS;
MA99G3*CH#M(]32N,YMKNTT^_\5W$/F"S00[_ +*^P^>1AL'LV2N33]-:_MO$
M\-E<K-#;WEF[&%M3DN&!! # L,J>3T/\JZE-)T^/3FT^.SA6S92K1!,*0?\
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M_P"BVKU:O*?"W_(XZ9_VU_\ 1;5ZO7)5^(Z(?"%%%%06%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNTR;CT^G3M3(M)L87NGC@"M=9\X[C\V<Y[^YZ4^47,<''I-H_@F74BC?:E<
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M3%_SS3_OFCR8O^>:?]\T>Q\P]H?3O_"1:'_T&=/_ / E/\:/^$BT/_H,Z?\
M^!*?XU\Q>3%_SS3_ +YH\F+_ )YI_P!\T>Q\P]H?3O\ PD6A_P#09T__ ,"4
M_P :/^$BT/\ Z#.G_P#@2G^-?,7DQ?\ /-/^^:/)B_YYI_WS1['S#VA]._\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKZ HH]K(.1'S_P#\*R\7_P#0-@_\"DH_X5EXO_Z!L'_@4E?0%%'M9!R(^?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU>N2K\1T0^$****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"O=W<-C9SW=R^R""-I9&P3M51DG YZ"N5_P"%J>"_^@S_ .2TW_Q%;/BW
M_D3=<_[!]Q_Z+:OFB'_4Q_[HK2$%(B4K'O\ _P +4\%_]!G_ ,E9O_B*/^%J
M>"_^@S_Y*S?_ !%>!T5?LD3[1GOG_"U/!?\ T&?_ "5F_P#B*/\ A:G@O_H,
M_P#DK-_\17@=%'LD'M&>^?\ "U/!?_09_P#)6;_XBC_A:G@O_H,_^2LW_P 1
M7@=%'LD'M&>^?\+4\%_]!G_R5F_^(H_X6IX+_P"@S_Y*S?\ Q%>!T4>R0>T9
M[Y_PM3P7_P!!G_R5F_\ B*/^%J>"_P#H,_\ DK-_\17@=%'LD'M&>^?\+4\%
M_P#09_\ )6;_ .(H_P"%J>"_^@S_ .2LW_Q%>!T4>R0>T9[Y_P +4\%_]!G_
M ,E9O_B*/^%J>"_^@S_Y*S?_ !%>!T4>R0>T9[Y_PM3P7_T&?_)6;_XBC_A:
MG@O_ *#/_DK-_P#$5X'11[)![1GOG_"U/!?_ $&?_)6;_P"(H_X6IX+_ .@S
M_P"2LW_Q%>!T4>R0>T9]':)XR\/^(KA[?2M22>=%W&,HR''J P&?PK?KY5@G
MGL[N&[M)F@NH6WQ2KU4_Y[5[OX%\=V_BFT^S7.R'5H5_>PCI(/[Z>WMVJ)TV
MBHSN=G1116984444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YKX\_P"1JA_Z\E_]#:N>KH?'G_(U0_\ 7DO_ *&U<]732^$P
MJ?$%%%%:F84444 0O:6TEPMP]O$TR_=D* L/H:FHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** -3PM_P CCIG_ &U_]%M7JU>4^%O^1QTS_MK_ .BV
MKU>N2K\1T0^$*CEE2")Y9#M1%+,?0"I*CFC2:&2*0 QNI5@>X/6H+.0M==\4
MZ[;_ -H:+I^FPZ>Q/D_;I6\R4 D9PO"].AJ\^O:O;>';K4;O062ZM'Q);"XS
MO3"DNC $'KT]CS67#X7\3:!"+;P_KD#V2,6CMKZ+.T$]-P!/\JU_"VO7.N6U
M[%?VL<%Y97#6TZQME&([BJ=B46Y_$6G0^'&UWS@]D(O-5AP6]%&>^>,>M8FK
M>-+S2=(TR[DT-GN;Y7;[,+CYHPJ[NNWD[>V/:L:ST IXY/AXSYT6U/\ :L5K
MCHQ( 3_=#9.*W?%6#XI\* ]/M4O_ *!197"[-2Z\0P1^%'U^VC,\(M_/1"VT
ML/0GG!K3M)_M5G!<;=OFQJ^W.<9&<5YKJO\ Q3MCXC\.,-MG<6[WFG<' !^_
M&/H><>G/>NPDOM5LM#TPZ7H_]I,T*!U^TK#L&T8/S=:&@3-?4;V+3=/N;Z?(
MB@C:1L=< 9KD&\4^);;3$UZZT>S&D,%<PQS,;A(VZ.?X3U''7Z4>+;G5+_X;
MZL]_IATVX!0"$7"RY0.A)W+^(Q[5IZZ5_P"%<WAXVG33C_OCBA(&7M1O]1?3
MK:?0;2&\:X 97EEV(B$9#'N?H*RK7Q!K%AKMGI/B"SLU:^W?9[FR=BA91DJ0
MW/I^=7_#,R6O@G2I[F01QQV,;N[G 50@Y_*LC3DF\6^)K;Q T;Q:18!UL0_#
M3N>#)CLOI]!0!>U?7M1_MQ=#T*TMYKT0B>::Y<K%"N<#..23[5+H'B"YOM0O
M-)U2VCMM4M &=8GW)(AZ.OMR.#ZU1T8,/B7XFW?Q0VQ3Z;/\:9#S\7KG;T&D
MC=CUWBBR [.BBBI*"BBB@#(\1ZE=:7I:SV:PF=YXH5\X$J-[A<D @]ZK:?JN
MHKK[:-JB6SRM;?:8IK4,J[0VTAE8D@Y/7-.\66,NI:/';11/+NNX"ZH2#M$B
MECD<CC/-5+'2IO#NO2?8[=Y]/OP-TA.^2WD P S,=S1G\=I^M4K6%U+\7B;3
MY+N*W9;N$ROY<;SVLD<;MZ!F7&>./6H=;\3VNF17T40GEN[> N?+MWD2-MI*
M[V487/OVKE6TO4KJ/3GN-.U:358K^&2ZGEGS" ),L44-MQZ87@5J7$.H:=:^
M(M/CTJZNVU"2::":';L(= ,,2W!!&/RQ19"NS8L]8N+B^T^!S;[9].^UR*%;
M?GY1\O;'S=.M2VGB2PO+N*W5+N%YLB(W%K)$LA S@%@ 3@'CVK*AT_48]1L9
M886CDCT)H%D8?*DV4P#^7Z5E6FFW<UUHD[:;JPO(;E&O)[NX+)G8VXJN\C&>
MX HL@NS8TOQ:U^-41[6:.2VFF2)VM91&%1<C>V.&]1UZ<5?7Q';6^EZ;/>.9
M+F]A5TBM(7D,AV@DJH&[:,]ZS+2"\LSK^GOI]TQO)Y[B&=54QE608&<YSD8Q
MBHH+/4-*ET#4?L$]PD&F"TGAAP9(VPASM)&>5P:+(-3;D\3:7%IL5^T["WDF
M$ _=-N60G&UEQD'/;%3:;K=GJDTT,'GI-"%+QSP-$P#9P<,!QP:YB32-1EMT
MNC9O&USKT-Z8."T40*C+8XS\N3C/6MQ+2X'CJ6\\IOLQTU(A)C@N)7./R(HL
M@NQWB34[W38M.6P%N9KN]2VS.K,JAE8YP"/[HIZ76I:=;7-YK4]D;6&,R$VL
M+JPQR>K'/%4?&=F]Y:Z7BP>^AAU".6>!(P^8PC@_*>#U%4[BUM+G0-9M]+\,
MRZ?<2V;H#]DCB,A(X4%3S0D!MVGB33KV]CM(FG6292T)EMWC64#KL9@ WX52
MT'Q4NJI=?:;>>#R9I1YCVTD<:HC?Q,W ;'49J2]LKF34/#;K"[);R,9C_<S"
MR\_C6;'IU[)I>NZ"UI/')=R7,D5RP'DD.25^8'/?THL@U-FR\3:;?W45O"UP
MK3 M \MN\:3 #/R,P ;CGBJS^+;*XTZ[GT_SG:*&5Q+):R^2K(#PS >W0<UF
M:/8#[?I_GZ7K@N+<Y9[J[+P0ML()7+G=U(&!WJ?3M-O(OAM>6$ENZW;P7:K$
M1\Q+-(5_/(_.BR"['Q^+9$U>TLY[:65)M/2Y=[6UE?+L1]WC[G/<5?BU](5U
M2>^EA%O:W?V>,0HY<DA<*1CYFRP^[69;V]YI6H:3?O87-Q&-*6SD2!06C<%6
M^8$CCK^5-DTR0V6N+=:;=7$<VJ><BV[[) H1,2(<CD,M%D&IT6G:O;:F95A2
MXCDBQOCN('B8 YP<,!Z'\JT*YKPNFJ)+>_:GOC8Y06HU#:9\X^;)7^'IC//6
MNEI,:"BBBD,**** ,;Q;_P B;KG_ &#[C_T6U?-$/^IC_P!T5]+^+?\ D3=<
M_P"P?<?^BVKYHA_U,?\ NBMJ/4RJ#Z***V,PHHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "GP3W%I=17=I,\%U"VZ.5#@J:9118#WKP+XZM_%-K]
MFN=D&K0+^]ASQ(/[Z>WMVKLZ^5(;F:QN8KVUG:"Y@;?'*O53_GM7T7X.UF^U
MWPS:W^H636MQ(O(/20=G4=0#[USSARFT)7.@HHHK,L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,445QVK:T+;Q1/9W>O3:;;
M);1R1B-(CN8EL\NC>@II7$W8[&BN=&NQ6-C9W(N'U#3I9#'+?NR@Q'/!8*@&
MW/&>,<4V7Q2R:3)J4.GO+;&X2&WQ* 9U8A=XR.!D\9Z^U%F%SI**YJ77;MA?
MV%Y8M8W0LWG@9)O,#J!@G( PP../UJ#2]>N1I&BV<$#7^HSV4<\GFS; J[1\
MS.03DGV/>BP7.LHKF9O%H32HKN.PEDG:\%G);;P'23)!&>AZ>W7M4IU+4O[:
MTNVN85MA.)RT<<HD#!0F"25!!^8\#]:+,+G0T5R=OXPN9K"+49-(,>GF?R9)
MOM )0[]@8+CD9QZ'V/6KMWK]PMS=QZ?IWVR.S7-Q(TXC ;&[:O!W'&,].M%F
M%S?HJGIE[_:.F6M[Y?E^?$LFS.=N1G&:RU\075S?7$=EIGVB"VN/L\S_ &A5
M<$8R0F.0,^H/M2L%SH**YFPU36IO$FJ6LEI UG!*B@_:,-&I0'@;/FSG/)XS
MCM4\?B3S/#EMJWV3'G2I'Y7F?=W.$SG'.,YZ4[!<WZ*YC5]=NY(-5ATRS,R6
MD3K-<^>(RC[<X08^8CC/(J72-8=3I5E<HQ-U9"5+EY,[W &Y2/7!!S18+G14
M5F:+JO\ ;%I)=+#Y</G.D3;\^8JG ;H,9QTK3I#"BBB@ HHHH \U\=_\C5#_
M ->2_P#H;5SU=AXPT+5M1UZ*ZL++SXEMEC+>:BX;<Q[GW%8?_"+^)/\ H$_^
M3,?_ ,56].<5&S,9Q;>AET5J?\(MXD_Z!/\ Y,Q__%4?\(MXD_Z!/_DS'_\
M%5I[2/<GD9ET5J?\(MXD_P"@3_Y,Q_\ Q5'_  BWB3_H$_\ DS'_ /%4>TCW
M#D9ET5J?\(MXD_Z!/_DS'_\ %4?\(MXD_P"@3_Y,Q_\ Q5'M(]PY&9=%:G_"
M+>)/^@3_ .3,?_Q5'_"+>)/^@3_Y,Q__ !5'M(]PY&9=%:G_  BWB3_H$_\
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M +HK:CU,J@^BBBMC,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI&8*I9C@"AF"J23@"O1?A[\/6U5XM;UN$BR!#VULX_UWH[#^[Z#O].JE*PTK
MA\/?AZVJO%K>MP$60.ZVM9%_UWH[#^[Z#O\ 3K[0  ,#@4  # X%+7+*3;-T
MK!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1V%C!:1#$<,81?H!BK-%%(84444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'6?%=GHE\EG
M-;7<TK1"4>0BL-N2.Y'I5#_A8&G_ /0-U3_ORO\ \565XP_Y&^+_ *\%_P#1
MC5E5U4L.JD;W,9U7%V.J_P"%@:?_ - W5/\ ORO_ ,51_P + T__ *!NJ?\
M?E?_ (JN5HK7ZI'N1[=]CJO^%@:?_P! W5/^_*__ !5'_"P-/_Z!NJ?]^5_^
M*KE:*/J<>X>W?8ZK_A8&G_\ 0-U3_ORO_P 51_PL#3_^@;JG_?E?_BJY6BCZ
MG'N'MWV.J_X6!I__ $#=4_[\K_\ %4?\+ T__H&ZI_WY7_XJN5HH^IQ[A[=]
MCJO^%@:?_P! W5/^_*__ !5'_"P-/_Z!NJ?]^5_^*KE:*/J<>X>W?8ZK_A8&
MG_\ 0-U3_ORO_P 51_PL#3_^@;JG_?E?_BJY6BCZG'N'MWV.J_X6!I__ $#=
M4_[\K_\ %4?\+ T__H&ZI_WY7_XJN5HH^IQ[A[=]CJO^%@:?_P! W5/^_*__
M !5'_"P-/_Z!NJ?]^5_^*KE:*/J<>X>W?8ZK_A8&G_\ 0-U3_ORO_P 51_PL
M#3_^@;JG_?E?_BJY6BCZG'N'MWV.J_X6!I__ $#=4_[\K_\ %4?\+ T__H&Z
MI_WY7_XJN5HH^IQ[A[=]CL]-\96.IZE#8QVE]%+-NVF:)57A2Q_B]JZ3O7F>
MA?\ (WZ3]9O_ $6U>EUR58<DG$WA+F5Q:***S*"BBB@ HHHH **** "BBB@
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MWQ%=M:Z7J2SSJN[RS&Z$CVW 9_"N@I6L,**** "BBB@ HHHH **** "BBB@
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MRG<P]C]*WJ0PHHHH **** "BBL_6YY;;0=0GA)66*VD=".Q"DB@"S]KMO/\
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MKTL+_#.2M\04445TF16N=1L;)U2ZO+>!F&0)954D?B:F:6-(FE=U6-5W%R<
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M-A;MDD#Y3R*ZS3XG@TVUAE&'2%%8>A &:3:L".3\5^(;34_AWJ]]I%T)HP!
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M3Q#96]I9SW=I/:M,/)\L%N5P06=<  _K6]<7 M[26X9'(C0N47EC@9P/>C5
M9=UX:M+AX98KB[M;B*(0B>VDV.R?W6XP:6?PY:2B!H9[NVN($\M+F*;]X5ZD
M,6SN&>><TB>)]/>\TVU'FB34(?-A)48 QD!N>"<'\C4*:^MY=Z8UJ9UBN1<$
M1&)<R["!U+?+UX]<\XIZAH68_#]K')82&>ZEDLI'E1Y9=[.S @[B?KVQ3I-
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MZBBBKBFMV2W<****H1;T+_D;])^LW_HMJ],KS/0O^1OTGZS?^BVKTRO+Q/\
M$9UTOA"BBBL#4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M&\6_\B;KG_8/N/\ T6U?-$/^IC_W17U%J]@=5T:^T_S/*^U6\D'F;<[=RE<X
M[]:\O7X)SJH4>)%P./\ CQ_^V5K3DH[D3BV>845ZA_PI2X_Z&1?_  !_^V4?
M\*4N/^AD7_P!_P#ME:>TB1R,\OHKU#_A2EQ_T,B_^ /_ -LH_P"%*7'_ $,B
M_P#@#_\ ;*/:1#D9Y?17J'_"E+C_ *&1?_ '_P"V4?\ "E+C_H9%_P# '_[9
M1[2(<C/+Z*]0_P"%*7'_ $,B_P#@#_\ ;*/^%*7'_0R+_P" /_VRCVD0Y&>7
MT5ZA_P *4N/^AD7_ , ?_ME'_"E+C_H9%_\  '_[91[2(<C/+Z*]0_X4I<?]
M#(O_ ( __;*/^%*7'_0R+_X _P#VRCVD0Y&>7T5ZA_PI2X_Z&1?_  !_^V4?
M\*4N/^AD7_P!_P#ME'M(AR,\OHKU#_A2EQ_T,B_^ /\ ]LH_X4I<?]#(O_@#
M_P#;*/:1#D9Y?17J'_"E+C_H9%_\ ?\ [91_PI2X_P"AD7_P!_\ ME'M(AR,
M\N9@BEF. *]*^'GP\:^>'7-<A*VX.^UM''W_ $=QZ>@_R=G0?A%::=JL=YJ>
MH#4HXN4@-OY:;O5OF.[Z5Z4.!@5G.I?1%1A;<,8I:**R- HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X'QQX-.IJ;^R %PHY
M'3</3_Z_].GE36ERMW]E,$OGYV^5M.[/IBOI*J+:39-=?:3;H9,8SCMZ?3VZ
M5V4<6X*SU/)Q>5QK3YX.W<XKP/X,:Q(U&_4><1\J]=@]/KZ_EZUZ'1C Q17/
M4J.I*[._#X>%"')$1E5QAE!'H12[5QC XI:*S-QNU?[HI<9I:* $VJ.BC\J
MH'84M% ";0!C Q2;5_NC\J=10 F!C&.*-JXZ"EHH :55B"5!(Z9%!56QN4''
MJ*=10 A )Z"@@$YP*6B@!-H]!1M&,8%+10 W:O\ ='Y4ZBB@#F_$VF75_<6$
MR6@O[2$OYUD90@<D#:W/!QSP?6L5="NK#2+F5K>RL##JBWL,!E58BH4#;NZ
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M\]\8?\C?%_UX+_Z,:LJM7QA_R-\7_7@O_HQJRJ]+"_PSDK?$%%%%=)D%%%%
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MNL_]^(__ (Y1_P +H\/_ /0-UG_OQ'_\<KQJBCV2#G9[+_PNCP__ - W6?\
MOQ'_ /'*/^%T>'_^@;K/_?B/_P".5XU11[)!SL]E_P"%T>'_ /H&ZS_WXC_^
M.4?\+H\/_P#0-UG_ +\1_P#QRO&J*/9(.=GLO_"Z/#__ $#=9_[\1_\ QRC_
M (71X?\ ^@;K/_?B/_XY7C5%'LD'.SV7_A='A_\ Z!NL_P#?B/\ ^.4?\+H\
M/_\ 0-UG_OQ'_P#'*\:HH]D@YV>R_P#"Z/#_ /T#=9_[\1__ !RC_A='A_\
MZ!NL_P#?B/\ ^.5XU11[)!SL]E_X71X?_P"@;K/_ 'XC_P#CE'_"Z/#_ /T#
M=9_[\1__ !RO&J*/9(.=GLO_  NCP_\ ] W6?^_$?_QRC_A='A__ *!NL_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4A!W*RLR.IW*RG!4]B#2T4
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M"%07<'VJSGM][1^;&R;UZKD8R*GHK U.2@TOQC:1/;1Z[8W,6,)/<VS>:@_
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MC3K:VBNKB&:UGDG@N8\;T9V9CU&"/F(P16GIUG-90.D]_<7LCN7,DX4$< 8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "5";2 R^;Y:[_7W]?K[U/11<32>X
M4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>syn-20210630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:syn="http://www.syntheticbiologics.com/20210630"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="syn-20210630.xsd" xlink:type="simple"/>
    <context id="As_Of_11_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember__J-NQrr_RUyU2Fj9hkVnmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-18</instant>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_Q4U6TfXbjUGV399zEsrnGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_slSCc3YOzk2ByscUunSdgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dvzYRfZpzUCe7pw2pnnTzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_bdhxK7hqDECM_T4Lq_vhjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ML7WRtDK4EuEsagAjFhinw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-11</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_CuZd8Dnu20mqdbWiRYxlvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-11</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_10_2018_To_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_7OFHeCdRt0-vhR2n4qUlMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-10</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_p9VkK2Ce20-b03B7rUyXiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_nSmA-ONebUWYUQwXwaT0Gw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aTsVxcHS_kyEMZppZUpQLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_X7y6Hk8vxEOjkWQto03hMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_19HxwprrtEmkvH9Lq7SqzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R1-WdN0260eTxfcWqIiCSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KLY6iI306EmWk0dZhmpc3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_VF5eg1rhD0m77f4_pFE9cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yO2RP4h8dkysRRaDK9-uEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_vFY0pex4Okuv5Sk4DegLEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZxMhHz9iRUiCA6Tf_pX0rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_5ldZMfCabU28j_zFOz5BcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0twBlUhqq06j7sVl2-oL5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UrUccS3ylEaTH5G8z_ou6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_0Bxf9tnUNU2MTTKPvvGusg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5tZWGDYmrUaKJjhAjOyXfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fp5r6nH_SUy0VUUzbxxn2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_GRpJOcy1vUmpHvwH4bofIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LjtrdEDbDkeCwbuDZRK4Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_P3gsqp5SGkCisHeuk5iOZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iref35WiQk68aCukJLQswQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_I1SZ6FMPUEiPzXXIzzj76g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kyVeOBFLm0uK15XMpvVbZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zlQvdoOjn0eIo5zMpiXNXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_LcbLiBbyFECO_hZVyJHpuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_RJbNJpRBXUSt0ueloEGWTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_81VpuqIrTUGMs7nm1_pSJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_mDQnCUaukkitwCFkDu49Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-17</instant>
        </period>
    </context>
    <context id="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_aNYaq92HaUaThT1YEHFknQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-11-02</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_9p8BUi9xpESM0XFssipxEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VBR-eClC6UGC07S2WEllbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zJO5Vy7y90-lmBQP2GMq9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_3_20_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_wLkfa3YyAUWs_EVe-EPt2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-03-20</startDate>
            <endDate>2007-03-20</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MlNR2bKVWUa5Wq8G6pRRRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_QlvAWBKoYkCi7DFbZ1TTXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_81t85iLAZkue0k_haly1qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_VjVpgqccckeC1Ovt7HdvKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-09-05</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_t4jWqATDt0GII2ExNce1_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_qSjb2MQlSkOywB4mpExYgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_6GJQIqP4z0u-0VYhtn0pwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_w5NkU2_sOU2NkvPwvNTs-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_V3AVcyTze0yXKy6SgCQQOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_GfHbuB9ZRUGhg2eteRKuJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2018_To_10_15_2018_9YpmMUjlgU6Rx_oNzkSWFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-10-11</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-11</startDate>
            <endDate>2017-09-11</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HMJmPJ9JF06CqnhSeF83-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_yr0zg1OZHUiIwiJG12_IyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HJ0Vognp00iLodsId7AO5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-11</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_SQNPifEGMk-kiOEU3qgr6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-27</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWKm6b2HsEu3yxsVRW_tpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__gb_XUJNFEe-pMBsJgUlhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__Tyt_vo2eUyKoSKTspRpcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_adtzoVUoL0KulWbPEZXKug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_83AqlMwHVEuP9zHFSSM5Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_D6zkksit4UCwIionHXMP8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_u4kbim5KiEyW-zB1-W8-HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-11</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_WSxxQJt6wkSqtxqIte9ptg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_njvvYCOrE0G7--zGCHARcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_11_15_2020_FnMilutR6Uaa49a8AX4Ozg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-11-15</instant>
        </period>
    </context>
    <context id="As_Of_11_6_2020_3pJ_Ridqok6114OiGur1oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-11-06</instant>
        </period>
    </context>
    <context id="As_Of_11_5_2020_iKgSvuSwK0Katgd-IjQ9Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-11-05</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2018_V2vD4wi4-UCmh8saJ-KESA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_cKJV1gyygk-EpbEXDFtKXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_93GgZzd5OUWNIi3WddVejA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_mdSu6IH6FkWLzuUBCfIegQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FyVHAd_teEGuTL1oBAt_OQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_5hLd6ZKkzkCO5-jO7JCpEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_RVKQ0qDznE-qz2ggQLkq-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OwL8Ke43jku7YbqZh3ch4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_RVsezu3jr0CBpCVpvdx8lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CseERA5zh0ynTz1Zu6va3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8Voeje09P0KdHrvytlGF5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_Zk4qTUzc2EeG7AwMKOnF_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_PFI4t1qvYUeUPVPhulwM0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_GjoOepJsFkG33JO-DraytA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_IC8EXhUAzkGZ5rMnpHL2gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_eIcfeMgtzUC9ndcccKwg3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_f5pVsHeOF0esc-wKzvKXnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_7LiVHRy2BUaPnoZoXiYlag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_gAS70YQ3kEWbAigVthvfbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_a9LDsj3uzkuOTiqR1RdjjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aqlwFNKohE-KfzX_Eclrdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5AoLC7KQ1Uawve2qPbgbzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aPnGd6B3pESapmPXpuMoYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_YSUSLqISakeFFs0u8z32iQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_dAV91tPf8kmgXysC3CKWIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-11</startDate>
            <endDate>2017-09-11</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_JR9Vjj4m3kihR7DJRSC05w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:OctoberTwoThousandEighteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice5248Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice138Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice5248Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice138Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-11</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_zr1590HAfU6H-r0oJu1zEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_onT3wd_AR0CjAZdM083VMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_CDRBLE4qQkaDOCYG-eI5Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="Duration_9_5_2018_To_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_DphhO0tkBE28K8KwCLVQRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-05</startDate>
            <endDate>2018-09-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_S0B-4Run_kKbm47QoMWZuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-05</instant>
        </period>
    </context>
    <context id="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-27</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Xxe3gAXhZU-l1BDNtcdQBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_BusinessAcquisitionAxis_syn_CedarssinaiMedicalCenterMember_z73xOnQ6cEihGg2og9Jxtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_7Uo71EUX6UCZ6ImKlbActA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2021_fvNYIeFxxEu--oykbEn2Hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-08-03</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA">
        <measure>syn:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg">
        <measure>syn:D</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      id="Hidden_9dXNRMZPnkq5ly83tC4RTA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      id="Hidden_Vt6DMeS51kOxMfvORNJaVg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Hidden_WncZ9lUjfE-MTJQXil_NHA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Hidden_xduacBc4F0Gmcu7XseHoeA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:PreferredStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_OZxyHpTX6k2qtd_txg-ggg_2_1">0000894158</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_RcErDEPLZkW2ovJJjlvUKQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_AYLGqKGDB0aCpBl-k_AhjA_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_1WTU2zuANkKGAWAtMcLb9A_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Hidden_nBJ8GuZ62UGLYSMG0yfutw">Synthetic Biologics, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_dt9BJfnIRUeSP5kFZHL2xw">false</dei:AmendmentFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Hidden_Qp3dlV33Gkug0H3pW_avuQ">false</dei:EntityShellCompany>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Hidden_eaHBVV3jI0G3SJsyY6yxlw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3973</us-gaap:PreferredStockSharesIssued>
    <syn:AdditionalNumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q"
      decimals="INF"
      id="Hidden_LwEQCHh2xU-yhl4vl9nF_A"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2420000</syn:AdditionalNumberOfCommonStockToBeIssued>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_oQ1Nppy7s0iMqsraMNEe3Q"
      decimals="INF"
      id="Hidden_uVawnFnrhUC47_sVB7xw5A"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.17</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Hidden_N8SN6UjVJEax0ioF-Lc0bA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">120000</us-gaap:TemporaryEquitySharesIssued>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_czUcULnlb0-z2sR11qMqSA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_GP1nloTea06rKLyGTtuSpQ_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_9rA_yzUtsECW9RVD5Z94BQ">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_ha1eEY68eEauZKukNXfVFQ_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_0O7lRNj8MUyuMtnMU_aylg">001-12584</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_xtjHZZ0HS0mD318brdxQyw_0_0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_FWTyqL5zREyQmXoWu-3G2w_0_1">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_Y9rvTnEEpUKBIZW5UYjyLQ_3_0">9605 Medical Center Drive, Suite 270</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_ruZmPz71TEmi2LfopwkxMg">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_QbTrDhUosECM7gg0Ihp0SQ">MD</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_aSmXutrBbUWVKpeTmlpftg_4_1">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_sgP0zBYoFUSOkDeqiVx9yA">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_5YxjaDyjtEmPMK7kDeEMqQ">417-4364</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_4SUq-421CkeZQHAD1JEObQ_1_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_Xb8ZxTJAUUmPAMBfMBjwcg_1_1">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_1cKUxlNsfE-P9gac_FpyQQ">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_zlkv6Fz3MEuuJVk4lqw1Nw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Narr_xWOTHtlakEuNK8ToA_Xazg">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_AcNhnTA64ECvGu-HxdYBOw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_jusZxN6VqU6-H7adQzTZEA_2_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tc_QufRMH65sUagvSyZjti0WA_4_4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_3_2021_fvNYIeFxxEu--oykbEn2Hw"
      decimals="0"
      id="Narr_KyBTNlSWzUmPDMG9NqQG_w"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132042538</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_sKC04oFjbUSI-vY7HYzQsg_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">74291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_JB6GmKsCAUSXwXACTT9lCQ_5_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_euHrSgu1y0-Htu2P_YUgiQ_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1341000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_xKMH9qMpRky4dRHDevNKiQ_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_JADzu0hME0qz82h7NT_tSA_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">75632000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_Ss0zuAjmnESzLTtyWw8UlQ_7_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7934000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_-PnUNe1nyEGxheyOwRXAJQ_9_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">132000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_KKRMqZCWvEq2mwiFl-XiQA_9_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">174000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_slc-bShfQUia1wXV96rA_A_11_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1468000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_9cBWuUxuCEmaaS5nTPkznw_11_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <syn:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_YPS8sq6Hn06YcqN6XkcSSQ_13_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">23000</syn:DepositsAndOtherAssetsNoncurrent>
    <syn:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_FOC0uyx0Vk2ohEJd_64wdQ_13_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">23000</syn:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_tvgzJWlQW0a7yqhhUqMDMA_15_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">77255000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_4H2YU--bZESDc6TCAd5t9g_15_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8410000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_x5cf_uV2NUG-vQeyYYnGuw_20_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">568000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_G0AUGQd_sEemVkDMk36Ldw_20_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">886000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_dLLaO4FBgku75l9-8HDREQ_21_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">794000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_7R-xx2p6rkqQHnVEj5HngQ_21_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">925000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_tShtDcg8mk-XaNldJ-HC3Q_22_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">540000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_mVxLBqR7sUCKjq-cCwfd_A_22_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">868000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_R-rdMCD1z0G0IwieeiQHIw_23_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_JGE2wEkAe0yEmcJx2qA6yA_23_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">287000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_WBUowp9VTUq44IVAFAwVYA_24_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2098000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_nxyTPTU62E6l4kuotG8V3Q_24_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2966000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_AIShUfX9m0ytXgY7M5E1wQ_26_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1426000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_oYOoFSgmeE-Y0y5FmV7DyQ_26_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">186000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_X1JVvi9jHU-_w7yQa2Wkjg_28_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3524000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_bFfRLJZxvkKAkuWn5h2qmQ_28_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3152000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="3"
      id="Narr_Z07XhIWUuk2s9l5oogiJjw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="3"
      id="Narr_ZIBoS8h2CE6P0DjVZMkQdw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_5y1ayAcXI0yP8IXz4vHPCw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_bTyZpPbYxESMyHXCJiq0YQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_855fRIHnCEKusbrXnN0WeA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr__KDT9eMVAkK2Hf0jYKlbkA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">120000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_Hzp0HwsMm0uwoDGiLnanSQ_30_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_ZaIIK2A1DEC4MUIB1rpjcQ_30_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">12798000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_Ow5IlD46A0e0ylbyXa2tWA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_UaOiXCBxp0K3hzi1VriELA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_4JKYoHTpPEa5CtqBrSEJRw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_-QHJpakDhU2agXpswqq8jA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_Izff0jspwkKGrAsyVhywWw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_1ycE-XuiO0qvOsMvlLn98g"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3973</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_y2laZxn2xU6fpfRMyVFTDQ_32_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_JjNjrO0u4Eu29830edu7uQ_32_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2477000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="3"
      id="Narr_b1bxrdxh7UGH1yqqrxxnuA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="3"
      id="Narr_FaJ6S8zhikiBYqsuP8_3Ng"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_Eg7TRe4NdUO34wr_G3JtBQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_eDmMhVVKeUS4DlRrO5tFfQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_z4bgKIVTjEKHCph4gojWvg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132044866</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_fB_omQlvL02qvMxKnm_ZaA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132042538</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_MNE-GbiDd06ZYn6bfmErQA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">29252253</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Narr_tquafKYK4Uyw9EF7-lHn-g"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">29249925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_26FNOuVI80OrXZjEwiv5uw_33_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">132000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_6eIqH7zDGkW_udyKchSx8Q_33_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">29000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_aZP83Z8lxU2tp2KfvEnDsw_34_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">339121000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_1Wpn3S8Wb0iBLEDWRFtxNA_34_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">240821000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_y6D9svsWBEe4YifhctDqLw_35_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-262748000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_oYMvqO1rbUeOcZHxDotp4A_35_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-248094000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_wzN48scP4E65lUQgBrp8yw_36_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">76505000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_gyvezuFsAEO6mzzBRcBk2g_36_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-4767000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_oFkeREj3ekGNag0WSgm1vw_37_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2774000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_UtzJV8eNvUaeFUB2SsA4mQ_37_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2773000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_WQjRlUL8YU-K_CxlT3piRg_38_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">73731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_CY738T_UZUmtjYpv3Gz8yg_38_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-7540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_UlZjpBv8S0ecNLeRluU-4Q_40_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">77255000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_B7fROcwaF0eGvVVsHL-r7w_40_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8410000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_jazdgiKzt0mOYYyLDijLDQ_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1265000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_aBwDsgM4pEiyNhryYwj-OA_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1286000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_H6erlwLasEKk5LbimUdKPw_4_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2685000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_ZofbW4I4H0GxD0g63dMLSw_4_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2679000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_hegWj3zcnkaELDvd7OOzPw_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1932000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_RiNm9GOvy0GxkZzr6VrH0w_5_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1603000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_PWyclazM-U65Lg1hYiUB9Q_5_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3049000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_anV9CcewVEaNAwSydXOx0A_5_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3238000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_tBWxLeNn-kC5HLcRpwchPw_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3197000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_d0z_4ojEck-DyI6FGRoZdg_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2889000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_O1I22x1IE06LfKgAZVG-_A_6_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">5734000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_cIbRmH24okamEDk7rW1MJA_6_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">5917000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_CedGHy8CXkarUBHcGnQ5Wg_8_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3197000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_b3OZMY4CdkOFri9Z8hkBBA_8_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2889000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_odLVJPGcNky_7wHKbUgCNg_8_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5734000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_OqxMe-29ekOIeTLlGoKnJg_8_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5917000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_gd1US6kMNE6zZbprkNSx4w_11_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_8UUl-McUYUKWzeObDWZJ2w_11_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_47sld0LX3EqvDfDtUE55kQ_11_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_FWVEQqUaTEOKVD4DHW0PKw_11_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">44000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_bNlfoKcAa0eVMQFGGmwM3w_12_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_c7PTUPtn40uwk2dDuJ84BA_12_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_6lTcMM2geECsK0l-nU1d-Q_12_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_iov7EPmzcUq7GPOCA4dHBQ_12_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">44000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_N3k35iJd1EG0zseqCtDrGA_14_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3195000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_5bpCNLHP8U2gSfQiPQsNuw_14_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2883000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_Be50bor6Q06zSgRUhLNdrg_14_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5732000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_FeUDO1FixEGIdAnW3qxGSg_14_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5873000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_c4IDxQz4zkSyuEcPv0-EuQ_16_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_od74mq2-2EmPR0BNz0wMJQ_16_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-16000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_xSKyxaQ47E6WVv_UGWNeTQ_16_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_cYmTsQzSJU2mlbe3yW2ssw_16_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-42000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_ajDhGFoIxkS6CCah6oT08A_18_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3195000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_niFUhUTgl02S2cuBuuqYdw_18_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_fF0y6yBAOEKjnOJZmCSJjg_18_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_22rXGwCgeUCtWTN2oIplnQ_18_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5831000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w"
      decimals="-3"
      id="Tc_8qrVNeCK7Eao6d-MkVKNKQ_19_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw"
      decimals="-3"
      id="Tc_MbsC1b-g70mdyKYeQ1I_Sg_19_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">63000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-3"
      id="Tc_BdZw-vHaeUKP1Oy35_r1hA_19_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw"
      decimals="-3"
      id="Tc_aYsHsJcVjUmQpy6acXEYng_19_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">125000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_38ojeFUjMUKf1MWt7xaU6w"
      decimals="-3"
      id="Tc_4YAUheQ0u0iwQwqnldbvMw_20_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw"
      decimals="-3"
      id="Tc_tjKp1PDyOUOsA0iLBsQbeQ_20_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-3"
      id="Tc_Ug8V0Ap-5kCGJTKOB2Cn3A_20_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-7402000</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw"
      decimals="-3"
      id="Tc_hRBtoOsHFEWC8g26VsIDgw_20_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:PreferredStockPriceAdjustment>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"
      decimals="-3"
      id="Tc_a-vRSm6yfUSUgCH9N8QbQw_21_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_AWOBdXNqbEeTrkTgsme9HA_21_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">392000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="-3"
      id="Tc_xNh4EcwpcU2RSWS5WPYTRg_21_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1497000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"
      decimals="-3"
      id="Tc_8YT3-H8EME6WdwH1sgP_kA_21_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">796000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_1sSleBRepki7I9Bk-ffSvw_23_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3195000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_21k9y-6DGkS6prwYl9hEOA_23_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3322000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_xh3e1LZTuUGh-SJ_DYPGzA_23_9"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-14654000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_DteRh46xeUmxCIfdazOqkA_23_12"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-6752000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="2"
      id="Tc_U24HSo-KpEq7Xe_ipI78ew_25_3"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="2"
      id="Tc_CTlA574bMUyjSdEn_22JWA_25_6"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="2"
      id="Tc_McCpmcLjzkmyJvY4_fqhlw_25_9"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="2"
      id="Tc_m5Pe_NAT1Ue7G8cV_D0TPw_25_12"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="0"
      id="Tc_W2qkItu0ZUKc4u8SWlZwAg_27_3"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132042538</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="0"
      id="Tc_ylGZnMtt60K2cdba1ek0HA_27_6"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">18405884</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_wOfxS1SrmE-ISCFNx137wA_27_9"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">111539024</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="0"
      id="Tc_j1Y-EX_Ua0KN3OLXO4potw_27_12"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">17748688</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A"
      decimals="0"
      id="Tc_0nlaUMXEQ0O-Yy0Iw5PC-A_4_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">29249925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bh62Y705cEeiUFEUEsPt1A"
      decimals="-3"
      id="Tc_se3wARcrJ0WxjQDLj0OR5g_4_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw"
      decimals="0"
      id="Tc_uO2zHK_Xmk2kkMUULRSoNw_4_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3973</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_9A3P5AIaJkWBYGddz4Sqrw"
      decimals="-3"
      id="Tc_HBNufuI5l0WWgcu0HtEf8Q_4_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2477000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0twBlUhqq06j7sVl2-oL5A"
      decimals="-3"
      id="Tc_ePUY_qh_OEOb3_We4RH8EQ_4_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">240821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZxMhHz9iRUiCA6Tf_pX0rQ"
      decimals="-3"
      id="Tc_oQhXh2up0kWE-_dF6QxJ9g_4_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-248094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_5ldZMfCabU28j_zFOz5BcA"
      decimals="-3"
      id="Tc_EJ162lhm5U2gDveOQ_ei1Q_4_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2773000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_PWeEqtcsh0WWhnkuwixI5w_4_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-7540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_PoEGNnebcUC05gddbWx_ig_6_2"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_Xxk43ckcBkq2az_A6i3gUQ_6_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_hQdW43sFS0GQUtBo7IObLA_6_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_LOwFIcpS2ECHqZ1xnBL9iQ_6_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_QdQyXACy2UW-7s1oXWAVRw_6_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_hl-Nf19eL02fNELrWcfdrw_6_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_zPi9n7VMqEi6FhGpCVWcaA_6_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_p2ZkD1ygyUWBdaswMAEz_Q_6_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">101000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <syn:StockIssuedDuringPeriodAtMarketOfferingShare
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_6s8-XuoM20qomIdPI7CiyA_7_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">78685315</syn:StockIssuedDuringPeriodAtMarketOfferingShare>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_nfy1J2K86EuN-kvBbtXc_w_7_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">79000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_52VuOZS5Vk-LFgg8NTw9Ow_7_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_q3eziVWWwkSF518jxM30hg_7_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_NWNNoiKBmUmSkHifl4gfuA_7_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">65881000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_b8RPWL5FE02Mug_mjzW7Sg_7_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_e7_mRxCQxEKa7N0wVnLy1w_7_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_uVN-Mzji8EKSgCzn41z6oA_7_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">65960000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_KctEZyR3w0On0aglilArlw_8_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">11655747</syn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_lnQTnQc4dku-p9MSWDOMdw_8_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">12000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_3g6ZVm4zQU2v_4CusjF6PA_8_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_k3k9Je0qu02VsosnvEY-AA_8_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_yxbOWu2mqkuvWXPFGGd-og_8_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8030000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_AZOOWhesp06UV8D8BeIKZQ_8_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_3CHnkFECUEqSreVNAxcUhQ_8_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_rYUORqvCjEm4mW_9ds5NNQ_8_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8042000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_WCFxZvN0KUmsVIzSFSQOPQ_9_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_c87BvsgBkECnTgipChKYww_9_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_pks3ITJNJEWV88FWEtHnTQ_9_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_R5UnesqNmUetL-iqaomY_w_9_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">24000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_-2SPZEVU00W8u06Qy01_5w_9_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">24000</us-gaap:DividendsPreferredStock>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_73K638knAUCpUUkCyMqikQ_10_2"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_2PdDnzJhCki9KWQp7yx5Yg_10_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_AbbRYLXEaku4HBXr6A37-A_10_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_ei3DneJ4gEmlIq-oLuz77A_10_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_gg7YvNBz8E2mltn6btjiUQ_10_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7402000</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_FCqY7LMJKUyQ_jq2N7r-Ww_10_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-7402000</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_ZWU92p4mwUel65k6KH-JoQ_10_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_Sa7jbWWIcEmssWKrLNZDpw_10_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:Conversionofseriesapreferredstocktocommonstockshares
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_JNJ3bW5TsE-qSyks0LcjYA_11_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">8996768</syn:Conversionofseriesapreferredstocktocommonstockshares>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_31eZ2GBpgEG3Sbx63gqlhw_11_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">9000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_fgV5grEWVUO5YsxFtCnVAQ_11_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_BTmYRjEbC0-p33YVL8xtxQ_11_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_mmoVGh4DxUWt0v-TXaPdEg_11_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">12813000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_PryCQLAgmUy2MKK7yDtPtw_11_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_Wqec-QGsDkWc5iqoZHVDzA_11_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_YFzeKW1KxkKE8ZHNVNjk3g_11_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">12822000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="0"
      id="Tc_JDHyBsauRkWOlLoac2S8Bw_12_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3454783</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_JJq3g4sa3kiiWAFy7dOebg_12_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="0"
      id="Tc_8RTCQfNjZEq38UQCmkpuLg_12_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">-3973</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_61zfXtBgWEOcz007cLaWag_12_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2477000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_NMyAWhlEGUyi7WpgBO2QJA_12_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3971000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_c9lOhJ82i0aBw3caoid1yw_12_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1497000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_-XUDwouw_UC_3oCEDCiZKw_12_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_SFMfIZn0MUWXhNt-nqB7Ow_12_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_D_55ASoV9UqC4iMSBdTmdQ_13_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_2vMxZwv3yU2Elmw3bv5M_g_13_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_gFVdA1tcUUWxzsJqD7mnGw_13_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BhAO9CIvdEiJdd57nw15dg"
      decimals="-3"
      id="Tc_b262EtANvE-7_iKYHDUndA_13_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_GzKJ2-j13UamXtWVFou30Q_13_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2536000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_cOB2GBFTt0yg4FgVmkDYRQ"
      decimals="-3"
      id="Tc_tjAp8M-rRUKzBUX4zIagDg_14_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_6sw-dmph70CZm7vj2HMRwQ"
      decimals="-3"
      id="Tc_XYOo48JQY0SYWHQ5GEIlDA_14_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_FHkTys4aS0eKI3Om6QdjLw"
      decimals="-3"
      id="Tc_eq0hp46DDEGede0wopYrCA_14_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_lGlnUFm3XUyI4cd_rBb_eg"
      decimals="-3"
      id="Tc_zIJhOyiO0E-QgKt1jwDa2w_14_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_3_31_2021_vPUqws987kOyrseYZzO1ew"
      decimals="-3"
      id="Tc_ELboQVvBd0ytPsjhJYEEmQ_14_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw"
      decimals="0"
      id="Tc_2ple3jL5BUWNx9hgvENg_A_16_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132042538</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__RIPcarovkKuqcrfW209tw"
      decimals="-3"
      id="Tc_L8xX_MUcD0-zPJ8m3Lq3wg_16_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_R1-WdN0260eTxfcWqIiCSw"
      decimals="-3"
      id="Tc__yZ5dsWBA0qmkT60JAO1-Q_16_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_yO2RP4h8dkysRRaDK9-uEw"
      decimals="-3"
      id="Tc_xVSVO8HLdEqs2HIzi688ug_16_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">339019000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_KLY6iI306EmWk0dZhmpc3w"
      decimals="-3"
      id="Tc_dhDqeji3PUWWKGBR14MZhg_16_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-259553000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_VF5eg1rhD0m77f4_pFE9cQ"
      decimals="-3"
      id="Tc__vMhrzF6dU-m2PMqS9CBaw_16_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2021_vFY0pex4Okuv5Sk4DegLEQ"
      decimals="-3"
      id="Tc_DSR0Mi9NNk2kaUrhXN4lJw_16_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">76824000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA"
      decimals="-3"
      id="Tc_A2Xh_COGZUGqi-ImIbp6vQ_18_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"
      decimals="-3"
      id="Tc_6p2mTtSAUUC_pk9f8inYxw_18_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w"
      decimals="-3"
      id="Tc_olbGoJTy_0erYJ7IiNBAOA_18_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_GrsFoQHNyECk94CoHuT75A_18_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">102000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_9vLhTk6T5EKU1nLAlHAUWA"
      decimals="-3"
      id="Tc_bzRX2GW-IkybxA9WrfqkmQ_19_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"
      decimals="-3"
      id="Tc_45L6B-HFaEe3VVO1An43Gg_19_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_BeYPaXCDe0WB6HjTgQ77-w"
      decimals="-3"
      id="Tc_XJf6JOkXyE2Dz80EEsCBCA_19_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mWKm6b2HsEu3yxsVRW_tpw"
      decimals="-3"
      id="Tc_s-C5ZXefjE-SZUK73thy_g_19_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3195000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="-3"
      id="Tc_HQthhHFKZUuoCwuMRAsrpA_19_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-3195000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg"
      decimals="0"
      id="Tc_gWlQbSbv70uki_XhHs6XyQ_21_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">132042538</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ucyVXMNGMk656hw5svH2Gg"
      decimals="-3"
      id="Tc_7ro9J49lu0-h10zzxHlgZw_21_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_nSmA-ONebUWYUQwXwaT0Gw"
      decimals="-3"
      id="Tc_nSCi2qfY4E60pCtyulROUw_21_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_19HxwprrtEmkvH9Lq7SqzQ"
      decimals="-3"
      id="Tc_1dDbvfXDQE-E-PYtG9ngYg_21_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">339121000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_aTsVxcHS_kyEMZppZUpQLw"
      decimals="-3"
      id="Tc_BuUROQ248kWpV0SO--tv_A_21_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-262748000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_X7y6Hk8vxEOjkWQto03hMA"
      decimals="-3"
      id="Tc_LzLf5DCWf0CObTojqo68kQ_21_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2774000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_-Hr_gu7J30ymh37zfUYL0Q_21_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">73731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg"
      decimals="0"
      id="Tc_4kDW2X_NQEuyhIuKoEO_sw_4_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">16806430</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg"
      decimals="-3"
      id="Tc_QU2EcEE5zUmsF3I1jyr3sQ_4_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ"
      decimals="0"
      id="Tc_PzeOcKa-4U2tVNQrki72sA_4_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">7638</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_NN3Wk1RP30WWdSCTqn5thQ"
      decimals="-3"
      id="Tc_J97h0RadV0u8cxefUooXuA_4_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">4761000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kyVeOBFLm0uK15XMpvVbZA"
      decimals="-3"
      id="Tc_KXbKo5xOOke6UCq2qvgBRg_4_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">232580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_iref35WiQk68aCukJLQswQ"
      decimals="-3"
      id="Tc_peAra28Wd0uAwpb0u2u9vQ_4_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-235537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_I1SZ6FMPUEiPzXXIzzj76g"
      decimals="-3"
      id="Tc_gV9Lsdpd20--cSmHEgNXWg_4_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA"
      decimals="-3"
      id="Tc_y1QhOB5xa0KOuhB9hj3rzQ_4_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1057000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="0"
      id="Tc_uuak98WitEK2EWT_7XO95Q_6_2"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_9rE55sRp0kCtoKhrK_ctCQ_6_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="0"
      id="Tc_4byig69qUE2Kri3F8U7sXA_6_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_HsPFw7dh9EONj0K3p_yZog_6_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc_Zur2kSHKukOzAMNyEawH8w_6_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">83000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"
      decimals="-3"
      id="Tc_jBHa65fzzUOWZ-rSaHQbFg_6_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"
      decimals="-3"
      id="Tc_OMJge_AjEkuYZnsAgfffEg_6_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_sQuszGC48E22zKuHbRwlUQ_6_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">83000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__Tyt_vo2eUyKoSKTspRpcA"
      decimals="2"
      id="Narr_XEER9xi970eM8U4UJ8mm0w"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.01</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="0"
      id="Tc_sflpKcrrhkORtQjIfVo6Og_7_2"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_7ES5CNpCj0abgR9U24BS-Q_7_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="0"
      id="Tc_yVWkMoafF0m71qtftcjdCw_7_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_8txmoTOvk02J0Nrm36KG4w_7_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc__RqEasvhn0SHSpuJjEMXAw_7_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"
      decimals="-3"
      id="Tc__23ny_xspkGo61cDz-U7-g_7_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">62000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"
      decimals="-3"
      id="Tc_IzDs0RcLgEK6jlZuhZ9Hmg_7_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_o6V0bbcSrEOKUC6yPMLAvg_7_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">62000</us-gaap:DividendsPreferredStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="0"
      id="Tc_gPl8GmMjtUumMyT9VxKx6g_8_2"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_izH6KWnrW0Smw1qApfZwEA_8_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="0"
      id="Tc_h2VECml3g0i6DxIiCQNwTQ_8_7"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_ep9rW-zO0kmNpIFI0bESNA_8_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc_RVNlW2HmxkG0MZgRRDukag_8_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"
      decimals="-3"
      id="Tc_UnPhorVYzk--axq5VS_t9g_8_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"
      decimals="-3"
      id="Tc_0d7cNN7WmkSfsPMki2FBBw_8_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">26000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_mwKOxyTj80KHPTc8lYc0Wg_8_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">26000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ"
      decimals="2"
      id="Narr__fP3-pKKR0a65U3Aul_6xA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.03</us-gaap:DividendsPayableAmountPerShare>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="0"
      id="Tc_3MoNe7vAoES1fDxqDqh0zw_9_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">933045</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_9FPXfcWLckGK1mv_nG8t1g_9_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="0"
      id="Tc_tra6e-xhzUG2BYp0zusg8g_9_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">-1073</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_UIwPONtkuU65pq56IRtT7Q_9_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-669000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc_RsqOwK5CJk6PPLc_EiocIQ_9_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1072000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"
      decimals="-3"
      id="Tc_h79f1hvseEmQaqtoMm1NdA_9_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-404000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"
      decimals="-3"
      id="Tc_E1L0f79nXk22ETb8zah8mw_9_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_EHYWjXndkEiq9OTkdWHpRQ_9_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_efKXfwpJAE6PSF-CMH4aDw_10_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_zavg1olvQUCatmumM76ixQ_10_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc_UwDpYKy4Xkiz8PyYcpXrOg_10_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4iskVlQW1UCtyn0bF5B5oA"
      decimals="-3"
      id="Tc_X3ARkBkYf0iiuDffPE1pcw_10_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2964000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_i-BmypNM0kqL6vWhDQVjOQ_10_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2964000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ"
      decimals="-3"
      id="Tc_Wk9sABFG7UqimZfn0cNgpw_11_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-3"
      id="Tc_R05cBJGHlkK8MHFDHzHeLQ_11_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_aUvrtTq4IUGr9oVl6j4mdQ"
      decimals="-3"
      id="Tc_sxlPKgJ-ykeTTCk2cYgMxQ_11_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_uAOvhcQDdkCNpxGLzezo_Q"
      decimals="-3"
      id="Tc_atL-5I-2D0C-UwfzaFHCHQ_11_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-26000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_3_31_2020_EIkdieY770uoUoVaV-rukQ"
      decimals="-3"
      id="Tc_n-_peT2iA0-_KGLOdwBV3Q_11_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-26000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ"
      decimals="INF"
      id="Tc_xM75bPqmQUSH0hhtwVB0Sg_13_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">17739475</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Tt74rK9ZQken53aggXrRcQ"
      decimals="-3"
      id="Tc_Rgm5BrfDLEqNDvcMhfpgbg_13_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ"
      decimals="INF"
      id="Tc_qqvQ6ejv-kWrR5bUe6fAmQ_13_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6565</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_I7cC9dxmjk2UwG9PeE6IbQ"
      decimals="-3"
      id="Tc_2VVJDRhsDEak59uQ-r1aKw_13_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">4092000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_LjtrdEDbDkeCwbuDZRK4Eg"
      decimals="-3"
      id="Tc_kl0B7hAjh0O7Kfk9qxqg9w_13_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">233735000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Fp5r6nH_SUy0VUUzbxxn2w"
      decimals="-3"
      id="Tc_4_i47LUC50C48ygMhz7GDg_13_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-238967000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_GRpJOcy1vUmpHvwH4bofIQ"
      decimals="-3"
      id="Tc_zWZ5d-tGf0KsO7WMDbFU2A_13_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_3_31_2020_P3gsqp5SGkCisHeuk5iOZg"
      decimals="-3"
      id="Tc_1E4zXz7160av7c2zYuvAtg_13_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_K2uLct-Mak6PkVBBiG5sQg_15_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_LIc6j7MgCUWFRM34Y0dWCQ_15_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_XRIBE_FXJU27XGeQrySs9Q_15_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">86000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_oNvnMSBYF0SsKziMopDJng_15_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">86000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__gb_XUJNFEe-pMBsJgUlhA"
      decimals="2"
      id="Narr_7EmsoQU-aU-38c6OqrkwXA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.01</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_AXci-R79YkaXFd3VVQtytA_16_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_WCnvwwvDzUi_KDVeIhxlJA_16_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_w9rb9zCzXEe7WRMI193kqw_16_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w"
      decimals="-3"
      id="Tc_fnmidggcyEehl_CGUm7pww_16_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">63000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_uz2yNSguyESyAt1WmVAd-g_16_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">63000</us-gaap:DividendsPreferredStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_tKarb0H_t0iweIIRBRTKsQ_17_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_zLAT5KC600W_kSPir_J0_A_17_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_cZPk_eORRkuTCHIGFd3WbA_17_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ"
      decimals="-3"
      id="Tc_DW_kaqLDQkSPfWgPozUuTQ_17_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">10000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_qYal5pQOi020JU1d0P4new_17_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">10000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA"
      decimals="2"
      id="Narr_Iy4wswLSmEaGUYEvwLtX7A"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.03</us-gaap:DividendsPayableAmountPerShare>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="INF"
      id="Tc_avwWQDRUtUuqgABRWeCX7Q_18_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">904349</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_RoYPslTWckSc95Y9QAwZOQ_18_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="INF"
      id="Tc_R7QHd47NF0CR0wy3JhjSQA_18_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">-1040</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_Uoj_T4IckkuEoOGmKOc-5Q_18_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-648000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_xFnM3nwDgUeoqwZgqoTuXA_18_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1039000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w"
      decimals="-3"
      id="Tc_fFhjbPyN2kGr2X7Zhq8DTQ_18_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-392000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_MZUV0fjAMEOW8cGBd6q6Aw_18_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_NtmSOe8zJ0COEDm5Hv5dow_19_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-3"
      id="Tc_VU1XkhBxyUqljDMfZIJ_Aw_19_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_maldTnm4tk--CvnA7vG2dQ_19_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5-DcSTUJP0CguQKi5VkT1w"
      decimals="-3"
      id="Tc_EqHx6nyDGUG-39U76RuQgw_19_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_ABzmhJZM_EmBj0efS6u71g_19_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2867000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_LSON59LC_0uxGyfoUAEFDw"
      decimals="-3"
      id="Tc_AsdajAxafEqbwjc0hbNT1g_20_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_GtdTgrU5B0qQDkM1rBXnGA"
      decimals="-3"
      id="Tc_k505g8z5rkmMzGhYOOhj-A_20_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_a7BhNFh4PU-oAOcjovkbeQ"
      decimals="-3"
      id="Tc_UqQzwMolAUW6rnBPewByvw_20_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-16000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="-3"
      id="Tc_RENMTXacM0iW-huSc-Gl6A_20_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-16000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A"
      decimals="0"
      id="Tc_N6jWB6WX8Ee2Wl5Ff-4mpw_22_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">18643824</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KCEGViZnJ0GS-MeP05H73A"
      decimals="-3"
      id="Tc_jweiNu2j2EGPK_Y6xL2Vgg_22_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">19000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA"
      decimals="0"
      id="Tc_fBTR99q6ykyVa58mbDeVGQ_22_7"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">5525</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_RS-jttD7rkGpX2dY0AXuBA"
      decimals="-3"
      id="Tc_CDiQkIMNM0O-WtTJAlAGGQ_22_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3444000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5tZWGDYmrUaKJjhAjOyXfg"
      decimals="-3"
      id="Tc_Ss8dv9X7yU211ISX5P88zQ_22_13"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">234860000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UrUccS3ylEaTH5G8z_ou6g"
      decimals="-3"
      id="Tc_RM48WvlrG0uhYZaggryw-g_22_16"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-242289000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_0Bxf9tnUNU2MTTKPvvGusg"
      decimals="-3"
      id="Tc_by0bI14YO0OKnaWNdlsl8g_22_19"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-2884000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA"
      decimals="-3"
      id="Tc_S85InnGkhEGUbHe6-TKNNg_22_22"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-6850000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_h-qTEbrWIU2_cg1AXXb7ug_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5732000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_ZlECbgFBvUufMYw-_-zuuw_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5873000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_-a245v6lHUyVAPx9arczKA_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">203000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_EJnTstUx8UaAPN5T0t12EA_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">169000</us-gaap:ShareBasedCompensation>
    <syn:SubsidiaryStockIssuesToVendor
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_kR6v9OzNIkWU73RxQsgRZQ_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:SubsidiaryStockIssuesToVendor>
    <syn:SubsidiaryStockIssuesToVendor
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_97aJJvIPt0qDICP4MysrAA_7_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">36000</syn:SubsidiaryStockIssuesToVendor>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_YcLNQTkXa0Obouzp7UMIRA_8_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">56000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_SO2juw5GEEG9FDUaRDTGVw_8_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">116000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_Un5Lu9yYaUOGGIjWjYMuhg_10_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-366000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_7Scjg1Md_UOBhK_-UToEgA_10_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-484000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <syn:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_bJTLvf-1P0KIaInemJY30Q_11_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">81000</syn:IncreaseDecreaseRightOfUseAssets>
    <syn:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_Y3hnoRrtZ0OUqZFLTp_enw_11_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">67000</syn:IncreaseDecreaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_MPNUjzO4aEuUhR-hfWnYAA_12_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-318000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_jp4GD_dC4UepjJI3dvi3Rw_12_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-1290000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_zbTUZNM-uEyjisck6GidvA_13_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-131000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_RgIANicgnECHn0AhYsqU9g_13_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-567000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_u2Cv-yHtWEGE8NDZeMNj8A_14_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-328000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_LLRz-PZNyEOHp04O2TB3Yw_14_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-8000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <syn:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_FNhNDxFOtEqywB_Sdv-KhQ_15_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-121000</syn:IncreaseDecreaseInOperatingLeaseLiability>
    <syn:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_9wAiqhMoU0ipMwhOj7AXcQ_15_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-120000</syn:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_n5qCFOqItUmDhHjzXIXzqw_16_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-5924000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_-5K7B6A8CUOBzQgyxgo_OQ_16_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-6986000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_p0fpbjzIDUSAJ6he7QuPEg_19_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_USa17cbuhkCA7GHkQ-caTQ_19_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_cqaNzULcFk2E2BNGS8aOGA_20_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_NLq0r2yEbkWgZw7li4KpZw_20_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_Sxw3zy6lUEyTMaY0gD23aA_23_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">65960000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_TX7zO15Wr0eN5FzOAYezrw_23_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_X4wO23A9R0WzhOXKbCA20g_24_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8042000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_gW0MB6fVoE-g0wV9A5rMcw_24_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_MiQV0b7lW0q9G3dqcwZnUw_25_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">74002000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_s2AISWt0VEqv0JodqKJ1BQ_25_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_lQy9SRgXhUG61GphtJaaig_27_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">68064000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_WRIdgm4C2UKa-jObVfuvqQ_27_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">-6986000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_cAjoDKOgY06g6ivK8P7Yfg_29_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA"
      decimals="-3"
      id="Tc_4f1h5RyEzkGK-_3OcjprBQ_29_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">15045000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_T6bxUea8806JKup1HXimfg_31_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">74291000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2020_hNq8ECoOGU-lDVqbNbDcwA"
      decimals="-3"
      id="Tc_Hgr-SXgtnEWFAIWtdPAEjg_31_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8059000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_K2_h2mx_tE6K6x4BdQ_GPA_34_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7402000</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_rip6yxPhpEK32apcLYd-Zg_34_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:PreferredStockPriceAdjustment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_bKPnXd9rz02nD4D9xMXvvQ_35_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1270000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_5uVmYkpawU67A7kfZ24N3Q_35_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_FWa4an93_0KMAxTpJgFUeQ_36_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2477000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_7W_XWjJwjkK_EgvJDfdRlQ_36_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1317000</us-gaap:ConversionOfStockAmountConverted1>
    <syn:DeemedDividendsWithBeneficialConversionFeature
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_Wd0c2icsBk2-GZ_59wRhKQ_37_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1497000</syn:DeemedDividendsWithBeneficialConversionFeature>
    <syn:DeemedDividendsWithBeneficialConversionFeature
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_8DP30rRsgUalyREIN6GjOg_37_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">796000</syn:DeemedDividendsWithBeneficialConversionFeature>
    <us-gaap:DividendsPreferredStockPaidinkind
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-3"
      id="Tc_RnSJgppipUaYy85uxCuYzA_38_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">23000</us-gaap:DividendsPreferredStockPaidinkind>
    <us-gaap:DividendsPreferredStockPaidinkind
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="-3"
      id="Tc_NOgdB06yx0eQeTp-4KJ_Ow_38_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">125000</us-gaap:DividendsPreferredStockPaidinkind>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_O5T9le_idEGw5nTPfcUV_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:2pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Organization, Nature of Operations and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Synthetic Biologics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Synthetic Biologics&#x201d;) is a diversified clinical-stage company developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#x2019;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) &lt;i style="font-style:italic;"&gt;Clostridioides difficile&lt;/i&gt; infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying condensed consolidated financial statements have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company&#x2019;s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full&#160;year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&#x2019;s 2020 Form&#160;10-K. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements and Developments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update &#160;(&#x201c;ASU&#x201d;)2020-06, &lt;i style="font-style:italic;"&gt;Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (subtopic 815-40)&lt;/i&gt;: &lt;i style="font-style:italic;"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Organization, Nature of Operations and Basis of Presentation&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Long-lived assets include property, equipment and right-of-use assets. In accordance with ASC 360, &lt;i style="font-style:italic;"&gt;Property, Plant and Equipment&lt;/i&gt; (&#x201c;ASC 360&#x201d;), management reviews the Company&#x2019;s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset&#x2019;s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. During the three months ended March&#160;31, 2020, the Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2021 and 2020.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="0"
      id="Narr_xCICwmPnfEy7yS7c-d2wXw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="0"
      id="Narr_Hw5E6X9ghU2l61_eoKfgbA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Narr_N6r5u8937U-QOX2khxsUBQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="0"
      id="Narr_9xitxy2sy02lqbxmK4JoRg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_UXiGgTrylUys1FCijJ53SQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;Level 1 inputs:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;Level 2 inputs:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;"&gt;Level 3 inputs:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt; Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The carrying amounts of the Company&#x2019;s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_r-DzZIj9Pkiz-7tadzuVhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Selected Balance Sheet Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Prepaid expenses and other current assets (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research organizations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 880&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid consulting, subscriptions and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock sales receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Prepaid clinical research organizations (CROs) expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Property and equipment, net (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (800)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,089)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"&gt;Accrued expenses (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical consulting services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vendor payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 794&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Accrued employee benefits (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued bonus expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_E4X17OGjwEK5q3EHRC4kwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Prepaid expenses and other current assets (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research organizations&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 880&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 280&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid consulting, subscriptions and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock sales receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,341&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <syn:PrepaidClinicalResearchOrganizationsExpenseCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_t9CUecMDXUi69qEBpguT7g_3_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">880000</syn:PrepaidClinicalResearchOrganizationsExpenseCurrent>
    <syn:PrepaidClinicalResearchOrganizationsExpenseCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_nuWp4yjwrUuQlwwJuXokiA_3_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">470000</syn:PrepaidClinicalResearchOrganizationsExpenseCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_THK7nCPL2EGMcnp48-oufw_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">280000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_ZS0AUKfrBUSXhKrhbUoXyg_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">639000</us-gaap:PrepaidInsurance>
    <syn:PrepaidConsultingSubscriptionsAndOtherExpenses
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_cJIawalzjEaSQeKSFApfYQ_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">181000</syn:PrepaidConsultingSubscriptionsAndOtherExpenses>
    <syn:PrepaidConsultingSubscriptionsAndOtherExpenses
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_VF66cUzSc0GxCtcSZCC-fQ_5_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">90000</syn:PrepaidConsultingSubscriptionsAndOtherExpenses>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_UcEX6sKKy0iNKlAExmkNDw_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_t_VLEE_kU0GHabwO3F8gEA_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">469000</us-gaap:OtherReceivablesNetCurrent>
    <syn:PrepaidManufacturingExpense
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_-E3UX4Yw40WSbO7B9fc0Xg_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:PrepaidManufacturingExpense>
    <syn:PrepaidManufacturingExpense
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_BNpCLNOWPkK_EOUGSSHZHQ_7_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">39000</syn:PrepaidManufacturingExpense>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_Ol5NU27tC0eDve2icl3J-g_9_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1341000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_NCXca-5Na0CnBIMoIuKxGw_9_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_Rul3vnK7dEmjjJgq83LjyQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Property and equipment, net (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (800)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,089)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_6GJQIqP4z0u-0VYhtn0pwA"
      decimals="-3"
      id="Tc_YuzGsLfOWkK83tAU1j4z-g_3_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_GfHbuB9ZRUGhg2eteRKuJQ"
      decimals="-3"
      id="Tc_87zdNBCSzUq9o_JNRVqvfQ_3_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_t4jWqATDt0GII2ExNce1_w"
      decimals="-3"
      id="Tc_cl499vMDFUCk-EqZWfaxlQ_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_w5NkU2_sOU2NkvPwvNTs-A"
      decimals="-3"
      id="Tc_sdOCeLWmdE2EvZOXXiVvfQ_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">439000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_qSjb2MQlSkOywB4mpExYgA"
      decimals="-3"
      id="Tc_EVAPWewJj0OfNThlWbiVRw_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">11000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_V3AVcyTze0yXKy6SgCQQOg"
      decimals="-3"
      id="Tc_jr5gF9F7n06_mm2Z2sRdJg_5_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">11000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_VZElBLZW40eY-GrpBqCHyA_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">932000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_QM7ys6SENUysRRLemIanCQ_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1263000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_-LDHi5WRqUGlSTa9LKlPQw_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_wjm5amvVvUOS2XYwJps0bA_7_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1089000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_vK0wdnMxbkOQH-XvmZD5-Q_9_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">132000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_X-siDkhnnkGU6j_w4BQgww_9_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">174000</us-gaap:PropertyPlantAndEquipmentNet>
    <syn:AccruedExpensesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_J3-gPAw5f0qZxZa8rWjQuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;"&gt;Accrued expenses (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical consulting services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vendor payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 794&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:AccruedExpensesTableTextBlock>
    <syn:AccruedClinicalConsultingServices
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_Ldqxl6AioEGqqGKXMI0pUQ_3_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">700000</syn:AccruedClinicalConsultingServices>
    <syn:AccruedClinicalConsultingServices
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_-a-x-d639EaimpacoMwldw_3_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">700000</syn:AccruedClinicalConsultingServices>
    <syn:AccruedVendorPayments
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_oAaS4sJY_0WSk5DmU21t9Q_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">92000</syn:AccruedVendorPayments>
    <syn:AccruedVendorPayments
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_jAEvbufOLU6ZrAi5CzicFQ_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">225000</syn:AccruedVendorPayments>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_shcIpdnkoEq-kn2rCz-S1w_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_8LDvsICCik2PL5sQ0Tx6_g_5_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_Xd4OYb5ioUqM4OQGSDJ-kQ_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">794000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_FWbYI9tbGUmuB5SIlNMlRg_7_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">925000</us-gaap:AccruedLiabilitiesCurrent>
    <syn:AccruedEmployeeBenefitsTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_OzvDxPdcoUCBQ-eBKxoKVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"&gt;Accrued employee benefits (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued bonus expense&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 361&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 540&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:AccruedEmployeeBenefitsTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_dVMmHg5ZJU-7ZNZHBM-8EQ_3_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">361000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_DwIYWw0O_0SPW4CBeWRBaQ_3_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">724000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_1Mrhjwr200-c0QN0ptva4Q_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">179000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_JAbIxaBp0Ei0yyDo94NAmQ_4_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">144000</us-gaap:AccruedVacationCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_NkZXIwgYCUG-IV3LjbiENA_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">540000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="-3"
      id="Tc_16BkV9Pk8EWbnEjl-g7FFA_6_6"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">868000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_aw-3DQByvE-0bM8TL3qtIg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Incentive Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 20, 2007, the Company&#x2019;s Board of Directors approved the 2007 Stock Incentive Plan (the &#x201c;2007 Stock Plan&#x201d;) for the issuance of up to 71,429 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and could be equal to or greater than the fair market value of the Company&#x2019;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 stock plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant and generally expire ten years after the grant date. As of June 30, 2021, there were 5,145 options issued and outstanding under the 2007 Stock Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#x201c;2010 Stock Plan&#x201d;) for the issuance of up to 85,714 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#x2019;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten years after the grant date. As of June 30, 2021, there were 2,452,273 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan (&#x201c;2020 Stock Plan&#x201d;) for the issuance of up to 4,000,000 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of June 30, 2021, there were 1,540,000 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event of an employee&#x2019;s termination, the Company will cease to recognize compensation expense for that employee&#x2019;s options. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has applied fair value accounting for all stock-based payment awards at grant date. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three and six months ended June 30, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected dividends&lt;/i&gt; &lt;i style="font-style:italic;"&gt;&#x2014;&lt;/i&gt;The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected volatility&lt;/i&gt;&#x2014;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#x2019;s common stock over a period approximately equal to the expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-free interest rate&lt;/i&gt;&#x2014;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected life of the option&lt;/i&gt;&#x2014;The period of time that the options granted are expected to remain unexercised. Options granted during the year have a maximum term of seven years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;immediate vesting,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;in full on the one-year anniversary date of the grant date,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;half vesting immediately and the remaining over three years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;quarterly over three years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;annually over three years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one-third immediate vesting and the remaining annually over two years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one-half immediate vesting and the remaining over nine months,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one-quarter immediate vesting and the remaining over three years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;one-quarter immediate vesting and the remaining over 33 months,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;monthly over one year, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;monthly over three years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of stock option activity for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,502,012&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.62&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.51 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,540,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.57&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.09 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - June 30, 2021 - outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.28 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 598,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - June 30, 2021 - exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,970,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.55 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 239,357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value of options granted &#x2013; three months ended June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value &#x2013; three months ended June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value of options granted &#x2013; year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value &#x2013; year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $34,000 and $67,000, respectively, and $40,000 and $79,000 for the three and six months ended June 30, 2020, respectively. Stock-based compensation expense included in research and &#160;development expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $16,000 and $31,000,respectively, and $15,000 and $31,000 for the three and six months ended June 30, 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $49,000 and $98,000, respectively, and $27,000 and $53,000 for the three and six months ended June 30, 2020, respectively.&#160;Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $3,000 and $7,000, respectively, and $4,000 and $6,000 for the three and six months ended June 30, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June&#160;30, 2021, total unrecognized stock-based compensation expense related to stock options was $483,000, which is expected to be expensed through April 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The FASB&#x2019;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June&#160;30, 2021 and 2020.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_9p8BUi9xpESM0XFssipxEA"
      decimals="INF"
      id="Narr_x-gcC2BYIki8KsrBHHK5IQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">71429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_20_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_wLkfa3YyAUWs_EVe-EPt2w"
      decimals="INF"
      id="Narr_BBAPhcnqAUCb_5fvb6vKzQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">7143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_81VpuqIrTUGMs7nm1_pSJQ"
      decimals="INF"
      id="Narr_SJaXoTtJmkqVjbvUycnuEw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">5145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_aNYaq92HaUaThT1YEHFknQ"
      decimals="INF"
      id="Narr_CVWx6bf2aUq4Q8eJmO1cMQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">85714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_LcbLiBbyFECO_hZVyJHpuQ"
      decimals="INF"
      id="Narr_7OS_1xIBnUGbGurKERS85w"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2452273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_mDQnCUaukkitwCFkDu49Aw"
      decimals="INF"
      id="Narr_L5Vw_XTg2UqPYQTjuDYkPg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_RJbNJpRBXUSt0ueloEGWTw"
      decimals="INF"
      id="Narr_0BNKk8PR3Ey_aJdkOKswiQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zJO5Vy7y90-lmBQP2GMq9w"
      decimals="0"
      id="Narr_WddvdXnK-UWSho3H3qTAeQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_VBR-eClC6UGC07S2WEllbg"
      decimals="0"
      id="Narr_ohl7IJM3a0aPvx6V_ZTGiQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="0"
      id="Narr_nxcbCHk90UKWsKac8p3Wzw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg"
      decimals="0"
      id="Narr_u9ws48CLOUekneGx1DkoNA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_obukUe9YmEK0F_7Jx1coHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of stock option activity for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,502,012&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.62&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.51 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 153,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,540,000&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (14,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17.57&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (29,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.09 years&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - June 30, 2021 - outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.28 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 598,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance - June 30, 2021 - exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,970,911&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.55 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 239,357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value of options granted &#x2013; three months ended June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value &#x2013; three months ended June 30, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant date fair value of options granted &#x2013; year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average grant date fair value &#x2013; year ended December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A"
      decimals="0"
      id="Tc_hktsnjR0zEee6qPkTT9Pgw_5_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2502012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A"
      decimals="2"
      id="Tc_DDdguYKFu06THcUIsNwhVw_5_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zlQvdoOjn0eIo5zMpiXNXQ"
      id="Narr_8A48e067bU--kl7n5A4HbQ">P6Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_kT4ScA47VECxw1EwCH5R-A"
      decimals="0"
      id="Tc_QCLZkHG0UECDBkKe-P8UMw_5_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">153353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="0"
      id="Tc_uxJxJrb4F0uSm1wAIXVatg_7_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="2"
      id="Tc_8lBnUtuX-UyJM9Q10tzlgg_7_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="0"
      id="Tc_Ng7eOXaQp0awKhFl67-jrA_8_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="2"
      id="Tc_1ubrPifx3kSOB-scO77WBQ_8_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="0"
      id="Tc_QiCT_1D620qLHR0Icdhflw_9_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">14944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="2"
      id="Tc__-FHhrLSKUe-llXgqWfL5g_9_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">17.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="0"
      id="Tc_3l-HPB_lTEu-_hH1iTD58g_10_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">29650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="2"
      id="Tc__OeTUY1l4068P4gLoVhhwg_10_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA"
      decimals="0"
      id="Tc_72-7nQf0_kWoX9Qf5e3ifA_11_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3997418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA"
      decimals="2"
      id="Tc_wBXsh1cObk6bX9NKNlSdaw_11_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      id="Narr_gpcMJIYARUKMSCM_bLoj3w">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_wl5WhKy53EiaPUbTL5pdPA"
      decimals="0"
      id="Tc_1EJieLkoZ0uYoBsyPQo4aw_11_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="0"
      id="Tc_RDk768TZP06SZEISL59p_g_13_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="2"
      id="Tc_A3TvGRpdLEWSKgNmXUqbcg_13_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="0"
      id="Tc__UcOrnI4k0iZlVHozMeDoQ_14_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="2"
      id="Tc_uixQ3Tz5Yk-NT_UDHaKWPg_14_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="0"
      id="Tc_m4JaG4J1xECEoRV6bcr1QQ_15_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="2"
      id="Tc_k3AgJ4KHQUSGTlja4VI_mQ_15_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="0"
      id="Tc_nfa95Q9_U0mtQBu6sHv92w_16_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      decimals="2"
      id="Tc_E8zjIv36u0-k-YzcfY1pxQ_16_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="0"
      id="Tc_mn9qEc6j8E6b7vKz-d5e-Q_18_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3997418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="2"
      id="Tc_o8CK-kp3LU2p3DXntutmMg_18_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      id="Narr_LwL3i2PAxEO55ba4MVABmQ">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="0"
      id="Tc_30ActVx93kmNwXMdPuunhg_18_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">598074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="0"
      id="Tc_0-glJ3ytmUiwIcU7kRkblg_20_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1970911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="2"
      id="Tc_L6AbNyctdUS6cUjc1Prrsg_20_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_GYr6JkRY1kaKm14zfGz_Sg"
      id="Narr_2k7TzQbfSUSBv-uIE4Et7Q">P4Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_u3kyYd4840W5U4bmi8tOVg"
      decimals="0"
      id="Tc_6BtdOt17i0u0b-YL-vQpYA_20_10"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">239357</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg"
      decimals="0"
      id="Tc_QhW1NEYCAUmu1TR8Z4UllQ_22_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg"
      decimals="2"
      id="Tc_G3qSFmjtw02bra2VwyZjTg_24_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="0"
      id="Tc_jPUzqvCZB0SKIMobb3sw7g_26_5"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">412000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ucIyMZaDQE-vZRccVFg14w"
      decimals="2"
      id="Tc_yDQDvp6AZECDAwR-iuq9LA_28_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg"
      decimals="-3"
      id="Narr_D5zQtc11wUOnLMnkObcf0g"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">34000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg"
      decimals="-3"
      id="Narr_5PGqrqKAJ0eLs7JEJ6V0Eg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">34000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_eIcfeMgtzUC9ndcccKwg3g"
      decimals="-3"
      id="Narr_UHU3qMiROky60n9GwFOgAg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">67000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_a9LDsj3uzkuOTiqR1RdjjQ"
      decimals="-3"
      id="Narr_9qBpmumvl0GUmKHkqPSIXQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">40000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_YSUSLqISakeFFs0u8z32iQ"
      decimals="-3"
      id="Narr_8oUEIyhPLUK3vnCcFU3kGg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">79000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_8Voeje09P0KdHrvytlGF5w"
      decimals="-3"
      id="Narr_nXKjAbVsskmAoi_xahqJmw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">16000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_GjoOepJsFkG33JO-DraytA"
      decimals="-3"
      id="Narr_HYmTeNkFYESHRj_6Wp-aMA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_7LiVHRy2BUaPnoZoXiYlag"
      decimals="-3"
      id="Narr_ie_UsdBf8EeV9szGRHx4eA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">15000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_5AoLC7KQ1Uawve2qPbgbzg"
      decimals="-3"
      id="Narr_5UwktT8g40-hJoiHzIROLQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">31000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_PFI4t1qvYUeUPVPhulwM0Q"
      decimals="-3"
      id="Narr_snqbLlz6v0KuhXKbKgyBaA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">49000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_f5pVsHeOF0esc-wKzvKXnA"
      decimals="-3"
      id="Narr_V67RxBah8U-HzOsTupFWaA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">98000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aqlwFNKohE-KfzX_Eclrdg"
      decimals="-3"
      id="Narr_bS4H2OCH-kWl3Rqz7mJzRw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">27000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_dAV91tPf8kmgXysC3CKWIg"
      decimals="-3"
      id="Narr_a2cQDhxOjUqtyP344o2Umw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_Zk4qTUzc2EeG7AwMKOnF_g"
      decimals="-3"
      id="Narr_rC8AwrKYeEu4fVhL0vJ_bg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_IC8EXhUAzkGZ5rMnpHL2gg"
      decimals="-3"
      id="Narr_qmd-EU04bkewu-tJ-eMLCA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_gAS70YQ3kEWbAigVthvfbQ"
      decimals="-3"
      id="Narr_5FssuGRVzEuEyq7IB54Erw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">4000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_aPnGd6B3pESapmPXpuMoYQ"
      decimals="-3"
      id="Narr_1oy7YQc-50u0_E7xJGQ8PA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Narr_ti5CO7cffUqO135yayXcxg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">483000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <syn:StockPurchaseWarrantsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_apvHBk6fukydPDZ0DSqjqQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the &#x201c;Class A Units&#x201d;), with each Class A Unit consisting of one share of the Common Stock, and one five-year warrant to purchase one share of Common Stock at an initial exercise price of $1.38 per share, which subsequently was reduced to $0.69 per share (each a &#x201c;Warrant&#x201d; and collectively, the &#x201c;Warrants&#x201d;), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the &#x201c;Class B Units&#x201d;, and together with the Class A Units, the &#x201c;Units&#x201d;), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company&#x2019;s Series B Convertible Preferred Stock (the &#x201c;Series B Preferred Stock&#x201d;), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants. On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of the Company&#x2019;s common stock, $0.001 par value per share (the &#x201c;Common Stock&#x201d;), to $0.69 per Warrant per full share of Common Stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#x201c;at the market offering&#x201d; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $880,000 during the year ended December&#160;31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#x201c;Underwriters&#x201d;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#x201c;Over-allotment Option&#x201d;) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the six months ended June 30, 2021, 11,655,747 warrants were exercised for cash proceeds of $8.0 million. There were no warrants exercised during the 3 months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Stock Warrants&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 18, 2016, the Company completed a public offering of 714,286 shares of common stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock. The stock and warrants were sold in combination, with two warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of common stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants was $50.05 and the per share exercise price of the Series B warrants was $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The Series A warrants expired November 18, 2020 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value will be recorded as non-cash income or expense in the Company&#x2019;s Statement of Operations at each subsequent period. At November 18, 2020, the fair value of the warrant liability was $100. The warrants were valued on the date of grant and on each remeasurement period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all warrant activity for the Company for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,714,999&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (714,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000,713&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,655,747&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all outstanding and exercisable common stock warrants as of June&#160;30, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.28 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.49 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.28 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</syn:StockPurchaseWarrantsTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg"
      decimals="-5"
      id="Narr_WAOIaebx8E24nOYIBnwUSA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">18600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_bdhxK7hqDECM_T4Lq_vhjQ"
      decimals="0"
      id="Narr_oKjxhP9tEk6CZKsml01qJw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2520000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syn:WarrantTerm
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_JR9Vjj4m3kihR7DJRSC05w"
      id="Narr_HWetZYs3rEGCNpL0p1O1LQ">P5Y</syn:WarrantTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w"
      decimals="2"
      id="Narr_kLYbSCxQNU-mZmUxNjtqEw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw"
      decimals="2"
      id="Narr_J_3IY1NzsUSQCK8IVUzs-w"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w"
      decimals="2"
      id="Narr_3gTs8oyOF0aB6OtGcYRXyA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_dvzYRfZpzUCe7pw2pnnTzA"
      decimals="INF"
      id="Narr_s7-vEgSdmk2Y0HrHaCkGAA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">15723</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg"
      decimals="0"
      id="Narr_9Rurn2JU6kCY8TJx-JJxBQ"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw"
      decimals="0"
      id="Narr_Ai2407qLBUWEFBaut32TWg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ"
      decimals="2"
      id="Narr_bVT6B8UxQ0GBuF7OioYUCQ"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.15</syn:PreferredStockConversionPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CaSV6ee9y0qvS0pZ4IUDdw"
      decimals="INF"
      id="Narr_dvdguscxeU-VR3CHbkrGTA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_u4kbim5KiEyW-zB1-W8-HQ"
      decimals="INF"
      id="Narr_FUHx6ihDpUO1Eay2kk10EQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_15_2020_FnMilutR6Uaa49a8AX4Ozg"
      decimals="2"
      id="Narr_vh71-6RqTECrQfQg6NwS6w"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw"
      decimals="4"
      id="Narr_thl0hRrJMU20WWIJ_jpHTA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw"
      decimals="2"
      id="Narr_1ZW4AgestUid_aQT2R1b2g"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg"
      decimals="0"
      id="Narr_RqQnKbsYDEm7WCPycmVHUQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">880000</syn:WarrantExercisePriceAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_slSCc3YOzk2ByscUunSdgw"
      decimals="INF"
      id="Narr_Jsujyl53g0KdtsmKJ5gLpA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2428825</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_njvvYCOrE0G7--zGCHARcQ"
      decimals="INF"
      id="Narr_kxvHf2qj1kO9TkyKNpVL1g"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2428825</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:IssueOfWarrantsToPurchaseCommonStock
      contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg"
      decimals="0"
      id="Narr_zRjDkVdPeEi-TpF_cZcfwg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1807826</syn:IssueOfWarrantsToPurchaseCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_11_16_2020_To_11_16_2020_Q4U6TfXbjUGV399zEsrnGQ"
      decimals="INF"
      id="Narr_QuhFm4VPEUOnYuAK0sAciA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_WSxxQJt6wkSqtxqIte9ptg"
      decimals="INF"
      id="Narr_4vFbrYWC50qUemIKfEILKw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">11655747</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-5"
      id="Narr_eLHHnAPaY0ijrW_gAodjMA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">8000000.0</us-gaap:ProceedsFromWarrantExercises>
    <syn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="0"
      id="Narr_CIrp6LehQkG1JrXbEsHgyg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</syn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_p9VkK2Ce20-b03B7rUyXiA"
      decimals="INF"
      id="Narr_vsf615aV9kqDqS3VPf1BEw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">714286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow"
      decimals="INF"
      id="Narr_HpVqWybDaUGuM797NB-s8Q"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1428571</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:NumberOfShareSold
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_CDRBLE4qQkaDOCYG-eI5Zg"
      decimals="INF"
      id="Narr_2pzui7iKL0W00URp2ueuOw"
      unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA">2</syn:NumberOfShareSold>
    <syn:NumberOfSharesPurchase
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_onT3wd_AR0CjAZdM083VMg"
      decimals="INF"
      id="Narr_nEmsDRdvBEmQ62C9pb3Xsg"
      unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA">1</syn:NumberOfSharesPurchase>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow"
      decimals="2"
      id="Narr_GY0ranx6xEycwGoED8rfWA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">35.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_93GgZzd5OUWNIi3WddVejA"
      decimals="2"
      id="Narr_sK7-JcHFck2cYj-gf9r32w"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">50.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_mdSu6IH6FkWLzuUBCfIegQ"
      decimals="2"
      id="Narr_uBV9pfmB7E2DYZ3zGDHfHw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">60.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_0Kk_l-dBqU2ZFX-IKrApow"
      decimals="-5"
      id="Narr_P0C1FZF1VUenjOMOZHMVbw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">15700000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember__J-NQrr_RUyU2Fj9hkVnmA"
      decimals="-6"
      id="Narr_0xv_1--mfEqIaJoHSLA-uA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <syn:ScheduleOfWarrantActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_eqmfrA9HKECAha9UBmg5rQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all warrant activity for the Company for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,714,999&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (714,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000,713&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,655,747&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at June&#160;30,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA"
      decimals="0"
      id="Tc_HQvjTFQDrkyxS8mrFWQpvw_4_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">18714999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA"
      decimals="2"
      id="Tc_llD__M-BAEmmOjpA3bE6JQ_4_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg"
      decimals="0"
      id="Tc_iKRj-U9zmUWO56HdcWBaeQ_7_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">714286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg"
      decimals="2"
      id="Tc_32E9SiwkVUCs5A1mOoRq0Q_7_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">50.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="0"
      id="Tc_9W7AwPjr-kiSMQBs2aC5Jw_8_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">18000713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg"
      decimals="2"
      id="Tc_7__S-bHTQkW9InGcuyIGIA_8_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_wuKsYiKmXkW_6SsAi0IgEw_9_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_gfrIpoNCLkSdYyxiGkKEfQ_9_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_6gbGgBaYZUS7DXFN4oxxgA_10_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">-11655747</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="2"
      id="Tc_xo59arK9R0CAlCPaNucINQ_10_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_OCnty1KrdkuL94fXGUtDRw_11_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Tc_Lo0KNTevREy1OmUVnWhYig_11_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="0"
      id="Tc_MyIWbFztv0OWbgBiFyo-rQ_12_2"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="2"
      id="Tc_7LViJ6VxY0GfvCUyo0TLsQ_12_5"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_jUYiVHDVNEOzKQFgDAazMw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all outstanding and exercisable common stock warrants as of June&#160;30, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.28 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.49 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2.28 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg"
      decimals="2"
      id="Tc_7KfqlU57IkicVgVMVfCeWw_4_1"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA"
      decimals="0"
      id="Tc_bHLXoKqswEu7EW5wfu64Eg_4_3"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_I7zdeh8-iUynOxbTlqe2UA"
      decimals="0"
      id="Tc_KyoADx6oBE2UVe8LhoeyHg_4_5"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344252</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg"
      id="Narr_BFoeVzlEtkKU7bl58_NOFQ">P2Y3M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ"
      decimals="2"
      id="Tc_Hs9mZtaM-ESCzIv6nt_RCw_5_1"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">18.20</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA"
      decimals="0"
      id="Tc_oaIKGhvhe0W7jj9YfuiX3g_5_3"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_Lb8SR4YjUES_Q6Fd7jRkqA"
      decimals="0"
      id="Tc_4Tu_GX-8VEq9gUqdvN5I6g_5_5"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">714</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_iZ8Dd1U5ZE2PV2ARkWwqTQ"
      id="Narr_wJWPaNjQX0OyqM6yj4Ptjw">P1Y5M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg"
      decimals="2"
      id="Tc_gERrM0yTVEicCbMhEDSmbg_6_1"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw"
      decimals="0"
      id="Tc_vS2ymYJKl0qHXhRWoVoxxQ_6_3"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_0YcUVrgNTkqKjd7bAljhdw"
      decimals="0"
      id="Tc_6boirPqCAkKV4iVETrsKeg_6_5"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344966</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice5248Member_X5-vz8USg0Cgh6PU22oNfg"
      id="Narr_rh-PyW7gN0ayESa5hVl1vw">P2Y3M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_PP4JjW9p9EeK0A1ZkRGXwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;stockholders for the six months ended June 30, 2021 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of the Series B preferred discount of $1.5 million as a result of converted shares and Series A preferred stock accrued dividends of $0.1 million and the deemed dividend of $7.4 million resulting from the effect of the Series A preferred stock price adjustment during the first quarter of 2021. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. There were no shares of common stock underlying Series B preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2021 since all remaining Series B preferred stock were converted to common stock. A total of 4,804,348 shares of common stock underlying Series B preferred shares convertible to common stock were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020. The number of options and warrants for the purchase of common stock were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2021 were 3,997,418 and 6,344,966, respectively, and for the six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively, because their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="-5"
      id="Narr_TqSvM-jVEECZeJl_oqra2Q"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="-5"
      id="Narr_gVmPKuKEWkmn_e48-X5WoA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1500000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-5"
      id="Narr_0lnDzSCzGE2X0drZJ3VCaw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-5"
      id="Narr_FzOmmrAISk--HCrc2-jq2g"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7400000</syn:AccretionOfPreferredStockDeemedDividend>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"
      decimals="-5"
      id="Narr_fScPcCssHkSS3zCzWQj3aQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="-5"
      id="Narr_dBqgHYEsFEG-PEqSFiRoDw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="2"
      id="Narr_5tDurpZKKkiQV63n5OeK4g"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">400000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="-5"
      id="Narr_6nzIFjKcRUmDNJC6gjzEag"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">400000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockAccretionOfRedemptionDiscount
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"
      decimals="-5"
      id="Narr_mSuomuwpxUWFoO1VztZgBQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">800000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw"
      decimals="-5"
      id="Narr_iXpC6E1nS0ulWfkc7PFrJg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw"
      decimals="-5"
      id="Narr_usqNJwxkgkm3iCmeFM01AQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="0"
      id="Narr_F2OqQCyeGE-vda9Kx3iHXA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares>
    <syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"
      decimals="0"
      id="Narr_sOB4BfGUEUi0mBvKcuKkVQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares>
    <syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"
      decimals="0"
      id="Narr_huc9lGrkck6GCflQbmBlcQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">4804348</syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares>
    <syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="0"
      id="Narr_jrtQv_EOKkqs7JbI5ihyAw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">4804348</syn:PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_FyVHAd_teEGuTL1oBAt_OQ"
      decimals="INF"
      id="Narr_1-LX3MOOok6T7A2hSyYWzQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3997418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_RVKQ0qDznE-qz2ggQLkq-w"
      decimals="INF"
      id="Narr_gNKLmJsGx02QZ5Pe0BEPyg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3997418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_5hLd6ZKkzkCO5-jO7JCpEg"
      decimals="INF"
      id="Narr_AotgLGDvtUmKabeU9lSqDw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">6344966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_OwL8Ke43jku7YbqZh3ch4w"
      decimals="INF"
      id="Narr__pXAjX74j0umK-X_tHL_oQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2472362</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember_CseERA5zh0ynTz1Zu6va3Q"
      decimals="INF"
      id="Narr_A9L4UEkCZE-zfm18N1cxzQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2472362</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_RVsezu3jr0CBpCVpvdx8lg"
      decimals="INF"
      id="Narr_tF9jxh3-AEmrLrIHLgccYQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">18714999</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_EjPck93_MU2iUDRtO_ph2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Non-controlling Interest&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s non-controlling interest is accounted for under ASC 810, &lt;i style="font-style:italic;"&gt;Consolidation&lt;/i&gt; (&#x201c;ASC 810&#x201d;), and represents the minority shareholder&#x2019;s ownership interest related to the Company&#x2019;s subsidiary, Synthetic Biomics, Inc. (&#x201c;SYN Biomics&#x201d;). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#x2019;s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#x201c;Study&#x201d;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#x2019;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (&lt;i style="font-style:italic;"&gt;M. smithii&lt;/i&gt;) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company&#x2019;s equity interest in SYN Biomics is 83% and the non-controlling stockholder&#x2019;s interest is 17%. As of June 30, 2021 and 2020, the accumulated net loss attributable to the non-controlling interest is $2.8 million and $2.9 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In consideration of the support provided by CSMC for the Study, the Company paid $328,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (&#x201c;Synbiomics&#x201d;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics&#x2019; common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. There was no expense recorded related to this transaction during the three and six months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. Non-controlling Interest &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#x2019;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#x2019;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients.&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ"
      decimals="INF"
      id="Narr_oDzf2-zkl0-8UnFBVXq7NQ"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.83</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ"
      decimals="INF"
      id="Narr_5w-HRzOROUyk_ATlgriJ7A"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.17</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_Aa0Ahmh6yUu3GyGF9CWNVQ"
      decimals="-5"
      id="Narr_Y4vL_9je3kGDFunxH__x5w"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2800000</syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest>
    <syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_7Uo71EUX6UCZ6ImKlbActA"
      decimals="-5"
      id="Narr_QSNuSt_PGUOzY8sX3GG9Ng"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2900000</syn:AccumulatedNetGainLossAttributableToNoncontrollingInterest>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg"
      decimals="0"
      id="Narr_Y-87kg_AbEC4UNo2GvJVuQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">328000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <syn:NumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA"
      decimals="0"
      id="Narr_zvcWC-6MzECBi7oLyNlsdQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">50000</syn:NumberOfCommonStockToBeIssued>
    <syn:AdditionalNumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ"
      decimals="INF"
      id="Narr_lFL27LSJK0icDFUEDea9UQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2420000</syn:AdditionalNumberOfCommonStockToBeIssued>
    <syn:NumberOfCommonStockToBeHeldByRelatedParty
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ"
      decimals="INF"
      id="Narr_CqYGwRYF5UOtkJ2u_1sf_A"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">7480000</syn:NumberOfCommonStockToBeHeldByRelatedParty>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_P0MDcj5P-kSb-MJWZ4YNQQ"
      decimals="2"
      id="Narr_4l1pA3laJU6FCSzmQBG6UQ"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.17</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syn:FairValueOfSharesIssued
      contextRef="Duration_9_5_2018_To_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_DphhO0tkBE28K8KwCLVQRA"
      decimals="0"
      id="Narr_MmzEFMz3xkms4luGHGyyIw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">285000</syn:FairValueOfSharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_QlvAWBKoYkCi7DFbZ1TTXw"
      decimals="0"
      id="Narr_zlYBCRmYhECwV4CgZgNv8w"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_81t85iLAZkue0k_haly1qg"
      decimals="0"
      id="Narr_3cWXoxTMPUiI0ZHDNjIlrA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">92000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_VjVpgqccckeC1Ovt7HdvKw"
      decimals="0"
      id="Narr_1tnCEKBD0ESF_MuljxRtnw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">0</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_LTQD6t4xS02GzuCQLOCyDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Common and Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;B Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units , with each Class&#160;A Unit offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#x2019;s Series&#160;B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#x201c;Over-allotment Option&#x201d;) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Units were offered by the Company pursuant to a registration statement on Form&#160;S-1 (File No.&#160;333-227400), as amended, filed with the SEC, which was declared effective by the SEC on October&#160;10, 2018.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Common and Preferred Stock &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of common stock to $0.69 per Warrant per full share of common stock. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#x201c;at the market offering&#x201d; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $880,000, which reduces the income available to common stockholders for the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The October&#160;2018 Warrants are immediately exercisable at a price of $1.38 ($0.69 effective November 16, 2020) per share of common stock (which was 120% of the public offering price of the Class&#160;A Units) and will expire on October&#160;15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#x201c;BCF&#x201d;) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#x201c;deemed dividend&#x201d; and impacts earnings per share. During the six months ended June 30, 2021 and 2020, 3,973 and 2,113 shares, respectively, were converted resulting in the recognition of a deemed dividends of $1.5 million and $795,000, respectively, for the amortization of the Series B Preferred Stock discount upon conversion. There we no shares converted during the three months ended June 30, 2021. During the three months ended June 30, 2020, 1,040 shares were converted resulting in the recognition of a deemed dividends of $392,000 for the amortization of the Series B Preferred Stock discount upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;A Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an investor (the &#x201c;Investor&#x201d;), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;A Preferred Stock&#x201d;) for an aggregate purchase price of $12 million, or $100 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Series&#160;A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights to the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $0.54 per share which was increased to $18.90 after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $1.50 on January 27, 2021, see below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The holder&#x2019;s ability to convert the Series A Preferred Stock into common stock was subject to (i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that would prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#x2019;s common stock or voting power at any time, and (iii) applicable regulatory restrictions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Common and Preferred Stock &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series A Preferred Stock were entitled to a preference on liquidation equal to the greater of (i) an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series A Preferred Stock (the &#x201c;Accreted Value&#x201d;), and (ii) the amount such holders would have received in such liquidation if they converted their shares of Series A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i) and (ii), is referred to as the &#x201c;Liquidation Value&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Except as otherwise required by law, the holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of &lt;i style="font-style:italic;"&gt;pari passu&lt;/i&gt; or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of (i) the Accreted Value and (ii) the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock were converted into common stock immediately prior to the change of control.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On or at any time after&#160;(i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Series A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#x2019;s control. Since the effective conversion price of the Series A Preferred Stock was less than the fair value of the underlying common stock at the date of issuance, there was a beneficial conversion feature (&#x201c;BCF&#x201d;) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#x201c;deemed dividend&#x201d; and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three months ended June 30, 2021, the Company did not record any Series A Preferred Stock dividends since all shares were converted to shares of common stock during the three months ended March 31, 2021. During the six months ended June 30, 2021, the Company accrued dividends of $24,000. During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. Common and Preferred Stock &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put, as an inducement for the holder to fully convert its Series A Preferred Stock. The Amendment to the Certificate of Designation for its Series A Convertible Preferred Stock (the &#x201c;Certificate of Amendment&#x201d;) with the Secretary of State of the State of Nevada adjusted the conversion price from $18.90 per share to $1.50 per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#x201c;Certificate of Designation&#x201d; from 4.99% to 9.99%, such increase to be effective 61 days from the date hereof. During the three months ended March 31, 2021, all outstanding shares of Series A Convertible Preferred Stock were converted to approximately 9.0 million shares of the Company&#x2019;s common stock. There are no remaining shares of the Series A Convertible Preferred stock outstanding after these conversions. During January and February 2021, the Company issued 8,996,768 shares of its common stock upon the conversion effected on such date by the holder of 120,000 shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion is accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated fair value of the inducement consideration of $7.4 million and as a result has recorded a corresponding deemed dividend of $7.4 million during the six months ended June 30, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;B. Riley Securities Sales Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp;amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of common stock from time to time through B. Riley Securities, Inc. as the Company&#x2019;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#x201c;at-the-market&#x201d; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Common Stock sold on the Company&#x2019;s behalf. The Company did not sell any shares of common stock during the three and six months ended June 30, 2020 through the Riley Securities Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;) and A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;) in order to include AGP as an additional sales agent for the Company&#x2019;s &#x201c;at the market offering&#x201d; program (the &#x201c;Amended and Restated Sales Agreement&#x201d;). The Sales Agreement amended and restated the At Market Issuance Sales Agreement, dated August 5, 2016, with B. Riley Securities, Inc. (formerly known as B. Riley FBR, Inc.), as amended by amendment no. 1, dated May 7, 2018, to the At Market Issuance Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the six months ended June 30, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 78.7 million shares of the Company&#x2019;s common stock and received net proceeds of approximately $66.0 million. The Company did not sell any shares of common stock during the three months ended June 30, 2021 through the Riley Securities Sales Agreement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_10_11_2018_To_10_15_2018_9YpmMUjlgU6Rx_oNzkSWFQ"
      decimals="-5"
      id="Narr_iroMYSWJYUSRTQzTARdOwA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">18600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_CuZd8Dnu20mqdbWiRYxlvw"
      decimals="0"
      id="Narr_aZp6_fszH06nq8QCOdkrtg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2520000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_hOCyTi32fkCaYMT9lgvS8w"
      decimals="2"
      id="Narr_qqY6Tz--Xk2pwmZ0FVvMqQ"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_ML7WRtDK4EuEsagAjFhinw"
      decimals="0"
      id="Narr_Adde7K9B0UyIO2toeeQqiw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">15723</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA"
      decimals="0"
      id="Narr_4Mi9-3vKwUWxQyGCMjBZsQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ"
      decimals="0"
      id="Narr_odmDaA-9mUGKXUT_jU6jzg"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_czXr4LZ-Y0aavsFga3_ebg"
      decimals="2"
      id="Narr_zb6kHYb640GtXxDx-aLG_g"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.15</syn:PreferredStockConversionPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_bGYoUZgXkEyszVpg6d8cTQ"
      decimals="0"
      id="Narr_7i_tydJERk2EP1uh6EHKyg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">13672173</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_11_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B_jowlFVeUC2FYrWZkSElA"
      decimals="0"
      id="Narr_2EeKPmaG5k2pyph-kPcKPg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_10_2018_To_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_7OFHeCdRt0-vhR2n4qUlMg"
      decimals="0"
      id="Narr_SeycJOQmXUmnodjzq71KKg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2428825</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg"
      decimals="0"
      id="Narr_JVfFKzSUd02N29gfjg3Ykg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2428825</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:IssueOfWarrantsToPurchaseCommonStock
      contextRef="As_Of_10_10_2018_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_SvJEcZwUDkyvjMnCb4_oZg"
      decimals="0"
      id="Narr_XXqWlvViEEOvN_3y18tAQQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1807826</syn:IssueOfWarrantsToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_5_2020_iKgSvuSwK0Katgd-IjQ9Wg"
      decimals="2"
      id="Narr_2cifPy8a9EWE-0QNR-mqng"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_6_2020_3pJ_Ridqok6114OiGur1oQ"
      decimals="2"
      id="Narr_8IKGy_-J60OVB2ov4Iwl9A"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_XUVT3c-AeES2iopS5w93Xg"
      decimals="0"
      id="Narr_dIDIZ68bZ0mvDxwzpCguiA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">880000</syn:WarrantExercisePriceAdjustment>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_15_2018_cKJV1gyygk-EpbEXDFtKXQ"
      decimals="2"
      id="Narr_yXp2ctAbM0-taAzRecIrdw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2018_V2vD4wi4-UCmh8saJ-KESA"
      decimals="2"
      id="Narr_xYUZ5q-MHk-AUazxPfASxQ"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_16_2020_XtY932a5wEK6kstCPp0ATw"
      decimals="2"
      id="Narr_23G3GcW3IkSSWMFE16Xmpw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syn:PercentageOfIssueOfThePublicOffering
      contextRef="Duration_10_1_2018_To_10_31_2018_zr1590HAfU6H-r0oJu1zEw"
      decimals="2"
      id="Narr_jnLmxB23uU6BQ-6bZaqpOg"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">1.20</syn:PercentageOfIssueOfThePublicOffering>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="0"
      id="Narr_W5yi2FFMZkmRNRwahjLVQg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">3973</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_92rU2snWtUaTjZlOEzbIkw"
      decimals="0"
      id="Narr_n9rfjJj0mESL-Iu40IjEcg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2113</us-gaap:ConversionOfStockSharesConverted1>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_jW-gat_95kSaf2CR9oynvw"
      decimals="-5"
      id="Narr_J-1co-0VfE2pNIcLQfqXMA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1500000</syn:AccretionOfPreferredStockDeemedDividend>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_1_1_2020_To_3_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_YMHw978dW0OYJpKaeA7DHw"
      decimals="0"
      id="Narr_VF0qd1kBK0ulyV9m4TWP5w"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">795000</syn:AccretionOfPreferredStockDeemedDividend>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_rXcxDIgMCk-YFDN7F_tb8A"
      decimals="INF"
      id="Narr_zqbZwaYPLECdFz-jA03Uug"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">0</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="0"
      id="Narr_aZ9ttxGpHUGJPkZkqO71fw"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">1040</us-gaap:ConversionOfStockSharesConverted1>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_7wA7G6wmDkSkU_Sq7bqIoQ"
      decimals="0"
      id="Narr_YkTvtY9kT0GONtlsu63BZg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">392000</syn:AccretionOfPreferredStockDeemedDividend>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg"
      decimals="0"
      id="Narr_aTw5WWrc0ECZygCFzI6_gg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_HJ0Vognp00iLodsId7AO5Q"
      decimals="3"
      id="Narr_PQNkTxFf8kOZTrF7ZXmlQA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg"
      decimals="-6"
      id="Narr_hrKt5-IpwUKyuVdqdTYwwA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">12000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_E8CqYTVzjkyHQskjf42tRg"
      decimals="0"
      id="Narr_Tmg1yLpvBUKOVEhUutUkbg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">100</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"
      decimals="3"
      id="Narr_SPtkVVy7-EKLoEacDxeDuQ"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.020</us-gaap:PreferredStockDividendRatePercentage>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ"
      decimals="2"
      id="Narr_T8LyOaatL0ijdSra_QsWLw"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">0.54</syn:PreferredStockConversionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPriceIncrease
      contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw"
      decimals="2"
      id="Narr_c6xPyggBeUmDKtrW5egRgg"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">18.90</us-gaap:PreferredStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw"
      decimals="2"
      id="Narr_b-1OYgwqskW_20WVEF5F2w"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.50</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"
      id="Narr_UkEy70eBkEmZ5DX0jTm65Q">(i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that would prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#x2019;s common stock or voting power at any time, and (iii) applicable regulatory restrictions.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"
      decimals="0"
      id="Narr_aow35V-mKUSrJ4CHA-0RPw"
      unitRef="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"
      decimals="0"
      id="Narr_z3FGOfC5Mkmur6aU5-L42g"
      unitRef="Unit_Standard_D_TIfDtM-CIk2DnxF_6cx0jg">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_K5yboAY4Ok68aBzOOqBQTQ"
      decimals="2"
      id="Narr_a-V7hvuAaku_JKjnadc0fg"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">70.00</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Grtesm3UAEu8EX3fNBzzGw"
      decimals="2"
      id="Narr_D3PTngFEBUOYB7Ox5yq8Cw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7875.00</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockSplit>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_SQNPifEGMk-kiOEU3qgr6w"
      decimals="-5"
      id="Narr_GJXHaU9vZEyOYHCFCecS3Q"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">6900000</us-gaap:PreferredStockDiscountOnShares>
    <syn:PercentageOfStatedDividendRate
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="2"
      id="Narr_OGG5DlecwkKrLQjRLCAxtA"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.02</syn:PercentageOfStatedDividendRate>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="0"
      id="Narr_fudsOdB0eUyPDICGCfQtHQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_I4IvUkS_wkSpcqWjIimSOw"
      decimals="0"
      id="Narr_VGf8NOFWjEamI40hl8zIyw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">63000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_mzvCU9gdB0OUfTRfX3jGYw"
      decimals="0"
      id="Narr_3XiAmaWnpkSFLARCVZKpLg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">125000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg"
      decimals="2"
      id="Narr_1uZwVK7Xb0OWhu98AgvN5Q"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">18.90</syn:PreferredStockConversionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_b9_U8lHrtkObWIJxOGY8tw"
      decimals="2"
      id="Narr_gE6GUiLHI02DDtyw9v1PeA"
      unitRef="Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ">1.50</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <syn:BeneficialOwnershipPercentage
      contextRef="As_Of_1_26_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Xxe3gAXhZU-l1BDNtcdQBw"
      decimals="4"
      id="Narr_A_4Csr5ovkaQAkX0B1DoAg"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.0499</syn:BeneficialOwnershipPercentage>
    <syn:BeneficialOwnershipPercentage
      contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_wlCjnjsUdUGCGgBm_Y2tSg"
      decimals="4"
      id="Narr_hdFdZgvb70OuYHylrn6L5A"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.0999</syn:BeneficialOwnershipPercentage>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_adtzoVUoL0KulWbPEZXKug"
      decimals="-5"
      id="Narr_wJopobILoUavmpzc5ock7w"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">9000000.0</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_1_31_2021_D6zkksit4UCwIionHXMP8A"
      decimals="0"
      id="Narr_PA_b28PL20yuyJeexFAjOQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">8996768</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_2_28_2021_83AqlMwHVEuP9zHFSSM5Bw"
      decimals="0"
      id="Narr_L84020NmgEmaV-E7kJjQiA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">8996768</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_1_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_yr0zg1OZHUiIwiJG12_IyA"
      decimals="0"
      id="Narr_AQ4w3qfpLkeBGhzPy0UvOA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">120000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HMJmPJ9JF06CqnhSeF83-w"
      decimals="0"
      id="Narr_kgkCicx460ue18Pp5b5AbA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">120000</us-gaap:PreferredStockSharesOutstanding>
    <syn:EstimatedFairValueOfInducementConsideration
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-5"
      id="Narr_dlcBttopP0aOhI3N43bgvg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7400000</syn:EstimatedFairValueOfInducementConsideration>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw"
      decimals="-5"
      id="Narr_VaUJ5ib2FUiy2_0fTPku0A"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">7400000</syn:AccretionOfPreferredStockDeemedDividend>
    <syn:BrokerageCommissionPercentage
      contextRef="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_S0B-4Run_kKbm47QoMWZuw"
      decimals="3"
      id="Narr_uFaI-wb86UuNP9erpoRWCg"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.030</syn:BrokerageCommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-5"
      id="Narr_-RHgwdA7SU6bLWAbPCiXVA"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">78700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-5"
      id="Narr_vU3EUgVuwki7LR-tMehVHQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">66000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_sADAAKvGPE-qlNmB0NSA1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Related Party Transactions&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#x201c;Study&#x201d;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#x2019;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (&lt;i style="font-style:italic;"&gt;M. smithii&lt;/i&gt;) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company: (i)&#160;issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional &lt;span style="-sec-ix-hidden:Hidden_LwEQCHh2xU-yhl4vl9nF_A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;two million four hundred twenty thousand&lt;/span&gt;&lt;/span&gt; (2,420,000) shares of common stock of its subsidiary Synthetic Biomics,&#160;Inc. (&#x201c;SYN Biomics&#x201d;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing &lt;span style="-sec-ix-hidden:Hidden_uVawnFnrhUC47_sVB7xw5A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"&gt;seventeen&#160;percent&lt;/span&gt;&lt;/span&gt; (17%) of the issued and outstanding shares of SYN Biomics&#x2019; common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#x2019;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment was completed. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In December 2013, through SYN Biomics, the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2021 and 2020, the Company did not owe and did not pay CSMC for milestone payments related to this license agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <syn:NumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA"
      decimals="0"
      id="Narr_k2gnfDEIikmcWyF3RWuk7w"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">50000</syn:NumberOfCommonStockToBeIssued>
    <syn:AdditionalNumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_BusinessAcquisitionAxis_syn_CedarssinaiMedicalCenterMember_z73xOnQ6cEihGg2og9Jxtw"
      decimals="0"
      id="Narr_bDYNAppCb0WwjT8guTKThQ"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">2420000</syn:AdditionalNumberOfCommonStockToBeIssued>
    <syn:NumberOfCommonStockToBeHeldByRelatedParty
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g"
      decimals="0"
      id="Narr_hkOWBmi4okCsCcBekfn7Pg"
      unitRef="Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w">7480000</syn:NumberOfCommonStockToBeHeldByRelatedParty>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g"
      decimals="2"
      id="Narr_BPOS5r2GkkmEzYnjZj3xSw"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">0.17</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_O0vkba6bL0mmsR4_-5p5KQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All of the Company&#x2019;s existing leases as of June 30, 2021 are classified as operating leases. As of June 30, 2021, the Company has one operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for 63 months beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a 3 month rent abatement. &#160;The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. &#160;The Second Amendment also gives the Company the Right to Expand their space by giving notice to the landlord before December 31, 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an 8.5% interest rate, which is the discount rate used in this modification analysis. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the three and six months ended June 30, 2021 approximated $68,000 and $118,000, respectively and for the three and six months ended June 30, 2020 approximated $50,000 and $101,000, respectively. For the three and six months ended June 30, 2021, operating cash flows used for operating leases approximated $80,000 and $160,000, respectively, and for three and six months ended June 30, 2020 approximated $77,000 and $154,000, respectively, and right of use assets exchanged for operating lease obligations was $1.3 million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A maturity analysis of our operating leases as of June 30, 2021 is as follows &lt;i style="font-style:italic;"&gt;(amounts in thousands of dollars)&lt;/i&gt;:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future undiscounted cash flow for the years ending June 30:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,146&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount factor&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability &#x2013; current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (196)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability &#x2013; long term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;"&gt;&lt;b style="font-style:normal;font-weight:bold;"&gt;10. Commitments and Contingencies &#x2013; (continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;"&gt;Risks and Uncertainties &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#x201c;COVID-19&#x201d; outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including halting the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#x2019;s suppliers and other commercial partners, the Company&#x2019;s corporate development objectives and the value of and market for the Company&#x2019;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <syn:NumberOfOperatingLeaseForFacilities
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="INF"
      id="Narr_5te6rDFM1UuDZYP6wjtXMw"
      unitRef="Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA">1</syn:NumberOfOperatingLeaseForFacilities>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      id="Narr_wZ4gsqgzXEC8jlWVWB1-QA">P63M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <syn:LeaseRentAbatementPeriod1
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      id="Narr_PTOxFFWtmEOdj7qnmAHI3g">P3M</syn:LeaseRentAbatementPeriod1>
    <syn:PercentageOfFundsToBeBorrowedByCompany
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="1"
      id="Narr_ZdkEDGiQOkWIDBKpLwBXgg"
      unitRef="Unit_Standard_pure_RIqJxEX8_0uNjsRY-aT0iQ">8.5</syn:PercentageOfFundsToBeBorrowedByCompany>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="0"
      id="Narr_7spLu6nDlEeC466hPQdGog"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">68000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Narr_9tZuYKGvSU6qNydZWmWS_w"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">118000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="0"
      id="Narr_LdeJ-bru1EqmFml8xjc8FQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">50000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="0"
      id="Narr_en5CqSYL9EONld9Hx_zncg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">101000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw"
      decimals="0"
      id="Narr_HP8fWfxtYkiPBbPnBCjEBg"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">80000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="0"
      id="Narr_E7qRmD5gaUevDH-nht8dPA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">160000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_4_1_2020_To_6_30_2020_UijfaenxIEumDuQDhoVIuQ"
      decimals="0"
      id="Narr_ugHo29gjKUqGivkxA2KR-g"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">77000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_6_30_2020_zlhfXqMHsUybIjrV2-cUug"
      decimals="0"
      id="Narr_ekpA8pgtTECiY9YuAoZpVQ"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">154000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      decimals="-5"
      id="Narr_6u-XznWmFE6B7mth-D8tzw"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1300000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2019_To_1_1_2019_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_MlNR2bKVWUa5Wq8G6pRRRw"
      decimals="0"
      id="Narr_FgCQKgYCe0SCRUJ_dZwmnA"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">538000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw"
      id="Tb_xpCFUDCTWEed2aDqBUBTGA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future undiscounted cash flow for the years ending June 30:&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,146&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount factor&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (524)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,622&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability &#x2013; current&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (196)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability &#x2013; long term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_8mkRMXZ3yEGh-PxVRcmdAg_2_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">163000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_BfVGt-tQs0-gIJmAtwY3Rw_3_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_8t6QpiNdzUmB6tY8HCYPDw_4_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_-KbzJw9kjU-CXL9D12RQHA_5_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">337000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_MjIy0cb3c0WJZx8jU4KDMg_6_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">347000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_RlRSLWOCOESBjhIipllH2w_7_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <syn:LesseeOperatingLeaseLiabilityToBePaidYearSix
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_D4-sLlW4pEuyJ3ulw_fhOQ_8_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">368000</syn:LesseeOperatingLeaseLiabilityToBePaidYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_QfrKbtS6mEiVwR4_LYAQIw_9_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">2146000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_BX2ADRhuXUqsV6LE_JvnKQ_11_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">524000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_Req-EpZ7aU2TXtp1EEhHhg_12_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1622000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_49ftlJ8WYUGKVcPuCz-Qcw_13_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">196000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw"
      decimals="-3"
      id="Tc_uHi6TAAeGkqFgqgcF52GHw_14_3"
      unitRef="Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg">1426000</us-gaap:OperatingLeaseLiabilityNoncurrent>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507961272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Synthetic Biologics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive, Suite 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,042,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507958488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 74,291<span></span>
</td>
<td class="nump">$ 6,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,341<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">75,632<span></span>
</td>
<td class="nump">7,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">1,468<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">77,255<span></span>
</td>
<td class="nump">8,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">568<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">794<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at June 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">339,121<span></span>
</td>
<td class="nump">240,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(262,748)<span></span>
</td>
<td class="num">(248,094)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</a></td>
<td class="nump">76,505<span></span>
</td>
<td class="num">(4,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(2,774)<span></span>
</td>
<td class="num">(2,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="nump">73,731<span></span>
</td>
<td class="num">(7,540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity (Deficit)</a></td>
<td class="nump">$ 77,255<span></span>
</td>
<td class="nump">$ 8,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845510299368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Equity, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Shares Authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Shares Issued</a></td>
<td class="nump">132,044,866<span></span>
</td>
<td class="nump">29,252,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Shares Outstanding</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="nump">29,249,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509420136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,265,000<span></span>
</td>
<td class="nump">$ 1,286,000<span></span>
</td>
<td class="nump">$ 2,685,000<span></span>
</td>
<td class="nump">$ 2,679,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,932,000<span></span>
</td>
<td class="nump">1,603,000<span></span>
</td>
<td class="nump">3,049,000<span></span>
</td>
<td class="nump">3,238,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
<td class="nump">3,197,000<span></span>
</td>
<td class="nump">2,889,000<span></span>
</td>
<td class="nump">5,734,000<span></span>
</td>
<td class="nump">5,917,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(3,197,000)<span></span>
</td>
<td class="num">(2,889,000)<span></span>
</td>
<td class="num">(5,734,000)<span></span>
</td>
<td class="num">(5,917,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">(3,195,000)<span></span>
</td>
<td class="num">(2,883,000)<span></span>
</td>
<td class="num">(5,732,000)<span></span>
</td>
<td class="num">(5,873,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(42,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</a></td>
<td class="num">(3,195,000)<span></span>
</td>
<td class="num">(2,867,000)<span></span>
</td>
<td class="num">(5,731,000)<span></span>
</td>
<td class="num">(5,831,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Effect of Series A Preferred Stock Price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,402,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss Attributable to Common Stockholders</a></td>
<td class="nump">$ 3,195,000<span></span>
</td>
<td class="nump">$ 3,322,000<span></span>
</td>
<td class="nump">$ 14,654,000<span></span>
</td>
<td class="nump">$ 6,752,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net Loss Per Share - Basic and Dilutive</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of shares outstanding during the period - Basic and Dilutive</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="nump">18,405,884<span></span>
</td>
<td class="nump">111,539,024<span></span>
</td>
<td class="nump">17,748,688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred Stock Dividends, Income Statement Impact</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (63,000)<span></span>
</td>
<td class="num">$ (24,000)<span></span>
</td>
<td class="num">$ (125,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Effect of Series A Preferred Stock Price adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,402,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred Stock Dividends, Income Statement Impact</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (392,000)<span></span>
</td>
<td class="num">$ (1,497,000)<span></span>
</td>
<td class="num">$ (796,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of preferred stock price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845586125768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Series B Preferred Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 232,580,000<span></span>
</td>
<td class="num">$ (235,537,000)<span></span>
</td>
<td class="num">$ (2,878,000)<span></span>
</td>
<td class="nump">$ 4,761,000<span></span>
</td>
<td class="num">$ (1,057,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">16,806,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A Preferred Stock Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(62,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueOfSynBiomicsStock', window );">Issuance of SYN Biomics Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B Preferred Stock to Common (in shares)</a></td>
<td class="nump">933,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,073)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B Preferred Stock to Common</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,072,000<span></span>
</td>
<td class="num">(404,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (669,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,964,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,964,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(26,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">233,735,000<span></span>
</td>
<td class="num">(238,967,000)<span></span>
</td>
<td class="num">(2,878,000)<span></span>
</td>
<td class="nump">$ 4,092,000<span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">17,739,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">232,580,000<span></span>
</td>
<td class="num">(235,537,000)<span></span>
</td>
<td class="num">(2,878,000)<span></span>
</td>
<td class="nump">$ 4,761,000<span></span>
</td>
<td class="num">(1,057,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">16,806,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,831,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(42,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">234,860,000<span></span>
</td>
<td class="num">(242,289,000)<span></span>
</td>
<td class="num">(2,884,000)<span></span>
</td>
<td class="nump">$ 3,444,000<span></span>
</td>
<td class="num">(6,850,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">18,643,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="nump">233,735,000<span></span>
</td>
<td class="num">(238,967,000)<span></span>
</td>
<td class="num">(2,878,000)<span></span>
</td>
<td class="nump">$ 4,092,000<span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">17,739,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A Preferred Stock Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(63,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueOfSynBiomicsStock', window );">Issuance of SYN Biomics Stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B Preferred Stock to Common (in shares)</a></td>
<td class="nump">904,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B Preferred Stock to Common</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">1,039,000<span></span>
</td>
<td class="num">(392,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (648,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,867,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,867,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="nump">234,860,000<span></span>
</td>
<td class="num">(242,289,000)<span></span>
</td>
<td class="num">(2,884,000)<span></span>
</td>
<td class="nump">$ 3,444,000<span></span>
</td>
<td class="num">(6,850,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">18,643,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">240,821,000<span></span>
</td>
<td class="num">(248,094,000)<span></span>
</td>
<td class="num">(2,773,000)<span></span>
</td>
<td class="nump">$ 2,477,000<span></span>
</td>
<td class="num">(7,540,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">29,249,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingValue', window );">Stock issued under "at-the-market" offering</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">65,881,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingShare', window );">Stock issued under "at-the-market" offering (in shares)</a></td>
<td class="nump">78,685,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants Exercised</a></td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">8,030,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants Exercised (In shares)</a></td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A Preferred Stock Dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdjustmentsToEffectOfPreferredStockPrice', window );">Effect of Series A Preferred Stock price adjustment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,402,000<span></span>
</td>
<td class="num">(7,402,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B Preferred Stock to Common (in shares)</a></td>
<td class="nump">3,454,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B Preferred Stock to Common</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">3,971,000<span></span>
</td>
<td class="num">(1,497,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (2,477,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_Conversionofseriesbpreferredstocktocommonstock', window );">Conversion of Series A Preferred Stock to Common</a></td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">12,813,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,822,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_Conversionofseriesapreferredstocktocommonstockshares', window );">Conversion of Series A Preferred Stock to Common (in shares)</a></td>
<td class="nump">8,996,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,536,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,536,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">339,019,000<span></span>
</td>
<td class="num">(259,553,000)<span></span>
</td>
<td class="num">(2,774,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,824,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="nump">240,821,000<span></span>
</td>
<td class="num">(248,094,000)<span></span>
</td>
<td class="num">(2,773,000)<span></span>
</td>
<td class="nump">$ 2,477,000<span></span>
</td>
<td class="num">(7,540,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">29,249,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,731,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">339,121,000<span></span>
</td>
<td class="num">(262,748,000)<span></span>
</td>
<td class="num">(2,774,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,731,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">339,019,000<span></span>
</td>
<td class="num">(259,553,000)<span></span>
</td>
<td class="num">(2,774,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,824,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">102,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 102,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants Exercised (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,195,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (3,195,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="nump">$ 339,121,000<span></span>
</td>
<td class="num">$ (262,748,000)<span></span>
</td>
<td class="num">$ (2,774,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 73,731,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdjustmentsToEffectOfPreferredStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustment to effect of preferred stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdjustmentsToEffectOfPreferredStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConversionOfSeriesBPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of preferred stock to common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ConversionOfSeriesBPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of conversion of series B preferred stock to common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ConversionOfSeriesBPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_Conversionofseriesapreferredstocktocommonstockshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred shares to common</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_Conversionofseriesapreferredstocktocommonstockshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_Conversionofseriesbpreferredstocktocommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Series B Preferred Stock To Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_Conversionofseriesbpreferredstocktocommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodAtMarketOfferingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodAtMarketOfferingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodAtMarketOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodAtMarketOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueOfSynBiomicsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of new stock of syn biomics stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodValueOfSynBiomicsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507226856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 11, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividend payable per preferred stock</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividend payable per preferred stock</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507423672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,732)<span></span>
</td>
<td class="num">$ (5,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">203<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SubsidiaryStockIssuesToVendor', window );">Subsidiary stock issuances to vendor</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">366<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseRightOfUseAssets', window );">Right of use asset</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(318)<span></span>
</td>
<td class="num">(1,290)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefits</a></td>
<td class="num">(328)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating Lease liability</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(5,924)<span></span>
</td>
<td class="num">(6,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from "at the market" stock issuance</a></td>
<td class="nump">65,960<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
<td class="nump">8,042<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">74,002<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">68,064<span></span>
</td>
<td class="num">(6,986)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the beginning of this period</a></td>
<td class="nump">6,227<span></span>
</td>
<td class="nump">15,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at the end of this period</a></td>
<td class="nump">74,291<span></span>
</td>
<td class="nump">8,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Effect of Series A Preferred Stock price adjustment</a></td>
<td class="nump">7,402<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use asset from operating lease</a></td>
<td class="nump">1,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Series B Preferred Stock</a></td>
<td class="nump">2,477<span></span>
</td>
<td class="nump">1,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividends for accretion of Series B Preferred Stock discount</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockPaidinkind', window );">In-kind dividends paid in preferred stock</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Deemed Dividends With Beneficial Conversion Feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An amount of increase decrease in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IncreaseDecreaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of preferred stock price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SubsidiaryStockIssuesToVendor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_SubsidiaryStockIssuesToVendor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845504971560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization, Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a diversified clinical-stage company developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#8217;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying condensed consolidated financial statements have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by Accounting Principles Generally Accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for complete financial statements. The accompanying condensed consolidated financial statements include all adjustments, comprised of normal recurring adjustments, considered necessary by management to fairly state the Company&#8217;s results of operations, financial position and cash flows. The operating results for the interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full&#160;year. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company&#8217;s 2020 Form&#160;10-K. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements are prepared in conformity with U.S. GAAP, which requires the use of estimates, judgments and assumptions that affect the amounts of assets and liabilities at the reporting date and the amounts of revenue and expenses in the periods presented. The Company believes that the accounting estimates employed are appropriate and the resulting balances are reasonable; however, due to the inherent uncertainties in making estimates, actual results may differ from the original estimates, requiring adjustments to these balances in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Recent Accounting Pronouncements and Developments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update &#160;(&#8220;ASU&#8221;)2020-06, <i style="font-style:italic;">Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (subtopic 815-40)</i>: <i style="font-style:italic;">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization, Nature of Operations and Basis of Presentation</b><b style="font-weight:bold;">&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Long-lived assets include property, equipment and right-of-use assets. In accordance with ASC 360, <i style="font-style:italic;">Property, Plant and Equipment</i> (&#8220;ASC 360&#8221;), management reviews the Company&#8217;s long-lived assets for impairment annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. The Company determines the extent to which an asset may be impaired based upon its expectation of the asset&#8217;s future usability as well as whether there is reasonable assurance that the future cash flows associated with the asset will be in excess of its carrying amount. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and the carrying value of the asset. During the three months ended March&#160;31, 2020, the Company identified COVID-19 as a triggering event and performed a qualitative assessment of the fair value of its long-lived assets. The results from this analysis determined that it is still more likely than not that the fair value of its long-lived assets remain higher than the carrying value of these assets. As a result, no impairment charges were recorded during the three and six months ended June 30, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506452440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 1 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 2 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Inputs, other than quoted prices, included in Level 1 that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Level 3 inputs:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;"> Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, other current assets, accounts payable and accrued liabilities approximate fair value due to the relatively short period to maturity for these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845505118760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected Balance Sheet Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Selected Balance Sheet Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Prepaid expenses and other current assets (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 880</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 469</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,707</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Prepaid clinical research organizations (CROs) expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Property and equipment, net (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 827</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,263</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (800)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,089)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;">Accrued expenses (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 794</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Accrued employee benefits (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506452440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Incentive Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 71,429 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November 2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and could be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 stock plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant and generally expire ten years after the grant date. As of June 30, 2021, there were 5,145 options issued and outstanding under the 2007 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 85,714 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten years after the grant date. As of June 30, 2021, there were 2,452,273 options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan (&#8220;2020 Stock Plan&#8221;) for the issuance of up to 4,000,000 shares of Common Stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of June 30, 2021, there were 1,540,000 options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee&#8217;s options. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has applied fair value accounting for all stock-based payment awards at grant date. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. There were no options granted during the three and six months ended June 30, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividends</i> <i style="font-style:italic;">&#8212;</i>The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#8212;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#8217;s common stock over a period approximately equal to the expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#8212;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected life of the option</i>&#8212;The period of time that the options granted are expected to remain unexercised. Options granted during the year have a maximum term of seven years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">immediate vesting,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">in full on the one-year anniversary date of the grant date,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">half vesting immediately and the remaining over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">quarterly over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">annually over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-third immediate vesting and the remaining annually over two years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-half immediate vesting and the remaining over nine months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-quarter immediate vesting and the remaining over three years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">one-quarter immediate vesting and the remaining over 33 months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">monthly over one year, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">monthly over three years.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,502,012</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.51 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,353</p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,540,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,944)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.57</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,418</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.09 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.28 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 598,074</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,970,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.55 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239,357</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense included in general and administrative expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $34,000 and $67,000, respectively, and $40,000 and $79,000 for the three and six months ended June 30, 2020, respectively. Stock-based compensation expense included in research and &#160;development expenses relating to stock options issued to employees for the three and six months ended June 30, 2021 was $16,000 and $31,000,respectively, and $15,000 and $31,000 for the three and six months ended June 30, 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Stock-based compensation expense included in general and administrative expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $49,000 and $98,000, respectively, and $27,000 and $53,000 for the three and six months ended June 30, 2020, respectively.&#160;Stock-based compensation expense included in research and development expenses relating to stock options issued to consultants for the three and six months ended June 30, 2021 was $3,000 and $7,000, respectively, and $4,000 and $6,000 for the three and six months ended June 30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June&#160;30, 2021, total unrecognized stock-based compensation expense related to stock options was $483,000, which is expected to be expensed through April 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The FASB&#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits during the three and six months ended June&#160;30, 2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845504785560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockWarrantsAbstract', window );"><strong>Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockPurchaseWarrantsTextBlock', window );">Stock Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i) 2,520,000 Class A Units (the &#8220;Class A Units&#8221;), with each Class A Unit consisting of one share of the Common Stock, and one five-year warrant to purchase one share of Common Stock at an initial exercise price of $1.38 per share, which subsequently was reduced to $0.69 per share (each a &#8220;Warrant&#8221; and collectively, the &#8220;Warrants&#8221;), with each Class A Unit to be offered to the public at a public offering price of $1.15, and (ii) 15,723 Class B Units (the &#8220;Class B Units&#8221;, and together with the Class A Units, the &#8220;Units&#8221;), with each Class B Unit offered to the public at a public offering price of $1,000 per Class B Unit and consisting of one share of the Company&#8217;s Series B Convertible Preferred Stock (the &#8220;Series B Preferred Stock&#8221;), with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 Warrants. On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of the Company&#8217;s common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), to $0.69 per Warrant per full share of Common Stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $880,000 during the year ended December&#160;31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#8220;Underwriters&#8221;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional Warrants to purchase an additional 2,428,825 shares of Common Stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of Common Stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of Common Stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the six months ended June 30, 2021, 11,655,747 warrants were exercised for cash proceeds of $8.0 million. There were no warrants exercised during the 3 months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">5. Stock Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 18, 2016, the Company completed a public offering of 714,286 shares of common stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock. The stock and warrants were sold in combination, with two warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of common stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants was $50.05 and the per share exercise price of the Series B warrants was $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The Series A warrants expired November 18, 2020 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value will be recorded as non-cash income or expense in the Company&#8217;s Statement of Operations at each subsequent period. At November 18, 2020, the fair value of the warrant liability was $100. The warrants were valued on the date of grant and on each remeasurement period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,714,999</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.24</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (714,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.05</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000,713</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,655,747</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all outstanding and exercisable common stock warrants as of June&#160;30, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.28 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.49 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.28 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockPurchaseWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to Stock Purchase Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockPurchaseWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506475144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">stockholders for the six months ended June 30, 2021 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of the Series B preferred discount of $1.5 million as a result of converted shares and Series A preferred stock accrued dividends of $0.1 million and the deemed dividend of $7.4 million resulting from the effect of the Series A preferred stock price adjustment during the first quarter of 2021. Net loss attributable to common stockholders for the three and six months ended June 30, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $0.4 million and $0.8 million, respectively, on converted shares and Series A preferred stock accrued dividends of $0.1 million. There were no shares of common stock underlying Series B preferred shares convertible to common stock that were excluded from the computations of net loss per common share for the three and six months ended June 30, 2021 since all remaining Series B preferred stock were converted to common stock. A total of 4,804,348 shares of common stock underlying Series B preferred shares convertible to common stock were excluded from the computations of net loss per common share for the three and six months ended June 30, 2020. The number of options and warrants for the purchase of common stock were excluded from the computations of net loss per common share and for the three and six months ended June 30, 2021 were 3,997,418 and 6,344,966, respectively, and for the six months ended June 30, 2020 were 2,472,362 and 18,714,999, respectively, because their effect is anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845504847640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interest</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest is accounted for under ASC 810, <i style="font-style:italic;">Consolidation</i> (&#8220;ASC 810&#8221;), and represents the minority shareholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, Synthetic Biomics, Inc. (&#8220;SYN Biomics&#8221;). In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders on the face of the Consolidated Statements of Operations. On September 5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). After the 2018 transaction with CSMC, the Company&#8217;s equity interest in SYN Biomics is 83% and the non-controlling stockholder&#8217;s interest is 17%. As of June 30, 2021 and 2020, the accumulated net loss attributable to the non-controlling interest is $2.8 million and $2.9 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In consideration of the support provided by CSMC for the Study, the Company paid $328,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (IRB) : (i) issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii) transferred to CSMC an additional two million four hundred twenty thousand (2,420,000) shares of common stock of its subsidiary SYN Biomics, Inc. (&#8220;Synbiomics&#8221;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing seventeen percent (17%) of the issued and outstanding shares of SYN Biomics&#8217; common stock. The services rendered are recorded to research and development expense in proportion with the progress of the study and based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the three and six months ended June 30, 2020, research and development expense recorded related to this transaction approximated $25,000 and $92,000, respectively. There was no expense recorded related to this transaction during the three and six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. Non-controlling Interest &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#8217;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845504890472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common and Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common and Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Common and Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Series&#160;B Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units , with each Class&#160;A Unit offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Preferred Stock, with a stated value of $1,000 and convertible into shares of Common Stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of Common Stock, and issued with an aggregate of 13,672,173 October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional 2,428,825 shares of Common Stock and/or additional warrants to purchase an additional 2,428,825 shares of Common Stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Units were offered by the Company pursuant to a registration statement on Form&#160;S-1 (File No.&#160;333-227400), as amended, filed with the SEC, which was declared effective by the SEC on October&#160;10, 2018.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Common Stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of common stock to $0.69 per Warrant per full share of common stock. The reduction was the result of the issuance of shares of Common Stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $880,000, which reduces the income available to common stockholders for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The October&#160;2018 Warrants are immediately exercisable at a price of $1.38 ($0.69 effective November 16, 2020) per share of common stock (which was 120% of the public offering price of the Class&#160;A Units) and will expire on October&#160;15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the six months ended June 30, 2021 and 2020, 3,973 and 2,113 shares, respectively, were converted resulting in the recognition of a deemed dividends of $1.5 million and $795,000, respectively, for the amortization of the Series B Preferred Stock discount upon conversion. There we no shares converted during the three months ended June 30, 2021. During the three months ended June 30, 2020, 1,040 shares were converted resulting in the recognition of a deemed dividends of $392,000 for the amortization of the Series B Preferred Stock discount upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Series&#160;A Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;Investor&#8221;), pursuant to which the Company offered and sold in a private placement 120,000 shares of its Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;A Preferred Stock&#8221;) for an aggregate purchase price of $12 million, or $100 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock ranks senior to the shares of the Company's common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights to the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series A Preferred Stock. The Series A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $0.54 per share which was increased to $18.90 after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $1.50 on January 27, 2021, see below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any conversion of Series A Preferred Stock may be settled by the Company in shares of common stock only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holder&#8217;s ability to convert the Series A Preferred Stock into common stock was subject to (i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that would prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii) applicable regulatory restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series A Preferred Stock were entitled to a preference on liquidation equal to the greater of (i) an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series A Preferred Stock (the &#8220;Accreted Value&#8221;), and (ii) the amount such holders would have received in such liquidation if they converted their shares of Series A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i) and (ii), is referred to as the &#8220;Liquidation Value&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by law, the holders of Series A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of <i style="font-style:italic;">pari passu</i> or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series A Preferred Stock at a redemption price equal to the greater of (i) the Accreted Value and (ii) the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series A Preferred Stock if all outstanding shares of Series A Preferred Stock were converted into common stock immediately prior to the change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or at any time after&#160;(i) the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#8217;s control. Since the effective conversion price of the Series A Preferred Stock was less than the fair value of the underlying common stock at the date of issuance, there was a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the year ended December 31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the three months ended June 30, 2021, the Company did not record any Series A Preferred Stock dividends since all shares were converted to shares of common stock during the three months ended March 31, 2021. During the six months ended June 30, 2021, the Company accrued dividends of $24,000. During the three and six months ended June 30, 2020, the Company accrued dividends of $63,000 and $125,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. Common and Preferred Stock &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put, as an inducement for the holder to fully convert its Series A Preferred Stock. The Amendment to the Certificate of Designation for its Series A Convertible Preferred Stock (the &#8220;Certificate of Amendment&#8221;) with the Secretary of State of the State of Nevada adjusted the conversion price from $18.90 per share to $1.50 per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#8220;Certificate of Designation&#8221; from 4.99% to 9.99%, such increase to be effective 61 days from the date hereof. During the three months ended March 31, 2021, all outstanding shares of Series A Convertible Preferred Stock were converted to approximately 9.0 million shares of the Company&#8217;s common stock. There are no remaining shares of the Series A Convertible Preferred stock outstanding after these conversions. During January and February 2021, the Company issued 8,996,768 shares of its common stock upon the conversion effected on such date by the holder of 120,000 shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion is accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated fair value of the inducement consideration of $7.4 million and as a result has recorded a corresponding deemed dividend of $7.4 million during the six months ended June 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">B. Riley Securities Sales Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of common stock from time to time through B. Riley Securities, Inc. as the Company&#8217;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#8220;at-the-market&#8221; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the Common Stock sold on the Company&#8217;s behalf. The Company did not sell any shares of common stock during the three and six months ended June 30, 2020 through the Riley Securities Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#8220;B. Riley&#8221;) and A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) in order to include AGP as an additional sales agent for the Company&#8217;s &#8220;at the market offering&#8221; program (the &#8220;Amended and Restated Sales Agreement&#8221;). The Sales Agreement amended and restated the At Market Issuance Sales Agreement, dated August 5, 2016, with B. Riley Securities, Inc. (formerly known as B. Riley FBR, Inc.), as amended by amendment no. 1, dated May 7, 2018, to the At Market Issuance Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the six months ended June 30, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 78.7 million shares of the Company&#8217;s common stock and received net proceeds of approximately $66.0 million. The Company did not sell any shares of common stock during the three months ended June 30, 2021 through the Riley Securities Sales Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506368904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which was exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In consideration of the support provided by CSMC for the Study, the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company: (i)&#160;issued to CSMC fifty thousand (50,000) shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional <span style="-sec-ix-hidden:Hidden_LwEQCHh2xU-yhl4vl9nF_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">two million four hundred twenty thousand</span></span> (2,420,000) shares of common stock of its subsidiary Synthetic Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;) owned by the Company, such that after such issuance CSMC owns an aggregate of seven million four hundred eighty thousand (7,480,000) shares of common stock of SYN Biomics, representing <span style="-sec-ix-hidden:Hidden_uVawnFnrhUC47_sVB7xw5A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">seventeen&#160;percent</span></span> (17%) of the issued and outstanding shares of SYN Biomics&#8217; common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Agreement also provided CSMC with a right, commencing on the six month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of the Company&#8217;s common stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC MAST formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment was completed. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2013, through SYN Biomics, the Company entered into a worldwide exclusive license agreement with CSMC and acquired the rights to develop products for therapeutic and prophylactic treatments of acute and chronic diseases, including the development of SYN-010 to target IBS-C. The Company licensed from CSMC a portfolio of intellectual property comprised of several U.S. and foreign patents and pending patent applications for various fields of use, including IBS-C, obesity and diabetes. An investigational team led by Mark Pimentel, M.D. at CSMC discovered that these products may reduce the production of methane gas by certain GI microorganisms. During the three and six months ended June 30, 2021 and 2020, the Company did not owe and did not pay CSMC for milestone payments related to this license agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845591530296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of the Company&#8217;s existing leases as of June 30, 2021 are classified as operating leases. As of June 30, 2021, the Company has one operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for 63 months beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a 3 month rent abatement. &#160;The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. &#160;The Second Amendment also gives the Company the Right to Expand their space by giving notice to the landlord before December 31, 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an 8.5% interest rate, which is the discount rate used in this modification analysis. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the three and six months ended June 30, 2021 approximated $68,000 and $118,000, respectively and for the three and six months ended June 30, 2020 approximated $50,000 and $101,000, respectively. For the three and six months ended June 30, 2021, operating cash flows used for operating leases approximated $80,000 and $160,000, respectively, and for three and six months ended June 30, 2020 approximated $77,000 and $154,000, respectively, and right of use assets exchanged for operating lease obligations was $1.3 million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A maturity analysis of our operating leases as of June 30, 2021 is as follows <i style="font-style:italic;">(amounts in thousands of dollars)</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending June 30:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 337</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 347</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,146</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (524)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,622</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;"><b style="font-style:normal;font-weight:bold;">10. Commitments and Contingencies &#8211; (continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 7pt 0pt;">Risks and Uncertainties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the &#8220;COVID-19&#8221; outbreak) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including halting the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#8217;s suppliers and other commercial partners, the Company&#8217;s corporate development objectives and the value of and market for the Company&#8217;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509697608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Prepaid expenses and other current assets (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 880</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurances</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 469</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,707</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Property and equipment, net (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 827</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,263</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (800)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,089)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedExpensesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt;">Accrued expenses (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other accrued expenses</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 794</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedEmployeeBenefitsTableTextBlock', window );">Schedule of accrued employee benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt;">Accrued employee benefits (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 361</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 540</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedEmployeeBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to accrued employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedEmployeeBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506385800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,502,012</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.62</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.51 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 153,353</p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,540,000</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (14,944)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17.57</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (29,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,418</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.35</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.09 years</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.28 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 598,074</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance - June 30, 2021 - exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,970,911</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.55 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 239,357</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; three months ended June 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant date fair value of options granted &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average grant date fair value &#8211; year ended December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845504776552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockWarrantsAbstract', window );"><strong>Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantActivityTableTextBlock', window );">Summary of all warrant activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the six months ended June 30, 2021 and the year ended December 31, 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,714,999</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.24</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (714,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.05</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000,713</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,655,747</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at June&#160;30,&#160;2021</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Summary of all outstanding and exercisable warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all outstanding and exercisable common stock warrants as of June&#160;30, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.28 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.49 years</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:20.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.28 years</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure relates to warrant outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845505119880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity analysis of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending June 30:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 163</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 337</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 347</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,146</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (524)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,622</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; current</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (196)</p></td></tr><tr><td style="vertical-align:bottom;width:83.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability &#8211; long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509698968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Nature of Operations and Basis of Presentation - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507879160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidClinicalResearchOrganizationsExpenseCurrent', window );">Prepaid clinical research organizations</a></td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurances</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidConsultingSubscriptionsAndOtherExpenses', window );">Prepaid consulting, subscriptions and other expenses</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Stock sales receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidManufacturingExpense', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,341<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidClinicalResearchOrganizationsExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amount paid in advance for clinical research organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidClinicalResearchOrganizationsExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidConsultingSubscriptionsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amount paid in advance for consulting, subscriptions and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidConsultingSubscriptionsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Prepaid Manufacturing Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507060504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(800)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember', window );">Computers and office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507057880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of accrued expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedClinicalConsultingServices', window );">Accrued clinical consulting services</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedVendorPayments', window );">Accrued vendor payments</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedClinicalConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value of accrued clinical consulting services payable as on balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedClinicalConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedVendorPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedVendorPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506941528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of accrued employee benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expense</a></td>
<td class="nump">$ 361<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation expense</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509512776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="nump">2,502,012<span></span>
</td>
<td class="nump">2,502,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="nump">2,502,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,970,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,970,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Balance Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 153,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845510174008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock incentive plan and other information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 20, 2007</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 17, 2020</div></th>
<th class="th"><div>Nov. 02, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 483,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember', window );">General and Administrative Expenses and Research and Development Expense [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000,000<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember', window );">Consultant [Member] | General and Administrative Expenses and Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember', window );">Consultant [Member] | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">71,429<span></span>
</td>
<td class="nump">5,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">7,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,452,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,452,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2020Member', window );">2020 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845609208984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants - Summary of all warrant activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockWarrantsAbstract', window );"><strong>Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
<td class="nump">18,000,713<span></span>
</td>
<td class="nump">18,714,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Number of Warrants, Exercised</a></td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(714,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending Balance</a></td>
<td class="nump">6,344,966<span></span>
</td>
<td class="nump">18,000,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509486232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants - Summary of all outstanding and exercisable warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice138Member', window );">Exercise Price 0.69 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">6,344,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">6,344,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member', window );">Exercise Price 18.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 18.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">1 year 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice5248Member', window );">Exercise Price 0.69 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">6,344,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">6,344,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">2 years 3 months 10 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice138Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice138Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice5248Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice5248Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845501758664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Warrants - Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2016 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 18, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 15, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 06, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 05, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from "at the market" stock issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfIssueOfThePublicOffering', window );">Percentage of issue of the public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,042,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,960,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfShareSold', window );">Number of Share sold | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfSharesPurchase', window );">Number of Shares purchase | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | October 2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantTerm', window );">Warrant Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockWarrantsMember', window );">Series A Warrants [Member] | IPO [Member] | Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent additional of warrant to purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IssueOfWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfShareSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Number of Share sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfShareSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfSharesPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the shares purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfSharesPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfIssueOfThePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issue of public offering price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfIssueOfThePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the warrant term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_OctoberTwoThousandEighteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_OctoberTwoThousandEighteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845510043736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (16,000)<span></span>
</td>
<td class="num">$ (26,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (42,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Preferred Stock Redemption Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,000<span></span>
</td>
<td class="nump">795,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,497,000<span></span>
</td>
<td class="nump">$ 796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares', window );">Convertible to common stock that were excluded from the computations of net loss per common share</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,804,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,804,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,472,362<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,997,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,472,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,344,966<span></span>
</td>
<td class="nump">18,714,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccretionOfPreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of accretion of the Series B preferred stock deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccretionOfPreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of preferred shares convertible to common stock that were excluded from the computations of net loss per common share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845503604088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">28 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,932,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,049,000<span></span>
</td>
<td class="nump">$ 3,238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income (Loss) Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(16,000)<span></span>
</td>
<td class="num">$ (26,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(42,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=syn_SYNBiomicsMember', window );">SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest', window );">Accumulated net loss attributable to the non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeIssued', window );">Number Of Common Stock To Be Issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_FairValueOfSharesIssued', window );">Fair Value Of Shares Issued</a></td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalNumberOfCommonStockToBeIssued', window );">Additional Number Of Common Stock To Be Issued</a></td>
<td class="nump">2,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeHeldByRelatedParty', window );">Number Of Common Stock To Be Held By Related Party</a></td>
<td class="nump">7,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated net loss attributable to the non-controlling interest as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalNumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalNumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_FairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the fair value of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_FairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be held by the related party under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SYNBiomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SYNBiomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845496829160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common and Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 27, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 11, 2017 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 26, 2021</div></th>
<th class="th">
<div>Nov. 15, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 06, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 05, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 05, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfIssueOfThePublicOffering', window );">Percentage of issue of the public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,996,768<span></span>
</td>
<td class="nump">8,996,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,960,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember', window );">Fbr Capital Markets Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BrokerageCommissionPercentage', window );">Brokerage Commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Preferred Stock Redemption Discount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceIncrease', window );">Preferred Stock, Convertible, Conversion Price, Increase</a></td>
<td class="nump">18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease', window );">Preferred Stock, Convertible, Conversion Price, Decrease</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii) if so elected by the Investor, a 4.99% blocker provision that would prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii) applicable regulatory restrictions.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt Instrument, Convertible, Threshold Trading Days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt Instrument, Convertible, Threshold Consecutive Trading Days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit', window );">Adjustments to Additional Paid in Capital, Stock Split | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,875.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BeneficialOwnershipPercentage', window );">Maximum percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued upon conversion | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EstimatedFairValueOfInducementConsideration', window );">Estimated fair value of inducement consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfStatedDividendRate', window );">percentage of stated dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,497,000<span></span>
</td>
<td class="nump">$ 796,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392,000<span></span>
</td>
<td class="nump">$ 795,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,000<span></span>
</td>
<td class="nump">2,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccretionOfPreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of accretion of the Series B preferred stock deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccretionOfPreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BrokerageCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent that percentage of commission revenue from buying and selling securities on behalf of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BrokerageCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EstimatedFairValueOfInducementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Estimated Fair Value of Inducement Consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_EstimatedFairValueOfInducementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent additional of warrant to purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IssueOfWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfIssueOfThePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issue of public offering price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfIssueOfThePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfStatedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of stated dividend rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfStatedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845509549864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 05, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=syn_SyntheticBiomicsIncMember', window );">Synthetic Biomics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalNumberOfCommonStockToBeIssued', window );">Additional Number Of Common Stock To Be Issued</a></td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeIssued', window );">Number Of Common Stock To Be Issued</a></td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeHeldByRelatedParty', window );">Number Of Common Stock To Be Held By Related Party</a></td>
<td class="nump">7,480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalNumberOfCommonStockToBeIssued', window );">Additional Number Of Common Stock To Be Issued</a></td>
<td class="nump">2,420,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalNumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalNumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be held by the related party under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SyntheticBiomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SyntheticBiomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=syn_CedarssinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=syn_CedarssinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845506805992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity analysis of operating leases payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LesseeOperatingLeaseLiabilityToBePaidYearSix', window );">2027</a></td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">2,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Discount factor</a></td>
<td class="num">(524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="num">(196)<span></span>
</td>
<td class="num">$ (287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LesseeOperatingLeaseLiabilityToBePaidYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LesseeOperatingLeaseLiabilityToBePaidYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139845507602968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewed lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LeaseRentAbatementPeriod1', window );">Lease rent abatement period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfFundsToBeBorrowedByCompany', window );">Rate of interest of funds borrowed by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
<td class="nump">$ 101,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,270,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfOperatingLeaseForFacilities', window );">Number of operating lease for facilities | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LeaseRentAbatementPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Duration of lease rent abatement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LeaseRentAbatementPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfOperatingLeaseForFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Number of operating lease for facilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfOperatingLeaseForFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfFundsToBeBorrowedByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage at which funds can be borrowed by company for tenants improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfFundsToBeBorrowedByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M!&1??!=\GYQ<$U.5M90OYN;.O^K8AHB'W--&@L'/*Y_S,#1*P/&C$.V499K
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MGC#T'&PMF,@^$IT[HG9[U#OI4U$4\#99\]B(/.45/KN^8=MZ)A<!NLQD.4.
MU M\9-]$D$'H6Y9"9YRHW3FUJCS"!K#8Q!6'MZ])+&$)Z)*?9?FNSSXWD:/C
MZ72N'78N!PJCT;D8.,P]5P*%N5&/#IUWHG;S]+E^V8=RCO?@G=:<E+MB"9)
MS4NM"KRB[I14H(GND^FNTA_0*PA8K4RDEXMF6B *NX''?#<Z%PZ!1I[C1Y%W
MKAV"I-1W1P[SSO5#H&'H14'4)V'GP6ADE;"W-_S]GFLM_['X,MH9,SIZ&ZO'
M.@_$[![H_'EGV3Y+>9D>>K_.TYY4D(=B&R?H_M@D"2S[(P*Y"A#3@.$8TA8P
M'&5^;UM@G4UB=IOT-AU_PDQ/8VCR(F2&0/!MPQKK5(G..S&[=VKX3UY3U:QS
M).R%@Y&+J[K;M)E]TWX+TS=EYD:L#859L9?AYB_C3MEVNSM[Y>[^?9:.F0<6
M1@';(*=LNEV9V7?E-^I(P<L=R81<N2/$JV! ZB&G!G,,&8X"<XZ'1P?*!:_6
M]4F^)(G8E>IPI-C>;7\MN*_/R,_N3^C-E"+W9_1F?O@MH M_^&GB?5RMLU*2
MG*\@E7,=PNQ5A]/^PX42V_HX>RF4$D7]=<-CL(8: /]?":&>+W2"]C>7\?]0
M2P,$%     @ C80%4X9,4WH>"@  UC\  !@   !X;"]W;W)K<VAE971S+W-H
M965T-2YX;6RMFUMOVT@2A?\*(>Q# BPCLB^\#&P#L2[<##"!,=Z9P6"Q#XQ$
MQ]Q(HH>D[,R_WZ:DJ$75Z6[*\(LMV:>+S=.7^E1L7;U4];?FL2A:[_MZM6FN
M1X]M^_33>-PL'HMUWGRHGHJ-^L]#5:_S5KVMOXZ;I[K(E[M&Z]68!4$T7N?E
M9G1SM?O;77US56W;5;DI[FJOV:[7>?WW;;&J7JY'X>C''WXMOSZVW1_&-U=/
M^=?BOFA_>[JKU;OQ,<JR7!>;IJPV7ET\7(\^AC]E4= UV"E^+XN7YN2UU]W*
MEZKZUKWYM+P>!5V/BE6Q:+L0N?KU7$R*U:J+I/KQUR'HZ'C-KN'IZQ_1Y[N;
M5S?S)6^*2;7ZHURVC]>C9.0MBX=\NVI_K5[^51QN2';Q%M6JV?WT7O;:.!YY
MBVW35NM#8]6#=;G9_\Z_'XPX:<"8H0$[-&!G#7AD:, /#?CY%5)# W%H(,ZO
MP T-Y*&!/&\@# VB0X/HK$%HND)\:!#O!FOO[FYHIGF;WUS5U8M7=VH5K7NQ
M&]]=:S4BY::;BO=MK?Y;JG;MS:3:+-7$*I:>>M54JW*9M^K-?:M^J1G7-E[U
MH-Y5BV^/U6I9U(TW^VM;MG][[Z;%0[DHV_>>[_UV/_7>_>/]U;A5/>KBCA>'
MJ]_NK\Z,5U^OU7S<Q??^\TNQ_E+4_P5A)O8P'Y?+LIO8^<J[R\NE7VZ\2?Y4
MMNJ])>C4$72QV*ZWJYT=AWNU19O9HWVN-HMJT];52OWGJ_=ITQ9UT5@CSNT1
M[XNZ+!KOUKM3B[>HZ]VH.7S,["'_72G+^LW&:CX=)Q4[3BJVBR,,<6[S5;Y9
M%%[>*N<6'SP>_M-C09BB";*/%.TB=?OF\TT8!T%P-7X^'7^J8IS))"#**57Z
MC$O):= 9DB9Q0H1S*A1Q%!)=!@*&@>Q=N><G/_K)!_GY3DWLYC%7$^?](&_W
M4>6IMU$21(*?WR 5QA%/<*?%L=/"VNG=9/2[-+'T%M5:Y<XF[Q8IZJ@@QIU/
M $%ZF' Z^%1U/N9.Q=S9E\S5EYY=\FB7M-NU7\X?R7*>EL^EVJ*7#3).NFYG
MXE1,J<*/&%TMSD!SIR)S7JIG772T+K):]ZEIMKOUT:6J/S][MV6U+A?-WC_D
M6N2<;I'3-:=B1A4LHGN+LR^9*T[/L_CH66SU3&7[9Y7-.QKL7#/EDK;R#CGZ
M9.]!EL:DDRGG@9!G=TME:H>,.;Z7Y'@OR9O>"^I_0M,0S4()W4^#F"Z5*=7Y
M(A!T25'=^>R@W?*C**69QQ:IYVEZ]#2U>OI9?0I:50W<=%+GIN-43*G"9VE$
M/9H[0V4#0O4L" /-QH'=A&KCGU);>: V"+J!TQ6W9 8D/MHUW*$R=ZB^*R>?
M&,*A=/=+7O\@$!9 5T*ZKBA@30ZRWA['><PE75M J@ O22, >% +"0_T4P0I
M7=H9"ME--;.O&IK#8=1\1GENCQG=EN*8IR(^WWV!,I*1-'1<TVDX#$^'(.DA
ME(OW0TJD)N '4B/Q0RV>$+2?F/E12"OTAQJ@0SM!OQ;[0PJH!NX'2C/XAQIE
M0SO+6I)'%@(&E D/S7YI# SM''C!=CT/*7>% 9U=64CIRQ=F9 TU?X5V #M9
M-#]O-VI  \L*CVEG*01,0DI7C(LD0HL&@!@3C"4T[ QJDP3D:M!/+@059BAD
ME$C++JI9,+3#H&'1N#T&<)>H)9,P<7Z75"DE,^VB&KA".W%=E%;386F5HI$Q
MK2**,J55I,6[*.VG(:V"D-:TRC3$,3O$O3:M,LI/AK0*E.:TRC1G,3MG75)
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MZU$[ #TOE+(O@9L._;]'^AM02P,$%     @ C80%4Y.1)R+_!0  @A<  !@
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M.+Q5D L7-RX71OTE.$1C^E6$VDFR&=U4TL5#3\*DM!9>>3Z_==)+$^*KLUD
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MYRBB61:!'YV,:*Y5?^< 6;*5ZY./JJZ GD=C>CZ0WP;=_F'F E1!7S.13RJ
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MJM\?#7ONLTG]8M6"?ADU4=:JG![G@J="(P#L3Y6R]0LR:'XJ=_E_4$L#!!0
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M2E=%(1+<.2,VK>,;2<SIP;[3^4VE94'&#NY9<<_JKG/)=RY#W]'0=XSN?5[
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MXG@!OJ^L#=T#']#_+\7E/U!+ P04    " "-A 53,8=_9-,(  !9%@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM6&MSV[@5_2L8-6V=&45O/S9Q
M/./8R20[NW5FG6RF'R$2$E&3  . EM5?WW,O0)J2'&^[TR^V2 #WGOL^X/G&
MNCM?*!7$0U4:_W90A%"_'H]]5JA*^I&ME<'*RKI*!CRZ]=C73LF<#U7E>#:9
MG(PKJ<W@XIS??787Y[8)I3;JLQ.^J2KIMN]4:3=O!]-!^^(WO2X"O1A?G-=R
MK6Y5^%I_=G@:=U)R72GCM37"J=7;P>7T];L%[><-OVNU\;W?@BQ96GM'#Y_R
MMX,) 5*ER@))D/AWKZY469(@P/B>9 XZE72P_[N5_H%MARU+Z=65+;_I/!1O
M!V<#D:N5;,KPF]U\5,F>8Y*7V=+S7[&)>^>3@<@:'VR5#@-!I4W\+Q^2'WH'
MSGYT8)8.S!AW5,0HKV60%^?.;H2CW9!&/]A4/@UPVE!0;H/#JL:Y<'%EJTH'
M>#EX(4TNKJP)VJR5R;3RY^, %;1QG"5Q[Z*XV0_$G8A?(:#PXKW)5;Y[?@QH
M';Y9B^_=[%F!/S=F).:3H9A-9M-GY,T[>^<L;_Y?VIO]V-X=^8M._H+E+_Y?
M_GQ>W'0R$L^*%+\HY*07EV4I[$J$0M'^6IKMW_YR-IN>OO%"/6A/!T09MTI/
M.^%8U3E62*=$5DKO]4JKG+?4RLG>L9&X/#PW["L4!1W#ZMY1@=8A5C+3I0Z$
M>*-#(20JFGH&[0K*54!9:T=/VI#HTY&X;OB9-'QOI,,NH2BKGH/@E%$;;-'P
M55*Y32B66QR'D*@C6$"X50A_'ETH+N'AG+PL-H7."@ *>.%9?)3 .,F8D[FH
M8IHOU5H;-@(=YE;5055+X)PRMAF'"T+2^K7*XO(\KI\*&80/,@ P@ =9"OA-
MQ2AKDY4-GY0BJ>--0BZQAW".Q!= 2S8\HI>EMS$4-?4]SXBE^**,Q.JGJG;V
MGL]3SMB--)EBA9T[WI/AW'2_P.#GM*S14/V._^DW-W8!![]_J$DPWFF,@5IF
M' 0<(JN,#1HOL(T=C(VE=3D<"KCJP%73'1B["(6FQ%PI1XD;T!S='8;9HR<A
M'Q*QR5A!YVVE,W(OS !^=D^,L?=*#>-V!K&?V[FB#$"%DDQHTB%*#:)&>K;E
M9YU&3B"6CTG#X",&:5)<*,]#@3<'KH5+?NGJ9L>Y5BRMHX:T:B@S>3V&53^&
MU6/ +O^%H4?[H>YL=/Q72G@ \-$MPY3A.L8NUSZSC8EKHO%4/@E;97,TA$S&
M 0JCMEZC$]SL%7AF/?4F6 ABX*G*N(6T7D&KPOXR9ED.!Z(?T7DX'U6/2")0
MK)$DH<(-0< O;TN=<W5PD43C("_U%VP8LLS63Z%P*N:RUP]MA3[1,H2LX:T'
M7;'L%R=GP\EDPN=>3*?\,$2I^5HQ8RBW?T;)9$_)\:2G9#(]5#(2'_Y',X:]
M1IM)7X@5RMG' !+:_0Z^A^BLC^AD<HBH[]P_9?/I:4_#\>)'&ASW"\05R)$V
M7@6:65DA,>.>M$389:G7,0/$!HGV8CI"B]1EB3>Q4>1RRZ/(6/.*?2/S7',6
M0\]3"O.&>Y',4W5B]?+V2IPM9E'#\9P3 U,0#29@,H5M5Q"<D\U3#G]BTFI^
MO;(E!^M(5E1Z*?]MXR45-@[EV""=?REHC$_F;_[P_X<&J%"^IBUGJJ$V*[KL
MW2H(;4=2 O:ZD\$ VX<78HHYQV-L7]=L<4H+\X.%^8P7%H<+<UXX/ER(HDX.
M%XY/XXP\6#@Y$U\L#<L#6,/IXE#0_O_KMMV!'P2X97_]Z'BV>)DZ<*GE,G*(
M_5W3X0D<\]2NZ?0-B+OC67T@>_K3R=.RZ51I6S+4B\%PT7/.']/!5M91)+:-
MRE]B(/N[N/<KIIX+H%U,Q&Z,^%D:4*MM5\&137VSKLS%1R5+D(X;MY9&_SO.
M@".2/YN\^?;QAG]-W[R$8 -_9M3SQ;JT2T2FB$?1LAT!VV*L9Y*J#9DM!2B:
MH F@N<PRZZR1]]HUOIV=(?' ;PV:P%!<%7@GC@A94G]U\_NGZU?3GQ(&5%]8
MXDIZ][(=^*AQLCFQ"YY^ABT N P.; P7<!R 47>ZU"832L*\I<%,5+*V$,%E
MS@!'XI,1OTJ'&=ISVL>;/H7FP9U@=OA(HQ3$BA1(R)#ODSE10X8L:\V\SW%^
MP'Y,1^NIJEM,3,([J5V(R<X('T,8L8C:Z9#:I<<T;IU6'"ST"=<DBACI#/9D
M(9'G9>-!='RZ).%: A90BN TB-^P1TX+!+IEZ0 ;:G1=9C$4V?:8UX'L00.6
M;7.E_9\+LG.Z',_DG@K:<?O/?[R:3!:QGS,99T83J<N.=UM_)@MV&&EW"VH-
MB@[IU.4*@\C6+>2D5!PYO90/L@+ F%.\T(:Z<\X/;ER^J>M2*Q>]9XE1<M8I
MEY%QQ(O B/SPR<.HA]HR%=O!QI2.^7:;XO>R;&)%X45BO7N4L2>TPMA&U=GL
M#O0/HQ+20;TX^59Q=/34I8P@1E=@6*(8FK9SQ(2@F@^H$")\N>:LX6L=4G*E
M<\5WBA Y9- 5LI"GON:Z@HRRG<"$E=K!O438H7<(WR&\J3 ;Y%;%GFC<3N8\
M5A#:"% 3JT#B9(D4TG514FTH$FC9Z4CW@+L.7ZA@01?"K(PEYM3W1KM$,A,;
M_8J4A66WQ#XAZ7WC,.)W8HHY@GI*/)2.*%Q$.$YM?L@LE9B\4^:QN2"3J7Q;
MAP84;VC9.)5_3/O43KM;B\<LS^W&Q,P!X0>M+GN5S&R[WX(S"J'?>K#GQ\2)
MX%TW%9J=J8 .1A[K0MKW-UF,R5# Y^AC%!JN5ID#B6^-;_M9RL&_]VMOA4YN
M.![$])F1,25$I/>H/2-;X[(#"""53!H]-]Z6R@W;]MXV!S+-K"V%^+ W)(S$
MYAGE\UTB$M.G< WIVE>!7J9[]KWJQ9VV%OPA4/%'@8J:;GLO?-;KO;:6>C7H
MB?*CISY)C7N?^WC"TD=-'[,Q?OGKWG;?32_CY\+'[?&C*X88YID'85WAZ&1T
M>CR(]+A]"+;FCX=+&X*M^"<R*U>.-F!]96UH'TA!]S7YXC]02P,$%     @
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MM^4"Y+9^$RA,AHKKYN+<S7;/CMOFMMTO;]XL'ZC<XI6#Y)"BJ',5XFDEFW=
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MH'8&A"^5LGO!!>C^-M/?4$L#!!0    ( (V$!5.' ![460(  +<&   9
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MPO[%A5%XRA!G)@LG*&3D@7(J4B +5SN/8E<@5NF/9(&UDU4<B%P1K)62LHS
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M@:<\G %= YZA -V5X1:)$WAW3P2.8OY>@G\\W8-W?[V_'@@I*C,]6&H!=[D
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M-?W^1M"U?ND[IT+01%^N" X)4P:R?T&I>+E1[Y'S'TM&_P%02P,$%     @
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M#]'*%XQLBQ_0/!/&R+IXNL(Q;P]"@'^^)(15+\1O<NJ? U[_%U!+ P04
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M7]K27%Y<@!8+P;;Y==J2"<&B_'$#U >> >3W%6-BO\@45-?0HW\ 4$L#!!0
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MS>6MAM4SAA[S59F9);H^[W[QI4>J:2IO*ZR^6_;:'KP<M <Y[UMJWO^1>U#
MUY:MM_FP5ZSI2>VK3VI.__[>L5R@IW?LDVJ:SVG34M/F]_6.5I?Q1$>I1ZHP
M?5S[@C[[TZ8[DCSY48H"N@8U[=2& "3%7PL5OV3Q-O_._BK.LCC,7VXH@5F,
M"<#GZSC.JE_8GP$<_F;K_']02P,$%     @ C80%4^6$]]#2 @  &0H  !D
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MN2"!HYNHG&7D_O3]SZ4R5^\"=S_Y<'+2NS^[.K2?-L 9";VD@Q>0GO=Z.#&
M&'GR,O+GN#'JRWWJ=KEEVG@VCF&;V?&H4'*;X)@X@V6F)0L>J,C(A H^U1R\
M"EIRL7;F/AAF2B@=&%M9&RH"2_WHX,C-H.@M3\FETDUL%\']G;;+#X#-# 1R
M(3J!?>(,XU%%C6%:7MM)L[@Q/H&"=GRWKJS"N:;KJ#\@6X?F9H-,E<Z9[L)$
M9&,:CP0K0([F\P7<C:I" (U1I1WDG,Z5I(V&C4<[L+0S)L0M/!$_BCWN5;%3
MLQY43'9#*Z@=.AHW ?Y=-L>]2_LZWJ#B#\I\7MKMR&8.7<9N-"OXJIFOBDX
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M.48@Q_N$S /("0(YV2?D*( \1" /XT+>VD>FQ5O;\9G,F*\M)Z8BMVMNH3&
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M7L[@*QRT%TP6<TN:/]V!PVC<U !5+>4%M-WJ&\/*S0\%FQ\YSOX 4$L#!!0
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M+GAM;%!+ 0(4 Q0    ( (V$!5-/TZ4*[@   "L"   1              "
M :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (V$!5.97)PC$ 8
M )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ C80%4S5$SJHE!0  =!4  !@              ("!#0@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (V$!5,U?,1(X04
M *\6   8              " @6@-  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    " "-A 53:C):.CL#  !>#   &               @(%_
M$P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ C80%4W&W
M:F:M!0  ?QD  !@              ("!\!8  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    ( (V$!5.&3%-Z'@H  -8_   8
M  " @=,<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "-
MA 533X8*S%T"  !)!@  &               @($G)P  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ C80%4Y.1)R+_!0  @A<  !@
M         ("!NBD  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   ( (V$!5-+XJ ]NP8  #L0   8              " @>\O  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "-A 53S&1)R]@#  "*"
M&               @('@-@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ C80%4]WUN5H7!   S@P  !D              ("![CH  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " "-A 539\N;>:<)
M   V)P  &0              @($\/P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    ( (V$!5,@P+>1. H  "0>   9              "
M@1I)  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ C80%
M4U-Z)M13!   -@T  !D              ("!B5,  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    " "-A 53!(S*O,$&  #+$   &0
M        @($36   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   ( (V$!5,16\UR(Q(  +X\   9              " @0M?  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ C80%4^CFT54*!P  L1
M !D              ("!97$  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    " "-A 53,8=_9-,(  !9%@  &0              @(&F>
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( (V$!5-1#PQ;
M_0,  )@-   9              " @;"!  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ C80%4U$OJ9F_ P  A X  !D
M ("!Y(4  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "-
MA 53UJ02AT0#  !,"0  &0              @(':B0  >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (V$!5.P[*:>IP(  'D&   9
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M970R-2YX;6Q02P$"% ,4    " "-A 53'$=KRTX"  #2!0  &0
M    @(&PFP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M (V$!5-QZCNR$P4  -\7   9              " @36>  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ C80%4]=N+573!   .!D  !D
M             ("!?Z,  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    " "-A 53K9>%/Q\#  !+"P  &0              @(&)J   >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (V$!5,]L(OB<0,
M *D-   9              " @=^K  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ C80%4[7\_7Z^!P  &B@  !D              ("!
MAZ\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "-A 53
M!Y\*F>0$  "2%@  &0              @(%\MP  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    ( (V$!5.@!F<I700  "42   9
M      " @9>\  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ C80%4V/$4B&7"@  OS4  !D              ("!*\$  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "-A 53Y83WT-("   9"@
M&0              @('YRP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    ( (V$!5.XE\=2\@(  *4)   9              " @0+/  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ C80%4P(7]S]=
M P  B@L  !D              ("!*](  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    " "-A 53+M(722 #   .$@  #0
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:+GAM;%!+!08     +0 M #(,   @X0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>181</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>41</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization, Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockWarrants</Role>
      <ShortName>Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Non-controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest</Role>
      <ShortName>Non-controlling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Common and Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock</Role>
      <ShortName>Common and Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables</Role>
      <ShortName>Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureStockWarrants</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>31003 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails</Role>
      <ShortName>Organization, Nature of Operations and Basis of Presentation - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of accrued expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Stock-Based Compensation - Stock incentive plan and other information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Stock incentive plan and other information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Stock Warrants - Summary of all warrant activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails</Role>
      <ShortName>Stock Warrants - Summary of all warrant activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Stock Warrants - Summary of all outstanding and exercisable warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails</Role>
      <ShortName>Stock Warrants - Summary of all outstanding and exercisable warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Stock Warrants - Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails</Role>
      <ShortName>Stock Warrants - Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Net Loss per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Non-controlling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails</Role>
      <ShortName>Non-controlling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails</Role>
      <ShortName>Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Maturity analysis of operating leases payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="syn-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>41002 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="syn-20210630x10q.htm">syn-20210630x10q.htm</File>
    <File>syn-20210630.xsd</File>
    <File>syn-20210630_cal.xml</File>
    <File>syn-20210630_def.xml</File>
    <File>syn-20210630_lab.xml</File>
    <File>syn-20210630_pre.xml</File>
    <File>syn-20210630xex31d1.htm</File>
    <File>syn-20210630xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>syn-20210630x10q001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "syn-20210630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 17,
   "contextCount": 181,
   "dts": {
    "calculationLink": {
     "local": [
      "syn-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "syn-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "syn-20210630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 351,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 7,
    "http://www.syntheticbiologics.com/20210630": 1,
    "http://xbrl.sec.gov/dei/2020-01-31": 7,
    "total": 15
   },
   "keyCustom": 53,
   "keyStandard": 249,
   "memberCustom": 18,
   "memberStandard": 21,
   "nsprefix": "syn",
   "nsuri": "http://www.syntheticbiologics.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Selected Balance Sheet Information",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation",
     "shortName": "Selected Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Stock-Based Compensation",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:StockPurchaseWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Stock Warrants",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockWarrants",
     "shortName": "Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:StockPurchaseWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Net Loss per Share",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Non-controlling Interest",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest",
     "shortName": "Non-controlling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Common and Preferred Stock",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock",
     "shortName": "Common and Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Related Party Transactions",
     "role": "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Selected Balance Sheet Information (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables",
     "shortName": "Selected Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Stock Warrants (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables",
     "shortName": "Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31003 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation - (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails",
     "shortName": "Organization, Nature of Operations and Basis of Presentation - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "us-gaap:AssetImpairmentCharges",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:PrepaidClinicalResearchOrganizationsExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of prepaid expenses and other current assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:PrepaidClinicalResearchOrganizationsExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of property, plant and equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedExpensesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:AccruedClinicalConsultingServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Selected Balance Sheet Information - Schedule of accrued expenses (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of accrued expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedExpensesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:AccruedClinicalConsultingServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedEmployeeBenefitsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of accrued employee benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedEmployeeBenefitsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "syn:StockPurchaseWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_11_16_2020_To_11_16_2020_Q4U6TfXbjUGV399zEsrnGQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Stock-Based Compensation - Summary of stock option activity (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_dytaXueexkemDVedbaUYSg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Stock-Based Compensation - Stock incentive plan and other information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
     "shortName": "Stock-Based Compensation - Stock incentive plan and other information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_vMLa_HE-R0SjMByjMZYsGg",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2020_KPYJ2mlg1k-T1J6Xt205gg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Stock Warrants - Summary of all warrant activity (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails",
     "shortName": "Stock Warrants - Summary of all warrant activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_h6fuFJH8kU6JXHZ1y1P1IA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:WarrantsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Stock Warrants - Summary of all outstanding and exercisable warrants (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails",
     "shortName": "Stock Warrants - Summary of all outstanding and exercisable warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice138Member_M9BrEQMvM0eqObMjQ7Zakg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:WarrantsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "syn:StockPurchaseWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Stock Warrants - Stock Warrants (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
     "shortName": "Stock Warrants - Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_CDRBLE4qQkaDOCYG-eI5Zg",
      "decimals": "INF",
      "lang": null,
      "name": "syn:NumberOfShareSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_paQSbZ0u4kOmOv_ozvbjqA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Net Loss per Share - Additional Information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
     "shortName": "Net Loss per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_HJInSeBBDkqzi0r8YAjPzw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:PreferredStockAccretionOfRedemptionDiscount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Non-controlling Interest (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
     "shortName": "Non-controlling Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_9_5_2018_To_12_31_2020_oE0qzvs460-mo18U5mMzWg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "syn:StockPurchaseWarrantsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_10_15_2018_To_10_15_2018_sO9s0zIclE6GzTI4fzfAQg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Common and Preferred Stock (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
     "shortName": "Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_2_28_2021_83AqlMwHVEuP9zHFSSM5Bw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_6Hyc7bxFGUOjO_fDA3SSYA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "syn:NumberOfCommonStockToBeIssued",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Related Party Transactions (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYJLsK0srkKOIF30sXB16g",
      "decimals": "0",
      "lang": null,
      "name": "syn:NumberOfCommonStockToBeHeldByRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_eD08I3A1jkGf8XKjxdrC3w",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Commitments and Contingencies - Maturity analysis of operating leases payments (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails",
     "shortName": "Commitments and Contingencies - Maturity analysis of operating leases payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_nkKE1znrUkK98gY4uT67Bw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41002 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_LdF61sejSkmDvY6J34arsw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4l9w-gtAfkqoK7QOOG4jJg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit)",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2020_To_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hDTOmr1ZUUuv0yYp5UsbQQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember__gb_XUJNFEe-pMBsJgUlhA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DividendsPayableAmountPerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_sPoZLd2FmEKOXrDSrTnEEQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Euvjo4DLQkamghi6eJcPhg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation",
     "role": "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation",
     "shortName": "Organization, Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_p6YIk2SlG0SXa3fKJIAhDw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 41,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r143",
      "r145",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r140",
      "r143",
      "r145",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r140",
      "r143",
      "r145",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r101",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_AccretionOfPreferredStockDeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of accretion of the Series B preferred stock deemed dividend.",
        "label": "Accretion of Preferred Stock Deemed Dividend"
       }
      }
     },
     "localname": "AccretionOfPreferredStockDeemedDividend",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccruedClinicalConsultingServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of accrued clinical consulting services payable as on balance sheet date.",
        "label": "Accrued Clinical Consulting Services",
        "terseLabel": "Accrued clinical consulting services"
       }
      }
     },
     "localname": "AccruedClinicalConsultingServices",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccruedEmployeeBenefitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to accrued employee benefits.",
        "label": "Accrued Employee Benefits [Table Text Block]",
        "terseLabel": "Schedule of accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_AccruedExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses.",
        "label": "Accrued Expenses [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_AccruedVendorPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.",
        "label": "Accrued Vendor Payments",
        "terseLabel": "Accrued vendor payments"
       }
      }
     },
     "localname": "AccruedVendorPayments",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccumulatedNetGainLossAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accumulated net loss attributable to the non-controlling interest as of balance sheet date.",
        "label": "Accumulated Net Gain (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Accumulated net loss attributable to the non-controlling interest"
       }
      }
     },
     "localname": "AccumulatedNetGainLossAttributableToNoncontrollingInterest",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AdditionalNumberOfCommonStockToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional number of common stock to be issued under stock purchase agreement.",
        "label": "Additional Number Of Common Stock To Be Issued",
        "terseLabel": "Additional Number Of Common Stock To Be Issued"
       }
      }
     },
     "localname": "AdditionalNumberOfCommonStockToBeIssued",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_AdjustmentsToEffectOfPreferredStockPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustment to effect of preferred stock price.",
        "label": "Adjustments To Effect Of Preferred Stock Price",
        "terseLabel": "Effect of Series A Preferred Stock price adjustment"
       }
      }
     },
     "localname": "AdjustmentsToEffectOfPreferredStockPrice",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_BalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Selected Balance Sheet Information"
       }
      }
     },
     "localname": "BalanceSheetInformationAbstract",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "syn_BeneficialOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership.",
        "label": "Beneficial Ownership Percentage",
        "verboseLabel": "Maximum percentage"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentage",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_BrokerageCommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent that percentage of commission revenue from buying and selling securities on behalf of customers.",
        "label": "Brokerage Commission percentage"
       }
      }
     },
     "localname": "BrokerageCommissionPercentage",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_CedarssinaiMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Cedarssinai Medical Center.",
        "label": "Cedarssinai Medical Center [Member]",
        "terseLabel": "Cedarssinai Medical Center [Member]"
       }
      }
     },
     "localname": "CedarssinaiMedicalCenterMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ComputersAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers And Office Equipment [Member]",
        "terseLabel": "Computers and office equipment [Member]"
       }
      }
     },
     "localname": "ComputersAndOfficeEquipmentMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Consultant [Member]",
        "terseLabel": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ConversionOfSeriesBPreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents conversion of preferred stock to common stock",
        "label": "Conversion of Series B Preferred Stock to Common Stock",
        "verboseLabel": "Conversion of Series B Preferred Stock to Common"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockToCommonStock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ConversionOfSeriesBPreferredStockToCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of conversion of series B preferred stock to common stock issued.",
        "label": "Conversion of Series B Preferred Stock to Common Stock Shares",
        "verboseLabel": "Conversion of Series B Preferred Stock to Common (in shares)"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockToCommonStockShares",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_Conversionofseriesapreferredstocktocommonstockshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred shares to common",
        "label": "ConversionOfSeriesAPreferredStockToCommonStockShares",
        "terseLabel": "Conversion of Series A Preferred Stock to Common (in shares)"
       }
      }
     },
     "localname": "Conversionofseriesapreferredstocktocommonstockshares",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_Conversionofseriesbpreferredstocktocommonstock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Series B Preferred Stock To Common Stock",
        "label": "ConversionOfSeriesBPreferredStockToCommonStock",
        "terseLabel": "Conversion of Series A Preferred Stock to Common"
       }
      }
     },
     "localname": "Conversionofseriesbpreferredstocktocommonstock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeemedDividendsWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Deemed Dividends With Beneficial Conversion Feature.",
        "label": "Deemed dividends for beneficial conversion features",
        "verboseLabel": "Deemed dividends for accretion of Series B Preferred Stock discount"
       }
      }
     },
     "localname": "DeemedDividendsWithBeneficialConversionFeature",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).",
        "label": "Deposits and Other Assets Noncurrent",
        "verboseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_EstimatedFairValueOfInducementConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Estimated Fair Value of Inducement Consideration.",
        "label": "Estimated Fair Value of Inducement Consideration",
        "terseLabel": "Estimated fair value of inducement consideration"
       }
      }
     },
     "localname": "EstimatedFairValueOfInducementConsideration",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ExercisePrice138Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price138 [Member]",
        "terseLabel": "Exercise Price 0.69 [Member]"
       }
      }
     },
     "localname": "ExercisePrice138Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ExercisePrice1820Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price1820 [Member]",
        "terseLabel": "Exercise Price 18.20 [Member]"
       }
      }
     },
     "localname": "ExercisePrice1820Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ExercisePrice5248Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Exercise Price5248 [Member]",
        "terseLabel": "Exercise Price 0.69 [Member]"
       }
      }
     },
     "localname": "ExercisePrice5248Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_FairValueOfSharesIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the fair value of shares issued.",
        "label": "Fair Value Of Shares Issued",
        "terseLabel": "Fair Value Of Shares Issued"
       }
      }
     },
     "localname": "FairValueOfSharesIssued",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_FbrCapitalMarketsCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FbrCapitalMarketsCoMember",
        "label": "Fbr Capital Markets Co [Member]",
        "terseLabel": "Fbr Capital Markets Co [Member]"
       }
      }
     },
     "localname": "FbrCapitalMarketsCoMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General And Administrative Expenses And Research And Development Expense [Member]",
        "terseLabel": "General and Administrative Expenses and Research and Development Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of operating lease liability.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Operating Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_IncreaseDecreaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount of increase decrease in lease liability.",
        "label": "Increase decrease Right of use assets",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseRightOfUseAssets",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_IntrexonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intrexon [Member]",
        "terseLabel": "Intrexon [Member]"
       }
      }
     },
     "localname": "IntrexonMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_IssueOfWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent additional of warrant to purchase of common stock",
        "label": "Issue of warrants to purchase common stock"
       }
      }
     },
     "localname": "IssueOfWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_LeaseRentAbatementPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of lease rent abatement.",
        "label": "Lease Rent Abatement Period 1",
        "terseLabel": "Lease rent abatement period"
       }
      }
     },
     "localname": "LeaseRentAbatementPeriod1",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "syn_LesseeOperatingLeaseLiabilityToBePaidYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Six",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidYearSix",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_NumberOfCommonStockToBeHeldByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional number of common stock to be held by the related party under stock purchase agreement.",
        "label": "Number Of Common Stock To Be Held By Related Party",
        "terseLabel": "Number Of Common Stock To Be Held By Related Party"
       }
      }
     },
     "localname": "NumberOfCommonStockToBeHeldByRelatedParty",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_NumberOfCommonStockToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common stock to be issued under stock purchase agreement.",
        "label": "Number Of Common Stock To Be Issued",
        "terseLabel": "Number Of Common Stock To Be Issued"
       }
      }
     },
     "localname": "NumberOfCommonStockToBeIssued",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_NumberOfOperatingLeaseForFacilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Number of operating lease for facilities.",
        "label": "Number of operating lease for facilities",
        "terseLabel": "Number of operating lease for facilities"
       }
      }
     },
     "localname": "NumberOfOperatingLeaseForFacilities",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "syn_NumberOfShareSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Number of Share sold.",
        "label": "Number of Share sold",
        "terseLabel": "Number of Share sold"
       }
      }
     },
     "localname": "NumberOfShareSold",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "syn_NumberOfSharesPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares purchase",
        "label": "Number of Shares purchase",
        "terseLabel": "Number of Shares purchase"
       }
      }
     },
     "localname": "NumberOfSharesPurchase",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "syn_OctoberTwoThousandEighteenWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October Two Thousand Eighteen Warrants [Member]",
        "terseLabel": "October 2018 Warrants [Member]"
       }
      }
     },
     "localname": "OctoberTwoThousandEighteenWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_PercentageOfFundsToBeBorrowedByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage at which funds can be borrowed by company for tenants improvements.",
        "label": "Percentage Of Funds to be Borrowed By Company",
        "terseLabel": "Rate of interest of funds borrowed by company"
       }
      }
     },
     "localname": "PercentageOfFundsToBeBorrowedByCompany",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "syn_PercentageOfIssueOfThePublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issue of public offering price",
        "label": "Percentage of issue of the public offering"
       }
      }
     },
     "localname": "PercentageOfIssueOfThePublicOffering",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_PercentageOfStatedDividendRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of stated dividend rate",
        "label": "percentage of stated dividend rate",
        "terseLabel": "percentage of stated dividend rate"
       }
      }
     },
     "localname": "PercentageOfStatedDividendRate",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred shares convertible to common stock that were excluded from the computations of net loss per common share.",
        "label": "Preferred Shares Convertible To Common Stock Excluded From Net Loss Per Common Shares",
        "terseLabel": "Convertible to common stock that were excluded from the computations of net loss per common share"
       }
      }
     },
     "localname": "PreferredSharesConvertibleToCommonStockExcludedFromNetLossPerCommonShares",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred Stock Conversion Price Per Share"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "syn_PreferredStockPriceAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents the effect of preferred stock price adjustment.",
        "label": "Preferred Stock Price Adjustment",
        "negatedLabel": "Effect of Series A Preferred Stock Price adjustment",
        "terseLabel": "Effect of Series A Preferred Stock price adjustment"
       }
      }
     },
     "localname": "PreferredStockPriceAdjustment",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrepaidClinicalResearchOrganizationsExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the amount paid in advance for clinical research organization.",
        "label": "Prepaid Clinical Research Organizations Expense Current",
        "terseLabel": "Prepaid clinical research organizations"
       }
      }
     },
     "localname": "PrepaidClinicalResearchOrganizationsExpenseCurrent",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrepaidConsultingSubscriptionsAndOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the amount paid in advance for consulting, subscriptions and other expenses.",
        "label": "Prepaid Consulting Subscriptions And Other Expenses",
        "terseLabel": "Prepaid consulting, subscriptions and other expenses"
       }
      }
     },
     "localname": "PrepaidConsultingSubscriptionsAndOtherExpenses",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrepaidManufacturingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Prepaid Manufacturing Expense.",
        "label": "Prepaid Manufacturing Expense",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpense",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_SYNBiomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S Y N Biomics",
        "label": "S Y N Biomics [Member]",
        "terseLabel": "SYN Biomics [Member]"
       }
      }
     },
     "localname": "SYNBiomicsMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrant activity.",
        "label": "Schedule Of Warrant Activity [Table Text Block]",
        "terseLabel": "Summary of all warrant activity"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure relates to warrant outstanding and exercisable.",
        "label": "Schedule Of Warrant Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Summary of all outstanding and exercisable warrants"
       }
      }
     },
     "localname": "ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series Warrants [Member]",
        "terseLabel": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number",
        "verboseLabel": "Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value",
        "terseLabel": "Grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share warrants exercised during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period",
        "negatedLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans are exercise in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "syn_StockIssuedDuringPeriodAtMarketOfferingShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period at the market offering.",
        "label": "Stock Issued During Period At Market Offering Share",
        "terseLabel": "Stock issued under \"at-the-market\" offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAtMarketOfferingShare",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_StockIssuedDuringPeriodAtMarketOfferingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period at the market offering.",
        "label": "Stock Issued During Period At Market Offering Value",
        "terseLabel": "Stock issued under \"at-the-market\" offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAtMarketOfferingValue",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Warrants Exercised (In shares)",
        "verboseLabel": "Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_StockIssuedDuringPeriodValueOfSynBiomicsStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of new stock of syn biomics stock issued.",
        "label": "Stock Issued During Period Value Of Syn Biomics Stock",
        "verboseLabel": "Issuance of SYN Biomics Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOfSynBiomicsStock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Plan2007 [Member]",
        "terseLabel": "2007 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2007Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPlan2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Plan2010 [Member]",
        "terseLabel": "2010 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2010Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Stock Plan.",
        "label": "Stock Plan2020 [Member]",
        "terseLabel": "2020 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2020Member",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPurchaseWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to Stock Purchase Warrants.",
        "label": "Stock Purchase Warrants [Text Block]",
        "terseLabel": "Stock Warrants"
       }
      }
     },
     "localname": "StockPurchaseWarrantsTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_StockWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants"
       }
      }
     },
     "localname": "StockWarrantsAbstract",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "xbrltype": "stringItemType"
    },
    "syn_StockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants [Member]",
        "terseLabel": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "StockWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SubsidiaryStockIssuesToVendor": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.",
        "label": "Subsidiary Stock Issues To Vendor",
        "verboseLabel": "Subsidiary stock issuances to vendor"
       }
      }
     },
     "localname": "SubsidiaryStockIssuesToVendor",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_SyntheticBiomicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Synthetic Biomics Inc [Member]",
        "terseLabel": "Synthetic Biomics Inc [Member]"
       }
      }
     },
     "localname": "SyntheticBiomicsIncMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_WarrantExercisePriceAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents the effect of warrant exercise price adjustment.",
        "label": "Warrant Exercise Price Adjustment",
        "verboseLabel": "Effect of Warrant exercise price adjustment"
       }
      }
     },
     "localname": "WarrantExercisePriceAdjustment",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_WarrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrant term.",
        "label": "Warrant Term",
        "terseLabel": "Warrant Term"
       }
      }
     },
     "localname": "WarrantTerm",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "syn_WarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of the warrants.",
        "label": "Warrants Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsExercisePrice",
     "nsuri": "http://www.syntheticbiologics.com/20210630",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus expense"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r29"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r7",
      "r29",
      "r139"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued vacation expense"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r26",
      "r116"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r241",
      "r242",
      "r243",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": {
     "auth_ref": [
      "r125",
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.",
        "label": "Adjustments to Additional Paid in Capital, Stock Split"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r147",
      "r168",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r49",
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r57",
      "r93",
      "r95",
      "r99",
      "r103",
      "r192",
      "r198",
      "r206",
      "r256",
      "r263"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r34",
      "r57",
      "r103",
      "r192",
      "r198",
      "r206"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r148",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r142",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r142",
      "r144",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r51"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value.",
        "periodEndLabel": "Cash and cash equivalents at the end of this period",
        "periodStartLabel": "Cash and cash equivalents at the beginning of this period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r46",
      "r207"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r55",
      "r57",
      "r75",
      "r76",
      "r77",
      "r80",
      "r82",
      "r88",
      "r89",
      "r90",
      "r103",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r137",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r122",
      "r259",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Common Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r59",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at June 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r112",
      "r113",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "verboseLabel": "Conversion of Series B Preferred Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r52",
      "r53",
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of Stock, Shares Converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r14",
      "r15",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Common stock issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r14",
      "r15",
      "r126",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.",
        "label": "Convertible Preferred Stock, Terms of Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r49",
      "r92"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "verboseLabel": "Dividend payable per preferred stock"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r131",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Series A Preferred Stock Dividends"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockPaidinkind": {
     "auth_ref": [
      "r131",
      "r262"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock, Paid-in-kind",
        "verboseLabel": "In-kind dividends paid in preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockPaidinkind",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net Loss Per Share - Basic and Dilutive"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common and Preferred Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r63",
      "r70",
      "r72",
      "r87",
      "r107",
      "r125",
      "r131",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r41",
      "r91"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturity analysis of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r222"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Discount factor"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewed lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r57",
      "r96",
      "r103",
      "r193",
      "r198",
      "r199",
      "r206"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r57",
      "r103",
      "r206",
      "r258",
      "r266"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders' Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r57",
      "r103",
      "r193",
      "r198",
      "r199",
      "r206"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r33",
      "r57",
      "r103",
      "r206",
      "r257",
      "r265"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Equity interest by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r33",
      "r39",
      "r190",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows From Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r46",
      "r47",
      "r50"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Flows From Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r36",
      "r37",
      "r38",
      "r50",
      "r57",
      "r62",
      "r66",
      "r67",
      "r68",
      "r69",
      "r71",
      "r72",
      "r78",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r103",
      "r206",
      "r260",
      "r269"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r36",
      "r37",
      "r71",
      "r72",
      "r195",
      "r201"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest",
        "verboseLabel": "Net Loss Attributable to Non-controlling Interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r69",
      "r73",
      "r74",
      "r79",
      "r82",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "negatedTotalLabel": "Net Loss Attributable to Common Stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Noncash Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r131",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income :"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Costs and Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating Costs and Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r93",
      "r94",
      "r97",
      "r98",
      "r100"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r219",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Lease liability - current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r216"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liability - long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesMaturityAnalysisOfOperatingLeasesPaymentsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r217",
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r29"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "verboseLabel": "Stock sales receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r148",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockAccretionOfRedemptionDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accretion of the preferred stock redemption discount during the period.",
        "label": "Preferred Stock, Accretion of Redemption Discount",
        "terseLabel": "Accretion of preferred discount"
       }
      }
     },
     "localname": "PreferredStockAccretionOfRedemptionDiscount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPriceDecrease": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.",
        "label": "Preferred Stock, Convertible, Conversion Price, Decrease"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPriceIncrease": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.",
        "label": "Preferred Stock, Convertible, Conversion Price, Increase"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDiscountOnShares": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.",
        "label": "Preferred Stock, Discount on Shares",
        "verboseLabel": "Preferred Stock Redemption Discount"
       }
      }
     },
     "localname": "PreferredStockDiscountOnShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Preferred stock accrued dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r110",
      "r111"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurances"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from \"at the market\" stock issuance",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from \"at the market\" stock issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of common stock for warrant exercises",
        "verboseLabel": "Cash proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r36",
      "r37",
      "r45",
      "r57",
      "r62",
      "r71",
      "r72",
      "r93",
      "r94",
      "r97",
      "r98",
      "r100",
      "r103",
      "r191",
      "r194",
      "r196",
      "r201",
      "r202",
      "r206",
      "r261"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r25",
      "r115"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r117",
      "r267"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r141",
      "r226",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r141",
      "r226",
      "r230",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r227",
      "r231",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r181",
      "r284"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r131",
      "r178",
      "r264",
      "r278",
      "r283"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit).",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r63",
      "r70",
      "r72",
      "r107",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r221",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use asset from operating lease",
        "verboseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r26",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyPlantAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r58",
      "r228",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r148",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r150",
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of Warrants, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Warrants, Ending Balance",
        "periodStartLabel": "Number of Warrants, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "verboseLabel": "Warrants Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r152",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Ending Balance",
        "periodStartLabel": "Options, Beginning Balance",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r146",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Balance Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r14",
      "r15",
      "r16",
      "r55",
      "r57",
      "r75",
      "r76",
      "r77",
      "r80",
      "r82",
      "r88",
      "r89",
      "r90",
      "r103",
      "r125",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r32",
      "r59",
      "r60",
      "r61",
      "r63",
      "r70",
      "r72",
      "r87",
      "r107",
      "r125",
      "r131",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r274",
      "r275",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Accrued employee benefits",
        "verboseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders Equity (Deficit)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r59",
      "r60",
      "r61",
      "r87",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r15",
      "r16",
      "r125",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r125",
      "r131",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r16",
      "r19",
      "r20",
      "r57",
      "r102",
      "r103",
      "r206"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' Equity (Deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r59",
      "r60",
      "r61",
      "r63",
      "r70",
      "r103",
      "r107",
      "r131",
      "r175",
      "r176",
      "r177",
      "r184",
      "r185",
      "r189",
      "r190",
      "r200",
      "r206",
      "r208",
      "r209",
      "r213",
      "r275",
      "r276"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r56",
      "r131",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Common and Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommonAndPreferredStockDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Selected Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "verboseLabel": "Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r65",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r241",
      "r242",
      "r243",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNetLossPerShareAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Warrants Not Settleable in Cash, Fair Value Disclosure"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average number of shares outstanding during the period - Basic and Dilutive"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-07)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r285": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r286": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r287": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r288": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r289": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001104659-21-100800-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-21-100800-xbrl.zip
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M7"PW'J@2K$R*3&F_0HHF86-YN>D&45_][+)6@LF@96I+!2!=*B1%I@C=$(=
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M"432)I 3DU!<^Z9]WSQ_AG 0TO'6LO8)>P*1D@JD]@G%M6_:%T_K;$?4ZF9
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M($ &3J,0I8_XAX/SR\'Y.9S(B:9@$S+9_((RL0*/SK-/;][3W N)Z=JWW&&
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M,DYE52O=(EK+55*:-V@0IPZH*-4$4YGP!),/R$+X%=ETHDD=614?:&LUTBW
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M$N+/@$%-'+/]REWT0M-0+4?[&F"@H,?(>B<(4D+Z#XH,;*AR*_E&LH%>]B+
M)6MM$O=;#@VJX#1'=6BF>C%U\&!J;A:@I^EJ8 AE-W&BS256N7F@K<)("4#/
M_:=.M[@A!S?0JR:'_+Q)(7>R4BT2J*E:1%'8JP8#RFB-[&A526 A@1;"DC5=
M'.NC!JC+,&'C+V83L2&%<!VF$T5_'];' +X04[-COQ%K\1:R$65+X_GD8; H
M$\#H1*15A7"O-_J;9%UI0CJ/<-YTAG/^X';N$,!YPXAS!I@ =%SDV9Z)2&C!
M+5G:R^T1>$$M7.IK;F>D4)8OZWV<:06#NV \5*KA.D:O?!%9<#9!K )VQQ"
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MC%KR'M=G[36+V^0,L8)00YTP!O7KHT"KG9H?!W5KFI7O,0-3,7X_.682!$9
MJM45PJI6'#P,E9)Y<5<G]:TRL"K=[N]HQ\Q !RT@I5*(8]4L"2<,]1HPY*YC
M$FHHF64C@S57Y!#RS\:$:FZ8P%EJ(P.U0>+:J#C-S[$QH(!0%N<8A]J00K P
MERC4C %L48XQZ$#1K"$HA/4L)@RLI1C#:1-".!:B#Z;UT$%8AC&4UBD29'[F
MPD+ 6H)]-V#%"L<F+'L!"TH0UF'?">BTR[ 1@+.31<0!2=,?N:EQP@1/YA^S
MG7% @TSY'QGG=U\!^-_%.+[P/DBXYJE ^T8 ?9/F*"FR+"I94T_^3 #PDD>2
MT'$'8\0 -R>7O8L!'-)\' /]KMGXV;*,,Y5Q@E3!;5<&HACW*EKH0&Q!OTO1
M@,+;@#&T5^D_]+/-21)40>U,!B+8MR5FE$#4W[(A,<'#&X(]=E=;P](;D2DF
MX2Q+%=XFY#J/BPUFT=_&WE1#"PUC$A;F96O0@'HW!",?"KW)$UKSF]53JHHL
M3=@>HD5G+].;BGH$ #(IO>'H(HNJZG;-K./L2ZHK.V: ATH=MPC0S0;7  ,D
M>!LY&2H4!:-*PP#1;Q1T4/S$X](L<7U9;**TW^_1! BT#&M9[BR^ RC_2ZZ&
M!8U.W+8ZP8&7*8ECKU<PCNO"QK5'%\C*EIQU#RK?LQ(%.N,U80"Y0;L0'4>H
M!_?O"FV\Z&N@]8Z)T6\<#<@$/ CBVRK.1UN%!@/2*HQ"#*U""0YD%09>].67
M0K2*104!*+E^U?3TL>R[#/# )=9U BA+J_>!X4JJJSDQE%(7" '4#)PNQ$51
M->5Y!2I@P< _X9SPE9WER5FR2?.4RD KIS6L:82W8L'8@Z,PLE584+S;AA,_
M ^5JL)A2=?&$CD&9R>'R1!T\R.)(%2:Z^$1$N<3/."NV=,=OMA,+#E1)) =!
MNM60# @ A9"LW"AJ('&<IF)DB[6H=5B#J:.1Q*F*TX&R)'NL@")"U\4_F C0
M*?*#C_B<(SV8]]>N_/('UZ;0+@!=YI<=-T5EU689$EB?ATPK-7H/!J?3?1X,
M6LU!T3<4>)"4Y5FUK6S3GQ#]/$'<;7TH\J++>F-BEDV[ QZ,JCL+)"N^%<F[
M&3ARI"KI50SLHD']=NG]O34TFRK5;?V$2R$.X+;^.G_&%6L$Q'FQ%!S3@T.E
M%)C9[^84J&$!D@I,C Q490_>Z,MJV2)<#D'\: GXSRAET &N#6.M.[BU8-0:
M$([OG^+S8<*AL2(T$;_DYB$?>Q7KM#8$]C( U!.N/HO=UUKB5X"'6=VAA[J*
MZVZX'EI118?'6@XB9N1G&,MS8N]&P9['=077^UW2 ?5<)] !6H>F"MQ9G\82
M\;]N3>/0[B/"=@BSB>U8C=E7V#KGYV2''HJO>.+R&8$\D\NT!.%1K-X"UA-,
MMO(E6PJ,,NH@%WI7#I6FY]X"(92B"Y?I<YK@/*EZCPRN-UO]*>4X$B&48W 3
M4U^;P8P/7*C!A3E;F0/4$ED)]]'209S0O/;X$Y<RQX_T>8HY]#YZ8:=5K#A0
M5/9R#$5Q7-+&>(D@-L7S5"\Y=2>G;W[X_@US)N0/_;)F91KCL^3?=_Q(KB>@
M [Q?-^$L /4)5N!%'$!2Q#M*G-UEC9U/W8'0$T81Z_N-2KPE7+$'863-0GB]
MQG%-'T?TVJ:2_R:44=227J;WELK=396R;^X,"^W1?'NRJ7)<M=]$FZU_U_LX
M?OW6@H+UM2Z0W<O9<Y1F?+<FO>EMZM6?1U4::US[:"H![(#<A=6?J%A) )^G
M./+GLL\2I.A.0'Z)WE!;(49O2>=S/VIW<Y#LROV/0FHXNQ4M&D5M(B81S?A+
MLUVM+6!BQ8*Q2T=A9#NTH'BW.R=^ADN%Z /:EK]J[(CGE')<F&A]FD"M\;0"
MH9.^1*"IX[_B]/&)\'_VC,OH$7_8T8=/MVO&JE1_PLV<IA*#L;+#1)>-;QHE
M[S9Y")L#S1;$4$,-<7(LS!N4+PG&BI>9@JB9@KR=@HI/@=R1/MF5]/_H]HNW
M90O,$[0G#LWC^DY7)TLFHR,N<.4.%\&453Q,B' 5/>Q<32L7(U,-J">7:VFN
M8.IQ.17A@J^\Y5JBRE>!+;>.G(Y,-\TG6>U1[I.72>9R;;0Y']O^#&]_P%/=
M%V=)DM(CRBB[B]+D.K^(MBG9AHJ0&"=D5TB3U-@Y)O,DMUN6GO\1$T]2I37^
MA,OG-*9%9,F,?<1Q\9BGBD-/[Z/#. G/DRN['D]#>W=H7N4:F*XT.CTDV8^/
M* .(&'3#0E/F[^0AXNOQGHU5<RK:<+)"+2^H809Q;I#$#E2&"^QL,QK-%,82
M[=GNO=@ O$#I)0O@.6=G]?NH_!LF,=@:T[^RNMB*\_)QZ/YOQ::()R[)QN""
MW)F-9W!X(,7#WY1=PM+@F&[?>#ES\A\Y_MQ<FZ5L%,4>+ZK9?VW8B 2'#^GW
M5FV&>> .B=- G(CP06<UXG20(,1+V/N_G)I-SN9K[LAFJ42OHOJ$?,(3_@E?
MM=_0MXM1]7L8CQZLBQET?AB+&[*+,;5+V)^;?5WNQ"3S.'<"T,UO5CF=W,FA
M>[TQKH5YP%^CLHQ(U';U!9=Q6@T.]2?@!^-<S ):O(L:.23W8N)PH(-_%M%*
MQ[5$%8H087F7M6$-;@C1__[<$ _"LXP2U^!:^$P(0JBE%(QK&26H78ZYW08_
MO3K ;V@)!.,X+"):/(<&.R378611<^9[U,YCI,!Z[]',1<#N8YRH0T'0-]?+
MGI(;CI,6% ONY+S-Z>ZF36I.TK30,"?3%N;EDV0-J/>37R,? TV1W@7T\E&A
M'C^,XU^;37LY>_9_YY"7Y_/>KA6YP JC=D?U'P2,%4LL_ZYX( O_..9,CP;(
M4KY/R::7&99G W[7^P/EE.]I[@O4)*G?KM5)]_[7^ /%\Y1T/_K4X7;]Z24_
M3XM-&E>JQ7 "?C";![. +J<. ^20M@XF#A4%5#L/CA17)G13\9*C!TZKL\$(
M8N,P2ESKJ0/MGD.D;4@M$68<%&./$I:BL_04ZEW^\L$LU&0O<E'D1):*J"CA
M2]7;H?.0@6\2% )/(^/?IQPBKG M4VB >)CIC!JN3^*6*/,MHKE'/U0A<4PL
M=5L$<3DSRG_1D5K;TJ3W7J<YS8#P0)"R+W'',DZ>@R<D?-]TF%<Z G]D#WFZ
MKLCB@0+V/+/ZG/"=S4SB+N!:BC5?SQY:76*J0_['1JRLKL6- *1K&2/BT+6X
M8 .[%G<631IX:]# >P\&9W<LL\CI8J[^#V7F_IBFXQD?[B0R<%_9=U1CR(3@
M6MS%U3L8.XU W(PKHQ;]E((7?@':1B_ [F4&^823.;-N0$)P-3-]4+O#">/9
MT?XR+'JA)2?.V*6$>'YOO4%3(T%?I9I$4=^HJC  +U;U[.CO5U&#M4(<;U\,
M >K1RD'RH"U'HCFY_;U=$,^W+Z+JZ5U6?+8UC36C@#_6UHJA>:,]@(=\FJUA
M9MJ+;$H,,6J@A;$H&W=E0:T@.7_YA3!]G;<]F\[BFMA'G5I;%4\A!%8>:Z+(
MO0I9(ZE %,F:Q**RW U35D$*/;R@;R@UE.;?2MWH]A0#Z)<\F_A[.T7OI.9D
M'7D!.R]U4@KHV\H\3C/<J1)&0M]9C'R9H0)XHCWSM&G?8\\T#NSCZUF%L+VT
M;@=#PVI]=&L3EENR5BJ"F\BRG<B\*<Y._TK_'=,YW/%I0_MV25$(SDW]QEP7
MJ&F  0O%:%D?5(L90,*4C-&PH7Y#H*AR +7:CV.>;NH6K2\@V@2\[#-SB&'_
MF>PS]_AR_HX9'B 7SD6 -O?-! R3ZV;GR/"BKD7NOH\AWC%+\8XEI5"7N2Y*
MFH]""UNPNV%>1Y4 $K_*'L_D=5J_O$8M8?I'/7':ZHM68B(TR!]17A OG6Y2
M3G"E'HDL>,],)M^O<B;,[QX'27EU+$V7XX$DSATFR/X3TLPYMJ(^*V7Q>,!*
M\Q7BE%D&^7>&Z3_.\N1L0UO(_:=I_71#!3IL'2%6Y\C5 <__P:LS4\/C2@EU
MA5ID5FU21@<[@YU'-,A&QG&)261PB?G_2Z%W4_?(LDD>0P"JV?%8$;OMCUVQ
M 1HBCV--T6"8(]+*F/Q?W])E?[^5;,@$<+QUL*P73^2_R)K5W?15%2;[1>I-
MLC1Z2#/H#>!0S+L2;Z,TN6QN:$2;]#QA/7+/F #.<^9&+!0S'2.ZV61=* 5@
MONYLNIIR0Q$UI)BF\^;*G!K4(]%991="8H[#[;E@4L:[DK8.; Q]M@UOG_V/
MM(;V[?H7PK#*(-U0_&][7<40.U\;/,CFUXVIX7EA+KT0387U) T1MOME_Q#K
MPHO?+>=$J:X'@C!$*N..FO\"1N^V\YPHSY#[D-;FLSBF&B02,)Q]W0 OE!57
M(Y!Y<>TA!;".*CER73(%LDCX"2?B=1.KY7^KYA_88&AKQYM]K#U&^ %J0&:C
M$<MJ.3V\,(Q'R=0(^V'M.R4"09F0FW!""A%3AF1%5YMM5KQ@_!%G+,Z>8$TF
M$J%8E5U,LW7I\0.P,AMSKM8FZ*"&4)AF-UK:UOR$> \XQ^MTP2V<=*!T0_];
M\/CB$,P:<.$W=5;!=+L[+6(0VSP+=\J20.TV[YNDM2&I/'&)M_34GOQ74ZB8
MV!?]>_3X6+(C#6G'N#]##&J;.'966J\B"*!K^?R7T6A=RHO_!R2'RM<7)=.)
M$F(.LL:]CB$0>LZQ:B5WQPXXQWB^W.)EC,ZA[>Y,DC;".<D&;H77^3.NYG@)
M8"04E%4ZB.Q@G08JH5BIE<6QUMH2/(J7 ./%[[\$4,D+>%=Z%[V(CDWQ?^S2
M$A.)B8^I7^Z(%/59GM"^-UL*HIFH,01@3':\B+*INF-[-]&QK WO_!H"K#T9
M)X$$C15B5%;L'K E!'75>;BHA*FGJ.(ES+<-,I,-ZV0+<1T]V%N%OVX>MEX&
MO$[.MSX&%<U.D%1$LRZR@5OANS2/\GB&:-9(*"BK=!#9P3H-5$*Q4BN+8ZVU
M)1C2 [+9A._'LBII(6/9LH@Q3BK*FZA,>[O6EUP<@0<4N;H*U E8;4C^XU0W
MCA0I:1P/K=G&2:HUO'AM,ZM-S2/3JTX7OU>]MR%0>U^_WPO&/S3-841K&%U@
M;4:!]PHZ,70.H0\/Z@O4S%C4JD%JF_IX+L@UFQRI9!Z=*M3TB6#3-ZOMI05V
M"SU!3!8D;#NRJEJ"'4.<?W \%7Y<?U@\'W </U_\'M1N^T!)7>3S9XF4/?H_
M>GCW'&7T@.\C)CN0-*YQ0G\XRY/N'R1(WJZB?[=]]86^B28"DG^PQTH?HQKS
M%CB:B?;-!(Q'@)EJV:OXY<"[9X(03[WVTD-M]@]I@)7H0:/(@(/Q;T',%_61
MJGRF-.?E&NA4LG_@_=B @0LQ<\+,_L U3UI_?EWCC?5<TAT?*&P9*V G:G%%
M]A^TC.-LJ*4<7SHNIWJY7\H9#?A3QIFD#.Q0L??&ZO:ACM*<1F+"R;PK2K>D
MUUDHPACF#),@F^H!Y+P;[\&\JI_CG13K$T*3OR!&@BI+1F_HLH. 0+)(%YZ,
MSMM$?F302PV&.O\XDJ_O<<LFE\RGYU6\8#;_,PG43G7AGAT/:&/D*E!G+V-#
M\K_]<./(UA& 8K;%V5MD*.N;22A-DYS97L%<8KS!25M)_M>T?CIG+VWB-,KV
MO+S#4;T;]"N80L#_>YAI(HI',>.P05[&3&%Q^."J?=G"R>W[KR-*$.TI(DE%
M&YI^W[S,(F\C9=)*21>MA[V04O.[-2<$4C9A.5FC."YY+353.[@DK=AK\A Z
MJ'3;AD=I0H9*\T3C@!WPH/NH6 12MU+1( %V4S%RI&^HLNHK&_D#03Y)\Q.*
M#M]599Q<UYQMR<I832(2%P?37>6V?(SRIBCAOE$'+UAXQ[M^LO^\73<'&5&V
M;^%A.:";B3:,2<XZ,;+9SD+8NVG/R/7P0:9$>X4^L&6+KD#-?I&,QDX(SZ,J
M9?GN\GA':CF79 W-BHH(>H^_U.>9/IMO_F&.T)X,TS6;:2G&."XKTPI@,;C.
M0,S2Y*&HP;6#R>V;]L.AW^B B(T(=%H/,G''XJG>16G)*K#O!;4MW684& _B
M(H;L#4SPWBW;SLQ V2C*OG+^W@:O<X+&=O^ E[<J>6Q+F04G'*TR+C)&A"#T
MRN;%),62L +PX@<*,Z>5*$]&SZ.,YKA^>L*T6]&Z*#=\C5'[4B<,_V>?CD*(
MPTX+.,CIIA-/ TW)OXN\GDE.X_(3SC!-$4(-.F+X2"( V(IJM]UF+&:*,EFZ
M$6O .!) ;:LFB-EI9C4"WW^+J]',*;J_[$GTU#2L]60.60,VQ[T8[#E3V\.K
MJ:AW451UQ9J"L39?HN: )?(_E"C4 ?H<4]$]73^$(L#1^^'L:IK$L99RQ@YW
M :K\N2RF;5$ZF&K@2F^>C$E:KR89KMJ;^%7<1[5'6_RU9TNW+:G***^0W .R
M+3\#O_ M,RUSN@-UST@Z0/,N3[=.&>  >D2:&&Y[0ZJ O%F*A0/U1Q;/4N?;
M.O,+TZ9JD:"N\\LN"$ ?VRI"YZMKH6%:@CJPI*R12]MX$E^8[-UBV;C!NFB2
M0@395G,\=^.<(IJ&<T#_?: HAUCM//'9553F:?Y(7S2Q]<6RV="#PT14-O;E
M4$D'ZST&,C.B?"1&FZS3@M8\?@E'76R!N@$^#(4Q!M=:8'"5L;D7 4^?77*=
M"2#('2M$2(I/7X?1)M9%EM'W9#D1%E>UPX-'$Q+<*T>[*/VGC7H,D/>,-G94
MS_M.)"PDT.!4ZGV:%V5:OPA.W%.,G#!AE&N$4+*&.:!Y5S-GGI1/216J%E8&
MSD'B!69*]&E^_6*+77M 0 &(DM5.U-&!\!]J*(97O'!B%:.:W+-#7S7-=-E)
MAW\JLH1H/A?B0U%C=Z\Z A_HFG.L@)T[3E=D_Q><XSA3;Z4;_']$G *B)+SZ
M6X=7"8<*&J+1-0?4=U%9O]R745X1GT'3*BV^V(X&5&C 49Q.-0$+CO^2 4X,
M#5^&-T>$# _)B.&IE[M7'T4A+*5S].PCT(-117>GI]?*L,+I)26%++>PV:0U
M3SW(DPL2]). '^=QBB7!++Y^) VH,@P3!.V69!A! * \PVCNE.%'0X,7)I.I
M!*ZBME5B+)& E=2X5HRC$*::NH3)LIYVR(2U:"PO+^!V/'["R2[#M^O;^@F7
M%SNR7<EK5G&HNJ<][:W[\1$$@#;DHT7L[,B=L?UOR4>R-MR3-P386SM* C4T
M>,DI>F5/R2!P"YQ5TFV)6;T T6^>F6/!Q(\;\5F),4"KU/8MLUFC"R)8/P)'
MD7I="2Q8$+T)G%A25?:7>^9U6^8%8VJ3Q>N:F!!UVXK:=M!;H1Q/NH509L U
M[>NO&F,VKED.\/[SWYP$$.EO1F"0[#<'CH;);]'#+HM*.?.-*$W$*;5^V6^J
MVQ0Y&APDD,"->*H@LNWV/\/LEKK99L4+QKRXEB7*'($'9[E. O4MV(@$:LD.
MG#E:=+I_SB6GMK8:UHS4%(/SG=QZB+RMY0L1!'90+F"*9$I7T/]0(>Q7]P\M
MY$<3[*+M=LMO4GAE\)>1^]CIA*'WMX=.B7K?.Y4JX'[X,):'-B$]1Y()KIHL
M_8;F2M2B?P'W LM/R6ZSB<H7ZB5X0[)BR^L<-43F>^'22M"DX3M9]2A,@#<O
MXX1J'[^XH<&\@AG#FV/\(!K<":7R_/CE((G:=?1VW78C#,8]S"#>WOZC+!M\
MJ>7,_W975W64)[QW2--FD'$\VA\XDPK 08P46^LQ'.F$X4)&,>OB4_@FI**;
M$*&QQ7X,?DRU'P78W1PFO<K_W/9DE6B&Z9(.G(*NCS)\Z0#ZC=[@JL)8TR7D
M/2V)Z+J3F40)9NMR@-#R7F4"&>^;D\D\#M2:4UKU^[ZL]HU?5D@0!#?K^<67
M#R@V0LPHC[*7ICIHKRD0H$VS"\KKS39*2[KN79 MV*.V7[ .&,8RS:S+QJ>&
M]&Y?)C:&QW>LH](>&C7@,+8QBG6)Z5C-].18^XY?C%\0N#2.LH^XPD1CGN3J
MO%5SK=#<P"O6\"E$_,?7TT45D?5X"B Q]50V5<$4=:[U$T81;V CFBY$R3,K
MX49;G<3-.*AL!D*%-)+?@'HVT1M"2%!"@A3JT!+7@"*)QG_\/+O$YL\)FB##
M&+S.R;:.*I\VF:$/!I7\HF:WF^K2A0%(;%$QH-6-%@XJ3V44MZF FW^Y)(:P
MRVB\^6GW4,5EVIRFYPG+51/W\ 9S=24 MTR.$[&_1+IA@RZ/8UB<NC2V8ZQ0
M)8\BY1_"I+[,,@GM(ME201TRB-!IDDRO-)DE_A;(620=\T$!^^E0/C[B&*?/
M='==?<"U.GAW00#J<6,5H=.M1@OMO^^,A95A(Q2F-!+&"A&<U:(1I<.3Z-%R
M\&OQ*B*P)'04>'.OO.^C?+>.8GH$E#\V1JLW>C4TV)IJ8KZW@*I (5=+/3^&
M7J?":W:0Q5( LMZ-$,/(/-@R-D& 34< ^-5I?^.CSSNGKL.:WF)#AT[-<A-/
MG8!EQ@5,LW)A;-(SB,$E10!/;\Y?[LG89U]2W0&^$V9@CV^&0CF]OMFCA?/\
MIL_3.,5;(8J-?J/X(6H?Y>ZRV$1I?UT>A1F8]@V%<GO[U:*%HWU]GK3:URC?
M6<?K<=WC^,&]^W*5S&A7&MDF;P%H$NN."D4W[>MU&N-VR/=X\X!+1=CD@.-_
M.^ LB-@46!&\UL!WY$;U')[C\7,AABF' 1P9( ?I<('8Z0\7"%L%\IE@%%68
MUC6[WFS+XIGW:%7:BA,&5,*058AN8I 6'" !R,*+(M&GP4 R"I!M>!/#:TT:
M9K*?BG7].2KQ=5X3OE.R_V 9&4;;<,0%JT#C+EBO\(P=$:+>C"M76K>,!#+:
M8_,J%\#V=(APK4SPMJ0-'V_2'%_7>#-ZURPA!K9M&8CDM&MIL<+9M/18&GM4
M0]$1PP]MS^(JV$R%*18VH3^5137:?!JDP$RG(XJ3V3",<$Q&8F?L1IBA!F8H
MAXI#MO=%'66 *=9QO-OL6&F!2[PM<9RRRROR[PRSMM!Y<K8IRKI)6=-.A&;B
MYB,/E,8]\_1T$K]GHNT_57Q6QE6U(01Y)--?H78$9DOR&,3&NM:VZIK;O&[C
M)SY'.7ZD3)H<Q\)315^%_$S+3+03EDBCL"F()/)SEZ(1B;)2/A NG]-8F:WG
M@ -6@L8N2*_\C!X!LO2,C2ME%\4X*LL7>IO]'&6[3MF2-GMYGZF%JH8@VD8O
M[&545"&B:0]-&_**M2%/B"J"U*(9/0&B#DV;FBZGWS6H8/5G)DMC^G!S^X _
MXSPI2M&K5R],'P[,UM4,]^R["P1ITRI.AJ<T71N.*I%/.[1+]L+O(4L?HWVN
M96/+K 5=':6T?1U]XOW,AJ:_LK%!+-I)?*'W'+CM> UFN*.8[LTR<*9KPY5X
M6IKBRB';U8 $F/%J%660]:K%@,E\M;"CR7X5>B6A+9L :]T]'R#,',449]LH
M4T[.BWQ7V8Q" PNVA=4SWMN/#@$A-I<Z+K0NM $&5O,IG#]08*'=X,K]YRAF
M48&3=@^ 0=5;P[I"OWN04 JN9$,?V3308:CX.-Z?&VAX-1<%/9L>1,Y!C@,>
M4)M-5X$ZG3=M2/Z;<;IQ-.S_W>"=B.*X_F(>>FIOLI2I(@%?!]CJ79[1,D^/
M/ /E_&4/T^QUSCY'9>+VX.!@^M O$F::H#$U8YV)!U<Z=B3GQJ)%NFJR2!X$
M/;QT )N!$!L)_I4$%]C\'J(' Q1>J1CM1%4R@/]@:CCZ, YAGSR(YPG3C6,O
M:)[0VZ$/T<;\GF&9H8"<[H+3UO&_"XSCWQ4O)H2ZKC<ZMWCB\\83-X!=3RP9
M)TUDI\,B.B[P:PZ/D]BT\FX6I@/>><R[1Y(JFQL3>0WPL'LBK0"JO=  &&P/
MI.%$N_?IE- 'SL4=*X,3ZP&MSCJ;O['DZ,Y!.-"5UWE*1JVS5JKAK:J.+#OW
MQI#74,MFY@8ZCSC<R3E"9])T$Y%*=W_8&=;?!<8Y,E=CF[!9/(]ND.-Q1&8)
MYC>]U;ZMCS3F"O%1%W%46URF17*5&U,R?4U@*_T5+YE_SE-Q%A3\4QV5=5"B
MG^/'-,^7EGZY]2ELFSF>Q>Q/K#G$=7[']-3T'F>1D8YS03-,VIQ+FF*8HUO4
MM#(L:J)\5%JGE(\+^D3)WQ1VY<>#&'L6>1VJ*G[52N/1M]-#F.NJVN'DDI6U
MXWPQ62JYOV'3/@@GNN\Q@1"09YXL<L?QCJ;BWZ].9'%1"Q!C248 ]3QKMOD9
M"'?$)P]77[9IR5\'".>XD =6CG2<P9IATN8,UA3#'%VPII5A8:_3CAJ W_$V
MA5WYC]DMO2O*-4[K'?DD"[LEY4C'Z98,DS:G6U(,<W1N22O#HFY)&O7XW9+[
M%/;E/V;')+557?2F1C'.<3HE[83-&RGU!CDZAZ21P,?>C(ZYZ$W-XL=9KI.G
MDOQX79%T:? K3A^?B%\]>\9E](C%OO2N3+7=WKR-?IQN:^3D+G3M;!KZZ%S<
M*+G\7;<)7E##3'NJ@Q@[7\7=]83YMDS+5WK3O<1$6>_% UIRM)G.RFN4)9:=
M.3D(=.F9?Y+G>=<P>OCPEJ"Y99NT#)G?HQFO!R$6HP7?1\PUZU8?J[F=/B+/
MVEZ403K7D4P<J7^=--6SNMA1'!R?EYT@WK*.5G$+_;7ZVCGFWA[['\'%MWVB
M!M=J,"YW)!M'ZW0G3??,;G<4#\?H>"<(N+3K55S%?[W.=X[Y=W"_7\_U/BU\
M[<<3+\M3H&[9QX=8*+E@/$/A.>SEI?66L,!*[']-SAS@VU@]^]>5(0'@Q9U'
M/TY_/7)R%\JQ^*I\\"BY_.5C?)4^];"Y=CV6"""MX\$^1P^C;R,_X@VOUW]1
MY'49Q?4NRNYQN7EK^EJ^.0'TJS"3/O"Q?MF \;<0,@*FA+2<(8DU1'D#],-!
M? /'J;I)US03HFE0(@U_O'Y:OY;IYO!TH:\YB9/C]-,'3/J<?GH"&T?GIR?+
M"!@C?VU^>KYO,,I/AQ-'SY/5=TT$3/,JC?],.V8MGT78'^\XSQJL$[A0TG-W
ML*,[3[!(XB^*;4=';/BO(I'9:4;/'A]+]OZM/P6VI.6C##Z[4^(AQAP,>/2A
MI&8*%XH8>Z,=<V"H%,5?_.?#P_F,\=RFT^3>#@O<E*U?#_7>_<I+Y+\N"?/O
MHK14A6-^AO3?D-;7-(K>MDN/!](FUX]0 XNCO^\[9E>LD/DW18D*UK:2BDO_
MCEEM_V_1(\]%1PDK,L0Z\_(PB;;JC1"9EUU6L];;^4N#U#B]6':.6]H=H1GA
M*:+]W1$69> Y"\7GG#BGIW3+8;^Y^G1[]ZW?QKU 'X31M/2B,+>B:,873S"N
M13(#_P.B3"#VV0%6%L")Y=*SUM'KCM(7S7P]!O_0XI"W*-;5"8R+XSQ"F#C9
MRU4\M;)P=,<-D^3S7/1R</@8@),-:_[;&8J:&7I4.6(XKRN:&QDZV'5!8/R5
MBDW9F<B_>[?TX> #-9 Z8@$WKW-J.Q=&PSA[JS?@)FU.G<%":88V$[/3CQOH
MUH;2)SS_0=F,3 L%L*G7,]ONPX<@WA30.+ZF09< !>HN-HYEQNB>[X/:BMFT
M\?2-BS;NH4"UL<^L0AL%")0V=L<W:N/IFS"TT<(R8]23-KYUTL:W86ACGUF%
M-KY=4ANMQXHZ/@:?^"/>$@8PW]^LBW+3G-7ALFZR*>H"42J2'G@^D7.61;:P
MMX%8F(7EWLP&T$;R.H^+#?Y$5(MM%F_H2'3_J-\G&3%@(F@'(>1PV@#N/;:V
M\C+0(8Z!6A0D<,#W7!I9C%LP"TY0^J3?H!D10M$IXX[(H%6@VSD_LDR.:/Z$
M<UQ&V5F>G"4;LH!6-7UD^8ROOM"C./;R\B-9;XGN/9%_7N)GG!5;RE,#H V"
MYB+L/VZ:=TI$J#4/5:][A3E9'EYT<>*L#WV7/!+TV6]B!/8?TA@""C!L\C(_
MD6%^(GE^HI'S,WE9K<I:6E+)?_674_*GOWZDI_>*(*SWFV?K5C'&#%3^P9^-
M#4<=[G?H[W,'1NY?4.W>^[\"?46%H^W^Y/]+FO>N_%O"^*LQ'!X09$S7M_?1
MEW2SVV@UKO>[?YU3,BBTKO.C5[U3C#SXK@T,H.[-P:6_C>!9QHCC1'TYW2RM
MFHC?%1EF:SA.-'F/Z(;I?;,XAJUA*J] 1MH$C(8 S.X12#A_EG;59%1^PN5S
M&F.UF!^*_!E7-*N#YGU4]T4=9?+O%T55?RCJO^#Z(XZ+QSS]3S)A4C])S>1Z
M&AO&SKU.K.PFO SLW<MXE&I@QV)LU RN-><5:CG@26'5JFON9'#T@FNT'W[5
MG.8W',!XN;_3R3V"G-TKEAU_G5=UR2[PJEN:#W__%.6-3.V<+-.,;?SX1Y:G
M.W6"9\G0'3OX\>3F3I-LB:Q<S@F26$&W^S<E;<YNR\^BC>"6?2T\TZ3S'^F;
MAU^CDB7W?A6]CA:<G6-J<#1Y>KIYWMZ_3G_XKVV=44^OGV6F._97M,JH! -<
M9/H/0Q;QH\^X?"@6>O(QSX2K7.@!_8MF?K3=DVC03D25O[7@8,?T4-MUZ@Y_
MHFT;Z<@>9[N)8S"DBKWS_=R8$\*B/<WP#?:Q/(^>."4S/(QFCOM><MQ2]Z1K
MJ*;UP/HE[02.H//1Y.6KK3X/%N8J./C:(EWM)/L)=@?#?T7QKD8VP)"WY6BI
MJ-?N.L.9=I4_/>:&%^Y'*M[+3,S*VM?F@<=_%L_'W5]1E8K9A0[CD!RPHD4H
MA^@'E[K0=O'X>SIL7VP6_PX/Y<-;9;_V,D]+?2"(<_^_IT4WF*)1$V\.0!?@
M@&X8%EL]CN<^8JS3!^?F:[K1&.70@5GYRNY$9JLT)]7YC"IZ.$,O2Z3R<VUE
MV\:#1^R:@%:<K>3RM$U5W%V>UM\VU4(;('K3(&YDJ O_NBYB#EH\/=S4!+I2
MAOE17#M,?IW'E5+'X_"V4N.8^]KV45,^C=?[)"?.OJ(=U'BQX6^A*+-_OSNG
M&;[8\;9O9W^MSG;U4U'2IR&_Y DNI><IM)I6=?[2Z<*LJZ&PZ$@A.>Y9)LWN
MA0\:)A"7.H,,PZ=1'>-"BY2B\&E>0^&-E;T6&>GHS,LV:3.9EVZ88S(OLPSN
M&U ^&-J/AMAPG<>$K/QBA=0F"EKPS/,$*E]J#F=PIYG!U;@IG'S^VA'M]/L?
MM773=(#^3RW-+(L#1364USIE)A8LBQJ!!BP@=@#CZ,WK'WZ:O\!QEZ,?#46.
MM9#0BCI@6JVI/RY:\-A-57^T5-OMZ>J/H$6"#V$=G?[XVL#\/.KZ^[>_<W2K
M,B2PN@Z95JKK'@SD%L7(R^#;YY'7JX5QS'45DX*'8E,C65]H!1"9P1W6%*QK
MX/R;DY%A84Q*(!!3,G"B_^!;]L&;JT'QRLKO!=X8O@5L+[:&N.(:Q;;Y=#&T
M,P^',]D/17/X.CR<W;=T7Z9RRZBA0SH5669:9[D+&C%N(.<F2PBUQ#T.8>*D
M.1887NFLD,3)HO59EKR?.7R>6[<N(< GJ.GEZOE^VI1=Z>O\#W]$*6@'3._!
M.6<3QCZN)+/) @YL\YX$AOT<L@?^[@!53Q@WN611C3X_I?%3TT8:5RBFG<UC
M,GR)&5+%CTYIDZ7RF3C*=5&BM*IVC!)QCTT%O&U1\HPGJ35UL7<+K!I]O"M+
M(DOV(K+/J!3-26P[U+YHP-9_JR;X[W9X%AKA!6F7+M0/Q=DG6' %6Z:G^O^?
M;]\9?O/-N&I&CG K94UOD8*B7GK+1[SAO>DNBKPNH[C>1=D]+C?C\CK >#RR
MS=F2'\I/1M\$!H]GN[><](#Y?9W]X> 8J>4;28PCQGE(5_1A?3S'6;Q)UQA]
MD^;H!4=E]2W<PG*1155UN[XO<53MRA>6:7!/USK--S# PSA<JP"R\],">W=$
M%DX&>L7@Z:Y%8#1)(;\Q),C$-M'MCQL9M<PBIS9FR@ UXP"MW"Z"=%92$X+_
ME<W.S?"BAB\3>UCP-,D>\\9$1PTL4-\*$^.=/A,J0/]](?1<6+4$.%%O$=;]
M:7BSKU1F?&A@8#1:R:BLR1T [QJL&%VWAP?*E)B3T^GW$S1*$&<9VC0C)13
M:;^>V?90?@CB-1-.._YP&\?BL_88"2Y;9P3+N$QI_K&=:X_QY>ZA2I,T(C%R
ME.';-9/&%%OJX8'B2IL G9A2!^P_GC1S,M0= D7W)\VV!/JYS9[G#]$&TXU6
ME%=D\YWVV\GWQ79 !-(C9Y$Z"F7%\J]9CBRI5>Q6J!C%I?\E84,_(3E(L+WM
M@,>HUW>WQOA4^AW&%@8,RBK?_NA=LWLC#[[S-;I#M\#1J)7'.SV'DZ-0]FSJ
M<YG6-<[O=@]9&M^NUYB6V->&I'84__&IJQ@B6+7!>XU<W9@9Z(.,AC@>$HB
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MOH<A&A'>);+2#+PJY?H'7'/W<P0/>H?@_UNAJ15$_OH!+,.(9 0H)?N'(H\
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M:^2Y)%3@8:?]F&.;!>3>@=Y-<.$L(5I1E_1!.S=MK&@?2UK*;,WYZ0/.#A,
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M3$";3K7NTM,_6H[-AH%Z2ABH8?"UE$=RL&E1D[M873:.0<NN^!,GOM0Q;'_
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M526,S\9'1_TD0#M)%3A1RH9[^\1<%'C.FE91H(O,9LTF(F/_OX#O5<\9^.U
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M05(ZIB1,'-]4'OT>>'F2 >!=O;O8)ST-1]:&5+2V/B[#A#3"R +%1;=Q1K<
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M;54P).FUXV+1(*C%P^&KU7]>=!%4@><7;^#KOWS'$CRC;O['_P!02P,$%
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M^T(H-27(U^( )-RRH:-YFH8&O8O!:L@>Y)RF.-?3NCGDD^&H8#43T<4\@DR
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M/&]R?=%Z$2<\W-_LC<$?L?3B5&;07<J1"M\JYQ2J)<M-,/*M4_XF!-<M$ Z
M\.L1Q#?:I9W[-=_3BOT$"R3.0-9CF7/H7)9.JZWBTN$3R7X.#'SKCYY$UHF
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M2P)4P+(F"3KK2M'>(IWA*Z.*T$\Q%,=U?&N.?7BCW]'%7\SC@O8X?D:/:TT
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MNN8@J80ANO&$ 9(%?U\LXQ7=3I^#4M94; 4^S/2F"DP@8Q/'M!P4&+<-#(Y
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M,; ;_2(+ [OQ^]J-5]7:OI$S9UN?+^7,M[&YV,.)@CL0(.]:7'U1LRYC<FV
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M-ART@JSA0-\5:E*O29AM0O?4>EA7PLZ 9DS0W1Y\D"T&3.2_KKL5;NZ>*!.
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M@1RN010W5BS76.)QU^P/IOOWO"._T'W@9OA-G=T!!+Z=MO.;4O,]!"ZNW.X
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MWW'\SE@'?M/(^U2-?A:LOV-O_IB$;NNY@N/Y^QI];K.,D]>]O\Y?^'IMA+Y
MSZLW8LD7AI(K5^^^E8ER\AJ"MUM\_7IQ/B<C7-N2!<Q^669_*UOAKIG]*R#[
M\9C4UV+VMR+:=\WLU[XM &:_-+)?@!@GX/5;<E7O9Q.7-3NZD"R2>XBL6H9M
M>+Z;A'[OSR-T(=_[M4VROY^F]]^U+PYG[T%>#/;EX'&9Y[Y=5M]YT3NKH99(
MQ-/F/=,JKD=D#<-EU_M\[ZQ'06-ME?U%S!XO_P?ZU,SEG:H;]9T/6_QHM&T4
MC7FC&)>O8M]^( \H^;X)=S=W:\H!F3U3MO8=RBS\4F9A23#F4UFS-U4NL(I!
MISAS!M6@<T&9E?-AT=.;^)(SMJV9NQV%<XAGH]V2B<S2Y'ED]BNJV6O;QZ=2
MLU>^Q5U.9)&#:G9)CJHFVEN4X=Y0QJ;U6I6=%2^I9BNDYB["ANQQ=9-H3 Q+
M4.OMN/<#$T]5(NDSJ=EK7V&!R)XG _<.)?8W);M;S*;#5;/B"=M)=>X.4$@1
M@L]W</RXQ(Z=Z43$JW@%+F^*L$YB:K/12[JUH(G(4LP1D;V+0./^[M[5/$UV
ME5ER>5>UM;9PEG&WJ_MV-&?)+Y7<&ZX8EL^"HW+O*;@V$;(!F!?Q)#R)?828
MQ9]"_SI<SC1=G&,[Q39EKE%<JQ3/[]IQQZK$C\!@Z(4GEMV#@P$@R,GCMM<F
M0J80Y+Q^C8\B2-=H64R97V\C@\L<[UQRX%;@&$$2KP8)IP?/ A/D8@ "7S<S
M, L LO>B7)L(V0"0BWA9/@H@;7&K+.1=$Q)(HJ$CLY$AY)E.!"#,MQ_8 XP?
MN[#=8_X  )!L 4CBT[DV#3*%'^?U^7P4/V1[P!04+1QP<HL->UMUR&]@-L*/
MV..#/: 8_3&/3V8=.TG[ZC=2R/>#WHXEDM]G0<\%0\'7AH+/P2'PW&3<<_,L
MLT^">@#J_+RX:6@M&S(+1*6A=)>A,FN'\9YBI$,8"F1] %'_9&K(M=\U4Z)^
M7A?+>T1=A7<2[LPYQ82*VRI9*G>=L:I'>R+C,!9-O^]6!)3Z7=]Q@"\DX[Z0
M]T@ZCU11=(-4.9AL3.LZ.QZ4(8F-]L1\^T$\4!@.<DR I .G1;:=%N\1=*4Z
MZ5H5%'>B77-%DW)%I%F+!3UV5! /#'+,?+^+U)0,.CCOP. !!<-?I#H^2^2Y
M"Z< D)PO4FJ?)?( E9.EM.\L$>/Z!1^9)L\]7%F!X'R-%@"?ILXM!:3AM^/1
M#<?S<E/7L0Y-V ;.:A"6NN4(=/I.\L_["$%7;<6QM%AVO^6\Z-6CYQSP9Q4T
MM5S9TH6A*;M"OJ*4[0XAZA+]>C3Z7W<1C@9B_[6CT9<7^PN%H]\G]A.,'S='
M>$$U^9)K,&-Z9N;S;"3VKT:F3R/V7U';?YV 5?9#TQ<4^\O&IM\G]H[:&-3:
M9:5E;B4JK-0G@EYHQ=K^U3#U:<3^#B[]0.QO-TY]>:F_4*#Z?5+/KS9-#4(9
MS>2K6K^Q*#MUNQ9+_>LQZW^!H#6(((#0&PA:9X\\5W<=@*!U5ED#!*V!R@&Q
M-Q"T!D%K(#@@:/VU@]:\/]/<W/Z"_.K<K:^H0;^BA0FN8"!("[C]:UV; +9_
M#5L.W'5 2 YP^]>\H-Q>(&K?V+L:3U?6/#]G)/<3X/4#W7C?C,J#?MZWFI);
MM=>1K,<-\/;NB"?I/Q"JUU5$Z)%FL\61N_%DZ9JMW@8/)02)\W&_6A]O !S9
M H[L9_7>68^I#P '+0@+J*D((Z$N[C1^4A3'-30!#O+;C_<-)0,6!^B^"]IW
MWT7+J@\ !TYY"Q5N##%NM2Y.B[[ $839B8&#N;S%<0=."0 <H&WWS286?P W
M2N* ZZP$N<_Q]4$1+U9$N%U/#(XXJQ@_UO#NEB+-'^C7_2+@#.+-H$P2>&*R
MYXEI.;;S:^W$ZR,))JW%U*DKK QK@V:G5"Y;81.+  Y]OROF*WI<@+@#_TE6
M_"<?$7>%:O>%MF_C<!":J%H,:C2>9V-Q?[<#!6CWN[[5 *]'QKT>'Q%W<M%7
MFDU4U[B"5X<7D"T@*M2)Q?W=;H^OZ-T X@Y\%1GQ57Q$V@UG37%M:Z<(*ZK<
MY@LLKE;RB;1_QEEQ>UDG&?1NWH'M XHX0?GSURM_SA0Q@.#<>QH_T#B@B!-4
M/X/JYZP0 PC.5RDNR/IM[EA(NJ7YN;@M& A$WW IZ*D#S9F2U!MOL]UVG:GA
MO]5YKX69&&'45(0KPSM/6Q7\HEMF)01_:J]-@/;:0%QOX29WX^VQWR>NQ&19
M:#4J;5I ]=ZT8[0[7BL(8W%];(N-@;;8=U.,>^I [Q<1UXM$<M\GKGF-@">.
M2W9@<M?3N\*LT5)=/1;7QW;6Z3@N:&<-Q#5[M]8;;T?]/FDM:4*11TK&ABM7
M5=86L=6FW$ND==^&FJ:.:E<0AP5><1!. G'8K)#G'J[80'! '!9H'!!.R@@Q
M,GB/SA)Y[N':"00'Q&&_8APVQ_J^:TP"7YXLM)SOY%J.#<4W=M=9+*+MYIXJ
MK4' %I02@LKAJ\1[=YKKJ+(W2Q4::/[/.6LOY;CO1%+\0HB/=$M0\&IQT]GA
M.[.W#3BEO88A+NA("!D'@B%03 P0X/Z*B2_HYKY,-?$G<.!5;[BC4KBU0B&4
ML]I=.-_:P6&SE@ "^>T'DJXW!G'F/PE<75M,0,'Q?<:I3PH)FUY]NY$[.,61
MXF M"66QI?432& B2 "A;( (]U>3?'E .'-1\BD!01E9?:^SZ]4$U%I,-&PK
MHIX7QH"05"T?S6X!X7(0O !1/Q NSPIY[L$; 00'A,N!Q@%1OXP0 X3+[_YJ
M"P0'A,M!N-QW<KVM[<^TZ+UR>2,Z>]U0O(>XU_;WG&RKN5XP\0S5D%U#N].*
MYQ2MKA9/PY:;G.H$\;EDP5=VE)W^?BIF.!1NOP(A/H8IQRASX]77O[C9CKG0
MY'EQ5BXYU8W9(PL%>48Z?9AF)80^6H!](@3)U)47(,A5$>10N!X@2$:"^<<0
MQ#9*PDSHZPL8[:%*D ^"U4@-8P39UX23U!D1!-@@!\-U7Q)!#D7W 8)D)/9_
M#$&F)7A+;O,LS]7G-E\;6X5>;:['"/)8IGXPMG\B!,F4$P0@R)5MD"S0X88
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MHACSV9#Z53 FY*>;'M)S+0ZJ]@JEU@;!J##!F+AV'4$B(X9Y@-%+@\P=>%\
MR)PYV XPYN.A]JM@S!P90=Q0$F2XWL+XQI#'EXX?QA@3!]X1ZH'"Z0>2/G99
M2GQ;_TZZ*Y[A+!4M(K'[DGO>ZEZQ7_J<]A'/GGPG2IQ\\_%(4&.Z?6OW^[]]
M%N1,;#U%]P1:XBT]BE!/TW*RHCA6M(=M[,:S'3_Z,-^)9$D.5"/V D;R$>W8
MVW^7)-_(\:^GABW;BB$OHDT_#F/POI_P-5XG]WO5A6JL?_PW^O+T=\I"D]T8
M"6>_G1$6?\@3#L+_. N<_7H4*/X$\\]'@;_8=/+U?_[?R\VG@?X1DE^\U6PO
M0&B"SKH&35Q--B%Y&GWP7_(BE+?>XUM2S/=GB_*O9U3'$N: OV/$/W(OOH_)
MD:*E)6^@%Q1[5 ;00IOZ?SW^V=/O$B!__J7C&3'T_.5J"SEV#,=/_^6YR<'X
MSO(O-+H*Q7P0_?CX8CCRG2+.=%2_R0CV\V#^*^=F;JP<_M;G"X<D_[,?N?\Q
M?E $RI'.6/SG)0P^_NH%"\7$C?;33UK@.M-<(59<D=0],[U\2A@YL_S]RCZ'
MN$).U)M$*"HQI7%$@DF,EG"%(25FRJC25*4(2F%@!9.I;_N7OXS>.A8ZZ6UM
M?Z9%AE<N;T12JAN*][ WWJJV\CV)B/2"B6>HAAP/TGF.BNS?M?"$M(470/L\
MZL9SIH]M:#+SNL\;SKW<<>[GEF,V?=D[)\>M@HAO<O\L:E-#,?R?;6^N_S+_
MK-HY?^8$7G1*WD-.VRA:A &)\9@<W%)V<VMY$40_61$.^]ZE-W_8Y*">D.0T
MYM.CU*FD@L$RK$BDK!(23DXT:4)JM*1J!$92LDR@%/+(AO*3&;K0[-V$VFAU
M4S;6-L;6&ZZBL;$A_?O*?I'NCBIL7A!Z&#)>BKO=V-#CE=3O*SU,6>\FFRDJ
MK)C)2B>Q7DD=A+%Y3OR^=.[!$-41U@.!A]N</1)GAHPF2^G?EP8+-6A,RZ,!
M9W1: [C&K(U6NQ/O-/52LMD;M3P.7L,]I2"N-83<4:(NH>F7PH1:I<Y4BR-!
M6^!0<Y4O+<O5R J7\-3*9IE?-T<D(JQZ6GXIV9V0H.*5J==OV"S)NH:U%- %
M/1VKDYV++3O12N;WE3ACUDIB,.O"J\EHW F:?A>+JX*2*\!O']^P"SJWJ=#F
M5IZC3K,--U Y?J4#-+4-?!JH51$VNGG-:Q+XDI'CST_3E,]S=6(X7O>$ M83
M5&X\+)?*":%2-"4'3F7;[.DN9VWG8A7JR4K-9"5<@G]?J6-#(^)@9BO4J8 A
M.\O)JM*-5Z9H&NSXVK1-^D.N;N*-RJX9NIX71BM3E*(59E:0%$'G@I%H-2MS
M83R ]-ASG:+48+5DVT6Z/^(L)BQ4JT2A7X]>'S] *4K/;Y=P?D[!_!SSUGDO
M+-%$\M04I0;><@T33'4 !WI^' @MJ>QNXI=*4PIINSY6V<%M$YJ0I<FR7JX'
M%AO=2%.4@KM]O $OB8')0[4&+OA2M13= :GTRHG4UV;MS4KF9**G4V)0]09J
M1Z+3*UG7A.R6(\PYR*HA&X^%.!)G)2:]DFD/I]*2+];-E;2QW0E10M%6)UJ9
M(FFGR57;_4(3Y@S;T*JBI7ML38]6IGB_I(^0"!30I0 M8:A:VBT5<A<_$TD?
M*6YQ!%T;\V:YRC@;5^I7II&8('!ZIVN'K8Y04Y%-<2B*T;,W.[&K2PAR@% X
M41^9JJ=RO-2F%YT6Z<.3"%#0]-)\@46,GCP6.<LE"4X<\9Q:C#: I9?NA*5+
M59<!+JSTBC28- 5X5TJ6IF@U&RG+?."C:]A:]=8XV\-IK!_&2U/$,A;D:#.I
MCR="P!)=<E?;B&B-C9>FJ34PZ\/N-D)X.+KZ=:J5>JMO!M$.#LA?.3\R670.
M5SC#%57=)6QH- OCI:G-VHP2.(,BI'-0<;TH:XLVJ2%LO#2U697PU:T_DC13
MM+=5Q^RNJIV*'B]%R-_7KOK%Q7@F00)7'PMK2AXT-2LFUP$1F,J8O&W* 0L'
MR")DS XMXF4V7II"BU6MT,.6RP%KULNK::-M&_,Z'<9+4YMMEB4<DHA2B1--
MW($V#%(CMWJ\-$58UB6$B4"8C" 'JR9-\');19.GIJ&ET8"I7G^Y5F'1[XB[
MP7I>'Y+)8]/84FJ5>SZG3R%N-6$]9ZW.U^@HH4$:7'I>K5U8F!S-K>A=F]3]
MYKH))\]-HPO?5$K!T)!(#FHK]6(+YB?+9K3V !3D]3XL(UX^--%*>8@ME@32
M:[/QTM2;D80SPEBXI\'0;,(ITTF].!'#>&F*ME5:(2 IQ!"AUVE,^PPC;DTJ
M69IF!*UI^/7":N@+A;971E!:;Q#C9+-I#F\0F-.HN34$AGI(EQTM6W.7CG9[
M +GR2HLOU&N]/KQ5'4X@&BZZ["9+4R]6<%9EB!K,VL)J;C=8NM<U1YLP7IIZ
M,4MT.Y/ESAL*04.H3C?(B,6;R=+T9JUZL]= AX.N0.XJJ#^!ZT@Y3&;NIC:[
M0"F[/3<Z!6&[@?WVF!D@G4X8+TUQ^&0$ZW6&,'VSWFYCQ(P0>_56LC2U6095
M?6J.K/-"?<A-*SC)4B+U-/3W-^A Y1DC=\L+P4)673C$YGK>>)ZJ^1L@.'[T
MKUT9@>O]QKI@V\@"K2>/37-XK1H9#R5/R@NK>EY@BK7J6"[NUZ8X'!D%!<N*
M/IQ#S6Y!:T7HT"*3-WOF\/V4F"?/R=ZIK3B+A;STM+^>OGEI?L>.AD<G0WPU
M5?8WZR<S.O%JR('O//UB[])(?O.+Y^.%7_QQ3=JSY+M/&WO\0&1OW;^O[ F%
MOQ-'<U!>W+=?/-^)GCE=..&3Z?_T,Q2' /[:^XG"B$YO^F<>;Q3)!S\ME2?1
MU2_PM4OX9=YH@/SLA/V0C^+QZQ\F]QZO80#G<IUSH;XCX%BR=RR1N-#@7+)X
M+NC1PD-P+E>#L:-%0^!<KH9C0%XR>"[D=PS(2P;/!<A+5L\%!?*2P7,ADZP)
M<"Y9.Q> 8UD]%X!C63P78(]E\UP CF7U7 ".9?%< (YE\UP CF7U7# 4G$OV
MSH7ZCAVM  3G G ,G NPQ[)^+LQW!*3#G.]</MB4^<WLI*L1@?P $<Z:!W2A
M&L_WTB15.?)!(BG.(O[E_WW#OWV68-1W_+H#>,B/$_1X450\,7Q?]I3[>_1W
M,)(4"DT.[K,0?>C$-:)]5;3%.BX=D^,]RK8'O=SHKQ_QU \@]=1?E[5E-S>(
M*Y9>Z[YW8N,D8[Q]>58FOM/T/;%R3XNK%'/Y7-O5IIKK:BK@I'.VQ+UL7^ ;
MH,E;[K:O2)/[EIUG%$8_B\+4N6W0$X,LJRB!%2SBRFF KA?A$/H[==0IF34.
M:3DV%#=[<)W%(MHFX)*+<$G<$NMH[4#6V*3O^/)B?S5XV7,A)A)"_>=7K@$7
M^\Q=[#_.#?NS3G\]P=LF93-W=)%)6L"=#CB/UJYDE1-.H3BQNW+5L$DCEUO1
MIYD"B/W-['Y8X=0(<9.L<)++%T (P!:'[^1WQ!;M:@$P!6"*7YCBL:<=X(N3
MN&?NAR^J\9]K'F",$WED[H<S#B(&<,UDSC5S@U&B-_J>?$62G-UO<Y,T.=[O
MXRO2Y*U>&U^1)O<=+ +)"8!/0&+/A64'\ F0'2 [0.\ V0&R V0'R$[&:'*\
M;ODKTN2MFN&O2!,@.T#OG*).]89I<B!>\=&IM!<*9)!OQ3&.Q6KR\D*V%2TG
M^[FBIFCQK-9]D M#'D>\Q2-B7XOQG6Y8\06R4-\.]9WS%<\=N?@MAI>:,XQ^
M1XG?W_H,HX993^*G\3 A[''2\.-88.EY>MY^5E[!L9:.'0_38S>&][QJ7V6:
MY'DW$V:4\C,2'5$PH7":(90X@?/:/L)^=CCQ/A_NQ1CB W.'87LA"\TAUX%Y
M:+2%JR'1+D#)(*MO/U#F <69!P8E+CS9_!(QGHMJFA,.?3]_WL QROS]S*AQ
M7J/CG+ A](H2%ZSG#EYL=$S9TF<&J=64]DR_.F9 V$= XT79R7XG55M9!/$Y
MM!TWI@#K^ZXQ"9(!/7VGY=CQZSW6-3WER3PC#?:,-)Z&A6Q7<6NPN)EWBHTY
MS'>3Z7I$C#271ICKBM'Y-?#9G20WHX(+"]GS^/W<W5]$:5\9GW^NBW\I5 R+
MM0FV*M=,,3\JJ^H.[ZW<\)R*..#17:4N#2T3-<VF(#2Z/:<5#[^DOOW 'A@*
MNR\)N6D=?'[)NIH./GM0[S9T\)E (QN:N))O!=.@2BQ@4=25 *[XW)1.1N+"
MD2I^P"D*8 W FHM@S>W:*!>R]]F((O$VY$5;-M2J79"7AB\O'A$']L/\0IBM
M5C YI[S! H6<!I%!VU]K"R-I-9-XCI]@DJCAW0K-)8B#18B#PP\TB@#, 9CS
M!3 G];JY?V8+<;J:+QNVIG*R:T>$\1ZA9KQISBH[QN@*1H$E^U-I.83=SO6A
M)B)R]-$',,?IS(8S-%C"ILA!DEHB.YL:$_L;XKG4*$X_P R>PIQ_ ="Y$NB<
M.59_9<?FF:/N-P\ZA\7[$7J(A3IN3@OR1$#IN;0K\3LBKV3 RGD5>K@:0J*+
MF44(J%Y<:WQ'T@PD,7>8^()%'7#F . !UL[IW^[L*0L9!)YZ>U1#K86.F% ?
MJ9%#'X4)7<\P6K1%C5OYBC>#17%FFT%H;*I$[/E%T6\_J <"AX^A!2@US6:I
M:98I<.G"TK=AX=H4N<.<@ZRE%F2> A>O&;T)L?CB3''Q8@/ %-EGBLMD1V>9
M A>O_01BD7VF &(!M 40"R 60"R 6&0@Y)-Y"ER\&!.(1?:9 FB+B]=97DPL
M[J?,,HF*0!/9T^*FH-92LSTYCDR NLDO6S?YWH!=,7 35I$0*8G8(5+?D;#'
M\!WRQ^50"I]'R_E2WX>W.E[2!Y99''4[1RHW=IKKJ+(W^SWPQZKSP//C'7A]
MYY4TS*2P(Q]+0>&%$"3;X9?QMUY7B[;O1<?=T]RUH6CMZ$@<M:LICFXG3SQ0
M"M)VN'++UB:*4( )754GXD8R=(F,:S(A4(J9F<2!>Z\A^Q+UF%>'H]^S$;*"
M1S\3%(8;$\<44\F;*U3>22QI8+K0B?"(N (>W;O073U!.8M"]ZER+-(+(=5:
MSBBX,+:H]1RM-+OA;5D"LXXJXIA7ZL'ECN#G':K*3QIL)'G4W4G>35L"UTTA
MO @HW7]5:$9 *?OV0(,/2U5EV4.Y0F4U1C9VOL$8L3T0UX\"6 *P!&REK%Y0
MCI>3EBIF?^OA<@_6ZE6,M\B..F]\OH#]>@C543O;(5O8HH((41[B#$5VT UC
MA,*^_4!@4&L*, I@5%8QZI4"U/R,Y9E"=:UR1DU5"<H.$4(]6M>1/<MIMH!:
M4X31&C Z;7$-5U2FJIO@$@DLIPRATI6+42_AVKUR1>K-H=+1"M5%>6$+)0L;
M"MLJKJB2FY](VHUATZYM,#8U:*XX@RS-RLO"0%3DV-<4%ZT";,H,-MV]Q73U
MHM4,8-.Z+:Q"CZ$ID]^ZGC8:[WA$N\6;V!(=FT5DJV\%,1_A7=ADN9T4^XKB
MXM;C-[',5;:^*RDF9WA>H*D1?ZB:F_O?5>#X_Y%]R)]I4/2WIN;O?Y5SIM/H
M^;9^"P6MG\>$+Y3_\H&FI5>/.;^G>:FWM??%[]6$H:,]QR7OB<BS?C-A9?Z1
MAQ/H.!"^(CT:&@9.$X57CE55VU6J8&Q9B8H362CZ@:2)!PQY7W-QD+AR/_DI
M( WE!M)0_A03!O(BT X8!/9TB]30.DUR00LRU_F)/U2D,,($(L*$][4!S]IM
MXF*2 'R)F<D-^;0D_-2.!#H(^'&/&)A0HZ3K=*L?,GPL">].[LB:(-R"4LSJ
M[1ED9&06"M[RW9U *ZXP;6<,1#$T>R4"H>>;)@;/] @+WI]2 <#@*X,!L NR
MEP=Q EQHB:V68]3SEF#US(HQ7>#Z-(AOT'$B TD\T/3[<AD . !P .!P[02$
M$P#"A.ZVQ091XF"T&>B2-=^)5"\Q%-Z=00"PX'[R 4#8_[;#_B= !(V2K.ZF
MT-EP=9EJP>' ;FR1V(WP_K@]0(0O:QV 8/O)@NTGD.5@T(*:N[E!<_6>7MC9
M.+(CG21@AB;F/D.F>T'?8WL)479=.8+B'+?17,7P-!4TEOBRC26^4&!]/RCT
MB?N?F?] \*"N^-QXV\5"F+=A65\8"]9=A!(=A]81Y($DB <*O_@<OWN+N8-F
M$2!*GRE\^5-#)#$\7L>7GY;(PN[T[8Z"JV8 +9EF3RSR337&%R+"%_2^LH&O
M+SS 1W<+@?TWA.>G<L9T<CRP\%U'0-<27@B\>8ELLY'P@+8-F=+)6;W#@[8-
MMP<K?^#I>[=2-C&3J6GP*H#1@>=X]IH;06R,*Z#Q @ 68*]DV=B_=L+!NS%F
MNYGP8H!:*S-8B\-VJ5Q6(4>/,0;[]H-^@+%C'DB ,P!G ,Y\M=R%=V,+.^9Y
M<:9Y2Y@4!G21SFO5^K@38PMH?Y E7,ELN@-H?_#U\B#>C2Y8H6*;):X@<*N>
MJPU:[$819@FZ@ 8&64*7N[=:0$[%)7(JWHT+[DC@NZMU8<Y9N"5*C.H1K5:,
M"W%2172CP8^%,VZO"4'BQ<JQN6<_5F[?EZ!HK(U(V%4/=!S(>F($!"K@004\
MB*UG=!##,Y#^&BDXH'G$0FDS7K?@NF!Y@^JN5^IU^'9'8MX_."%K=N<7KUHY
M$3#?V]W@?JX (,!ZLP'6C\.S0E/YM:?G3:Y@]W5C69C51V$8P3,HN@:R?Z,:
M*LM&V:ECH'^. $O3PZK]6JO&B0.:+HF<7['[L8$6!SL! @ $R#8"I%XM]\\L
MR__)8I-'>YV^7_J[A&!KWJIE"9K?@(R5[%@C*='_Y+<?*)X2_W\!^0?5U)F/
M(H([*M!2F8I&75U+G;B9]OL5#(3VVF-N(,"P2 <PV=G"B$3$"B:./!U7,/=3
MR\M-IYKBYYQI[M70U-(U%"TG/S<I!\6^7[;8]V:B!>\H(_JEZ_Y>#/CIKZ#1
MCCG_0 41A=5)C#9M5B@L!<$L;)LKP^Q(" QFP&<KER6KX190UGM+8/*>]+@/
MH\E/.P1MJT5[5YL53(.IBYTEM=T0(SU&$S#!'22MWW)0Z+Q:F)U,NJ/&D)/-
M *_DAR[)8A3$QG(#"GDSI86S>E4'A;RW!REGUL6:@15MK8;KG+6HKB"G$>PH
M*L$44,0+0 78*5DV[2]6Q/L'^*+KU&C=RN]H#K46ODU._+DA))Z#.*9-/>#P
MG77O 1@#,";#P8<LA<@_""T10:,''\"84F$UHAK-6EW8=J3Y"FU1+B2&"<:0
MKV',P> Y !E0S0NJ>>^RFO</3)BQ*##H$K="05N0A$G6*U#-V9LPH)(W2\AR
M]^;+U7,G,H L'\^>.#$<]&1J/A'%JL)9GB?6W49K7%PFU@;Z1C#TYHIW"XX=
M;="+#_58OH3OY/91)E#*>R=I#_?8X_PG,SM3+V%E>?G$R%[\B=%_R<<G/^PI
M<" (4VO5L(E(]#T.6O6VI@<WE/F(E1!$2LKW&89\H$@:#!$')=0@C^':T/!N
M+T0:&R9'L.%0LQ]$&T>;6>I<&>M--B2FKQ:S,$8%XML/,$8\VTZY+,K"]1(4
M/BD+/S7D5!\0NLN) X$G1MZFY!?L =N)90%,$@?U 2"W(#MH\)Z;\A^KQGS?
M&G7GW*0 0TL,&PT:],;?)'  ZMH!'@#KX';3 OX8&J)_&Y1G>'$CB#Z\AOI#
MN:UR>@(-6#S7YX%&,( / !\ /F0RJ'\6<Z'M;@N=!JM;PA9MUNO4MNBW_>0F
M#4:*@R)X$'R_Q>#['X."N-(4J%/VBJ:H$,;*&5<&Q5WB= =3Q8&- .+FE^V
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M8("PL94>F_P[6+P:&9Z@),KY;&O-091DU$>5HF"K;((:9)Q>1V#D^R+# #I
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M N!30'$_UX\/?"]^M>AL#DSV0Y<+#9LWB+P@MC;,3%]S+5UB)82,I_\B&/H
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MOOC9'YH3#_1+.@1[:]+QM4.T;VD9G&B0>:A2DCD-&PQXA+5QK*S'6N;]@50
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M]^I^V*>H30W%\._8C06\5I=S4H'@X,W,6+W@2-6O3(&W>GQ\4;GXXEP!4BD
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M@ 0 "2CL+ !2]B+)GX0E;[-HU_4:M#6U?K]@HLI(;V[VL/3N:#. )0!+ );
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MW"+/J@T,&*1@GP#&EP4,$M@\4E?V&"R>C%T*\\(R8:ZR>3$?B:9$+M'T&J-
MS4C\^,/>)!/<ZZ*7!#I(+/+KAAP)=1/!>&UQPK,+Q@]N$/YJF<:GU]-QZ;XB
M"=/TA ;#5L+CF!&2:2@L^*),NYY"_!<CA)89V>F>0FEA^Q12"GZ^4O"!9:O
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MUHS>6]\I8J+3BN;U1"7N)>$.'"'".UH#4V[44X56H^&J<FD\G*Q':.C!!):
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M;#NNN$R*,E^OQMNTR[ "8D5HFS*)8WWFK]XP?2S_-[7!*_@>J I0FN-X4!>
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M<>L:$^_:-*C&<^L:WP=KVT?\??TQ[WT59:."H#1#!>])J)O K:5\V;9ETZ7
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M%GV"74.<##7X8-.V7'83JB@A3^/MP45WD :0\)HB/KVA)IXZ>MA(V7&\Z2S
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M<D AHJ?FD+PU-W U!OKX!H$>+2,\B ..">ASZ^0,W"0HMFC*QLK!T;:09-6
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M"Y2QJ<T]$"3$PY6'6N:>MAM CK/=;^0%G*)DK1G<8P-ME7/$I?B@B*JXZF*
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MLSM\#W\V /H!(BF_P_Y/HNRQWL9WV8(6[S;G8MYHM>747=FH-_R@MW&2/KP
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M#54TE5L*RC*JY0T<3=5D6T,]A@>?->D# 'QN!57+A2]V+;3)*HH6J^@G'!M
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M[Y9JCS6'FB'"]^4='AFL\'?Q;,80'N"[*;CH*OPC.C:*#9@/?1]08 EL17,
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M?T?B/KF3[A(7_1T/^H4DPZ^XYI<2^"YXS4>4SL-./8H"P'#XN,G3I6FC:=G
M-]A'MO6N@9$696Z"'UB:21T[[;<N^'+9?9/3<+HU?GI %U?9[BXZ^GC1)[O5
MG6&E*"JT9U+OOHM4;\=:"A_C.D)FZ3."GRG$FQ'^Z;M(SWR_.VH#H[N..6G2
M:P& Q/S_L_>F/ZIJ6=SP]R=Y_@=SG^[DW$2K&1QO]WL25)S+&:<O!@$105 &
MI[_^W7LSB(K6:&G5(>G</J4([+WFM7YK[:;<[6::(AS$0OSUFX@F,"**X43
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M\0W34&O/JMR8<%-,_.N%8Z!"XCT$\1+-XDI?5:D*)M2,5(6N)'L8#8A'QB_
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M]@"U(,*X8!L_!AW<+(80! XR&DUD<P?@!S?Y>E N0-.&/1D.S1@R/5WF#,2
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MA$7\AW1 7I-FN*TR>8_/L=42&5:O9MI8CE)R3;9N<>5Z"RJ9GYA:" $4WQ)
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M;%4:S-I]K:=MMRVXN_>:LQ>*<BC*WU.4'R"(3$XT26^N<I1<[<6E'MW5C:H
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M%Z,$ND-(VK*3V&3(P;OB;F?Y1]Q*>=Y\()/RY7QYE$Q/1MABG=]N]LN<:$F
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M-,\.J:ZK?A6"%ARGNI;H$@$ATE7_\X_1U2)"P^K.A&D?%OL0 Q]=?S3T<:E
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MK<MC\*S\,M5M3R^2!I3QYO*T*.]4"I4%R%%)@(69@3>7,<.#$D\NEW 89->
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M\//OW>V-[_[7+U^W6O7/71SF*SW0HN-G]03P6B"S EGLE&?CM$D029<^#(K
M!^UU=*]ETP0.U <##R.1L6I;ESZ]_33'A=2MSB;I]J2AR=T-+7.FR/GQ[=[>
MUV2T>^Q^7_\1C+H'ARO8\\9G-'5$$44RU/,:%F<!S[E/$:DGHQN*KP])L&0Q
M#]LZ%P%6#AV.,/3.4:4NAN4HR4)1)?6H720YZEK$F[W[70,P@@N=IU2$+_%O
M=F_',OR(:+!CVR$F@"\9:%@R^>##!WT<_=[#DC@Q==<MF5HH6Z=%@<(^15>
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MQ&GILBCFTTLPDBZ,MI7=6P=A]:B)N*RH[.]V=^=TF/Y]\2/^TOFX>_G^.OA
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MP@81@8N(E W"O03PUUKIEX'UQB$AS.361K@]!*JDN.G:]E-F7OC%B*&-"KA
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MJ0FEA8R2AAHL2*V( H?8L$-5_ 3P$0LLAI1/@D_JQ8^YSEG=%3A:&+FASN=
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M*).DG(C(RS23W3/&4OV>?$1&02%HJMAVM+S_$U/Y>OFYO\K$AZIRIT0_Y@E
M/#L.I3 &<AJAV4]O7_%<)3&FP:B8("TDM[.QV8B%H_OTLUW*8V NQ"6PML]5
M:/9M!^4LF^]L$1EK9PU"BEUOG;6S>@F+%)G-074!=.](8!J@;9IV)[.L$ZT
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ME!P-2!7QE^AIV^P$3$5/]9$HS9 ;C:4G8-0*38J?WL=/GF%;'6"TLWO',#I
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M,!5GJ%5>BZF3')+  'I_$,@%M5T7,-[J#/QS-#S3^M,THT5%3V;1@EIX6E0
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M,B2 8FHP&Z8Y\]6$K6SV2.8$94$X/G/*>!5%%/SM>3'AXGX)^$_]6E64%C:
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M=HJN1!JK/I618S%;U5M)HZ4R9(6KJOSA"I6P&)B+.?-?TH-T,;P^/K7+6"3
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M6+>42T2)]NZ:Y-CP)IP(%E9NZA65RE7*QB[+%3 K7[A.L'DZ'HO?'_%.A"X
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M?]RW@$T>[D6RE?#"*:('5Z$.DH0:X6T7,'I_#9T;KQ\ YCCRQ[AV=_-#-+5
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M-:UEM"&6H, <_N?%/]^BM2/ :BPI*M(A$S<=RAL8L^ -Z\[327%3!XBJPN]
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ME&,)<R"/T,.6MK:"F8]6G(AF]!>]6H\(. B_&^*Z=IRGE40E+RX*4\JOO?'
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M&JL.0;1*KVZ+RURH;;Z"#^#LK RWWY.Z^\)5_/)0QY FTM.(,)Y(+]B*";L
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M/QI;_E?\N+ ;(5'J9N-E9V7^8V;5=TVZ\YG@#@'W><@&5%G1'_WJ0=CV)$A
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M)7K4I<O)D>A$.CAC:*#+_)UO,CN*(3SN,;;/K8()WH5:3ST#>_TWO>%,3.\
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M_ 9*MSX>3(.%[(NNB\<YS&O=77WV7A?@,SW:^>Y[7.!F[QRLXR4ED:!9^,&
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MK#**_N?_;];8P.\"ZVA3MI%[M?$<RQLM;K^)DEF%)7S22$*Y'7 [A)QB?T$
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M6),<\1IUP8LAO_:TWLE>=UYG9G,C/%=B^$-T!PJI#.J!D'.:L3X.<O41ET$
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M=?GT.#\&<O1>;)PIY85N.5F /H4Z?=5LIKDFSQJ\5:^+50K&E\3# +S*)H*
MD]K\350*GBM7HX2&7MF*,GB@/"G*M22HU0N%P:(+E=[6)41<;DM^S]7>=%*9
MTY<K:2'JX?1B+3+>J&6>"-HWG !W8J@K)Y^1.)R=Q(G--J!:RD_B5IO#D1>+
MOT]P=VHSTB=Z^"=3;6XR^5[/^58Z?U76Y'5X6XCW7RG3?R^F0\0K<#)^QUDV
M*)$)(N\KC!?Q@MC7H3T 30_,D=]::H%EJ ]!5;%GTMV*%C1+R[V7_NVO-:SG
MSSKX=S5K2XY$&"[<+-A*^PS!3]CWKC- 3;KWO9YT7H07T_;-E,@R<$.CZ+X=
M2BNUZYN?'0F_$:48O;>AX6RG"9=U$-EGH9V9?EK:,6AO:6M_#W_UCK&*Y-7H
M]Y+J6G_!(OSU*(G6U#F:0!0?!7OQ2 ^7/D4PV3BG2\!;'VR1)97:K/2F7BVG
M.,:]!U&['1F?7U/$2KB*Y%B9'="=]356DA2.H]CKH :M@[J=.5T#F)K8A+QP
M4"LM#2PZ6J^\:RI@)'$)Q &[3X5;*_LR")G7)'L5%F3M:P;(KY10[2BR@*]>
MTT[J.W]^$/R^'&K_R.UVV.M)C;[<%3@[IW CQ*W8-G4:\L6@,38<[S$;AV+)
M38'-#_6@L\JA50D++M*@@&\=3-TS/SHFZ*?HQLQ1JF"UP1O2'^<#5\P3[?$O
MORXL"TLUO)_@=ARJ6+3O6A/L(<.1JC.W(/?)I2OI6IE(Z;@_=Y'?/KZTM+G@
M8:84-CC3Y:\FYR?*:[/:\6ZX/$+."QLH0%%&L2Q[-PY$BY-!)QH+_DH:-( Q
M0S&C]&CU\FX,UC L))_3BAGRH\SU4+><^M,LA]J[$BK*-G6SD!U"Z8.:NNKJ
M^K'=(I/ $,&:,>4N,'I-+,<D#1F/FP9UL45M2H1)GHN9TJC)6,6WQ:JZ"LC"
MW1G &E\(9GCNS^GCP5ATV,M#((JU;V7U5KF0^1X[M3'45#QF/L4<!1;RDH8)
MCSSCN=O[V![]/O+Y4"O'D+XB\S-L@;?KJ]&OF\G"+U 1  KNW@V,CX?Z12 [
M3E*B(NN/G[/LQ8)HVSG<=KMT4YJ54#,\RBAAMR',ZZ[Z-C."3NN4[MD>^7VN
M$FDU]?(L1-R4M*L'IS62R5/IK&M0%(P3:[SE)))=(6JN"#-7S/9O7-NY+'(.
M+61U2[.5"AL#)E2^H1C&@ZA2?PC-/036D<I>?'&.*YF1Q%HHER1#V?;5C?<O
M<MP5?=,X1JA0Q0D?<-Q8HL6X7VY+2DQFIU=IMGDE7Y5LQESHGAFL13XCZYN\
M$BW@N 9Q>](A2)%1,#6U 4^ZBH"KW+DLQ\VT!0?2$).BD98)=PU42EJ?UNQR
M;V]4^@=JZLH]#]@YC&5(6@SG$".S%;L:_YGC9U7$\MQ.>*5$IVH;:&$RBT<W
M)LG9;LNA(*CN$>]GG+*N"GKCWKD+936.U,YL[4EXO%!"%GIE[![L_*;\U1:A
MJ?OV=7,P\8V \9-FMGYC/JH#RY]%_1G"9V$YVO,>T7/RK/TQ/7Z/.QE$=$.Q
M&K^XJZ^.^UJ A=L*A[^G]$[AOP&@.=OS;1]3'N3H;#B-3U3!9&BR98&JEI\#
M6^1\8SKT'Q**&4&\GEFJUY)M]8_,O<R&N_6_>!CXX.;ZT3T^<F&@K%C3Z-K8
M&BP93&Q5'[G)O9O_H_NRQ> K0$I\&(H _. U/).=-L.MU9NI[,&=-%^AXW^#
M2B3,X(Y)O<.++;A%.&'=4^&1KJ2&6I:+<MAN7HO. 2UW=;[-R[%P<KA-@,+J
MXP&,'.E&?AAH70,J6.S#9: U#Y;Y-AN>+(9.6&"!PPICHYR=]_U[/AU\F_MZ
M!#F98OEH6JN0Q[N3%9S-S0*X;':1DF@[$JJ*Z%KHI#U2D"VUNDAYFFC9>*S[
MBY]WNWT1@/&E+X-$HG!(#-)#A6'GHIF.&*?PU@?CQ[X[L*5>1A5MXU39+.O*
MNB#XX<KM_I-3_/[; @P5#G:4E3 GC)B1M8%WTU4'8Q4DT?,]SJY@6RJ@O37-
M XYG*=X  :>?;X5>67(=?YR ]=TO$ZZV(.3YJ=A3LCM <9F^P=0]1S[&NCIN
MPW4]XM(=13.8V+DD Z#]C-JS3(;5?)KW2>5A7W]4CMQ/$,O>N_Y[[0?YFJ_.
M:!SW@VMRS)]:7(7"EK;VEI;,VZS/<1]U/HAT02%WM]O5X";GF5"KY#FWBY=O
M&?51BPJ0?&"/=IH%MCOA[[.1*QVR/@G9Y1@GE?5UB=M=>=E" THJN->RF>+V
ML41(##GWN]'S*AD=98&YC7T6:]XWTKS2R\)V25BMVWH8;K2G 8&&-;$LE2'@
M>Q_B@'ZSEHH8[Y*_EPD>S6B(Y5D<;#FEFB5GOL>E27ASK[O$<-0MN&!2O49(
M11QL&2W9P\1!__QSYP<)$YET\S.($)N!%%F5NBN85Y/!-Z6A&A6_@F^IK+(/
MB]R)Z&/*VMI#?S&JHW<W'57BKU IW\56]\ZCPU'U)/?02 84ZR,]XAZ2\N0J
M\7J+["T/K,HN I7-\K8'F<K?$6QZNF:R=)P#1R%CI2.TY>$F'BI7Z[U$CQPH
MC+:[=\6NUK/41CX)WB;FRKM H!F"<M-9,A .J"V #@W[M>"0+>_?VDG\*7P-
M[5$^V(O/GV7N6ZV3X<B)(WK7<[229"N5ES]_X+<A>KR& %S@T"$ ^-J23NJT
M[>O,$F#1WR](W3QWP[ZY;+I[((, _%0]\UGAMV3,0P"^L(HA *F\"$!SD.A%
MON@B^J#7>A\"</!"\8XAPIPLX)]Q4MY%B5S-A>;</6U O?LTCP#<IT$ EG+_
MS%@XS9ZL$G\4.1\)TQ" @40$8.%MZHT:Y9]85V")QZ77IEZ\.:&\//:Z08M!
M ((S_L3Z['.G_:B&*@* IH^</"(V",!G7*_#]UZ_<Z88Y,?2#M[R^OV%?F<,
M1WW>HZRG^/O[_)FO^^M_45/<O\=V2POKF3,F]7\Z@RQ[A+3@?9Q5'&PN=(/C
M?69TSO;1)<I_R.K]=PV-N@K_NWYWP:_S#PXK5%B6>!DQ<*(&Q'6+;QB*D:AW
MD!0!>)F-5.%V67I(!748 N"GL=!TA>*U,CI_HT=YD']#B "\MKF!('48 FT/
M_M3+%"YXAV_@@W0S,1& &%6O0T>O'P4'!K?WFHXL;>Y8ZDCHUPR-[>9_I\SX
MG00\.23%B4X=_L^>QO]-B\SYAJ'ICX)N_$[DQ*7<^Z-SN6E1[8+USGO^DAOY
M8Q!*_8EFNS0]W)1 BAP!>%+<XG7R" 'HRFNZJ!7]C4@O#,^!K8QO_T+-$QT!
M2..]DY='_O9#?Z+9,<](\(OJ^.V=(WXGF3"2(/N/FOZC)J2:^&5%_>=P2NJ#
M]^:EQ+CD:]#[J+T]G,IQ]$QHF1EG#/^%+G,/97=Y>E3]/C96^B_BM*9W?ZXJ
MV6@=O!Y%?3VL/0R4&@'ISSG-,MD\-7Q^:G6[W+RM_5[ID=Y$0 5PUF?[77D2
MC:?*90FC(6=R?7C"K@9U195?5(8/E[$B\Y-BAD9?>"'2TUK^ 0=<JW/)"WD@
M5^C,CU.B[OV>UOSKD#)'#Z[NZ%N?F=J':C;T9NCG7BQSL4CONDN$>#"LQGOC
M[.4SUB35G6WD+S'7+G#D>I['-<NYPSG7NTO:!>9! *+9/BL!<IN\40[[+)1?
M$[.[ ,7]5UD^#NT8)9-UEC$](>+?:E[..\VC%!LV"5[CY^J1"M\\[R]Z$L7H
M5M)!-U>1FX:Q,L15O0ME;D^U_EA#E(SQ(4B2W7] 7]B2[J _@+9 NS'BX_@^
MS%'R(7S:(334(32UOQ))]/X@/D"Y-^C[YM:*;[T.U*6?OZ/F9JOMBB &3%[O
ML%D5W6'%_J2>X:W1D,MRVDW!NV! )P7AH-@#\W$RJM"/LRY*]J@*"6L5S+MI
M%:$=-D_>?HE[_HA#455UZ%^OB?_/^,_X__D@(ID(8:I@7"FOAM7%20:^PZ O
M9(\6+#GYU1)1$V)P<[%E<+[I=9'?=CA_$Z:$ $S\.HP=I'L*>F+Y;LT^.3G\
M^([@5_\I$8'XVRN#7S#LCU0+&_EG]*GF_?_DIHS)M+/0?='%CQ9>Q\MY7O-9
M?X69?K_.S!@(1_[Q1!('0[&"A8.Q_\/L#\Q.0)SM$,^"/'$CS*(5^[[D[/=*
M]??GYT[PAR>^NNC<29%SWL&1OU=5L4:A&86&D71=@1^>JNQ#E=[7*-'R,N*Y
M4#4A<YBI%E<?H>HHL]'')@M_;K2+;9C#_3&VP]B(,[S:NBF#3#;Y%5W) [_H
M9QU,F2>7 7*G.89ZY+3XVCK3YE;:E^N*986>%E_)H+UF0N"EFNU]"HLJ$@G_
M'.&LJU;WZK9T;I;[Y]3.<@XGWU_^6%>3,)O;)HASHX'4,#.G2ZRC$#PV:1?#
MMYP#UU0%.SZ@"207V_;AE#8>?:\Z@%]97]Z[^")(MHX"::RXNXLCBCX%%IL,
M5]([=I&]F*L7-Z.[%]C_YGH)(A]41^Z!'UNPS9@ECEX4.[O=.ZTB*'T>TV[O
MNN ^QDA)(&%7T)$U9S%1"Y[IUL:QS[#ZMG7OP;'$-]V-W$)F@[9!"[<O H[J
M\1H31WF1.M/TM*K7;=$ _)<!2Z0@AUWV3,YI/>W&KEWH,V"V&^7W]%X6JZ'_
M(<(W=DFQ^'"04L[%(63?821(G8%O\B%4#+6T.'GY$*MQ*(/RZ=8E%>7%;<P-
M<./OQ1$J:1WX(5X'D4 $X(1M"SE-2>DN?K4G?]2$ (AC%2-=FS*O,+,A[:,,
MP7+Q.UQ,KSM_<@,$ ,48 2 17:1".IT;AF-(WX9'\;#PBGY5S,G<ZX<8DFRP
MM0#I7UFE+DO=T) @ +<8 DUWC[KNN%,ER')9^K OI+D1@"LBL-<-9LS-KT[G
MODBFWP,TD#[3E&A[^49&[,.I[W\6@_)W,<<]\.S3ZKC^)$7&GX0<2 ]_3VBR
MAE0(H".0VZL>]<:S:_NTV(B"L!/UVJM-]((SNI[]BO6ZY^:GQPN1C:OW%<%R
M+4B!-+T&_WHUXD(BX!;U1AP!\.5G] Q6%Q]M_@>7F7Q54>YP#!$ I OXJSBF
M_YWH(@'E">4A]AW&2M$5?1FF'/8?*.C_R JVD=[)S?:'^S-^YS2?'D+U[WPX
M0^5X?.&&O["LQ!B8=.HY?USWU6:6S$@U\771!C#WU\-27T_LU$ME%ZTFXOA6
M:289+MF-:3IQ%^E[Y%MHU)IF?Q)?7+U_@GU2(+?(,C(_=(L)]J3\"P'S:B)%
MG4G0A4MJ;<D.D%CR9XZ#]O^)NK1_>4 5VU)8$N7&0"<>K(K7GCD">SCQ\'S^
M+2]LRX@WAWZSX]57%# DC#?;$G1NQS_/"&^0\CK@NM3S<W3"TV!!:O,3,RF^
MAY::[U>JUI=BE <4*;>,4N\/6:(R:#"]W$I=;]KNE\=3I-&_C/VF1W*BSAP1
M?"+_#KUFU\97PIQ3L(SC 0+0Z'V2>X( $&V09"UI:VTQTAR9?:RP3FST\WX4
MPE;+FPO5[_B)$P1.8-TO[(.FOAP_>OZ5RXC&\!S[V\EUI7!$V"?!/ ,)$[,\
M&AAN:+J570KG:*@9//F;'CDFOE_N1:O8L(UV_]D-[0_,WI!G-<JAQQ5DZOX)
M>7#+,YRY2?FUZ:[DX@JHK:T+%45Z[#?=.J03P?:'X"Y*WR=7!(#ZO>CI2M,5
MJ8:P'G:$Z(IEP%T]TF:(6ZX79,?_,%1=>D*?7LGYY_J)_VYP"S$CN84G(  @
MKQ,=C0*-KQ>_V0_HNR:<(>PO#*3?"+;&@<XT3+F=TML^[*KO">UDA),.)5[Y
M2X7%&I,K1;7<,*#S);\2TEN4O9<-C;(IT-)9[XXC;E/0X%]55-V]V4X;XJYC
MQ=^,9P!E1@"Y&\:*?ASE$#%8ACY>#GS^M&XC7D*2P)F#FK>.GN@F_]R_@G"(
M&:J]M+[+"XM)#$G =X(>3TFEY1MGA 7(C;X<BV\>:=QE@"M6<15>NC*7\;SU
M6M"E',D1;&3T>7F([0>"<[-5''V7LX.9LE^J)VDS=[LL>9A72,)E\6%/'L\1
MB>Q]:Q<ET0-*U8R"&W"/",*,2I-7OO)316J0V2E<^86_6=,8KN=>4D37K6,O
MAUE8S4Z_E'42PK[ 5D0 U)Q0- -DAKC&(>@U]9U/[X%0WDGB@:>'R^MM%F4C
M<'3$69*9E.;?DG <&:,&M1/+ .XHPQRKV"H;_.JQ?8;:<ML<.XDRX>:X_*)$
MELM*%^ "7?A/!RR>-G47;9X6QP',:<SQ8F 4U07(F6*HU'$.-?M9Q*J.6W8J
M04&6GJ;\'73I96B2&3&Y9T;QHN[76NP0ZQ/:06OKDQ;3]^*T<!M.HL^4K6$U
MS1V7?8_3S,06><P._,/[[3T["$4/<#0?B2T-D$[.3&%>F08;SSO<</2VDBJ=
MHP#6$8 B;8J70V!@ \F$[*"I#WR,+2:C[KFY-X#JPV,4Y*H](9NEXQ*A**O#
M-7(BS?2"H;"DCT6-LY^C'J;?($]AN*(V5$[7-H_+&?IMH>HMWT;6/=$B'@#U
M11VXXH-,%J.(8.2"V4D!)"ZL0&*)O6C#'AYD\D7<P09<3>-M7Q1+W"?Z9H@5
M= K<!6I$SYZB9VF.@<ZM_+EWT!VZ6D3?L:#*_*U*_*-+O')M:7F5_\]QP8+I
MW%VCJ'C;""<9*^<?!<J/0L!F#GB'0+<OWB*FLG%:!!)[@&:XFSV#A[.4GNE/
MPV/(X_18.A\3O79^O!4R9P1@>\S=14B"N<T 5#.R!)/L]8'S,K.2BQ@=1?1>
MC^#$$H8OQ7=5XVA[A%N,T_[<2O0FK@I@!RT8G\PFJ7(S2[I[7<AH05FJ)%S-
MHP*S)XTP2M8MJ+PY.H0<8K8AI4:+#>+RFE:["$!9RC A*<M+&+-(WU3+C@+?
M[-7[VH@ %IMG6N\AM+SG/"-223?IHJQ4AW<M-UL5U94T$Y]D6$($?2#F849S
MZ<M*1YDQ4QJ&=V!JER HJ4* ?,6SF7F=VSP5BT^5X4Q86MY&225$@#&=8NPM
M:K51*)-)V=$IGM*^';'%B^=.BW:CSNO?LPRPYJ<Z,G4G9W1N:]L[M3K+'[%W
M5^L>\9-!+<Q)$L]4].3-(YRMJHZCQ27+;%"B'Y&B\!,)"TX(XB==%0>>5H(T
ME& Z%NG2T7.@_+0?H9XJ:%ORCNJR3G%V(9LOHM>CU_ 9&EP SU(>H38R8E;L
M.DUHC^Y5G(^$\I9)7E;/:?&TYPVYW<YK2UME@D.&,F9;/3@;QN*R,#,4K7]0
MTYO)\;Y!Q>R\.BEH.HB>5<R;T]:<G)8_DZG/#I=M(1MHILG';^=?B"/.M$'O
MKF6$AS0)[ $G]_98:$F=RVI+F\GYE #Y5QW^8$Q35^KDBOE7F1CQ/O=A2M =
M[YSLU\M.7D_<T%7TI'[^@-\=C<,%7_*XX"86K'J7&SF-ZN4(X70UY^T+O?LX
M8L6ZH(/GLX=##]P>L@GU?DW):'RLK'OA=D2NLK>OJ"=@7&_B++O10S3#,I-'
M+@:P]1)@J2!_:^FD'588AZLK;G&FA>L2&&J/=8*2DRU,/\C] FG[AVB&*Z:K
M00O'K-G1..MZ#X)YY*=Z/RNBVI Y0&#N2_R.LQR/]T&@Y9KJ)/$GZ*6K/)+.
M"6A$NB@W_&=K^=,7[JH5PP^S;WEV(6M:)N%;N$8Q[M:HM]$B 442V+Z9 5+A
MM) IFQ?UP,[(M_*U!$3L#^_6L$2UN3#EY9^UH>?/SFK53C_>'3/@@;UPF=7A
M>U["W\G_P,UM?-78@H"W:EB6%FYQB I@<K*-[="7I6B24V]XR?7GJ#[1'-(X
M1/'J(@ E'AUW(9:7Z92G[ A +>.FU]\#J139:JA#$OBEW_Z[%B=3 DCTAD2/
M3ZXH56O=R2F.]JBRI9GGU# '8U4D@>M!__NR2J7[[HN](2+& 92VK-K[W5*G
M>7&KU/%-ASP%V7!IF.C'. =+V"O:>BL>;'8\_S<ZN=98[A2,;A,&%77^JQG!
M.S+6^0/HTP*=:K5/,XU]?2_5=(HQIA& 'X(LR88@"R!3.ML^F1@*O@E-$I:;
MBB7\X=@-/#1R)O/E&IPH9A\<-A5H]6&7?[KE-,UX<\E#N"@[=GR+SF^8QT?6
M64N6=_8>>TRJI<-%=#^C9K:+C7CW3I#-F<:Q9F[7)7O2O?DL(YT+E2UT]U,=
M#\I;^C;/?FH[HNFDXU$>:<&F=U:-3^MC%"NP[3 F"(ZD>_"B>U;S1>8C^4 W
M('*/BS2L_/:K>>7R\*VIGK;+%BH?-#XJWT'?=@8D/IC3M[P*2Q[+=-JVHGX5
MQ!N'61?MM4 =G/IV)#P^2\I2!<_$].-S)HUHQ4-<I/.#3OZ1\NGLW(Q'P,X$
M0_Y;J^MFO6FW4"]"+G_M +VJ>!4"3,P93G9#4GGKSFC\[<K EF6(K\$X[0A-
MN3\_B/ENN%]DQ$DQGF(HR5929K=S \@J>U TFU)DX<I?ZF##%#J27YIB8O*!
ME_TJ7$!]K>A1AH#4&66I0&C0\_HWW;-L8N3L ]8G][2WWS>4'RS/EI97UW_$
MG>^<,8J=]%/@3,F9.,Q?UVN,:24X-X\[W,*T(R_,W>J-ZC3!@?5$NJTLB\0^
M<5&0DG4Q@W!77:O.R9-#-YRZ8)9,[@IOPA4<HBU,#OKZ&AI6!#YM=-&.$D:&
M))!W1A'+^AM%BTUB+UD$-IGE;CW=RLNVS+,R@?#$$>_"&*I5[JD416=:D_>)
M%VX[3&U%3DH(QZ8F$":>A>SL6-N5OF:,VY^H7LHI&[')')U0&3.%6:2'I?LP
M?FC!T?1IBUN)J7!SS!HKXA8,TMCQE8?,0$E(.[_M"MTT1ZR&C_JKU1R2P4%S
MJ6:NQL=]#NB= Q^+&&XRC<S;%1Q2K07&$\9V']8JUE0)=U52LMY48*DB &\>
ME2X?K*[Z; Y/*EI-$#3:&L<2&TV_PGCC=_U=NIGB:_'WK2+ZS]9,=S^0L,Y*
M-\,UJ=/8Y&0+"3^T/V.-?E(D<[;5GJ+I;S\3='UY1-3&,6DR/P*VZ"C2ZB&O
M*Z@R2RX:0FNUT=U[X-0^HMFW>*ML*NNRQ]2?@F0&>AA;/Y+ &WNRYWKEF'=R
M2U,< B;=><<\&L' _PQ]K:SXV^:NGW*JRDGS1@%DS+%NEE-%Y/G!P?USE%WU
M9-Q=U",O<3UF!X&4'/="2]#B/C8/"])/TS^5E3@Y=YCTBF+M-=]VQ/3L:7.S
MG-,J)1(T"6JGH"-7"S#2'HO];JZN3SZ"V_X33?E8AIJL/F+VV_G+2F R).U?
M2&K\-X[N42&)+ M55XT)(/KNK+^ZD,?K-$QM1E&%\8I;G=YKS,[$'D 57J@9
MWY9PP:\JY,+E(HL?G,]KU)3M0?;O(^;62=W<@@$KGZ2RMN!FH1\.1>(_P'U<
M]74/J T[B)9/-E.^SE)T:!VBAJ4?4GS/;DP  1^'$V6)"B;A=-XH&L(;[@=#
M/UJY"E=]]D  GIRW*<ED#9QUV3C_\'_6$/^J.]3XL.ZT '?*8%-[W1]LE*/H
M6+*YC1%WX&TJ^43L$EMX>Q08?\AVD#4VJGZ% 'P];D^,TG%AR&GJ.<G.9%'U
M'W+<+L:U$&$+'WLB[V!;1&:UG/MQ6H9,W4=SZ^IVPM^J/<(Y)SNJ,@?B.!E
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M8 K\7'VSZC\R'XYJ&;[^=J28^4-5RBB7^C*.8: Q40<&EA3%B2Z3QL&H6ZB
M8^26>WU;0GW)L2OT:5*NZ=YK;LRFFXCX^=-E[+LOIWF&.=H63C_FNA_Z,\7!
M:U92,E/6\N<OG&5']^[&G*T'>)K]XLSD<C>PAH7E&4/7X'LCBDV'>FTB'\K%
ML!" LL;6]2C_EITIQAC%$>V[Z;:#*=W"P>DYK3HB'=7HQ<\/ ,TEW2F*XC<%
M>?)TBA$*(!%!/O6^KP5OGSU!KDG"ENBL6)O:'MVZTUI?DO%R(^LX/RQ31;MN
M"(S4XH=KO-4!L2[>.(=/K*XJ4W3NTQA\:P3H5HVNDWDS[ 6]_ Y<6C:R+9/
MJ-*W]=M?J6W!#EUMUR@6V]3Q;86\N\U%IWGL$,5@#2J*2:U+PG)=2C9:O&65
MKR'DB0LA6\3P-#TS94Q:0#Z+OA:=^([MJ+$O&SW)X^L6CNMTX]X,#Z^[];3\
MH5<<U7"O3B.<-?V:-_Z\]F;^@+RFSY&S!;.7&;--ADF!K>N%OSK%P@1/(X&
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M%D7!BG4?+!1P_[3@<JK?^(W)R8#X0:K(E]:-U(!%7O_N_EAK/^$' "I^V -
M,EW\ ?!$\V\X*E+J[SP9[WE/"!((;D]4;]9CZ=BOUC,O!LB[^T6_G1[\,RO4
MOV+%XT/!<1XVUGH89QUP2C3V #BD%7_$??(UXM?H6X_ [$7FB@FG%V? $,\#
MH,7Z^-T#(,/F > [LNO;#J=0>118,H^&S[#5([+[_OEO6)#J48IM<A<\@D'%
M@&C?SM7.!X#(V/U53F_DO5?!W8E<Y0G6_Y??3,FF2,\D&=^C=@J)LTZ*J46L
MCM>A!3@*91Y T8Q4'Z/!GI.;O30WWFZOXSW%^M $M%@>X# $QN&->Q+@=]R.
MP,Y0*@N_DBI%)0@),61G_1<?L?Z'T+\SU(';;>>J9H#*KL2SO:<.D?J5LW?J
M>NG9G1'8]=>%XP+M.IIT7%07O\O8[1'0F(W?3#*@"KSV/MG*Z.O&M2[A"1 H
MURH?-P.AM(:P9G I^M:]P]I1I]LWU DK5-<CQXJ?V\3N1O\QCWJ"\CKWZPI>
MJTYZ[^\X<,H_SEOS3\8>U$LUI'75:4Q\K_P^TO;,>[7DB S[\G4*33BN*G6%
MEH1^^"Z26'8&;ATLG@A90X:A?3J*.&C0>*K3H*7DI=$6.:E=V@OY"*]R_)<,
M*$3/M8[.BE:/1.?(*>HGV%R%"\E'C1)F&Z-_2#QM^/HV.7/X6L<H-'H%"P-X
M%ZG8, 8^O801FC6@5P%4W-<\;X>\X8>33;XR%N[).K*3VW =6'W@1PMT42PG
MK5&:5K[JM\@?X>V&C%785VWJMXI>A!<B3H;W>2NA8SP@OGLC<N>+'S.F+S!Z
MBOG-C^X6[#"GI-+N7U0NT:<#I6K >PS+E/%]\K,X0X>A]#NW,%^=B 7ZPV(\
M).7^K")2,PM\7;1JVQ,C6.WA>.HJY1RP](DK8(\EU^J0]YN=0'U-J&/=B^P6
M+/NHJ=1MK+O@7,^$ME%L2OP!CX+5KU=O_,TW;@JNIRQY&6OV7JI8U\PV+A]2
M4DTS,A_'-'[\EO5FO+DQM*W/IS%T%IW!W&43,. <UM4096#OW3P4NAZIX$LA
M8E@4IY9!VAV3&<W?Q7]!'-9>9@"N,-*7YV-/%E#K],A7?7H4%$"M>_8]>*ES
M&@ BMNF^.^I$1;2,*2B:GYT%]N9M#13Q;#!764BC1>VS>'9: 3VS]T6=IY0F
M>8(+>CU)=H]9V_IC= M_H6NWHLE3'QHGT$#P=/JX^KL!@)S3SG<&!$<!$7N\
MGG$)LJ/]D6!J=+]\S1\6#P!S4Y>]LQ^FO&XF+Y3MRN1RME+M; GV"-*IO-IH
MPKFCJK$#F!)>'Z%..!RPL.W"N]5KJ =@-HBW!3G,F#D/@#+]!@ZS(_:.O!LI
M^Y?B\S/W/#V>E\U.L)9X?K.[H\E(ROJ9$1D\VM\ZG?0B2GP5!_0 ,#EOO>:U
MRTP)J!)1SK/6>PN^^W;>2"4K$9V3X&U5T+<1N-G6.$.M(*&/H_>$!)V[9Y58
M+HB(1L&8QHMZL(L)U?#LQYZR,&K.P+YX%8G"U%HK=OE'G7T3QABQD77$FSB*
M([-],[Q&JSR@K3_#^)1.3>BV_.X>5U6A!;ITRN.F\-Y.A<]OZ"\\@UO<5.$B
MA0V/?;"NX@G$%080O5]=R;<Y>=[-O!2P)^C[,A]#S$<KSJ.(7[TZ^MLT@*_J
M^GG9,OV)&QF_Z@2!C/Y 4WS:SUF_$72NH(]1\][D0*B[D_2G+NIH/&Q7;<(G
M:;PU! C2P]T,FHF8@15^7GE^#L+67EU?5[>\I5^;)S'X*IJ%YR@7P3!E1Q)"
M-@)3FQU$Q'G@.YY9!GZ5[#1$C=_CWCX DOQ-?$%;L#(/<0O8R@7.X;WI%<K"
M_<740A@4EF2>*D_MI;G?2$GK'YK>$??#$!)+VQT^:XB_"$=E1G,1?"(3^Y/<
M)#'#>V/_HJC,7E/S2">.O-H^^47T4Y%PQ\!6KV8NQ8S;U+W5VB#]%PJFX:NJ
M#?WO$Z^)/1(IOM(>3_6CP?P%9Z>(3K.7S ;-9S#?)R5$61_N'$L*!3R1H $5
M+^[NSVK8HEF'+[N-^ ;F83!SE=4N,ACZ+GJ B>#(3GNIISA/%2&1+Y"<E0 Y
MZ*J&=S9%-F"R>IB29]++KUV%3S+;8DS7!(G@2VZ-735#<+FPSYTPR-T0C"):
M>>GS86^P8M+LKCB\[)GPY_*,H>J-Q1B%G:]3.J\^*JP_&Q:;;PPZB57-XV0%
M+:>LQSR+U[T9+$0 %^4Y36_<6D?3)B5%,LL.%,\B4 4F"E]'!7&?X:9>]^9;
MO_2#+$%Y,O2R'P#A05U4D2X(S;54MUF?5/R$(C;7Y/4E4]2**TP-$8.$*,J$
MI!74XV4PHSBT0R5Q#5F\%I+MGDVY"3_+&V/+RE1D.YH&?HCT=$;6XGXR=W:!
M.PX=7CVD2Z91LQFH M(W,U4>G12:T?_2([U./678,_U0%/$LAZD1N0,1[>O*
M5BK^Z(S(0-(1>]I]]3.Q@/(RL;?.7_-K[4^5_(0[A-ZH^47TIA+%#S/(A@QB
M\AUUI*EN ,D)JU+'9/39/I>MS4(GOE,3>FR ?W&TAB@76@^;3+>_RY6TK::)
MQ;4&Q&G#[,^?KO 6*32CF&9'O/[^1.$[V<"K2!E*RO>2/:*=K  S3]B]]+S+
M_8\+BD<[??UCP'CW_69YWBWP 4#E4/\ ,+V)O<.?.)$6WS9[ +CJC'NG:%'(
MX.IT_66ZD4Y-L\:-U/C*N.M,4\F7RXW]GN:),$?;,ER'9]?L;<:L54<.*>>1
MOITNY/C+\[$#) %J/L2;)6L#[%K-PV<"4%$A$Z9U=I-&J@L=LDX_K"55'+GE
MZ"<8*@(T'UJT5QP]W_Z !WSTF>)9ZAM884[[K"XC^5]Y[OVO5,1.=H-,&QA#
MOX:N[>,A5DG:L.0R#J).%Y!A &S5M?<<XO>14GD3U1N\*FH>I9]OQ5-_[7?O
MGS.1A$_"X?JKO?*?&LT@@ &YMS[D.06S"VV$,B)V5,B$ M34/ BV$4PUL I)
M#Z32&.FQ?4[(J >HRXL4,Z<,H/]/^KY$Q@?,.]#9!&ZP<\[6ALN.2E#O_"!C
M&@#@:A'HHMK8\/8'1DB'3+,;(B0H6#DGUSK.RQ+2%)))N?T@RD+[=QQJ/"Z%
M_/^Y%/ V6$6K=QJR;0T2UYKL>#)T/P],.:U\RYT/31R2S:X71S5>(,,_MDG?
M3Z)ZH[X_=XN9T30^>EGE(RO;.K(!"XD1:;L23V)8)XM)_000_%X*,NE0R#/4
M+YA)=:TCZN.G=!HVRX#J['1R&]@LVB4KIHJ.72F1EJK%P81;]DA[=*QD 60
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MG*FY-*0G-O,!L*3OV7H?6!'PZW=KFN<_.Q\ IQC!#X G\2WOLV/M*%?EAAX
M?QCZNT.OQ?(#X!KYQV_WDHF$NASTDS/UQ@/@4L>8_0&094]QB?LYH*WJ*. .
MT?0!\#VW/(LA!]XCB/.XF6Z9V0D>=SD?UNUS1?%_9JP[C*N^9T[Z\5^?,<-Y
M%::T[P/@S[.,_0/;Q%,D7!]]%"JQ@#]/4NZ/?*^?1(B6!L=1B#\ _C#)G#\R
M]D.0(9^4[(E]>?AXCY_.AI;LU$K,0IMXRDJ,Z0#G_;Z<Y,Z]T^[D^2$<V T&
MOY!!_[N^U%2/"%?XZ1PO__<:7?^M:-4-I*DYS@K-'<N!*@D+K(;J9+I?$=(/
MP$C1K5I<]HS<7)*-R9K,BN3,BEFA+5E*BM&@=:Y*PG=E=8Y^/\X[>>BL8.&8
MZ5:Y6R-STT!EVM3^L<7>6EY#4P 7/Z?82A[[+9W*]1M-V4DEQD8[!;;4UY,]
M$O3^2^,X4:X[DS5#8?FA2B21S$<8\V5UM6R'!PIJWI"EQ0PL[\2:^;=EVIB5
M:/VDU35)$EW; 6$.OSP? -X90>-]K1/LN6,\,\;K,Y';ZG(;>F\6#$L2,NZ;
ML!6V-(UV4IO"BXUL1O31E,7[I<[?KZVY:NA%-R%D"&^0%8:UH>$5%\"'%<&3
MUU*D"-B)*[99X@Q=PJD#$V4'K ^ 6A;7C6:JTVHODYG!7XU19-56[\HALG("
MCRA@+!DX83E1NLN24X7A]/8\R0OVEL21%.!%>KJR \].[M3EV+1S8L$_,BI;
MJDJ5H^\)#Z2L/X#%3I79&%B#,$NL"IM67/G$+3B1MCT0&P7/MR+LO<G62OD9
MK8IHP*)SR1CK0!0-TH2*J*@8[R"&85Z6S608?VTY;4<M]])A@KZ\ 3^%BJ-?
ME9U&Y:DRM@V&![,2:8*1/-GM%VGU* !',6JW2CUOY3_WW_C[R15*ZI_E/L6?
M0L&4V3^T%?P^Z;"U=.*O'9Z_E8Y!^S@IGR)FX1!V83[FQFQ^>!!>2COV /#
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M&*N9[6DA,=93<-AQ/S0J[I#K5^()"1")'8RD;*2@B#17-AX=]+&Q4*@YK?>
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M&%6JU=2T;M6*/&SZK 3F?=<V-]]=L+5H'S/@XD2M0HU0V6A[Z$%J)BHT8DG
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MXLUL)O=:\4+G1FM>JZ]25<S&"\=M:8DOF=K\#CB8$#_H>[2(M1-7L*Y(EA\
MOSLFC43K:T\H81;+7G"FZQ*8/8*AD,""!\ PO];CSF?^G_8T&J+JH^!Q>+3'
M_75_5^;7B9C:CMN7@_G%E-SC(V<^ "3F->]OR_]F[K-@B-\'-A3<79G<,]4;
M,%Q_]0G[/_?];]\WI'R4&%-0)&5&EG>J,=!HDTJKO:1$L7P.26CVR@AY %#[
M)YRE_2VBQ\A9.XSFJ_(2FX63=79$_W]TGBL"H^UOCR'^/WD,:Q.@6N9?,;V?
MKP4LV5[^LR],)@UOL"MBI?5/#C*Y?W"S,1Y7- @3,\?\@[>-XA\\8XDA(],C
MAAY_X:,C+66+^4N.#&MO7=UY=,G^53^>'#-:3F5VW<&?'7?J_S!&4,^(+!JO
M^U_S]:GWM6WN6D.$_^S:P_W3D!@= CDS&:?%?]4;B.O\^*&8F#-'1.R6%G&,
MH)#D(I:3XOWC?H</L:#O5H>0H,32OP0X_TT)<<CW[>,*]C4Y>_PS.4N8H'^^
M;&9A/QQ47,16E\$;-?^WV'3 X=95\*A_]>]PY3?EW'^Z8G]Y*^LV^CO K13C
M=<2ZY='@9[H4UG<MK7J8M$F#,WG16(V83/W&;"/T(S&0Y _3I4'TR7T!<75+
MH5Q",:JD$>[O&OAM&.-_DF(WC3;DRN>E3/]B(%/@#7=:87TRIE(S3M_":.>J
M)_4J5#43;,RWZL]3RNT?4>16"->W&;5]V8\_R7-"+(,4NF@L-'[8E_ ZOLN#
M)H)(12AX]#U-=@IUJ7I-/(>6FA*G ,![BILBMD8N#G,G%QJORLAN/)^$#):X
M?  (9 ]$;&C*6.P0[\6$@$EAY?0')N8*I/:[>YN X@9P),^>DMK]T*R;C:^N
M]^R"Q(@P>^$ _EL7[XBN21&%@LUJ*;!@*K"H/@*^0$T3(^HH/H3'%EVN9U>A
M1/LYQH#^>"U"FN$(EL.X)9.QY*+Q#Q$Z_U9"YO\76WQ?FW2V'M/M9)YCU?U.
M2#+AD;K/%[^0 4GW95TS9-?^97U^,MQJX)R,"XBYW>DE.$9+@,EN7@1EI<=7
M%7PN//II^XA]B/"7HGA+Z[A[.6J!#,OD%([A[)O#.>G9G$3,YZGA[5\*^[HG
M7'5Q?HF3MR_[.%EYU9(9X%V-97T.\ LHW#-J=H&:F>__9T!U5&4/+9+TH%@-
M)Q6(3Y>S E8HA#9"-D;F:0GC#Q249BVS 9JH[:%X3*/HH9K?-<UR'@ M(10V
M8?<^<@\ O^=7)S<^>H]")>_@[@$ /H*T8;PT2)#URC1) ?]\$G=7N(MXD[MQ
M0+R3\3+!B]R(96*BE89/5',/.V#H$0X<?%-1P.E2#\92<S$1;8&5=NU&%RT@
M:P;?G#]:[&>+"*J\0Z%O4[W(%8AB-ESBO<X*RT)=5P9<#.G>5>()XMJ[:>ER
M%AH.Y'GF"U?SM)JF:*!]L**EMJ0W"YR-J[F3X5=N\KI5"O!R<OQIS4J=A,M%
M]C'DJT.WRNO@RRG>6,7'A>H,-\[Q=//Y0A\O ?YVHUR82/BLYU?W4-:TYQFO
M 2K[$C9\".,,4DW;5(1[K+P.'&";6UV*$3*WD"/*_N%2E5WOQW?$RM;A,=D0
MDMX'KV[-Y$_##92?^QXJ$G6-.* =:]1<(?2M[H1L8:1\SRR1$,0D9GW5/7\5
M<%#,0O H,#%_*BO-L\&7E7XF9\@H1.T(8W0'?T<A42UXHZU,I2"S#B5(\'$.
MVNW*5?U44JF"O/'43534!FDP(V*)Q5AWS)>5VG">(.-7N$*=;]WT!DJ&UY/:
M,STP^?:AS?X#P.:&Q0*[OZ=@0[AR^@4R=X0[6CHR X1>O4EFU,TZB4RE[9S9
M(OEGDK-/7#V18:S9D.UTS=CHTBH6?HY#%CV6YT: \0?!;N-N*#Y:VK@N\]*\
M()@GCF=*MW1=7[W:@YY2WNG6T&]8X**099>==A1L55G?X--1G\$PJ01KI_P<
M7?_.T3T*$1Z)]*AE?XQ LD&OEZ=G3>"&ST9225+XBTBC^SPXSL45%W+_H!:&
M)C>29B7'Z3\D)C';D#W;?1W/\&0(OM?T*&[W.+T63X8\YZ^TSGHZEP;P;JF;
M]Y;F)A><FF93I,P\4EH/K$3.BN$.>27;R<2T%>/&,PX\[4[<- SZTWA$)($_
M-K;V5-KJ9WIIG$ G9+I.<'Y2\VOU]2Y:' +U5T3/5&F\EYMNU.M:6JN#)K>O
MI423&I(6O*D8G:)"J6T [_T3JSV<Z%*6!9IZ,1;C\H;$4UB<P@E+V(^8HKQ-
MG51^N)1FU_6<D1F/MLM.T(TK]RT.D#K/?HE3EPZ._H QYY.0JL]V%OGQ5M*%
MO)P&[2U+T+/X9SVOU/@($VEB\[&:F9$&^[)NM%O368Q]C<V9B*47N-Z?L@AC
M8EA FGK-K(2WIJJA'<RO^(8/M'LV5>Q>K+].'8JB5>-JL'^#6/CV'J*2=>@?
M^B%HP[H4\NUS4,$G&:%Z)>&T/95#F_.+,C.\LEPN;DE<B_2OI([?0]1CWGML
M,V&H:DVP0O5XXIS\Z)/M:9.6^T;(%0CCD:4LM)RVKM3[?J_,<"--XT17H(U5
MTJ!=6DIVO +KN'!V$9-B!@(E9OH#@"GS1@H8[G:#9I-QO=_391HW@OAIFS *
M4"Q/U%U&^LVE/+LN]X@F2<@]3]C$:,X(.!LND__-MJ*G('\)JNN\>G.ZHV$C
ME 2E*W@'X17\E2)?QZ_CU/'1Z9-:N< 0(<W9X]ZJ_%UO[^_!V2>+A $]BP1W
MCT90E&U?F<D?K\J5T&ZYXV&_8R]=4_ @;B0D]%H-3;# +^:H%MHT_G3Y-F;R
MJ;IN>A,>!/0 +,.IC,OKF0,1N?S95PCK,M$*6_&7Q<=VU8N7.F.OE1<=O%J&
M*$5?,ZY<8UVBEI(!^5(*:$>MLF=-9A;V;VC'7^YV'3!)S/K7E>!M9&)NQ$P.
MZ=6EU':_Z-I?>(]"ER$"++%E%IW(6T^T0#??#5J6H'%$]CF[8RPN2>2CQ[#W
M&-PB)G!_GE-$#U G+6("1T^,7VC&&;).?62#'B N*)&JE8Y4*&6Y1'\97+L8
M%#?(_#Y4&F YRQ S=L/MLG8/YA<4N]Q1UFHJ#8[OV;,57(^!+^BO@RJ[\N:;
M<=$3#'7R2G?.587%2K)SY.KNOHJ9;$6YW=KN)=6S-?]*UUGVC*.-0<T!I9.L
M#OHUC.R]'#8,DWE;"+=-6K2N_J*$O]SXGCJSJTPWY=)_HX/#TU*?I] 4_[#G
M6+BU?^][C_9YV:PX\<%A*3R]@_'\BSF.EZTC6:S4W@-@DB='&ZA>YRYT751H
MZ^ZMW3#DPQ%*!PJ,2#@Q_>ITRMO9TKP\70.=S T=VP6%'I\'H&YZ;U!$"W=>
MQ]O>/QL[&'F.ZJ"5*/I1]ZF_Z9B;JSNFD0KDP&1T%[2WS^;0X60(V4PS(VN/
ME=QGEB$40M%,?/O)+GCR#*? TT0RH&)F'O\]NI%,*[BO6;#,!.<R_=2:E;6,
M4H&=#1M70TR;3,C/1ZT8[+BVZX:KRUXPL#P-17M;V ZB+2T+1_?L]_4).-LI
M+(F"*.D\ZN]"F6:T>]D[^AW^^TC;T[X3T3]>'1^)=U@9L7]@(BGT'['A08@@
MPDEPW.;B3$W-:M"'#UI +92"29ZE-"!W/[WG#2SZL0E/@OW:8Q)E>@"T>^BJ
MS2:AN9CZ?M^)=X&5;T1LN<[.$W1Z\T[-9.O OM9X<(KXD/(!A,,N*F/\PO*L
MNDL\!Y&PAY;2[(H /^I"KW (K_<<;#=">(33J="V#G+#R\'[!NL6'WP_JAY&
M'?M#5>L95M]&ZM2EB"!P)O0&*1_/;SC<O(HNZ7:Y"% UF#FRS+2CJUPR$LQ2
MK>*I:E\SB\XP_MUE1\AHV?=UW00QQ2G_6!)2@O/QS8\N[HS/#?<I7C[+6%A&
MP/86$J4PKUE'$DE#S(+,MO0S--*FY)?ZGMP=QL1-[G;17$]>N1.>L [-@=L+
M8'B3_!]YFE&DQTPT&_!W6)YA?S:+Q[7*XHU;.< PL1WN]LGI*/>GMK-1JS#A
MP]^+E[A2I6H8$*,/5H:&JH?)J^MY8R/;\)4^6[W572915EU:*/?+-4+- 4@,
MXB4?<(62!MZRZIS]E)=K9T[SBUSK+GB20_8\B_H,#UJV%5ZZ"4MU#4,3L4 0
M;YN/_>5H%Y=!0;BX27$8JYP[*]/"":;+9OO\3?*]O&ISO'@Z:K 0&*UOBAQW
ME/;SOHL-N=[934[JCV:G9:R/!N_TWBZ-?(AU<TY'K/@>1;X1(U=_6F),4S-E
M7X/&RMZ.WSFB)<6,JDTC_QGAN)J<\ '@\U6+^&G#0B(>) TE6*S7DDPZ_E'Q
M2J])BG/#B,P68CF.*7+O'V%=P$>:.$D?'SO/;/!^"<,[<2&+0FQ?8+/\O7;=
M&+X"X)X.'2">J%HT;4=L%;XZ>6K'4!Z_C1>Q/I./P[=V4TIX-!:1T'ZMDT/7
M[+>,83S/"BD(-PV=IST1*>RF9Q&@2?5 +,J.8'K^VPCE]%4OGK>&,QOI2Y%.
MT>FMR*\.$E8C[9V5@K$])TI=F4GV^ @WDM:>=IK0R!%^MU^IL]2^7H?>JMN)
M+J0\=3_B@<!J]U]'+>EHT]P!\,*7*9X_XV%U.SU-\CHPYI.7F%^+Y1%&.F?1
M;[W35H=I& W&W!A6CD&0F@:X!S7[.7\@]O75=ZT_QT29K(;XZC\5JDU'YQQP
MLO*PG7HBSYK[.4/7@2]XVV6K^\VD>U&>$F@9./]:'NH%.J".M+.IYDHT1U*L
M0^?>QJK/@U4ERZ7)-H4IM-ZP8,])#S.^&""*FPAT\!K$>K,BD-W#-C"[B#.M
MI\SB$EE!A9 ;9[]F+B'KK,>&@@=4.R*>MJO5&;CYJ12I3XM,F*%KB5X')Q D
MI(>^V]%)GDH6:O)P3VW^*0(ZQP%QRC^Q7W&?-$ESW]T?]-S1E$Y.!:T'NUZ[
MK6XA?S;]+$6^+B=F\O2%>(-U%5JUIV>LDI#"^/VH?S_%3_%&T-()S++?83YC
MNOAB@2;L!DV[J6+^/(U0'T[RQ9A/$T;M7(N)\4XAUS; TNA_M/?507%];9I-
MD 2'!-<$=W<-$#QH@C80@EOCKB$$" TT 8*[NSL-@2"-NX7&W=U]2<W,[I??
MS#?S[=8WM;55^\>IKG/[/O>]1^Z][WO.<YZCP1+?<U=VEW%.]3JZ=[IJBO3H
MQ%ALSO+Q8S7PT65.651L?58QUP?RS/0U34)EO_*P^S9@J)E PM69<[L4/NYJ
M1]L(LT'NPXX7$*Y(OIMK@5C:W$KG?9CMPH0.OFTXSK:V)!#DG+*.@7NZ\D9X
M9<_K[W 7ONF.ME"RHOUX'(+N3']6=$V0X?JR:LQLE/UE%)&F8(Z+VO,8/>^2
MM"1ZHDYFC)IE5ID-Q5&E@<(W8PF9(6\:9DX:2Y7%:MYN7Y<FN%D35("L#O45
M7BDFR=A0IS42 U,]32@WU"]KB=>'O]9]EI]C>QG=%^+8P5+8A;B)J0:-NNG0
M\O3&V8K3C(V]4)L=$H5_$7\U6U@4I:SBRRGY@FWF,HAH\3$:3<3%;S[1E7DI
M3QRR@EY';+9QZ<C4X4LU9C"XO;<6]:S$8<,GDS D6E1,$W"BMW%NDO9Q8O+D
M[8\$FLG496ZK&=IPU_#*/&J1,(<=M;[<G41(L&>873:8--Z\$K+W18LM7\*A
MP9-R/WI06O@E5"A4!<?R(DJ%A'A4F_K$0+!D-?S<SYT9('>MKG,9U'9^Q/IB
MCU.%BC"<C34[U!.2X\8P9# Q-*,S2UD[:UF;..[YJ3)*P'Q\?;:PHP M(_XD
M,OETN<BRT7MO611KBX7W"RYJ8/_4"?<M3,0>G<QI ;'F=_.=W].,V9:J/S-P
MQ5KGC=L=?980_/&5?G.S)?V16 S(\;!')!XB@1?-PC8BLT')+(<R(0+) V\X
MW^A+CFE4A<K73NPN\1-#:Z%,YR-=/:!@F@U1OM0SK1LL18LRYYL^5M?-/I'B
MS-'5KW1:1NVNVL@[ 6F3H8]%G2E[OE7KQ@WLGL(X-!ZT*,F.I.KNGNW-QA(L
M-*";8C^5?M'&$H;L6,01[1PF%)8/3VFPZIDH/C <9\L9975)TI>140I_403O
M?ZV*ON'?^G/3O31"]?"NMK"S=)\=8'';0!VTMA(^5<^$Q3""DINMLOXF(LQ6
MU1[+2L&("@;^"M @ KCB74=]?HS/,?[>_IBG+?]A$ Z/>,<4L)D)_M7_7R_:
MBXRGBC7^Q("@Z<%*!]E&341= AWUYB$K^9 N[FFI3WIS6WL53B<!X\C%-S+/
MO5V'<CP6VH>"P[V'=Q)7B>J(O(#R3Q=.W2A2 UI.SCF[\(?4Y9LQTQ,)P S%
M??_LL>_GY2)F02H8!H;.X2&/T;.2W83U)?) 6/EW+'+?K8,]C:>6=.::(N.S
M*B1C3;SX$[$Q?LAC,!-O?7.D#G1\33(W)MDI_!Q7>'CREC5%3K&^/$=D%L[L
M(E41/B#,NRLL-6:0Z&"O9GQT8/4(.<9(_4LRYK0ZBJ?)QE'1 \!DW+CRY %0
M4XI@L9:<__3E9T2W%>&&,HW<"_.^-@7&_,[2:TCS",B .:F!+F452+0OL_6]
MPNRE(]_I5?":0<RB-F9+(.@]1$?JWI!RQT!1R$H*Z,-H9QX9'^HH3\TX0WV3
M5>(%B;:H%=(CV"1"4OLT)UOCM)RDJF9ST$>5HS' #)3\D8/RO<W]#+%)+UWK
M2Q7?VM,PAE/13HUZI2<K+N-UKZ1[0QW?[&9\WEB%>9D<G>6#;*.5CNB*>8D)
M"!N<K77H0$4T'P&_B*[Y]D5/YJMX]:V8H:QBKEY *EY0T:MO0@*JK2V'JWYG
M15_.]^WT?P3[G%O:LJV(O<T52!ID#J8F]3Q[>2I6?<5SQX5+7M,?)>@.%YBT
M3/BJSB%YLK508C*GM^69DDQ0IS7I9LVZ!=&A9BI<S<)Y*OJ:2>C00?V7WIS.
M]GFC6.8 S;<#=S:Y9?>*L.B[I59Q_X/7!!H\P@,522OV S<Y9O5&[B+Y@F=D
MD,OUW$00UODY7)YMV7)OE;/S9KG>^*=!4_2F]0N)"<.V]$D676X_\6L&N EH
M](=XZ'C 6(Z:8OT\L($VD='YRX3^OG<F^IN?_N$]]^M+0RJEW+_CRU#%L>H-
M,%%N[!R-TQHP-.@9L!3?:5?Y*=[ERECU3@]HU)B\<X<8C:=89Q! 8W(GY*4E
M6J)"5\SF@BE80JO$&I,1/[N"U<*]")"E7EV%G+'"H+E#99LDP3/IBAX@6R*1
M*";_-/: Z*F *Q*IAC*Q\!R@)>=/!HL25N" +#<'1^0LGZ-0VF#BD<7AM$>T
M?@5D,YWPN?),<D ,0M7.,/:.3%F^KMZEBGICT#)]'=\8PW<!N#+:H6^3EGC!
M6^/#\U">QF*NUU-\G3(3@$_MXGQ>JM2>YZSX'Q/AYZY.3,CQU<5 .U6BB,:F
M&[2J%N4JZ>0Y8=1WN'6)H\];=B$^#?AQ&58$DY1V->/F$/0*)Y:<7,,?5MS/
MBQMNVHDH@YB%X/W:Q=Q^5KG1@E%K)5GUTLRKW/OH-5]_4C(N'KTFQ\R&B\6!
M\'#TJ:3%MJA1U&<J'>6&IG@QC"6!*I6R[C\T9H,T9NP[H/NS"LF/#ETJ,]F"
M(NU%4.<8'#[7DHK_NBV5HQ@O>7'%_^"='A!N:?!J>"]Q"2.JSXDEZ=>3_16:
ME=F-)Y\:2JS]LB2$\<:IH]S0T.79UJGI[8;-Q4NLBH]X]I[T!KU7[?]TC#"(
M)8YXI25\WO?,6S^?9FRF4/8CUIF9'@/6ZM%>Y!6XG__ U,]X67"@2;,.8A0K
M(28?_@"86'.(B .0O1@?,6SX]=/'VHFE0DI(GD;V.5/J^VN2*KW8M)*M6-VA
MKYBP#! QOX)D@I:3$0T9QDDW56.K! !R&A1?K2%\,\TR*<X&V]Y+7@']&!3M
M,5,5%QJBH*\DL9ERE'9Z(2T^#9\;]L@UZ ;0/'<47@[%F,WE*LK05.UM1\+]
M)FW<M<PPT-E/2.*S5UP.)(W5>>/'Y31<]$T%)<%N^2O=F%]U*NQ\OAM6&M5;
M<-/F$*B!H1V=]M9KK H?1OE,V\-L5L\@%'&R0X^2?NMNU\N<8H(@)UWO@WOL
MY#)C*2NK495[TX[E$ZX*P]<_AXB&K)I!99VLT[4-5="*Z!YN=OAG0+?0-XVO
M1-W= OGI1Z)->U:PP6-F8-TT\C@XDU^ QH]@*=DAACA+=?C[I9W*?>_]D!H3
M?<*&1Z;4ND?"X%W7995RL%20<+=M;NKRNL7>_ )WC/!(_ LHP.3H/>U13+6J
MGEX*OSI?[ F1:3UN;N>KVHT#D[!K1"V;FE5HBZ(@"SN()I::168)#Q4/!XNO
M8M7$WM[CT1AXJJV6+PZGL<^-AH/ODC4GOEHU38-B^K$_U.@J$4R_&L_$9)N3
M2,E=-2'0SR/S1,M/9:RQCV9-6:KP^,+L5>.=V;'W], 6KD(\ [&L<L\EFK_I
M&W-!'>WL':*Q2-)"I DKIX]0]LD?Y^$#L:H/#I):].&%/&&TK4?$EP&A3%J'
M*YAY!%AQ/*/[2<:@+F8@(&"\HW-A\*I1!6<:"-<9<K,4+7HKDL9"L&8O8:X'
MP-X!3A$^F1\%!LE2\;"I>1C[)V-[\KXVG7.W&EU:BF4.A0*_9N*$[&7_VDV;
ML^6P-#]<R\Y$"?*"6G]]T:<8GWNW9)#-:;-/O)$\2A]R>M$T!I)-I!E_=?*1
M5@8 >VWK3O_TF!?->L?#+9>W(,6H@1#IC9%>7[G_>%W?5(3>"=@S*##^5MR:
M+/8Y\7Y.5*]L#(6.6U75$ZQEW^8*Y>C7-;'+]XX7:!<S&($T#._3$10BNS>9
M4VJ.^(I<%J$S%[6)S%^CS!2+I=?6]#X]V:<7.-.SMW;MZD#G'2C)&8B9JZ[#
MC0N2GY#L^\0=QOGR)!F'H8H@H*1)T!)=^8)K]H.BB*]B\TRPV(<+&0# 2=YT
MZ9>-+77<'OQ+#R&N%.]/AF3C=)C[_;GE/,,X&T\+IL$\G*OXZ"6#CB/W-R%?
MWJ%M,99QZL-,1=O\QL8#G?'2-S*<<4:B8IN4!V#\7Q:09?!Z2TT-\TVHDMC/
M3(A9+3 TJ8!ZGAIS1'+544[4"ZTR0+<"O%5:!BI=DB,>E<".HZK?E9&CB@EV
M<@2O?(#%&O]<W[2Z]CO/FY:Z\G6T/>$<,_/QTM*QV6,M5N>?-T$:GO 7CE:3
MQ@OR. @37[4+O6\B? #(\)IJEOV1U<H)O"?N ?X6UVU\"^'NF-1RNNQZDTJJ
MLQK$'^$=0FSZ8=X\&EYC?%@3\Z-.K(+X6_]-O"QLN%^0^NQVQQ,\-%TT6VIF
M+X8VL@])*88;S.@!T>,G.4S""E8%:,Q+N76^61(FTD0!%]S-;Y04GT=U:!^=
MJ;I?@\](F'S E?K!@PZUNOH30T&\VEIR$2JQBT8,_H(V6-S1.Z?Y3>QB!:#<
M!X#1CQ@7I/AH0N4<-4?4IP)GI?-@W\%)-T+.M4;;!"=C:R]KMZ6BT*(N#.KD
M7 U?@RZBBY42&W>KMF-L9&N^$UT5LE$6*+7[M$X5!<I3S_W\[ (:V(93_VE?
MLY?BX2W<1@ASVC+4R)C4&QJ$W5=;S=I$[NY-+)J=I'DN_V:'6)2# R\MUT_H
M@"%#75_;*=6!MBN$?IBPO>M-/(=&Z-!/V+ ,BN^!;4.1T'J A^6BOKA*$"H;
M&W4]-E5;X-&WU=-=+F2W<;5=:/F&R$W'M<M95Y S0T95?91<YI,W<@G@VZ)Q
M8W#S<C/*_='IG:**"I>7B>H(11-9P.UEZ2#8M\>*;(,]=^=Z[^ZNZ;F%NFXG
M].*XFY3H 6#^TD]WFR&SE+%DFG7VT:7-(#AEOR(]32M>N&8M&F/N_R/7U_$
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M>+@<-9,<J-5V!FKK99[CC/>N7AL6(8%KY>;&Z"50 S6Z(##%S7)EP$N.F15
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M_81<LYWV_O+O&(7C,- B3SQ=\8=_=S8^;VKT:2O7DX6YM_!0F>/^&S=3SC$
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M,C R,3 V,S N>'-D4$L! A0#%     @ C80%4^QCFLOO"P  NIT  !0
M         ( !<P\  '-Y;BTR,#(Q,#8S,%]C86PN>&UL4$L! A0#%     @
MC80%4U<G9J)9(   RB8" !0              ( !E!L  '-Y;BTR,#(Q,#8S
M,%]D968N>&UL4$L! A0#%     @ C80%4V[$:<X-40  -K,$ !0
M     ( !'SP  '-Y;BTR,#(Q,#8S,%]L86(N>&UL4$L! A0#%     @ C80%
M4SD57L*2.0  J!P$ !0              ( !7HT  '-Y;BTR,#(Q,#8S,%]P
M<F4N>&UL4$L! A0#%     @ C80%4Y&X\87<T0$ W+X5 !0
M ( !(L<  '-Y;BTR,#(Q,#8S,'@Q,'$N:'1M4$L! A0#%     @ C80%4P0^
M^6E#^P  15 ! !<              ( !,)D" '-Y;BTR,#(Q,#8S,'@Q,'$P
M,#$N:G!G4$L! A0#%     @ C80%4RD/8(_5"   NR@  !<
M ( !J)0# '-Y;BTR,#(Q,#8S,'AE>#,Q9#$N:'1M4$L! A0#%     @ C80%
M4T)K?#6+!0  Q1<  !<              ( !LIT# '-Y;BTR,#(Q,#8S,'AE
?>#,R9#$N:'1M4$L%!@     )  D 5P(  '*C P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
